Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,23417472,target concentration,"Following a loading dose of 3.0 mg/kg, the combination of continuous infusion of 14, 12, 10, and 8 mg/kg/h resulted in a target concentration of 3.0-4.0 μg/ml, the required level for pediatric GKS.",How to control propofol infusion in pediatric patients undergoing gamma knife radiosurgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23417472/),[μg] / [ml],3.0-4.0,286,DB00818,Propofol
,12401611,FIO(2),"After intubation of the trachea, the lungs of the patients were ventilated to normocapnia with an oxygen-air mixture (FIO(2) = 0.33).",Changes of propofol concentration in cerebrospinal fluid during continuous infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12401611/),,0.33,394,DB00818,Propofol
,12401611,concentration,The CSF propofol concentration at 180 min (21.4 +/- 14.0 ng/mL) was not significantly different from the concentration at 150 min.,Changes of propofol concentration in cerebrospinal fluid during continuous infusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12401611/),[ng] / [ml],21.4,395,DB00818,Propofol
,10320599,steady-state blood concentration,We aimed to produce a manual infusion regimen capable of maintaining a steady-state blood concentration of 3 microg ml(-1) in children aged 3-11 years.,The use of propofol infusions in paediatric anaesthesia: a practical guide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10320599/),[μg] / [ml],3,943,DB00818,Propofol
,10320599,target concentration,A variability of 5% was allowed about the target concentration of 3 microg ml(-1).,The use of propofol infusions in paediatric anaesthesia: a practical guide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10320599/),[μg] / [ml],3,944,DB00818,Propofol
,10320599,pseudo-steady state target concentration,"A loading dose of 2.5 mg x kg(-1) followed by an infusion rate of 15 mg x kg(-1) x h(-1) for the first 15 min, 13 mg x kg(-1) x h(-1) from 15 to 30 min, 11 mg x kg(-1) x h(-1) from 30 to 60 min, 10 mg x kg(-1) x h(-1) from 1 to 2 h and 9 mg x kg(-1) x h(-1) from 2 to 4 h resulted in a pseudo-steady state target concentration of 3 microg x ml(-1) in children 3-11 years.",The use of propofol infusions in paediatric anaesthesia: a practical guide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10320599/),[μg] / [ml],3,945,DB00818,Propofol
,10320599,half-time,"The context sensitive half-time in children was longer than in adults, rising from 10.4 min at 1 h to 19.6 min at 4 h compared to adult estimates of 6.7 min and 9.5 min, respectively.",The use of propofol infusions in paediatric anaesthesia: a practical guide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10320599/),min,10.4,946,DB00818,Propofol
,10320599,half-time,"The context sensitive half-time in children was longer than in adults, rising from 10.4 min at 1 h to 19.6 min at 4 h compared to adult estimates of 6.7 min and 9.5 min, respectively.",The use of propofol infusions in paediatric anaesthesia: a practical guide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10320599/),min,19.6,947,DB00818,Propofol
,10320599,half-time,"The context sensitive half-time in children was longer than in adults, rising from 10.4 min at 1 h to 19.6 min at 4 h compared to adult estimates of 6.7 min and 9.5 min, respectively.",The use of propofol infusions in paediatric anaesthesia: a practical guide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10320599/),min,6.7,948,DB00818,Propofol
,10320599,half-time,"The context sensitive half-time in children was longer than in adults, rising from 10.4 min at 1 h to 19.6 min at 4 h compared to adult estimates of 6.7 min and 9.5 min, respectively.",The use of propofol infusions in paediatric anaesthesia: a practical guide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10320599/),min,9.5,949,DB00818,Propofol
,10320599,steady state concentrations,Children require higher infusion rates than adults to maintain steady state concentrations of 3 microg x ml(-1) and have longer context sensitive half-times than adults.,The use of propofol infusions in paediatric anaesthesia: a practical guide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10320599/),[μg] / [ml],3,950,DB00818,Propofol
,2248845,steady state plasma concentration,Atracurium was infused for the first 1 h to maintain a target steady state plasma concentration of 1.0 microgram ml-1.,Pharmacokinetics of atracurium during continuous infusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2248845/),[μg] / [ml],1.0,1378,DB00818,Propofol
,2248845,clearances,"The clearances of atracurium, estimated by the constant infusion rate required to maintain the steady state plasma concentration, at 50-60 min and during estimation of Cpss90 were 3.8 (1.0) and 3.9 (1.1) ml kg-1 min-1 (ns), respectively.",Pharmacokinetics of atracurium during continuous infusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2248845/),[ml] / [kg·min],3.8,1379,DB00818,Propofol
,2248845,Cpss90,"The clearances of atracurium, estimated by the constant infusion rate required to maintain the steady state plasma concentration, at 50-60 min and during estimation of Cpss90 were 3.8 (1.0) and 3.9 (1.1) ml kg-1 min-1 (ns), respectively.",Pharmacokinetics of atracurium during continuous infusion. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2248845/),[ml] / [kg·min],3.8,1380,DB00818,Propofol
,2248845,Cpss90,"The clearances of atracurium, estimated by the constant infusion rate required to maintain the steady state plasma concentration, at 50-60 min and during estimation of Cpss90 were 3.8 (1.0) and 3.9 (1.1) ml kg-1 min-1 (ns), respectively.",Pharmacokinetics of atracurium during continuous infusion. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2248845/),[ml] / [kg·min],3.9,1381,DB00818,Propofol
,2248845,volume of distribution at steady state,"The volume of distribution at steady state of atracurium after 1 h of infusion, calculated using the clearance and the area under the plasma concentration-time curve to 1 h, was 130 (50) ml kg-1.",Pharmacokinetics of atracurium during continuous infusion. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2248845/),[ml] / [kg],130,1382,DB00818,Propofol
,2248845,area under the plasma concentration-time curve to 1 h,"The volume of distribution at steady state of atracurium after 1 h of infusion, calculated using the clearance and the area under the plasma concentration-time curve to 1 h, was 130 (50) ml kg-1.",Pharmacokinetics of atracurium during continuous infusion. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2248845/),[ml] / [kg],130,1383,DB00818,Propofol
,6600929,alpha-phase half-life,The blood profiles could be described by a two-compartment open model with a mean alpha-phase half-life of 2.5 min and a mean beta-phase half-life of 54.5 min.,Pharmacokinetic evaluation of ICI 35 868 in man. Single induction doses with different rates of injection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6600929/),min,2.5,2062,DB00818,Propofol
,6600929,beta-phase half-life,The blood profiles could be described by a two-compartment open model with a mean alpha-phase half-life of 2.5 min and a mean beta-phase half-life of 54.5 min.,Pharmacokinetic evaluation of ICI 35 868 in man. Single induction doses with different rates of injection. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6600929/),min,54.5,2063,DB00818,Propofol
,6600929,total body clearance,The mean total body clearance was 3454 ml min-1.,Pharmacokinetic evaluation of ICI 35 868 in man. Single induction doses with different rates of injection. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6600929/),[ml] / [min],3454,2064,DB00818,Propofol
,6600929,mean recovery time,The mean recovery time (4.4 min) and concentration of ICI 35 868 at awakening (1.05 micrograms ml-1) were also independent of the rate of injection.,Pharmacokinetic evaluation of ICI 35 868 in man. Single induction doses with different rates of injection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6600929/),min,4.4,2065,DB00818,Propofol
,6600929,concentration,The mean recovery time (4.4 min) and concentration of ICI 35 868 at awakening (1.05 micrograms ml-1) were also independent of the rate of injection.,Pharmacokinetic evaluation of ICI 35 868 in man. Single induction doses with different rates of injection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6600929/),[μg] / [ml],1.05,2066,DB00818,Propofol
,14580052,infusion rates,"In the isoflurane group, lower infusion rates were needed (3.0 +/- 1.6 versus 3.6 +/- 1.6 microg kg(-1) min(-1)) and there was a slower recovery (significant for train-of-four ratio 70%: 21.9 versus 17.9 min).",Neuromuscular block and relative concentrations of mivacurium isomers under isoflurane versus propofol anaesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14580052/),[μg] / [kg·min],3.0,2929,DB00818,Propofol
,14580052,infusion rates,"In the isoflurane group, lower infusion rates were needed (3.0 +/- 1.6 versus 3.6 +/- 1.6 microg kg(-1) min(-1)) and there was a slower recovery (significant for train-of-four ratio 70%: 21.9 versus 17.9 min).",Neuromuscular block and relative concentrations of mivacurium isomers under isoflurane versus propofol anaesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14580052/),[μg] / [kg·min],3.6,2930,DB00818,Propofol
,14580052,train-of-four ratio,"In the isoflurane group, lower infusion rates were needed (3.0 +/- 1.6 versus 3.6 +/- 1.6 microg kg(-1) min(-1)) and there was a slower recovery (significant for train-of-four ratio 70%: 21.9 versus 17.9 min).",Neuromuscular block and relative concentrations of mivacurium isomers under isoflurane versus propofol anaesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14580052/),min,21.9,2931,DB00818,Propofol
,14580052,train-of-four ratio,"In the isoflurane group, lower infusion rates were needed (3.0 +/- 1.6 versus 3.6 +/- 1.6 microg kg(-1) min(-1)) and there was a slower recovery (significant for train-of-four ratio 70%: 21.9 versus 17.9 min).",Neuromuscular block and relative concentrations of mivacurium isomers under isoflurane versus propofol anaesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14580052/),min,17.9,2932,DB00818,Propofol
,15807987,CL,"The total and unbound volume of distribution was significantly lower in the streptozotocin group with no differences in clearance (CL) between streptozotocin and controls, (mean (inter-animal CV%)) CL = 0.026 (17%) and 0.025 (62%) L min(-1), respectively.",Altered dose-to-effect of propofol due to pharmacokinetics in rats with experimental diabetes mellitus. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15807987/),[l] / [min],0.026,3953,DB00818,Propofol
,15807987,CL,"The total and unbound volume of distribution was significantly lower in the streptozotocin group with no differences in clearance (CL) between streptozotocin and controls, (mean (inter-animal CV%)) CL = 0.026 (17%) and 0.025 (62%) L min(-1), respectively.",Altered dose-to-effect of propofol due to pharmacokinetics in rats with experimental diabetes mellitus. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15807987/),[l] / [min],0.025,3954,DB00818,Propofol
,15807987,Vd(ss),"Individual Bayes Vd(ss) (volume of distribution at steady state) were different, (mean (s. d.)) Vd(ss) = 7.7 (2.67) and 1.11 (0.09) L, respectively.",Altered dose-to-effect of propofol due to pharmacokinetics in rats with experimental diabetes mellitus. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15807987/),l,7.7,3955,DB00818,Propofol
,15807987,Vd(ss),"Individual Bayes Vd(ss) (volume of distribution at steady state) were different, (mean (s. d.)) Vd(ss) = 7.7 (2.67) and 1.11 (0.09) L, respectively.",Altered dose-to-effect of propofol due to pharmacokinetics in rats with experimental diabetes mellitus. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15807987/),l,1.11,3956,DB00818,Propofol
,20587537,E(max),"A close sigmoid relationship was observed between the propofol effect-site concentration and both PSI [coefficient of determination rho(2)=0.91 (sd 0.05)] and BIS [rho(2)=0.92 (0.03)], which was significantly steeper for PSI [gamma=2.2 (0.6)] than for BIS [gamma=1.8 (0.4)], and reached significantly lower values for PSI [E(max)=0.3 (1.1)] than for BIS [E(max)=5.3 (6.7)] at maximal propofol concentrations.",Patient state index vs bispectral index as measures of the electroencephalographic effects of propofol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20587537/),,0.3,3978,DB00818,Propofol
,20587537,E(max),"A close sigmoid relationship was observed between the propofol effect-site concentration and both PSI [coefficient of determination rho(2)=0.91 (sd 0.05)] and BIS [rho(2)=0.92 (0.03)], which was significantly steeper for PSI [gamma=2.2 (0.6)] than for BIS [gamma=1.8 (0.4)], and reached significantly lower values for PSI [E(max)=0.3 (1.1)] than for BIS [E(max)=5.3 (6.7)] at maximal propofol concentrations.",Patient state index vs bispectral index as measures of the electroencephalographic effects of propofol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20587537/),,5.3,3979,DB00818,Propofol
,20587537,k(e0),A significantly smaller k(e0) was obtained for PSI [0.09 (0.03) min(-1)] compared with BIS [0.10 (0.02) min(-1)].,Patient state index vs bispectral index as measures of the electroencephalographic effects of propofol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20587537/),1/[min],0.09,3980,DB00818,Propofol
,20587537,k(e0),A significantly smaller k(e0) was obtained for PSI [0.09 (0.03) min(-1)] compared with BIS [0.10 (0.02) min(-1)].,Patient state index vs bispectral index as measures of the electroencephalographic effects of propofol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20587537/),1/[min],0.10,3981,DB00818,Propofol
,20587537,E(0),"NONMEM revealed E(0)=89.3 and 92.3, E(max)=1.9 and 8.6, C(e50)=1.38 and 1.92 microg ml(-1), gamma=1.6 and 1.48, and k(e0)=0.103 and 0.131 min(-1) as typical values for PSI and BIS, respectively.",Patient state index vs bispectral index as measures of the electroencephalographic effects of propofol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20587537/),,89.3,3982,DB00818,Propofol
,20587537,E(0),"NONMEM revealed E(0)=89.3 and 92.3, E(max)=1.9 and 8.6, C(e50)=1.38 and 1.92 microg ml(-1), gamma=1.6 and 1.48, and k(e0)=0.103 and 0.131 min(-1) as typical values for PSI and BIS, respectively.",Patient state index vs bispectral index as measures of the electroencephalographic effects of propofol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20587537/),,92.3,3983,DB00818,Propofol
,20587537,E(max),"NONMEM revealed E(0)=89.3 and 92.3, E(max)=1.9 and 8.6, C(e50)=1.38 and 1.92 microg ml(-1), gamma=1.6 and 1.48, and k(e0)=0.103 and 0.131 min(-1) as typical values for PSI and BIS, respectively.",Patient state index vs bispectral index as measures of the electroencephalographic effects of propofol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20587537/),,1.9,3984,DB00818,Propofol
,20587537,E(max),"NONMEM revealed E(0)=89.3 and 92.3, E(max)=1.9 and 8.6, C(e50)=1.38 and 1.92 microg ml(-1), gamma=1.6 and 1.48, and k(e0)=0.103 and 0.131 min(-1) as typical values for PSI and BIS, respectively.",Patient state index vs bispectral index as measures of the electroencephalographic effects of propofol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20587537/),,8.6,3985,DB00818,Propofol
,20587537,C(e50),"NONMEM revealed E(0)=89.3 and 92.3, E(max)=1.9 and 8.6, C(e50)=1.38 and 1.92 microg ml(-1), gamma=1.6 and 1.48, and k(e0)=0.103 and 0.131 min(-1) as typical values for PSI and BIS, respectively.",Patient state index vs bispectral index as measures of the electroencephalographic effects of propofol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20587537/),[μg] / [ml],1.38,3986,DB00818,Propofol
,20587537,C(e50),"NONMEM revealed E(0)=89.3 and 92.3, E(max)=1.9 and 8.6, C(e50)=1.38 and 1.92 microg ml(-1), gamma=1.6 and 1.48, and k(e0)=0.103 and 0.131 min(-1) as typical values for PSI and BIS, respectively.",Patient state index vs bispectral index as measures of the electroencephalographic effects of propofol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20587537/),[μg] / [ml],1.92,3987,DB00818,Propofol
,20587537,gamma,"NONMEM revealed E(0)=89.3 and 92.3, E(max)=1.9 and 8.6, C(e50)=1.38 and 1.92 microg ml(-1), gamma=1.6 and 1.48, and k(e0)=0.103 and 0.131 min(-1) as typical values for PSI and BIS, respectively.",Patient state index vs bispectral index as measures of the electroencephalographic effects of propofol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20587537/),,1.6,3988,DB00818,Propofol
,20587537,gamma,"NONMEM revealed E(0)=89.3 and 92.3, E(max)=1.9 and 8.6, C(e50)=1.38 and 1.92 microg ml(-1), gamma=1.6 and 1.48, and k(e0)=0.103 and 0.131 min(-1) as typical values for PSI and BIS, respectively.",Patient state index vs bispectral index as measures of the electroencephalographic effects of propofol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20587537/),,1.48,3989,DB00818,Propofol
,20587537,k(e0),"NONMEM revealed E(0)=89.3 and 92.3, E(max)=1.9 and 8.6, C(e50)=1.38 and 1.92 microg ml(-1), gamma=1.6 and 1.48, and k(e0)=0.103 and 0.131 min(-1) as typical values for PSI and BIS, respectively.",Patient state index vs bispectral index as measures of the electroencephalographic effects of propofol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20587537/),1/[min],0.103,3990,DB00818,Propofol
,20587537,k(e0),"NONMEM revealed E(0)=89.3 and 92.3, E(max)=1.9 and 8.6, C(e50)=1.38 and 1.92 microg ml(-1), gamma=1.6 and 1.48, and k(e0)=0.103 and 0.131 min(-1) as typical values for PSI and BIS, respectively.",Patient state index vs bispectral index as measures of the electroencephalographic effects of propofol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20587537/),1/[min],0.131,3991,DB00818,Propofol
,21262611,response rate,A total of 168 responses were received (response rate 98.2 per cent).,Survey of the current use of pharmacokinetic model-driven drug delivery in small animal anaesthesia and analgesia in Italy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21262611/),%,98.2,4525,DB00818,Propofol
,25880448,Ce50,"The overall calculated propofol Ce50 and Ce95 were 3.8 μg·ml(-1) (95% CI: 3.1-4.4 μg·ml(-1) ) and 6.1 μg·ml(-1) (95% CI: 4.6-7.6 μg·ml(-1) ), respectively.",Propofol concentration to induce general anesthesia in children aged 3-11 years with the Kataria effect-site model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25880448/),[μg] / [ml],3.8,4687,DB00818,Propofol
,25880448,Ce95,"The overall calculated propofol Ce50 and Ce95 were 3.8 μg·ml(-1) (95% CI: 3.1-4.4 μg·ml(-1) ) and 6.1 μg·ml(-1) (95% CI: 4.6-7.6 μg·ml(-1) ), respectively.",Propofol concentration to induce general anesthesia in children aged 3-11 years with the Kataria effect-site model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25880448/),[μg] / [ml],6.1,4688,DB00818,Propofol
,19156973,Vc,"The pharmacokinetics of rocuronium in DMD patients were Vc 63 +/- 14 ml kg(-1), Cl 3.0 +/- 1.0 ml min(-1) kg(-1), half-lives 2.0 +/- 0.6, 20 +/- 10 and 129 +/- 98 min, SE.",Pharmacodynamic modelling of rocuronium in adolescents with Duchenne muscular dystrophy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19156973/),[ml] / [kg],63,4924,DB00818,Propofol
,19156973,Cl,"The pharmacokinetics of rocuronium in DMD patients were Vc 63 +/- 14 ml kg(-1), Cl 3.0 +/- 1.0 ml min(-1) kg(-1), half-lives 2.0 +/- 0.6, 20 +/- 10 and 129 +/- 98 min, SE.",Pharmacodynamic modelling of rocuronium in adolescents with Duchenne muscular dystrophy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19156973/),[ml] / [kg·min],3.0,4925,DB00818,Propofol
,19156973,half-lives,"The pharmacokinetics of rocuronium in DMD patients were Vc 63 +/- 14 ml kg(-1), Cl 3.0 +/- 1.0 ml min(-1) kg(-1), half-lives 2.0 +/- 0.6, 20 +/- 10 and 129 +/- 98 min, SE.",Pharmacodynamic modelling of rocuronium in adolescents with Duchenne muscular dystrophy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19156973/),min,2.0,4926,DB00818,Propofol
,19156973,half-lives,"The pharmacokinetics of rocuronium in DMD patients were Vc 63 +/- 14 ml kg(-1), Cl 3.0 +/- 1.0 ml min(-1) kg(-1), half-lives 2.0 +/- 0.6, 20 +/- 10 and 129 +/- 98 min, SE.",Pharmacodynamic modelling of rocuronium in adolescents with Duchenne muscular dystrophy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19156973/),min,20,4927,DB00818,Propofol
,19156973,half-lives,"The pharmacokinetics of rocuronium in DMD patients were Vc 63 +/- 14 ml kg(-1), Cl 3.0 +/- 1.0 ml min(-1) kg(-1), half-lives 2.0 +/- 0.6, 20 +/- 10 and 129 +/- 98 min, SE.",Pharmacodynamic modelling of rocuronium in adolescents with Duchenne muscular dystrophy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19156973/),min,129,4928,DB00818,Propofol
,19156973,T(1/2)ke0,"In patients with DMD, the equilibration between the central and effect compartment was significantly slower (T(1/2)ke0: 9.7 +/- 0.3 vs. 1.3 +/- 0.1 min) and the EC(50) was significantly smaller (512 +/- 20 vs.",Pharmacodynamic modelling of rocuronium in adolescents with Duchenne muscular dystrophy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19156973/),min,9.7,4929,DB00818,Propofol
,19156973,T(1/2)ke0,"In patients with DMD, the equilibration between the central and effect compartment was significantly slower (T(1/2)ke0: 9.7 +/- 0.3 vs. 1.3 +/- 0.1 min) and the EC(50) was significantly smaller (512 +/- 20 vs.",Pharmacodynamic modelling of rocuronium in adolescents with Duchenne muscular dystrophy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19156973/),min,1.3,4930,DB00818,Propofol
,19156973,EC(50),"In patients with DMD, the equilibration between the central and effect compartment was significantly slower (T(1/2)ke0: 9.7 +/- 0.3 vs. 1.3 +/- 0.1 min) and the EC(50) was significantly smaller (512 +/- 20 vs.",Pharmacodynamic modelling of rocuronium in adolescents with Duchenne muscular dystrophy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19156973/),,512,4931,DB00818,Propofol
,19156973,ED(50),"1170 +/- 64 ng ml(-1)), whereas the ED(50) was 0.16 +/- 0.02 mg kg(-1) in both groups.",Pharmacodynamic modelling of rocuronium in adolescents with Duchenne muscular dystrophy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19156973/),[mg] / [kg],0.16,4932,DB00818,Propofol
,26612706,population,"In the basic model, the estimated population Ce50 values for adequate and deep sedation were 0.94 and 1.52 μg/ml, respectively.",Modelling of the Sedative Effects of Propofol in Patients undergoing Spinal Anaesthesia: A Pharmacodynamic Analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26612706/),[μg] / [ml],0.94,5071,DB00818,Propofol
,26612706,Ce50,"In the basic model, the estimated population Ce50 values for adequate and deep sedation were 0.94 and 1.52 μg/ml, respectively.",Modelling of the Sedative Effects of Propofol in Patients undergoing Spinal Anaesthesia: A Pharmacodynamic Analysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26612706/),[μg] / [ml],0.94,5072,DB00818,Propofol
,26612706,Ce50,"In the basic model, the estimated population Ce50 values for adequate and deep sedation were 0.94 and 1.52 μg/ml, respectively.",Modelling of the Sedative Effects of Propofol in Patients undergoing Spinal Anaesthesia: A Pharmacodynamic Analysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26612706/),[μg] / [ml],1.52,5073,DB00818,Propofol
,26612706,Ce50,"The simulated Ce50 values for adequate sedation in 20-year-old patients with a T12 sensory level and in 80-year-old patients with a T4 level were 1.63 and 0.53 μg/ml, respectively.",Modelling of the Sedative Effects of Propofol in Patients undergoing Spinal Anaesthesia: A Pharmacodynamic Analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26612706/),[μg] / [ml],1.63,5074,DB00818,Propofol
,26612706,Ce50,"The simulated Ce50 values for adequate sedation in 20-year-old patients with a T12 sensory level and in 80-year-old patients with a T4 level were 1.63 and 0.53 μg/ml, respectively.",Modelling of the Sedative Effects of Propofol in Patients undergoing Spinal Anaesthesia: A Pharmacodynamic Analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26612706/),[μg] / [ml],0.53,5075,DB00818,Propofol
,19336539,c(P)G,"The c(P)G ranged between 2.8 and 22.5 ppb, whereas the corresponding c(P)PL varied between 0.3 and 3.3 microg ml(-1).",Propofol concentration in exhaled air and arterial plasma in mechanically ventilated patients undergoing cardiac surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19336539/),ppb,2.8 and 22.5,5212,DB00818,Propofol
,19336539,c(P)PL,"The c(P)G ranged between 2.8 and 22.5 ppb, whereas the corresponding c(P)PL varied between 0.3 and 3.3 microg ml(-1).",Propofol concentration in exhaled air and arterial plasma in mechanically ventilated patients undergoing cardiac surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19336539/),[μg] / [ml],0.3 and 3.3,5213,DB00818,Propofol
,25149986,EC50,The EC50 of 2.80 mg/L and the biophase distribution rate constant of 3.33 min(-1) were found for a typical patient.,Pharmacokinetics and pharmacodynamics of propofol in children undergoing different types of surgeries. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25149986/),[mg] / [l],2.80,8027,DB00818,Propofol
,25149986,biophase distribution rate constant,The EC50 of 2.80 mg/L and the biophase distribution rate constant of 3.33 min(-1) were found for a typical patient.,Pharmacokinetics and pharmacodynamics of propofol in children undergoing different types of surgeries. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25149986/),1/[min],3.33,8028,DB00818,Propofol
,22006632,standard curve,"The standard curve ranged from 50.1 to 15,030 ng mL(-1).",Determination of HX0969w in rabbit whole blood by liquid chromatography-tandem mass spectrometry and its application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22006632/),[ng] / [ml],"50.1 to 15,030",8358,DB00818,Propofol
,1796602,Duration of sleep,Duration of sleep ranged from 5 to 8 min.,"Species differences in blood profiles, metabolism and excretion of 14C-propofol after intravenous dosing to rat, dog and rabbit. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1796602/),min,5 to 8,10368,DB00818,Propofol
,1796602,blood 14C concentration,3. Infusion of 14C-propofol in dog gave a blood 14C concentration of 117 micrograms equiv./ml at the end of the 6 h infusion period; this declined at a similar rate to that after the bolus dose.,"Species differences in blood profiles, metabolism and excretion of 14C-propofol after intravenous dosing to rat, dog and rabbit. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1796602/),[equiv·μg] / [ml],117,10369,DB00818,Propofol
,17567340,target concentration,We assessed the sedation score and Bispectral index score in 40 un-premedicated patients undergoing surgical procedures under spinal anaesthesia with propofol sedation to a target concentration of 2 microg.ml(-1).,Effect site concentration during propofol TCI sedation: a comparison of sedation score with two pharmacokinetic models. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17567340/),[μg] / [ml],2,10615,DB00818,Propofol
,1785233,volume of distribution,"The volume of distribution was 2.5-2.8 l.kg-1, mean elimination half-life, 23.9 min and mean clearance 0.08 l.kg-1.min-1.",A comparative study of intravenous and rectal administration of propofol in piglets. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1785233/),[l] / [kg],2.5-2.8,12463,DB00818,Propofol
,1785233,elimination half-life,"The volume of distribution was 2.5-2.8 l.kg-1, mean elimination half-life, 23.9 min and mean clearance 0.08 l.kg-1.min-1.",A comparative study of intravenous and rectal administration of propofol in piglets. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1785233/),min,23.9,12464,DB00818,Propofol
,1785233,clearance,"The volume of distribution was 2.5-2.8 l.kg-1, mean elimination half-life, 23.9 min and mean clearance 0.08 l.kg-1.min-1.",A comparative study of intravenous and rectal administration of propofol in piglets. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1785233/),[l] / [kg·min],0.08,12465,DB00818,Propofol
,26649908,elimination clearance,An epidural blockade of 20 segments reduced propofol's elimination clearance from 2.64 ± 0.12 to 1.87 ± 0.08 L/min.,Epidural Blockade Affects the Pharmacokinetics of Propofol in Surgical Patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26649908/),[l] / [min],2.64,12753,DB00818,Propofol
,26649908,elimination clearance,An epidural blockade of 20 segments reduced propofol's elimination clearance from 2.64 ± 0.12 to 1.87 ± 0.08 L/min.,Epidural Blockade Affects the Pharmacokinetics of Propofol in Surgical Patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26649908/),[l] / [min],1.87,12754,DB00818,Propofol
,30924939,recovery,"Mean recovery from plasma was 91-93% for propofol, 89-93% for ketamine and 90-92% for rocuronium.","Simultaneous quantification of propofol, ketamine and rocuronium in just 10 μL plasma using liquid chromatography coupled with quadrupole mass spectrometry and its pilot application to a pharmacokinetic study in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30924939/),%,91-93,12804,DB00818,Propofol
,30924939,recovery,"Mean recovery from plasma was 91-93% for propofol, 89-93% for ketamine and 90-92% for rocuronium.","Simultaneous quantification of propofol, ketamine and rocuronium in just 10 μL plasma using liquid chromatography coupled with quadrupole mass spectrometry and its pilot application to a pharmacokinetic study in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30924939/),%,89-93,12805,DB00818,Propofol
,30924939,recovery,"Mean recovery from plasma was 91-93% for propofol, 89-93% for ketamine and 90-92% for rocuronium.","Simultaneous quantification of propofol, ketamine and rocuronium in just 10 μL plasma using liquid chromatography coupled with quadrupole mass spectrometry and its pilot application to a pharmacokinetic study in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30924939/),%,90-92,12806,DB00818,Propofol
,30924939,Mean plasma concentrations,"Mean plasma concentrations with standard deviations were propofol 2.0 μg/mL ±0.5%, ketamine 3.9 μg/mL ±1.0% and rocuronium 3.2 μg/mL ±0.8% during ventilation.","Simultaneous quantification of propofol, ketamine and rocuronium in just 10 μL plasma using liquid chromatography coupled with quadrupole mass spectrometry and its pilot application to a pharmacokinetic study in rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30924939/),[μg] / [ml],2.0,12807,DB00818,Propofol
,30924939,Mean plasma concentrations,"Mean plasma concentrations with standard deviations were propofol 2.0 μg/mL ±0.5%, ketamine 3.9 μg/mL ±1.0% and rocuronium 3.2 μg/mL ±0.8% during ventilation.","Simultaneous quantification of propofol, ketamine and rocuronium in just 10 μL plasma using liquid chromatography coupled with quadrupole mass spectrometry and its pilot application to a pharmacokinetic study in rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30924939/),μg,3.9,12808,DB00818,Propofol
,30924939,Mean plasma concentrations,"Mean plasma concentrations with standard deviations were propofol 2.0 μg/mL ±0.5%, ketamine 3.9 μg/mL ±1.0% and rocuronium 3.2 μg/mL ±0.8% during ventilation.","Simultaneous quantification of propofol, ketamine and rocuronium in just 10 μL plasma using liquid chromatography coupled with quadrupole mass spectrometry and its pilot application to a pharmacokinetic study in rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30924939/),[μg] / [ml],3.2,12809,DB00818,Propofol
,17457123,time to peak effect,The observed time to peak effect after a bolus of both formulations was 1.5 min.,Pharmacokinetics and pharmacodynamics of propofol microemulsion and lipid emulsion after an intravenous bolus and variable rate infusion. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17457123/),min,1.5,14075,DB00818,Propofol
,3264670,elimination half-life,"The calculated pharmacokinetic parameters were: elimination half-life = 41.7 +/- 20 min, clearance = 2.14 +/- 0.55 l.min-1 and equilibrium distribution volume = 43.4 +/- 15.2 l.","[The course of blood concentrations of propofol administered at a constant rate, combined with fentanyl]. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3264670/),min,41.7,14109,DB00818,Propofol
,3264670,clearance,"The calculated pharmacokinetic parameters were: elimination half-life = 41.7 +/- 20 min, clearance = 2.14 +/- 0.55 l.min-1 and equilibrium distribution volume = 43.4 +/- 15.2 l.","[The course of blood concentrations of propofol administered at a constant rate, combined with fentanyl]. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3264670/),[l] / [min],2.14,14110,DB00818,Propofol
,3264670,equilibrium distribution volume,"The calculated pharmacokinetic parameters were: elimination half-life = 41.7 +/- 20 min, clearance = 2.14 +/- 0.55 l.min-1 and equilibrium distribution volume = 43.4 +/- 15.2 l.","[The course of blood concentrations of propofol administered at a constant rate, combined with fentanyl]. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3264670/),l,43.4,14111,DB00818,Propofol
,12723460,times to cessation,The mean times to cessation of counting out loud (17 vs. 18 s) and to eye opening (245 vs. 244 s) were not statistically different between treatment groups.,Pharmacokinetics and pharmacodynamics of a single bolus of propofol 2% in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12723460/),s,17,14777,DB00818,Propofol
,12723460,times to cessation,The mean times to cessation of counting out loud (17 vs. 18 s) and to eye opening (245 vs. 244 s) were not statistically different between treatment groups.,Pharmacokinetics and pharmacodynamics of a single bolus of propofol 2% in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12723460/),s,18,14778,DB00818,Propofol
,12723460,times to cessation,The mean times to cessation of counting out loud (17 vs. 18 s) and to eye opening (245 vs. 244 s) were not statistically different between treatment groups.,Pharmacokinetics and pharmacodynamics of a single bolus of propofol 2% in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12723460/),s,245,14779,DB00818,Propofol
,12723460,times to cessation,The mean times to cessation of counting out loud (17 vs. 18 s) and to eye opening (245 vs. 244 s) were not statistically different between treatment groups.,Pharmacokinetics and pharmacodynamics of a single bolus of propofol 2% in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12723460/),s,244,14780,DB00818,Propofol
,9578008,time,"The time from initiation of high-dose barbiturate therapy to attainment of control of RSE was longer (123 min) than the time to attainment of seizure control in the group receiving propofol (2.6 min, p = 0.002).",Treatment of refractory status epilepticus with propofol: clinical and pharmacokinetic findings. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9578008/),min,123,18122,DB00818,Propofol
,9578008,time to attainment of seizure control,"The time from initiation of high-dose barbiturate therapy to attainment of control of RSE was longer (123 min) than the time to attainment of seizure control in the group receiving propofol (2.6 min, p = 0.002).",Treatment of refractory status epilepticus with propofol: clinical and pharmacokinetic findings. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9578008/),min,2.6,18123,DB00818,Propofol
,9578008,Plasma concentrations,Plasma concentrations of propofol associated with control of SE were 14 microM +/- 4 (2.5 microg/ml).,Treatment of refractory status epilepticus with propofol: clinical and pharmacokinetic findings. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9578008/),μM,14,18124,DB00818,Propofol
,9578008,Plasma concentrations,Plasma concentrations of propofol associated with control of SE were 14 microM +/- 4 (2.5 microg/ml).,Treatment of refractory status epilepticus with propofol: clinical and pharmacokinetic findings. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9578008/),[μg] / [ml],2.5,18125,DB00818,Propofol
,16415315,mode,"In the normal domain the mode of S(+) ketamine clearance was found to be 35.8 ml kg(-1) min(-1) with 5 and 95% confidence limits of, respectively, 11.5 and 111.1 ml kg(-1) min(-1).",Pharmacokinetics of S(+) ketamine derived from target controlled infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16415315/),[ml] / [kg·min],35.8,18659,DB00818,Propofol
,16415315,clearance,"In the normal domain the mode of S(+) ketamine clearance was found to be 35.8 ml kg(-1) min(-1) with 5 and 95% confidence limits of, respectively, 11.5 and 111.1 ml kg(-1) min(-1).",Pharmacokinetics of S(+) ketamine derived from target controlled infusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16415315/),[ml] / [kg·min],35.8,18660,DB00818,Propofol
,16415315,clearance,"In the normal domain the mode of S(+) ketamine clearance was found to be 35.8 ml kg(-1) min(-1) with 5 and 95% confidence limits of, respectively, 11.5 and 111.1 ml kg(-1) min(-1).",Pharmacokinetics of S(+) ketamine derived from target controlled infusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16415315/),[ml] / [kg·min],11.5,18661,DB00818,Propofol
,16415315,clearance,"In the normal domain the mode of S(+) ketamine clearance was found to be 35.8 ml kg(-1) min(-1) with 5 and 95% confidence limits of, respectively, 11.5 and 111.1 ml kg(-1) min(-1).",Pharmacokinetics of S(+) ketamine derived from target controlled infusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16415315/),[ml] / [kg·min],111.1,18662,DB00818,Propofol
,26899676,Onset time,"Onset time at the masseter (mean ± SD, 1.5 ± 0.9 min) was faster than at the adductor pollicis (2.7 ± 1.4 min, P < 0.05).",Rocuronium pharmacokinetics and pharmacodynamics in the adductor pollicis and masseter muscles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26899676/),min,1.5,19617,DB00818,Propofol
,26899676,Onset time,"Onset time at the masseter (mean ± SD, 1.5 ± 0.9 min) was faster than at the adductor pollicis (2.7 ± 1.4 min, P < 0.05).",Rocuronium pharmacokinetics and pharmacodynamics in the adductor pollicis and masseter muscles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26899676/),min,2.7,19618,DB00818,Propofol
,26899676,time to TOF ratio,"Recovery, measured as the time to TOF ratio = 0.9 was similar between muscles 29.9 ± 6.7 (adductor pollicis) vs. 29.3 ± 8.1 (masseter).",Rocuronium pharmacokinetics and pharmacodynamics in the adductor pollicis and masseter muscles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26899676/),,0.9,19619,DB00818,Propofol
,26899676,time to TOF ratio,"Recovery, measured as the time to TOF ratio = 0.9 was similar between muscles 29.9 ± 6.7 (adductor pollicis) vs. 29.3 ± 8.1 (masseter).",Rocuronium pharmacokinetics and pharmacodynamics in the adductor pollicis and masseter muscles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26899676/),,29.9,19620,DB00818,Propofol
,26899676,time to TOF ratio,"Recovery, measured as the time to TOF ratio = 0.9 was similar between muscles 29.9 ± 6.7 (adductor pollicis) vs. 29.3 ± 8.1 (masseter).",Rocuronium pharmacokinetics and pharmacodynamics in the adductor pollicis and masseter muscles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26899676/),,29.3,19621,DB00818,Propofol
,26899676,half-time (teq),"The estimated pharmacodynamic parameters [mean (95% CI)] of the adductor pollicis muscle and the masseter muscle were; plasma effect-site equilibration half-time (teq) 3.25 (2.34, 3.69) min vs. 2.86 (1.83, 3.29) min, (∆OFV 383.665); Ce50 of 1.24 (1.13, 1.56) mg/l vs. 1.19 (1.00, 1.21) mg/l, (∆OFV 184.284); Hill coefficient of 3.97 (3.82, 5.62) vs. 4.68 (3.83, 5.71), (∆OFV 78.906).",Rocuronium pharmacokinetics and pharmacodynamics in the adductor pollicis and masseter muscles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26899676/),min,3.25,19622,DB00818,Propofol
,26899676,half-time (teq),"The estimated pharmacodynamic parameters [mean (95% CI)] of the adductor pollicis muscle and the masseter muscle were; plasma effect-site equilibration half-time (teq) 3.25 (2.34, 3.69) min vs. 2.86 (1.83, 3.29) min, (∆OFV 383.665); Ce50 of 1.24 (1.13, 1.56) mg/l vs. 1.19 (1.00, 1.21) mg/l, (∆OFV 184.284); Hill coefficient of 3.97 (3.82, 5.62) vs. 4.68 (3.83, 5.71), (∆OFV 78.906).",Rocuronium pharmacokinetics and pharmacodynamics in the adductor pollicis and masseter muscles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26899676/),min,2.86,19623,DB00818,Propofol
,26899676,Ce50,"The estimated pharmacodynamic parameters [mean (95% CI)] of the adductor pollicis muscle and the masseter muscle were; plasma effect-site equilibration half-time (teq) 3.25 (2.34, 3.69) min vs. 2.86 (1.83, 3.29) min, (∆OFV 383.665); Ce50 of 1.24 (1.13, 1.56) mg/l vs. 1.19 (1.00, 1.21) mg/l, (∆OFV 184.284); Hill coefficient of 3.97 (3.82, 5.62) vs. 4.68 (3.83, 5.71), (∆OFV 78.906).",Rocuronium pharmacokinetics and pharmacodynamics in the adductor pollicis and masseter muscles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26899676/),[mg] / [l],1.24,19624,DB00818,Propofol
,26899676,Ce50,"The estimated pharmacodynamic parameters [mean (95% CI)] of the adductor pollicis muscle and the masseter muscle were; plasma effect-site equilibration half-time (teq) 3.25 (2.34, 3.69) min vs. 2.86 (1.83, 3.29) min, (∆OFV 383.665); Ce50 of 1.24 (1.13, 1.56) mg/l vs. 1.19 (1.00, 1.21) mg/l, (∆OFV 184.284); Hill coefficient of 3.97 (3.82, 5.62) vs. 4.68 (3.83, 5.71), (∆OFV 78.906).",Rocuronium pharmacokinetics and pharmacodynamics in the adductor pollicis and masseter muscles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26899676/),[mg] / [l],1.19,19625,DB00818,Propofol
,26899676,Hill coefficient,"The estimated pharmacodynamic parameters [mean (95% CI)] of the adductor pollicis muscle and the masseter muscle were; plasma effect-site equilibration half-time (teq) 3.25 (2.34, 3.69) min vs. 2.86 (1.83, 3.29) min, (∆OFV 383.665); Ce50 of 1.24 (1.13, 1.56) mg/l vs. 1.19 (1.00, 1.21) mg/l, (∆OFV 184.284); Hill coefficient of 3.97 (3.82, 5.62) vs. 4.68 (3.83, 5.71), (∆OFV 78.906).",Rocuronium pharmacokinetics and pharmacodynamics in the adductor pollicis and masseter muscles. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26899676/),,3.97,19626,DB00818,Propofol
,26899676,Hill coefficient,"The estimated pharmacodynamic parameters [mean (95% CI)] of the adductor pollicis muscle and the masseter muscle were; plasma effect-site equilibration half-time (teq) 3.25 (2.34, 3.69) min vs. 2.86 (1.83, 3.29) min, (∆OFV 383.665); Ce50 of 1.24 (1.13, 1.56) mg/l vs. 1.19 (1.00, 1.21) mg/l, (∆OFV 184.284); Hill coefficient of 3.97 (3.82, 5.62) vs. 4.68 (3.83, 5.71), (∆OFV 78.906).",Rocuronium pharmacokinetics and pharmacodynamics in the adductor pollicis and masseter muscles. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26899676/),,4.68,19627,DB00818,Propofol
,20299348,infusion rate,Mean infusion rate of Aquafol was not statistically different from that of Diprivan (median: 6.2 vs 6.3 mg kg(-1) h(-1)).,"Effectiveness, safety, and pharmacokinetic and pharmacodynamic characteristics of microemulsion propofol in patients undergoing elective surgery under total intravenous anaesthesia. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20299348/),[mg] / [h·kg],6.2,21311,DB00818,Propofol
,20299348,infusion rate,Mean infusion rate of Aquafol was not statistically different from that of Diprivan (median: 6.2 vs 6.3 mg kg(-1) h(-1)).,"Effectiveness, safety, and pharmacokinetic and pharmacodynamic characteristics of microemulsion propofol in patients undergoing elective surgery under total intravenous anaesthesia. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20299348/),[mg] / [h·kg],6.3,21312,DB00818,Propofol
,20299348,Times to LOC,"Times to LOC and ROC were slightly prolonged in Aquafol (median: 21 vs 18 s, 12.3 vs 10.8 min).","Effectiveness, safety, and pharmacokinetic and pharmacodynamic characteristics of microemulsion propofol in patients undergoing elective surgery under total intravenous anaesthesia. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20299348/),s,21,21313,DB00818,Propofol
,20299348,Times to LOC,"Times to LOC and ROC were slightly prolonged in Aquafol (median: 21 vs 18 s, 12.3 vs 10.8 min).","Effectiveness, safety, and pharmacokinetic and pharmacodynamic characteristics of microemulsion propofol in patients undergoing elective surgery under total intravenous anaesthesia. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20299348/),s,18,21314,DB00818,Propofol
,20299348,Times to LOC,"Times to LOC and ROC were slightly prolonged in Aquafol (median: 21 vs 18 s, 12.3 vs 10.8 min).","Effectiveness, safety, and pharmacokinetic and pharmacodynamic characteristics of microemulsion propofol in patients undergoing elective surgery under total intravenous anaesthesia. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20299348/),min,12.3,21315,DB00818,Propofol
,20299348,Times to LOC,"Times to LOC and ROC were slightly prolonged in Aquafol (median: 21 vs 18 s, 12.3 vs 10.8 min).","Effectiveness, safety, and pharmacokinetic and pharmacodynamic characteristics of microemulsion propofol in patients undergoing elective surgery under total intravenous anaesthesia. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20299348/),min,10.8,21316,DB00818,Propofol
,20299348,VAS,Aquafol (vs Diprivan caused more severe (median VAS: 72.0 vs 11.5 mm) and frequent (81.9 vs 29.2%) injection pain.,"Effectiveness, safety, and pharmacokinetic and pharmacodynamic characteristics of microemulsion propofol in patients undergoing elective surgery under total intravenous anaesthesia. ",AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20299348/),mm,72.0,21317,DB00818,Propofol
,20299348,VAS,Aquafol (vs Diprivan caused more severe (median VAS: 72.0 vs 11.5 mm) and frequent (81.9 vs 29.2%) injection pain.,"Effectiveness, safety, and pharmacokinetic and pharmacodynamic characteristics of microemulsion propofol in patients undergoing elective surgery under total intravenous anaesthesia. ",AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20299348/),mm,11.5,21318,DB00818,Propofol
,20299348,dose-normalized AUC(last),The dose-normalized AUC(last) of Aquafol and Diprivan was 0.71 (0.19) and 0.74 (0.20) min litre(-1).,"Effectiveness, safety, and pharmacokinetic and pharmacodynamic characteristics of microemulsion propofol in patients undergoing elective surgery under total intravenous anaesthesia. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20299348/),[min] / [litre],0.71,21319,DB00818,Propofol
,20299348,dose-normalized AUC(last),The dose-normalized AUC(last) of Aquafol and Diprivan was 0.71 (0.19) and 0.74 (0.20) min litre(-1).,"Effectiveness, safety, and pharmacokinetic and pharmacodynamic characteristics of microemulsion propofol in patients undergoing elective surgery under total intravenous anaesthesia. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20299348/),[min] / [litre],0.74,21320,DB00818,Propofol
,21351496,CL,"The results were as follows: the typical value of CL, V1, Q2, V2, Q3 and V3 were 0.965 x (1 + 0.401 x VESS) x (BW/59)(0.578) L x min(-1), 13.4 x (AGE/45)(-0.317) L, 0.659 x (1 + GENDER x 0.385) L x min(-1), 28.8 L, 0.575 x (1 + GENDER x 0.367) x (1 - 0.369 x VESS) L x min(-1) and 196 L respectively.",[Population pharmacokinetic modeling and evaluation of propofol from multiple centers]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21351496/),[l] / [min],0.965,22063,DB00818,Propofol
,21351496,V3,"The results were as follows: the typical value of CL, V1, Q2, V2, Q3 and V3 were 0.965 x (1 + 0.401 x VESS) x (BW/59)(0.578) L x min(-1), 13.4 x (AGE/45)(-0.317) L, 0.659 x (1 + GENDER x 0.385) L x min(-1), 28.8 L, 0.575 x (1 + GENDER x 0.367) x (1 - 0.369 x VESS) L x min(-1) and 196 L respectively.",[Population pharmacokinetic modeling and evaluation of propofol from multiple centers]. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21351496/),[l] / [min],0.575,22064,DB00818,Propofol
,21351496,V3,"The results were as follows: the typical value of CL, V1, Q2, V2, Q3 and V3 were 0.965 x (1 + 0.401 x VESS) x (BW/59)(0.578) L x min(-1), 13.4 x (AGE/45)(-0.317) L, 0.659 x (1 + GENDER x 0.385) L x min(-1), 28.8 L, 0.575 x (1 + GENDER x 0.367) x (1 - 0.369 x VESS) L x min(-1) and 196 L respectively.",[Population pharmacokinetic modeling and evaluation of propofol from multiple centers]. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21351496/),l,196,22065,DB00818,Propofol
,14531255,EPECs,The EPECs at awakening were 1.5 +/- 0.2 micrograms.,[Effect of body fat percentage on estimated propofol concentrations at awakening from anesthesia using target controlled infusion]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14531255/),μg,1.5,24830,DB00818,Propofol
,2186650,time,The corresponding time was 125 minutes in those given midazolam.,Propofol sedation after open heart surgery. A clinical and pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2186650/),min,125,25278,DB00818,Propofol
,2186650,elimination half-life,Pharmacokinetic analysis in 20 patients showed that the elimination half-life of propofol was prolonged (470 minutes) and clearance was reduced (1.14 litres/minute) compared with subjects who had not undergone cardiopulmonary bypass.,Propofol sedation after open heart surgery. A clinical and pharmacokinetic study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2186650/),min,470,25279,DB00818,Propofol
,2186650,clearance,Pharmacokinetic analysis in 20 patients showed that the elimination half-life of propofol was prolonged (470 minutes) and clearance was reduced (1.14 litres/minute) compared with subjects who had not undergone cardiopulmonary bypass.,Propofol sedation after open heart surgery. A clinical and pharmacokinetic study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2186650/),[l] / [min],1.14,25280,DB00818,Propofol
,2186650,redistribution half-life,"The rapid clinical recovery was reflected in a rapid redistribution half-life (13.4 minutes), but this was also longer than the redistribution time of 2-4 minutes in other patients.",Propofol sedation after open heart surgery. A clinical and pharmacokinetic study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2186650/),min,13.4,25281,DB00818,Propofol
,2186650,red,"The rapid clinical recovery was reflected in a rapid redistribution half-life (13.4 minutes), but this was also longer than the redistribution time of 2-4 minutes in other patients.",Propofol sedation after open heart surgery. A clinical and pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2186650/),min,2-4,25282,DB00818,Propofol
,19207899,target plasma concentrations,Twelve children received dexmedetomidine 1 microg x kg(-1) given over 10 min as well as a continuous infusion of propofol delivered by a computer-assisted target-controlled infusion (TCI) system with target plasma concentrations ranging from 2.8 to 4.0 microg x ml(-1) (DEX group).,Determination of the pharmacodynamic interaction of propofol and dexmedetomidine during esophagogastroduodenoscopy in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19207899/),[μg] / [ml],2.8 to 4.0,25664,DB00818,Propofol
,19207899,EC50,"The EC50 +/- SE values in the control and DEX groups were 3.7 +/- 0.4 microg x ml(-1) and 3.5 +/- 0.2 microg x ml(-1), respectively.",Determination of the pharmacodynamic interaction of propofol and dexmedetomidine during esophagogastroduodenoscopy in children. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19207899/),[μg] / [ml],3.7,25665,DB00818,Propofol
,19207899,EC50,"The EC50 +/- SE values in the control and DEX groups were 3.7 +/- 0.4 microg x ml(-1) and 3.5 +/- 0.2 microg x ml(-1), respectively.",Determination of the pharmacodynamic interaction of propofol and dexmedetomidine during esophagogastroduodenoscopy in children. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19207899/),[μg] / [ml],3.5,25666,DB00818,Propofol
,8572340,Target plasma concentrations,"Target plasma concentrations for propofol were 150, 300, and 600 ng/ml for 1 h at each concentration; for alfentanil it was 40 ng/ml for 3 h.","Effects of combining propofol and alfentanil on ventilation, analgesia, sedation, and emesis in human volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8572340/),[ng] / [ml],150,26130,DB00818,Propofol
,8572340,Target plasma concentrations,"Target plasma concentrations for propofol were 150, 300, and 600 ng/ml for 1 h at each concentration; for alfentanil it was 40 ng/ml for 3 h.","Effects of combining propofol and alfentanil on ventilation, analgesia, sedation, and emesis in human volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8572340/),[ng] / [ml],300,26131,DB00818,Propofol
,8572340,Target plasma concentrations,"Target plasma concentrations for propofol were 150, 300, and 600 ng/ml for 1 h at each concentration; for alfentanil it was 40 ng/ml for 3 h.","Effects of combining propofol and alfentanil on ventilation, analgesia, sedation, and emesis in human volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8572340/),[ng] / [ml],600,26132,DB00818,Propofol
,8572340,Target plasma concentrations,"Target plasma concentrations for propofol were 150, 300, and 600 ng/ml for 1 h at each concentration; for alfentanil it was 40 ng/ml for 3 h.","Effects of combining propofol and alfentanil on ventilation, analgesia, sedation, and emesis in human volunteers. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8572340/),,40,26133,DB00818,Propofol
,8230404,elimination half-life,"The elimination half-life was long in both groups (90.9 min and 75.2 min, respectively), the volume of distribution at steady state large (4889 and 4863 ml/kg) and the clearance rapid (58.6 and 56.3 ml/kg.min).",The effects of halothane and nitrous oxide on the pharmacokinetics of propofol in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8230404/),min,90.9,26142,DB00818,Propofol
,8230404,elimination half-life,"The elimination half-life was long in both groups (90.9 min and 75.2 min, respectively), the volume of distribution at steady state large (4889 and 4863 ml/kg) and the clearance rapid (58.6 and 56.3 ml/kg.min).",The effects of halothane and nitrous oxide on the pharmacokinetics of propofol in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8230404/),min,75.2,26143,DB00818,Propofol
,8230404,volume of distribution at steady state,"The elimination half-life was long in both groups (90.9 min and 75.2 min, respectively), the volume of distribution at steady state large (4889 and 4863 ml/kg) and the clearance rapid (58.6 and 56.3 ml/kg.min).",The effects of halothane and nitrous oxide on the pharmacokinetics of propofol in dogs. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8230404/),[ml] / [kg],4889,26144,DB00818,Propofol
,8230404,volume of distribution at steady state,"The elimination half-life was long in both groups (90.9 min and 75.2 min, respectively), the volume of distribution at steady state large (4889 and 4863 ml/kg) and the clearance rapid (58.6 and 56.3 ml/kg.min).",The effects of halothane and nitrous oxide on the pharmacokinetics of propofol in dogs. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8230404/),[ml] / [kg],4863,26145,DB00818,Propofol
,8230404,clearance,"The elimination half-life was long in both groups (90.9 min and 75.2 min, respectively), the volume of distribution at steady state large (4889 and 4863 ml/kg) and the clearance rapid (58.6 and 56.3 ml/kg.min).",The effects of halothane and nitrous oxide on the pharmacokinetics of propofol in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8230404/),[ml] / [kg·min],58.6,26146,DB00818,Propofol
,8230404,clearance,"The elimination half-life was long in both groups (90.9 min and 75.2 min, respectively), the volume of distribution at steady state large (4889 and 4863 ml/kg) and the clearance rapid (58.6 and 56.3 ml/kg.min).",The effects of halothane and nitrous oxide on the pharmacokinetics of propofol in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8230404/),[ml] / [kg·min],56.3,26147,DB00818,Propofol
,8735509,duration,"The mean (SD) duration of anaesthesia was 64.8 (3.1) minutes for group 1 and 60 (0) minutes for group 2; the mean total dose of propofol given to the sheep in group 1 was 801 (84) mg, and the sheep in group 2 received 470 (46) mg of propofol and 267 (30) mg of ketamine.","Pharmacokinetics of propofol infusions, either alone or with ketamine, in sheep premedicated with acepromazine and papaveretum. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735509/),min,64.8,26609,DB00818,Propofol
,8735509,duration,"The mean (SD) duration of anaesthesia was 64.8 (3.1) minutes for group 1 and 60 (0) minutes for group 2; the mean total dose of propofol given to the sheep in group 1 was 801 (84) mg, and the sheep in group 2 received 470 (46) mg of propofol and 267 (30) mg of ketamine.","Pharmacokinetics of propofol infusions, either alone or with ketamine, in sheep premedicated with acepromazine and papaveretum. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735509/),min,60,26610,DB00818,Propofol
,8735509,elimination half-life,"The mean elimination half-life of propofol was 56.6 (13.1) minutes in group 1 and 50.3 (21.4) minutes in group 2; the mean volume of distribution at steady state was 1.037 (0.480) litre kg-1 in group 1 and 1.515 (0.939) litre kg-1 in group 2; the mean body clearance was 85.4 (28.0) ml kg-1 min-1 in group 1 and 128.0 (35.0) ml kg-1 min-1 in group 2; the mean residence time corrected for a bolus injection was 12.1 (4.2) minutes in group 1 and 11.9 (6.6) minutes in group 2; for the infusion, the mean residence time was 72.1 (4.2) minutes in group 1 and 69.9 (7.9) minutes in group 2.","Pharmacokinetics of propofol infusions, either alone or with ketamine, in sheep premedicated with acepromazine and papaveretum. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735509/),min,56.6,26611,DB00818,Propofol
,8735509,elimination half-life,"The mean elimination half-life of propofol was 56.6 (13.1) minutes in group 1 and 50.3 (21.4) minutes in group 2; the mean volume of distribution at steady state was 1.037 (0.480) litre kg-1 in group 1 and 1.515 (0.939) litre kg-1 in group 2; the mean body clearance was 85.4 (28.0) ml kg-1 min-1 in group 1 and 128.0 (35.0) ml kg-1 min-1 in group 2; the mean residence time corrected for a bolus injection was 12.1 (4.2) minutes in group 1 and 11.9 (6.6) minutes in group 2; for the infusion, the mean residence time was 72.1 (4.2) minutes in group 1 and 69.9 (7.9) minutes in group 2.","Pharmacokinetics of propofol infusions, either alone or with ketamine, in sheep premedicated with acepromazine and papaveretum. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735509/),min,50.3,26612,DB00818,Propofol
,8735509,volume of distribution at steady state,"The mean elimination half-life of propofol was 56.6 (13.1) minutes in group 1 and 50.3 (21.4) minutes in group 2; the mean volume of distribution at steady state was 1.037 (0.480) litre kg-1 in group 1 and 1.515 (0.939) litre kg-1 in group 2; the mean body clearance was 85.4 (28.0) ml kg-1 min-1 in group 1 and 128.0 (35.0) ml kg-1 min-1 in group 2; the mean residence time corrected for a bolus injection was 12.1 (4.2) minutes in group 1 and 11.9 (6.6) minutes in group 2; for the infusion, the mean residence time was 72.1 (4.2) minutes in group 1 and 69.9 (7.9) minutes in group 2.","Pharmacokinetics of propofol infusions, either alone or with ketamine, in sheep premedicated with acepromazine and papaveretum. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735509/),[l] / [kg],1.037,26613,DB00818,Propofol
,8735509,volume of distribution at steady state,"The mean elimination half-life of propofol was 56.6 (13.1) minutes in group 1 and 50.3 (21.4) minutes in group 2; the mean volume of distribution at steady state was 1.037 (0.480) litre kg-1 in group 1 and 1.515 (0.939) litre kg-1 in group 2; the mean body clearance was 85.4 (28.0) ml kg-1 min-1 in group 1 and 128.0 (35.0) ml kg-1 min-1 in group 2; the mean residence time corrected for a bolus injection was 12.1 (4.2) minutes in group 1 and 11.9 (6.6) minutes in group 2; for the infusion, the mean residence time was 72.1 (4.2) minutes in group 1 and 69.9 (7.9) minutes in group 2.","Pharmacokinetics of propofol infusions, either alone or with ketamine, in sheep premedicated with acepromazine and papaveretum. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735509/),[l] / [kg],1.515,26614,DB00818,Propofol
,8735509,body clearance,"The mean elimination half-life of propofol was 56.6 (13.1) minutes in group 1 and 50.3 (21.4) minutes in group 2; the mean volume of distribution at steady state was 1.037 (0.480) litre kg-1 in group 1 and 1.515 (0.939) litre kg-1 in group 2; the mean body clearance was 85.4 (28.0) ml kg-1 min-1 in group 1 and 128.0 (35.0) ml kg-1 min-1 in group 2; the mean residence time corrected for a bolus injection was 12.1 (4.2) minutes in group 1 and 11.9 (6.6) minutes in group 2; for the infusion, the mean residence time was 72.1 (4.2) minutes in group 1 and 69.9 (7.9) minutes in group 2.","Pharmacokinetics of propofol infusions, either alone or with ketamine, in sheep premedicated with acepromazine and papaveretum. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735509/),[ml] / [kg·min],85.4,26615,DB00818,Propofol
,8735509,body clearance,"The mean elimination half-life of propofol was 56.6 (13.1) minutes in group 1 and 50.3 (21.4) minutes in group 2; the mean volume of distribution at steady state was 1.037 (0.480) litre kg-1 in group 1 and 1.515 (0.939) litre kg-1 in group 2; the mean body clearance was 85.4 (28.0) ml kg-1 min-1 in group 1 and 128.0 (35.0) ml kg-1 min-1 in group 2; the mean residence time corrected for a bolus injection was 12.1 (4.2) minutes in group 1 and 11.9 (6.6) minutes in group 2; for the infusion, the mean residence time was 72.1 (4.2) minutes in group 1 and 69.9 (7.9) minutes in group 2.","Pharmacokinetics of propofol infusions, either alone or with ketamine, in sheep premedicated with acepromazine and papaveretum. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735509/),[ml] / [kg·min],128.0,26616,DB00818,Propofol
,8735509,mean residence time,"The mean elimination half-life of propofol was 56.6 (13.1) minutes in group 1 and 50.3 (21.4) minutes in group 2; the mean volume of distribution at steady state was 1.037 (0.480) litre kg-1 in group 1 and 1.515 (0.939) litre kg-1 in group 2; the mean body clearance was 85.4 (28.0) ml kg-1 min-1 in group 1 and 128.0 (35.0) ml kg-1 min-1 in group 2; the mean residence time corrected for a bolus injection was 12.1 (4.2) minutes in group 1 and 11.9 (6.6) minutes in group 2; for the infusion, the mean residence time was 72.1 (4.2) minutes in group 1 and 69.9 (7.9) minutes in group 2.","Pharmacokinetics of propofol infusions, either alone or with ketamine, in sheep premedicated with acepromazine and papaveretum. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735509/),min,12.1,26617,DB00818,Propofol
,8735509,mean residence time,"The mean elimination half-life of propofol was 56.6 (13.1) minutes in group 1 and 50.3 (21.4) minutes in group 2; the mean volume of distribution at steady state was 1.037 (0.480) litre kg-1 in group 1 and 1.515 (0.939) litre kg-1 in group 2; the mean body clearance was 85.4 (28.0) ml kg-1 min-1 in group 1 and 128.0 (35.0) ml kg-1 min-1 in group 2; the mean residence time corrected for a bolus injection was 12.1 (4.2) minutes in group 1 and 11.9 (6.6) minutes in group 2; for the infusion, the mean residence time was 72.1 (4.2) minutes in group 1 and 69.9 (7.9) minutes in group 2.","Pharmacokinetics of propofol infusions, either alone or with ketamine, in sheep premedicated with acepromazine and papaveretum. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735509/),min,11.9,26618,DB00818,Propofol
,8735509,mean residence time,"The mean elimination half-life of propofol was 56.6 (13.1) minutes in group 1 and 50.3 (21.4) minutes in group 2; the mean volume of distribution at steady state was 1.037 (0.480) litre kg-1 in group 1 and 1.515 (0.939) litre kg-1 in group 2; the mean body clearance was 85.4 (28.0) ml kg-1 min-1 in group 1 and 128.0 (35.0) ml kg-1 min-1 in group 2; the mean residence time corrected for a bolus injection was 12.1 (4.2) minutes in group 1 and 11.9 (6.6) minutes in group 2; for the infusion, the mean residence time was 72.1 (4.2) minutes in group 1 and 69.9 (7.9) minutes in group 2.","Pharmacokinetics of propofol infusions, either alone or with ketamine, in sheep premedicated with acepromazine and papaveretum. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735509/),min,72.1,26619,DB00818,Propofol
,8735509,mean residence time,"The mean elimination half-life of propofol was 56.6 (13.1) minutes in group 1 and 50.3 (21.4) minutes in group 2; the mean volume of distribution at steady state was 1.037 (0.480) litre kg-1 in group 1 and 1.515 (0.939) litre kg-1 in group 2; the mean body clearance was 85.4 (28.0) ml kg-1 min-1 in group 1 and 128.0 (35.0) ml kg-1 min-1 in group 2; the mean residence time corrected for a bolus injection was 12.1 (4.2) minutes in group 1 and 11.9 (6.6) minutes in group 2; for the infusion, the mean residence time was 72.1 (4.2) minutes in group 1 and 69.9 (7.9) minutes in group 2.","Pharmacokinetics of propofol infusions, either alone or with ketamine, in sheep premedicated with acepromazine and papaveretum. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735509/),min,69.9,26620,DB00818,Propofol
,8735509,times to extubation,"All the sheep recovered quickly from anaesthesia; the mean times to extubation, sternal recumbency and standing for the animals in group 1 were 2.8 (0.4), 6.3 (1.2) and 10.9 (1.6) minutes from the end of the infusion, and the times for group 2 were 5.3 (0.9), 11.2 (1.7) and 15.1 (2.2) minutes.","Pharmacokinetics of propofol infusions, either alone or with ketamine, in sheep premedicated with acepromazine and papaveretum. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735509/),min,2.8,26621,DB00818,Propofol
,8735509,times to extubation,"All the sheep recovered quickly from anaesthesia; the mean times to extubation, sternal recumbency and standing for the animals in group 1 were 2.8 (0.4), 6.3 (1.2) and 10.9 (1.6) minutes from the end of the infusion, and the times for group 2 were 5.3 (0.9), 11.2 (1.7) and 15.1 (2.2) minutes.","Pharmacokinetics of propofol infusions, either alone or with ketamine, in sheep premedicated with acepromazine and papaveretum. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735509/),min,6.3,26622,DB00818,Propofol
,8735509,times to extubation,"All the sheep recovered quickly from anaesthesia; the mean times to extubation, sternal recumbency and standing for the animals in group 1 were 2.8 (0.4), 6.3 (1.2) and 10.9 (1.6) minutes from the end of the infusion, and the times for group 2 were 5.3 (0.9), 11.2 (1.7) and 15.1 (2.2) minutes.","Pharmacokinetics of propofol infusions, either alone or with ketamine, in sheep premedicated with acepromazine and papaveretum. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735509/),min,10.9,26623,DB00818,Propofol
,8735509,times to extubation,"All the sheep recovered quickly from anaesthesia; the mean times to extubation, sternal recumbency and standing for the animals in group 1 were 2.8 (0.4), 6.3 (1.2) and 10.9 (1.6) minutes from the end of the infusion, and the times for group 2 were 5.3 (0.9), 11.2 (1.7) and 15.1 (2.2) minutes.","Pharmacokinetics of propofol infusions, either alone or with ketamine, in sheep premedicated with acepromazine and papaveretum. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735509/),min,5.3,26624,DB00818,Propofol
,8735509,times,"All the sheep recovered quickly from anaesthesia; the mean times to extubation, sternal recumbency and standing for the animals in group 1 were 2.8 (0.4), 6.3 (1.2) and 10.9 (1.6) minutes from the end of the infusion, and the times for group 2 were 5.3 (0.9), 11.2 (1.7) and 15.1 (2.2) minutes.","Pharmacokinetics of propofol infusions, either alone or with ketamine, in sheep premedicated with acepromazine and papaveretum. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735509/),min,5.3,26625,DB00818,Propofol
,8735509,times,"All the sheep recovered quickly from anaesthesia; the mean times to extubation, sternal recumbency and standing for the animals in group 1 were 2.8 (0.4), 6.3 (1.2) and 10.9 (1.6) minutes from the end of the infusion, and the times for group 2 were 5.3 (0.9), 11.2 (1.7) and 15.1 (2.2) minutes.","Pharmacokinetics of propofol infusions, either alone or with ketamine, in sheep premedicated with acepromazine and papaveretum. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735509/),min,11.2,26626,DB00818,Propofol
,8735509,times,"All the sheep recovered quickly from anaesthesia; the mean times to extubation, sternal recumbency and standing for the animals in group 1 were 2.8 (0.4), 6.3 (1.2) and 10.9 (1.6) minutes from the end of the infusion, and the times for group 2 were 5.3 (0.9), 11.2 (1.7) and 15.1 (2.2) minutes.","Pharmacokinetics of propofol infusions, either alone or with ketamine, in sheep premedicated with acepromazine and papaveretum. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735509/),min,15.1,26627,DB00818,Propofol
,26682512,effect site target,With an effect site target of 4 μg.,"The influence of target concentration, equilibration rate constant (ke0 ) and pharmacokinetic model on the initial propofol dose delivered in effect-site target-controlled infusion. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26682512/),μg,4,26727,DB00818,Propofol
,1540461,elimination half-lives,"Pharmacokinetic variables were similar in uraemic and control patients; mean elimination half-lives were 1638 (SD 340) min and 1714 (842) min, respectively.",Pharmacokinetics of propofol and haemodynamic changes during induction of anaesthesia in uraemic patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1540461/),min,1638,28932,DB00818,Propofol
,1540461,elimination half-lives,"Pharmacokinetic variables were similar in uraemic and control patients; mean elimination half-lives were 1638 (SD 340) min and 1714 (842) min, respectively.",Pharmacokinetics of propofol and haemodynamic changes during induction of anaesthesia in uraemic patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1540461/),min,1714,28933,DB00818,Propofol
,10582751,heart rate,Mean heart rate of all dogs varied from 52 to 140 beats/min during the infusion.,Total intravenous anesthesia in greyhounds: pharmacokinetics of propofol and fentanyl--a preliminary study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10582751/),[beats] / [min],52 to 140,28977,DB00818,Propofol
,10582751,times,"Mean times (+/- SEM), after termination of the propofol infusion, to return of spontaneous ventilation, extubation, head lift and standing for all dogs were 26 +/- 7, 30 +/- 7, 59 +/- 12, and 105 +/- 13 minutes, respectively.",Total intravenous anesthesia in greyhounds: pharmacokinetics of propofol and fentanyl--a preliminary study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10582751/),min,26,28978,DB00818,Propofol
,10582751,times,"Mean times (+/- SEM), after termination of the propofol infusion, to return of spontaneous ventilation, extubation, head lift and standing for all dogs were 26 +/- 7, 30 +/- 7, 59 +/- 12, and 105 +/- 13 minutes, respectively.",Total intravenous anesthesia in greyhounds: pharmacokinetics of propofol and fentanyl--a preliminary study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10582751/),min,30,28979,DB00818,Propofol
,10582751,times,"Mean times (+/- SEM), after termination of the propofol infusion, to return of spontaneous ventilation, extubation, head lift and standing for all dogs were 26 +/- 7, 30 +/- 7, 59 +/- 12, and 105 +/- 13 minutes, respectively.",Total intravenous anesthesia in greyhounds: pharmacokinetics of propofol and fentanyl--a preliminary study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10582751/),min,59,28980,DB00818,Propofol
,10582751,times,"Mean times (+/- SEM), after termination of the propofol infusion, to return of spontaneous ventilation, extubation, head lift and standing for all dogs were 26 +/- 7, 30 +/- 7, 59 +/- 12, and 105 +/- 13 minutes, respectively.",Total intravenous anesthesia in greyhounds: pharmacokinetics of propofol and fentanyl--a preliminary study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10582751/),min,105,28981,DB00818,Propofol
,10582751,Mean residence time (MRTinf),"Mean residence time (MRTinf) for propofol was 104.7 +/- 6.0 minutes, mean body clearance (Clb) was 53.35 +/- 0.005 mL/kg/min, and volume of distribution at steady state (Vdss) was 3.27 +/- 0.49 L/kg.",Total intravenous anesthesia in greyhounds: pharmacokinetics of propofol and fentanyl--a preliminary study. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10582751/),min,104.7,28982,DB00818,Propofol
,10582751,body clearance (Clb),"Mean residence time (MRTinf) for propofol was 104.7 +/- 6.0 minutes, mean body clearance (Clb) was 53.35 +/- 0.005 mL/kg/min, and volume of distribution at steady state (Vdss) was 3.27 +/- 0.49 L/kg.",Total intravenous anesthesia in greyhounds: pharmacokinetics of propofol and fentanyl--a preliminary study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10582751/),[ml] / [kg·min],53.35,28983,DB00818,Propofol
,10582751,volume of distribution at steady state (Vdss),"Mean residence time (MRTinf) for propofol was 104.7 +/- 6.0 minutes, mean body clearance (Clb) was 53.35 +/- 0.005 mL/kg/min, and volume of distribution at steady state (Vdss) was 3.27 +/- 0.49 L/kg.",Total intravenous anesthesia in greyhounds: pharmacokinetics of propofol and fentanyl--a preliminary study. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10582751/),[l] / [kg],3.27,28984,DB00818,Propofol
,10582751,Plasma concentration,Plasma concentration of fentanyl for seven dogs during the infusion varied from 1.22 to 4.54 ng/mL.,Total intravenous anesthesia in greyhounds: pharmacokinetics of propofol and fentanyl--a preliminary study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10582751/),[ng] / [ml],1.22 to 4.54,28985,DB00818,Propofol
,10582751,MRTinf,MRTinf for fentanyl was 111.3 +/- 5.7 minutes.,Total intravenous anesthesia in greyhounds: pharmacokinetics of propofol and fentanyl--a preliminary study. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10582751/),min,111.3,28986,DB00818,Propofol
,10582751,body clearance,Mean body clearance was 29.1 +/- 2.2 mL/kg/min and Vdss was 2.21 +/- 0.19 L/kg.,Total intravenous anesthesia in greyhounds: pharmacokinetics of propofol and fentanyl--a preliminary study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10582751/),[ml] / [kg·min],29.1,28987,DB00818,Propofol
,10582751,Vdss,Mean body clearance was 29.1 +/- 2.2 mL/kg/min and Vdss was 2.21 +/- 0.19 L/kg.,Total intravenous anesthesia in greyhounds: pharmacokinetics of propofol and fentanyl--a preliminary study. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10582751/),[l] / [kg],2.21,28988,DB00818,Propofol
,25928922,concentration,"Its concentration reached 13.8 ± 2.7 μg mL(-1) and 16.1 ± 2.1 μg mL(-1) at 12°C and 17°C, respectively, during the first minute of exposure.",Pharmacokinetics of propofol in rainbow trout following bath exposure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25928922/),[μg] / [ml],13.8,29985,DB00818,Propofol
,25928922,concentration,"Its concentration reached 13.8 ± 2.7 μg mL(-1) and 16.1 ± 2.1 μg mL(-1) at 12°C and 17°C, respectively, during the first minute of exposure.",Pharmacokinetics of propofol in rainbow trout following bath exposure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25928922/),[μg] / [ml],16.1,29986,DB00818,Propofol
,25928922,half-life time,"The half-life time of propofol was 1.5 h and 1.1 h at 12°C and 17°C, respectively.",Pharmacokinetics of propofol in rainbow trout following bath exposure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25928922/),h,1.5,29987,DB00818,Propofol
,25928922,half-life time,"The half-life time of propofol was 1.5 h and 1.1 h at 12°C and 17°C, respectively.",Pharmacokinetics of propofol in rainbow trout following bath exposure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25928922/),h,1.1,29988,DB00818,Propofol
,9345798,recovery time,The median therapeutic target blood propofol concentration was 2.5 micrograms/ml and the median recovery time was 9 minutes.,Computer controlled infusion of propofol for conscious sedation in dental treatment. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9345798/),min,9,32347,DB00818,Propofol
,27556962,clearance,The typical value of the propofol clearance (1.46 l/min) approximated the hepatic blood flow.,The pharmacokinetics of propofol in ICU patients undergoing long-term sedation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27556962/),[l] / [min],1.46,33800,DB00818,Propofol
,27556962,volume of distribution at steady state,"The volume of distribution at steady state was high and was equal to 955.1 l, which is consistent with other studies involving propofol in ICU patients.",The pharmacokinetics of propofol in ICU patients undergoing long-term sedation. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27556962/),l,955.1,33801,DB00818,Propofol
,31802534,infusion rate,The mean propofol infusion rate was significantly higher in patients not monitored by BIS scores than in those who were (5.44 ± 2.12 vs 4.76 ± 1.84 mg/kg/h; P = 0.016).,Target-controlled propofol infusion with or without bispectral index monitoring of sedation during advanced gastrointestinal endoscopy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31802534/),[mg] / [h·kg],5.44,34296,DB00818,Propofol
,31802534,infusion rate,The mean propofol infusion rate was significantly higher in patients not monitored by BIS scores than in those who were (5.44 ± 2.12 vs 4.76 ± 1.84 mg/kg/h; P = 0.016).,Target-controlled propofol infusion with or without bispectral index monitoring of sedation during advanced gastrointestinal endoscopy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31802534/),[mg] / [h·kg],4.76,34297,DB00818,Propofol
,21539423,volume of the central compartment,The typical volume of the central compartment equaled 7.67 L and depended on rabbit body weight.,Influence of time of day on propofol pharmacokinetics and pharmacodynamics in rabbits. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21539423/),l,7.67,35139,DB00818,Propofol
,21539423,rate constant,"Delay of the anesthetic effect, with respect to plasma concentrations, was described by the effect compartment, with the rate constant for the distribution to the effector compartment equal to 0.335 min(-1).",Influence of time of day on propofol pharmacokinetics and pharmacodynamics in rabbits. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21539423/),1/[min],0.335,35140,DB00818,Propofol
,21555936,target plasma concentration,"Propofol target plasma concentration was 7 μg/ml for 15 min, followed by 1 μg/ml for 15 min or until signs of awakening, followed by 5 μg/ml for 15 min.",An evaluation of using population pharmacokinetic models to estimate pharmacodynamic parameters for propofol and bispectral index in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21555936/),[μg] / [ml],7,35324,DB00818,Propofol
,12374713,steady-state serum concentration,"Half of the patients received propofol in an escalating fashion, initially targeting an estimated steady-state serum concentration of 3 microg x mL-1, which was then doubled.",Propofol decreases cerebral blood flow velocity in anesthetized children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12374713/),[μg] / [ml],3,36746,DB00818,Propofol
,15841152,Time to peak concentration,"Time to peak concentration of propofol in serum was about 1 min, and time to peak concentration of propofol in brain was about 3 min.",[Elimination half-life of propofol in effect-site of mice]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15841152/),min,1,36856,DB00818,Propofol
,15841152,time to peak concentration,"Time to peak concentration of propofol in serum was about 1 min, and time to peak concentration of propofol in brain was about 3 min.",[Elimination half-life of propofol in effect-site of mice]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15841152/),min,3,36857,DB00818,Propofol
,15841152,elimination half-life,The elimination half-life of propofol in brain were (9.6+/-0.5) mins.,[Elimination half-life of propofol in effect-site of mice]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15841152/),min,9.6,36858,DB00818,Propofol
,21040374,Respiratory,"Respiratory and heart rates were stable throughout the experiments (28-68 breaths minute(-1) and 72-144 beats minute(-1) , respectively).",Hypnotic effects and pharmacokinetics of a single bolus dose of propofol in Japanese macaques (Macaca fuscata fuscata). [corrected]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21040374/),[breaths] / [minute],28-68,36860,DB00818,Propofol
,21040374,heart rates,"Respiratory and heart rates were stable throughout the experiments (28-68 breaths minute(-1) and 72-144 beats minute(-1) , respectively).",Hypnotic effects and pharmacokinetics of a single bolus dose of propofol in Japanese macaques (Macaca fuscata fuscata). [corrected]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21040374/),[beats] / [minute],72-144,36861,DB00818,Propofol
,21040374,V(1),"The population pharmacokinetic parameters were: V(1)=10.4 L, V(2)=8.38 L, V(3)=72.7 L, CL(1)=0.442 L minute(-1), CL(2)=1.14 L minute(-1), CL(3)= 0.313 L minute(-1), (the volumes of distribution and the clearances for the central, rapid and slow peripheral compartments, respectively).",Hypnotic effects and pharmacokinetics of a single bolus dose of propofol in Japanese macaques (Macaca fuscata fuscata). [corrected]. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21040374/),l,10.4,36862,DB00818,Propofol
,21040374,V(2),"The population pharmacokinetic parameters were: V(1)=10.4 L, V(2)=8.38 L, V(3)=72.7 L, CL(1)=0.442 L minute(-1), CL(2)=1.14 L minute(-1), CL(3)= 0.313 L minute(-1), (the volumes of distribution and the clearances for the central, rapid and slow peripheral compartments, respectively).",Hypnotic effects and pharmacokinetics of a single bolus dose of propofol in Japanese macaques (Macaca fuscata fuscata). [corrected]. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21040374/),l,8.38,36863,DB00818,Propofol
,21040374,V(3),"The population pharmacokinetic parameters were: V(1)=10.4 L, V(2)=8.38 L, V(3)=72.7 L, CL(1)=0.442 L minute(-1), CL(2)=1.14 L minute(-1), CL(3)= 0.313 L minute(-1), (the volumes of distribution and the clearances for the central, rapid and slow peripheral compartments, respectively).",Hypnotic effects and pharmacokinetics of a single bolus dose of propofol in Japanese macaques (Macaca fuscata fuscata). [corrected]. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21040374/),l,72.7,36864,DB00818,Propofol
,21040374,CL(1),"The population pharmacokinetic parameters were: V(1)=10.4 L, V(2)=8.38 L, V(3)=72.7 L, CL(1)=0.442 L minute(-1), CL(2)=1.14 L minute(-1), CL(3)= 0.313 L minute(-1), (the volumes of distribution and the clearances for the central, rapid and slow peripheral compartments, respectively).",Hypnotic effects and pharmacokinetics of a single bolus dose of propofol in Japanese macaques (Macaca fuscata fuscata). [corrected]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21040374/),[l] / [minute],0.442,36865,DB00818,Propofol
,21040374,CL(2),"The population pharmacokinetic parameters were: V(1)=10.4 L, V(2)=8.38 L, V(3)=72.7 L, CL(1)=0.442 L minute(-1), CL(2)=1.14 L minute(-1), CL(3)= 0.313 L minute(-1), (the volumes of distribution and the clearances for the central, rapid and slow peripheral compartments, respectively).",Hypnotic effects and pharmacokinetics of a single bolus dose of propofol in Japanese macaques (Macaca fuscata fuscata). [corrected]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21040374/),[l] / [minute],1.14,36866,DB00818,Propofol
,21040374,CL(3),"The population pharmacokinetic parameters were: V(1)=10.4 L, V(2)=8.38 L, V(3)=72.7 L, CL(1)=0.442 L minute(-1), CL(2)=1.14 L minute(-1), CL(3)= 0.313 L minute(-1), (the volumes of distribution and the clearances for the central, rapid and slow peripheral compartments, respectively).",Hypnotic effects and pharmacokinetics of a single bolus dose of propofol in Japanese macaques (Macaca fuscata fuscata). [corrected]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21040374/),[l] / [minute],0.313,36867,DB00818,Propofol
,8126766,time to standing,Recovery times were rapid with a mean time to standing after halothane inhalation ceased of 13.7 min.,Propofol as an induction agent in the goat: a pharmacokinetic study. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8126766/),min,13.7,37604,DB00818,Propofol
,8126766,elimination half-life,"The mean elimination half-life was short (15.5 min), the volume of distribution at steady state large (2.56 l/kg) and the clearance rapid (275 ml/min.kg).",Propofol as an induction agent in the goat: a pharmacokinetic study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8126766/),min,15.5,37605,DB00818,Propofol
,8126766,volume of distribution at steady state,"The mean elimination half-life was short (15.5 min), the volume of distribution at steady state large (2.56 l/kg) and the clearance rapid (275 ml/min.kg).",Propofol as an induction agent in the goat: a pharmacokinetic study. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8126766/),[l] / [kg],2.56,37606,DB00818,Propofol
,8126766,clearance,"The mean elimination half-life was short (15.5 min), the volume of distribution at steady state large (2.56 l/kg) and the clearance rapid (275 ml/min.kg).",Propofol as an induction agent in the goat: a pharmacokinetic study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8126766/),[ml] / [kg·min],275,37607,DB00818,Propofol
,30327545,kr,"The parameter estimates were as follows: kr (mL/min) = 124 + (MAP/70)14.2, Vc0 (mL) = 0.95 + 3440 × (WT/63), Vt0 (mL) = 2730, and kt (mL/min) = 181.",Population-based volume kinetics of Ringer's lactate solution in patients undergoing open gastrectomy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30327545/),[ml] / [min],14.2,39398,DB00818,Propofol
,30327545,Vt0,"The parameter estimates were as follows: kr (mL/min) = 124 + (MAP/70)14.2, Vc0 (mL) = 0.95 + 3440 × (WT/63), Vt0 (mL) = 2730, and kt (mL/min) = 181.",Population-based volume kinetics of Ringer's lactate solution in patients undergoing open gastrectomy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30327545/),ml,2730,39399,DB00818,Propofol
,30327545,kt,"The parameter estimates were as follows: kr (mL/min) = 124 + (MAP/70)14.2, Vc0 (mL) = 0.95 + 3440 × (WT/63), Vt0 (mL) = 2730, and kt (mL/min) = 181.",Population-based volume kinetics of Ringer's lactate solution in patients undergoing open gastrectomy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30327545/),[ml] / [min],181,39400,DB00818,Propofol
,7482686,initial distribution phase t1/2 pi,"The pharmacokinetic parameters were as follows: The mean (SD) of the initial distribution phase t1/2 pi, intermediate distribution phase t1/2 alpha, and elimination phase t1/2 beta were 2.22 (1.04) min, 42.9 (16.4) min, and 370 (138) min, respectively.",Pharmacokinetics of propofol infusion in Asian patients undergoing coronary artery bypass grafting. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7482686/),min,2.22,39406,DB00818,Propofol
,7482686,intermediate distribution phase t1/2 alpha,"The pharmacokinetic parameters were as follows: The mean (SD) of the initial distribution phase t1/2 pi, intermediate distribution phase t1/2 alpha, and elimination phase t1/2 beta were 2.22 (1.04) min, 42.9 (16.4) min, and 370 (138) min, respectively.",Pharmacokinetics of propofol infusion in Asian patients undergoing coronary artery bypass grafting. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7482686/),min,42.9,39407,DB00818,Propofol
,7482686,elimination phase t1/2 beta,"The pharmacokinetic parameters were as follows: The mean (SD) of the initial distribution phase t1/2 pi, intermediate distribution phase t1/2 alpha, and elimination phase t1/2 beta were 2.22 (1.04) min, 42.9 (16.4) min, and 370 (138) min, respectively.",Pharmacokinetics of propofol infusion in Asian patients undergoing coronary artery bypass grafting. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7482686/),min,370,39408,DB00818,Propofol
,7482686,clearance,"The mean clearance of 1.31 (0.50) L/min was lower than those reported from other studies, whereas the mean blood concentration of 2.2 (1.0) mg/L at the 1-h infusion period was higher.",Pharmacokinetics of propofol infusion in Asian patients undergoing coronary artery bypass grafting. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7482686/),[l] / [min],1.31,39409,DB00818,Propofol
,7482686,blood concentration,"The mean clearance of 1.31 (0.50) L/min was lower than those reported from other studies, whereas the mean blood concentration of 2.2 (1.0) mg/L at the 1-h infusion period was higher.",Pharmacokinetics of propofol infusion in Asian patients undergoing coronary artery bypass grafting. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7482686/),mg,2.2,39410,DB00818,Propofol
,7482686,apparent Css,The mean calculated apparent Css was 3.9 (1.5) mg/L.,Pharmacokinetics of propofol infusion in Asian patients undergoing coronary artery bypass grafting. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7482686/),[mg] / [l],3.9,39411,DB00818,Propofol
,20876699,T₄/T₁ ratio,The primary efficacy variable was time from the start of sugammadex administration to recovery of T₄/T₁ ratio to 0.9.,Sugammadex rapidly reverses moderate rocuronium- or vecuronium-induced neuromuscular block during sevoflurane anaesthesia: a dose-response relationship. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20876699/),,0.9,40194,DB00818,Propofol
,20876699,recovery times of T₄/T₁ ratio,"A statistically significant dose-response relationship was demonstrated for mean recovery times of T₄/T₁ ratio to 0.9 with increasing sugammadex dose with both NMBAs: rocuronium, 96.3 min (placebo) to 1.5 min (sugammadex 4.0 mg kg⁻¹); vecuronium, 79.0 min (placebo) to 3.0 min (sugammadex 4.0 mg kg⁻¹).",Sugammadex rapidly reverses moderate rocuronium- or vecuronium-induced neuromuscular block during sevoflurane anaesthesia: a dose-response relationship. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20876699/),min,0.9,40195,DB00818,Propofol
,20876699,recovery times of T₄/T₁ ratio,"A statistically significant dose-response relationship was demonstrated for mean recovery times of T₄/T₁ ratio to 0.9 with increasing sugammadex dose with both NMBAs: rocuronium, 96.3 min (placebo) to 1.5 min (sugammadex 4.0 mg kg⁻¹); vecuronium, 79.0 min (placebo) to 3.0 min (sugammadex 4.0 mg kg⁻¹).",Sugammadex rapidly reverses moderate rocuronium- or vecuronium-induced neuromuscular block during sevoflurane anaesthesia: a dose-response relationship. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20876699/),min,96.3,40196,DB00818,Propofol
,20876699,recovery times of T₄/T₁ ratio,"A statistically significant dose-response relationship was demonstrated for mean recovery times of T₄/T₁ ratio to 0.9 with increasing sugammadex dose with both NMBAs: rocuronium, 96.3 min (placebo) to 1.5 min (sugammadex 4.0 mg kg⁻¹); vecuronium, 79.0 min (placebo) to 3.0 min (sugammadex 4.0 mg kg⁻¹).",Sugammadex rapidly reverses moderate rocuronium- or vecuronium-induced neuromuscular block during sevoflurane anaesthesia: a dose-response relationship. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20876699/),min,1.5,40197,DB00818,Propofol
,20876699,recovery times of T₄/T₁ ratio,"A statistically significant dose-response relationship was demonstrated for mean recovery times of T₄/T₁ ratio to 0.9 with increasing sugammadex dose with both NMBAs: rocuronium, 96.3 min (placebo) to 1.5 min (sugammadex 4.0 mg kg⁻¹); vecuronium, 79.0 min (placebo) to 3.0 min (sugammadex 4.0 mg kg⁻¹).",Sugammadex rapidly reverses moderate rocuronium- or vecuronium-induced neuromuscular block during sevoflurane anaesthesia: a dose-response relationship. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20876699/),min,79.0,40198,DB00818,Propofol
,20876699,recovery times of T₄/T₁ ratio,"A statistically significant dose-response relationship was demonstrated for mean recovery times of T₄/T₁ ratio to 0.9 with increasing sugammadex dose with both NMBAs: rocuronium, 96.3 min (placebo) to 1.5 min (sugammadex 4.0 mg kg⁻¹); vecuronium, 79.0 min (placebo) to 3.0 min (sugammadex 4.0 mg kg⁻¹).",Sugammadex rapidly reverses moderate rocuronium- or vecuronium-induced neuromuscular block during sevoflurane anaesthesia: a dose-response relationship. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20876699/),min,3.0,40199,DB00818,Propofol
,30208893,VTI,"The median (range) VTI and VTI*HR were similar at the two time points [11.9(8.1-17.3) vs 13,3(9,4-16,5) cm, and 1172(806-1554) vs 1002(630-1159) cm*bpm, respectively].",Haemodynamic changes during propofol induction in dogs: new findings and approach of monitoring. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30208893/),cm,11.9,40762,DB00818,Propofol
,30208893,VTI*HR,"The median (range) VTI and VTI*HR were similar at the two time points [11.9(8.1-17.3) vs 13,3(9,4-16,5) cm, and 1172(806-1554) vs 1002(630-1159) cm*bpm, respectively].",Haemodynamic changes during propofol induction in dogs: new findings and approach of monitoring. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30208893/),bpm·cm,1172,40763,DB00818,Propofol
,30208893,VTI*HR,"The median (range) VTI and VTI*HR were similar at the two time points [11.9(8.1-17.3) vs 13,3(9,4-16,5) cm, and 1172(806-1554) vs 1002(630-1159) cm*bpm, respectively].",Haemodynamic changes during propofol induction in dogs: new findings and approach of monitoring. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30208893/),bpm·cm,1002,40764,DB00818,Propofol
,27227503,Maximum bupivacaine plasma concentration,"Maximum bupivacaine plasma concentration was 1,030 ± 497.5 ng/mL at a mean ± SD value of 30 ± 24 minutes after administration.",Pharmacokinetics of bupivacaine after intraperitoneal administration to cats undergoing ovariohysterectomy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27227503/),[ng] / [ml],"1,030",40903,DB00818,Propofol
,27227503,elimination half-life,Mean elimination half-life was 4.79 ± 2.7 hours.,Pharmacokinetics of bupivacaine after intraperitoneal administration to cats undergoing ovariohysterectomy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27227503/),h,4.79,40904,DB00818,Propofol
,27227503,clearance,"Mean clearance indexed by bioavailability and volume of distribution indexed by bioavailability were 0.35 ± 0.18 L•h/kg and 2.10 ± 0.84 L/kg, respectively.",Pharmacokinetics of bupivacaine after intraperitoneal administration to cats undergoing ovariohysterectomy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27227503/),[h·l] / [kg],0.35,40905,DB00818,Propofol
,27227503,volume of distribution,"Mean clearance indexed by bioavailability and volume of distribution indexed by bioavailability were 0.35 ± 0.18 L•h/kg and 2.10 ± 0.84 L/kg, respectively.",Pharmacokinetics of bupivacaine after intraperitoneal administration to cats undergoing ovariohysterectomy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27227503/),[h·l] / [kg],0.35,40906,DB00818,Propofol
,27227503,volume of distribution,"Mean clearance indexed by bioavailability and volume of distribution indexed by bioavailability were 0.35 ± 0.18 L•h/kg and 2.10 ± 0.84 L/kg, respectively.",Pharmacokinetics of bupivacaine after intraperitoneal administration to cats undergoing ovariohysterectomy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27227503/),[l] / [kg],2.10,40907,DB00818,Propofol
,8291699,central compartment (V1),The pharmacokinetic parameters of the weight-proportional pharmacokinetic model (pooled-data approach) were: central compartment (V1) = 0.52 1 x kg-1; rapid-distribution compartment (V2) = 1.01 x kg-1; slow-distribution compartment (V3) = 8.2 1 x kg-1; metabolic clearance (Cl1) = 34 ml.,The pharmacokinetics of propofol in children using three different data analysis approaches. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8291699/),[1] / [kg],0.52,41305,DB00818,Propofol
,8291699,rapid-distribution compartment (V2),The pharmacokinetic parameters of the weight-proportional pharmacokinetic model (pooled-data approach) were: central compartment (V1) = 0.52 1 x kg-1; rapid-distribution compartment (V2) = 1.01 x kg-1; slow-distribution compartment (V3) = 8.2 1 x kg-1; metabolic clearance (Cl1) = 34 ml.,The pharmacokinetics of propofol in children using three different data analysis approaches. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8291699/),1/[kg],1.01,41306,DB00818,Propofol
,8291699,slow-distribution compartment (V3),The pharmacokinetic parameters of the weight-proportional pharmacokinetic model (pooled-data approach) were: central compartment (V1) = 0.52 1 x kg-1; rapid-distribution compartment (V2) = 1.01 x kg-1; slow-distribution compartment (V3) = 8.2 1 x kg-1; metabolic clearance (Cl1) = 34 ml.,The pharmacokinetics of propofol in children using three different data analysis approaches. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8291699/),[1] / [kg],8.2,41307,DB00818,Propofol
,8291699,metabolic clearance (Cl1),The pharmacokinetic parameters of the weight-proportional pharmacokinetic model (pooled-data approach) were: central compartment (V1) = 0.52 1 x kg-1; rapid-distribution compartment (V2) = 1.01 x kg-1; slow-distribution compartment (V3) = 8.2 1 x kg-1; metabolic clearance (Cl1) = 34 ml.,The pharmacokinetics of propofol in children using three different data analysis approaches. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8291699/),ml,34,41308,DB00818,Propofol
,8291699,rapid-distribution clearance (Cl2),kg-1 x min-1; rapid-distribution clearance (Cl2) = 58 ml.kg-1 x min-1; and slow-distribution clearance (Cl3) = 26 ml.kg-1 x min-1.,The pharmacokinetics of propofol in children using three different data analysis approaches. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8291699/),[ml] / [kg·min],58,41309,DB00818,Propofol
,8291699,slow-distribution clearance (Cl3),kg-1 x min-1; rapid-distribution clearance (Cl2) = 58 ml.kg-1 x min-1; and slow-distribution clearance (Cl3) = 26 ml.kg-1 x min-1.,The pharmacokinetics of propofol in children using three different data analysis approaches. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8291699/),[ml] / [kg·min],26,41310,DB00818,Propofol
below,34365190,detection limits,The developed methods provided detection limits below 100 ng L-1 for all target analytes and high precision (below 4% RSD intraday).,"Quantitative analysis of human brain microdialysate for target site pharmacokinetics of major anesthetics ketamine, midazolam and propofol. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34365190/),[ng] / [l],100,41389,DB00818,Propofol
,31325395,steady state concentrations,Simulated steady state concentrations were 6-8 µg.,A manual propofol infusion regimen for neonates and infants. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31325395/),μg,6-8,42070,DB00818,Propofol
,31325395,steady-state concentration,A new manual infusion regimen for propofol that achieves a steady-state concentration of 3 µg.,A manual propofol infusion regimen for neonates and infants. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31325395/),μg,3,42071,DB00818,Propofol
,31325395,steady-state plasma concentration,A manual dosing regimen predicted to achieve steady-state plasma concentration of 3 µg.,A manual propofol infusion regimen for neonates and infants. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31325395/),μg,3,42072,DB00818,Propofol
,31325395,clearance,Propofol clearance increases throughout infancy to reach 92% that reported in adults (1.93 L.min.70 kg-1 ) by 6 months postnatal age and infusion regimens should reflect clearance maturation and be cognizant of adverse effects from concentrations greater than the target plasma concentration.,A manual propofol infusion regimen for neonates and infants. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31325395/),[l·min] / [70·kg],1.93,42073,DB00818,Propofol
,34139982,V1,"For the height of 162cm, the final pharmacokinetic parameter values were as follows: V1=1.42 (95% CI, 1.01-1.83, L), V2=5.52 (95% CI, 4.07-6.97, L), V3=63.9 (95% CI, 41.95-85.85, L), Cl1= 1.30 (95% CI, 1.19-1.41, L/min), Cl2= 1.21 (95%CI, 0.95-1.47, L/min), and Cl3=0.584 (95%CI, 0.95-1.21, L/min), respectively.",Obstructive Jaundice doesn't Change the Population Pharmacokinetics of Etomidate in Patients who Underwent Bile Duct Surgery. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34139982/),l,1.42,42331,DB00818,Propofol
,34139982,V2,"For the height of 162cm, the final pharmacokinetic parameter values were as follows: V1=1.42 (95% CI, 1.01-1.83, L), V2=5.52 (95% CI, 4.07-6.97, L), V3=63.9 (95% CI, 41.95-85.85, L), Cl1= 1.30 (95% CI, 1.19-1.41, L/min), Cl2= 1.21 (95%CI, 0.95-1.47, L/min), and Cl3=0.584 (95%CI, 0.95-1.21, L/min), respectively.",Obstructive Jaundice doesn't Change the Population Pharmacokinetics of Etomidate in Patients who Underwent Bile Duct Surgery. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34139982/),l,5.52,42332,DB00818,Propofol
,34139982,V3,"For the height of 162cm, the final pharmacokinetic parameter values were as follows: V1=1.42 (95% CI, 1.01-1.83, L), V2=5.52 (95% CI, 4.07-6.97, L), V3=63.9 (95% CI, 41.95-85.85, L), Cl1= 1.30 (95% CI, 1.19-1.41, L/min), Cl2= 1.21 (95%CI, 0.95-1.47, L/min), and Cl3=0.584 (95%CI, 0.95-1.21, L/min), respectively.",Obstructive Jaundice doesn't Change the Population Pharmacokinetics of Etomidate in Patients who Underwent Bile Duct Surgery. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34139982/),l,63.9,42333,DB00818,Propofol
,34139982,Cl1,"For the height of 162cm, the final pharmacokinetic parameter values were as follows: V1=1.42 (95% CI, 1.01-1.83, L), V2=5.52 (95% CI, 4.07-6.97, L), V3=63.9 (95% CI, 41.95-85.85, L), Cl1= 1.30 (95% CI, 1.19-1.41, L/min), Cl2= 1.21 (95%CI, 0.95-1.47, L/min), and Cl3=0.584 (95%CI, 0.95-1.21, L/min), respectively.",Obstructive Jaundice doesn't Change the Population Pharmacokinetics of Etomidate in Patients who Underwent Bile Duct Surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34139982/),[l] / [min],1.30,42334,DB00818,Propofol
,34139982,Cl2,"For the height of 162cm, the final pharmacokinetic parameter values were as follows: V1=1.42 (95% CI, 1.01-1.83, L), V2=5.52 (95% CI, 4.07-6.97, L), V3=63.9 (95% CI, 41.95-85.85, L), Cl1= 1.30 (95% CI, 1.19-1.41, L/min), Cl2= 1.21 (95%CI, 0.95-1.47, L/min), and Cl3=0.584 (95%CI, 0.95-1.21, L/min), respectively.",Obstructive Jaundice doesn't Change the Population Pharmacokinetics of Etomidate in Patients who Underwent Bile Duct Surgery. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34139982/),[l] / [min],1.21,42335,DB00818,Propofol
,34139982,Cl3,"For the height of 162cm, the final pharmacokinetic parameter values were as follows: V1=1.42 (95% CI, 1.01-1.83, L), V2=5.52 (95% CI, 4.07-6.97, L), V3=63.9 (95% CI, 41.95-85.85, L), Cl1= 1.30 (95% CI, 1.19-1.41, L/min), Cl2= 1.21 (95%CI, 0.95-1.47, L/min), and Cl3=0.584 (95%CI, 0.95-1.21, L/min), respectively.",Obstructive Jaundice doesn't Change the Population Pharmacokinetics of Etomidate in Patients who Underwent Bile Duct Surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34139982/),[l] / [min],0.584,42336,DB00818,Propofol
,28541533,effect-site concentrations (Ces),"The target effect-site concentrations (Ces) of propofol were, in order, 2.5, 3, 4, 5, 6 and 2 μg ml -1 .",Predictive performance of the modified Marsh and Schnider models for propofol in underweight patients undergoing general anaesthesia using target-controlled infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28541533/),-1·ml·μg,2.5,42834,DB00818,Propofol
,28541533,effect-site concentrations (Ces),"The target effect-site concentrations (Ces) of propofol were, in order, 2.5, 3, 4, 5, 6 and 2 μg ml -1 .",Predictive performance of the modified Marsh and Schnider models for propofol in underweight patients undergoing general anaesthesia using target-controlled infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28541533/),-1·ml·μg,3,42835,DB00818,Propofol
,28541533,effect-site concentrations (Ces),"The target effect-site concentrations (Ces) of propofol were, in order, 2.5, 3, 4, 5, 6 and 2 μg ml -1 .",Predictive performance of the modified Marsh and Schnider models for propofol in underweight patients undergoing general anaesthesia using target-controlled infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28541533/),-1·ml·μg,4,42836,DB00818,Propofol
,28541533,effect-site concentrations (Ces),"The target effect-site concentrations (Ces) of propofol were, in order, 2.5, 3, 4, 5, 6 and 2 μg ml -1 .",Predictive performance of the modified Marsh and Schnider models for propofol in underweight patients undergoing general anaesthesia using target-controlled infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28541533/),-1·ml·μg,5,42837,DB00818,Propofol
,28541533,effect-site concentrations (Ces),"The target effect-site concentrations (Ces) of propofol were, in order, 2.5, 3, 4, 5, 6 and 2 μg ml -1 .",Predictive performance of the modified Marsh and Schnider models for propofol in underweight patients undergoing general anaesthesia using target-controlled infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28541533/),-1·ml·μg,6,42838,DB00818,Propofol
,28541533,effect-site concentrations (Ces),"The target effect-site concentrations (Ces) of propofol were, in order, 2.5, 3, 4, 5, 6 and 2 μg ml -1 .",Predictive performance of the modified Marsh and Schnider models for propofol in underweight patients undergoing general anaesthesia using target-controlled infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28541533/),-1·ml·μg,2,42839,DB00818,Propofol
≤,28541533,Ce,"The pooled median (95% confidence interval) biases and inaccuracies at a target Ce ≤ 3 μg ml -1 were -22.6 (-28.8 to -12.6) and 31.9 (24.8-36.8) for the M-Marsh model and 9.0 (1.7-16.4) and 28.5 (21.7-32.8) for the Schnider model, respectively.",Predictive performance of the modified Marsh and Schnider models for propofol in underweight patients undergoing general anaesthesia using target-controlled infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28541533/),-1·ml·μg,3,42840,DB00818,Propofol
≥,28541533,Ce,"These values at Ce ≥ 4 μg ml -1 were -9.6 (-16.0 to -6.0) and 24.7 (21.1-27.9) for the M-Marsh model and 19.8 (12.9-25.7) and 36.2 (31.4-39.7) for the Schnider model, respectively.",Predictive performance of the modified Marsh and Schnider models for propofol in underweight patients undergoing general anaesthesia using target-controlled infusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28541533/),-1·ml·μg,4,42841,DB00818,Propofol
,28541533,Ce,"These values at Ce ≥ 4 μg ml -1 were -9.6 (-16.0 to -6.0) and 24.7 (21.1-27.9) for the M-Marsh model and 19.8 (12.9-25.7) and 36.2 (31.4-39.7) for the Schnider model, respectively.",Predictive performance of the modified Marsh and Schnider models for propofol in underweight patients undergoing general anaesthesia using target-controlled infusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28541533/),-1·ml·μg,24.7,42842,DB00818,Propofol
,28541533,Ce,"These values at Ce ≥ 4 μg ml -1 were -9.6 (-16.0 to -6.0) and 24.7 (21.1-27.9) for the M-Marsh model and 19.8 (12.9-25.7) and 36.2 (31.4-39.7) for the Schnider model, respectively.",Predictive performance of the modified Marsh and Schnider models for propofol in underweight patients undergoing general anaesthesia using target-controlled infusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28541533/),-1·ml·μg,19.8,42843,DB00818,Propofol
,28541533,Ce,"These values at Ce ≥ 4 μg ml -1 were -9.6 (-16.0 to -6.0) and 24.7 (21.1-27.9) for the M-Marsh model and 19.8 (12.9-25.7) and 36.2 (31.4-39.7) for the Schnider model, respectively.",Predictive performance of the modified Marsh and Schnider models for propofol in underweight patients undergoing general anaesthesia using target-controlled infusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28541533/),,36.2,42844,DB00818,Propofol
≤,28541533,Ce,"In particular, the M-Marsh model showed greater inaccuracy at target Ce ≤ 3 μg ml -1 and the Schnider model showed greater inaccuracy at target Ce ≥ 4 μg ml -1 .",Predictive performance of the modified Marsh and Schnider models for propofol in underweight patients undergoing general anaesthesia using target-controlled infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28541533/),-1·ml·μg,3,42845,DB00818,Propofol
≥,28541533,Ce,"In particular, the M-Marsh model showed greater inaccuracy at target Ce ≤ 3 μg ml -1 and the Schnider model showed greater inaccuracy at target Ce ≥ 4 μg ml -1 .",Predictive performance of the modified Marsh and Schnider models for propofol in underweight patients undergoing general anaesthesia using target-controlled infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28541533/),-1·ml·μg,4,42846,DB00818,Propofol
,27236490,clearance,"Propofol clearance, intercompartmental clearance, and central volume of distribution were 805 mL/min, 1140 mL/min and 18.8 L, respectively.",Obesity Does Not Affect Propofol Pharmacokinetics During Hypothermic Cardiopulmonary Bypass. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27236490/),[ml] / [min],805,43176,DB00818,Propofol
,27236490,intercompartmental clearance,"Propofol clearance, intercompartmental clearance, and central volume of distribution were 805 mL/min, 1140 mL/min and 18.8 L, respectively.",Obesity Does Not Affect Propofol Pharmacokinetics During Hypothermic Cardiopulmonary Bypass. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27236490/),[ml] / [min],1140,43177,DB00818,Propofol
,27236490,central volume of distribution,"Propofol clearance, intercompartmental clearance, and central volume of distribution were 805 mL/min, 1140 mL/min and 18.8 L, respectively.",Obesity Does Not Affect Propofol Pharmacokinetics During Hypothermic Cardiopulmonary Bypass. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27236490/),l,18.8,43178,DB00818,Propofol
,27236490,V2,V2 was calculated as 9.86×exp.(1.88×[age/40]) L.,Obesity Does Not Affect Propofol Pharmacokinetics During Hypothermic Cardiopulmonary Bypass. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27236490/),l,9.86,43179,DB00818,Propofol
,8750122,central compartment distribution volume (V1),ICU long-term infusion population pharmacokinetics (open three-compartment model) revealed for propofol: central compartment distribution volume (V1): 31.2 +/- 5.3 l; steady-state distribution volume (Vdss): 499 +/- 173 l; total clearance (Cltot): 1001- +/- 150 ml/min; redistribution half-life (t1/2 gamma): 90 +/- 23 min; elimination half-life (t1/2 beta): 558 +/- 218 minutes.,Pharmacokinetics and pharmacodynamics of propofol/alfentanil infusions for sedation in ICU patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8750122/),l,31.2,43540,DB00818,Propofol
,8750122,steady-state distribution volume (Vdss),ICU long-term infusion population pharmacokinetics (open three-compartment model) revealed for propofol: central compartment distribution volume (V1): 31.2 +/- 5.3 l; steady-state distribution volume (Vdss): 499 +/- 173 l; total clearance (Cltot): 1001- +/- 150 ml/min; redistribution half-life (t1/2 gamma): 90 +/- 23 min; elimination half-life (t1/2 beta): 558 +/- 218 minutes.,Pharmacokinetics and pharmacodynamics of propofol/alfentanil infusions for sedation in ICU patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8750122/),l,499,43541,DB00818,Propofol
,8750122,total clearance (Cltot),ICU long-term infusion population pharmacokinetics (open three-compartment model) revealed for propofol: central compartment distribution volume (V1): 31.2 +/- 5.3 l; steady-state distribution volume (Vdss): 499 +/- 173 l; total clearance (Cltot): 1001- +/- 150 ml/min; redistribution half-life (t1/2 gamma): 90 +/- 23 min; elimination half-life (t1/2 beta): 558 +/- 218 minutes.,Pharmacokinetics and pharmacodynamics of propofol/alfentanil infusions for sedation in ICU patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8750122/),[ml] / [min],1001,43542,DB00818,Propofol
,8750122,redistribution half-life (t1/2 gamma),ICU long-term infusion population pharmacokinetics (open three-compartment model) revealed for propofol: central compartment distribution volume (V1): 31.2 +/- 5.3 l; steady-state distribution volume (Vdss): 499 +/- 173 l; total clearance (Cltot): 1001- +/- 150 ml/min; redistribution half-life (t1/2 gamma): 90 +/- 23 min; elimination half-life (t1/2 beta): 558 +/- 218 minutes.,Pharmacokinetics and pharmacodynamics of propofol/alfentanil infusions for sedation in ICU patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8750122/),min,90,43543,DB00818,Propofol
,8750122,elimination half-life (t1/2 beta),ICU long-term infusion population pharmacokinetics (open three-compartment model) revealed for propofol: central compartment distribution volume (V1): 31.2 +/- 5.3 l; steady-state distribution volume (Vdss): 499 +/- 173 l; total clearance (Cltot): 1001- +/- 150 ml/min; redistribution half-life (t1/2 gamma): 90 +/- 23 min; elimination half-life (t1/2 beta): 558 +/- 218 minutes.,Pharmacokinetics and pharmacodynamics of propofol/alfentanil infusions for sedation in ICU patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8750122/),min,558,43544,DB00818,Propofol
,8750122,V1,"For alfentanil: V1: 31.9 +/- 10.1 l; Vdss: 124 +/- 41 l; Cltot: 345 +/- 70 ml/min; t1/2 gamma: 36 +/- 15 min; t1/2 beta: 275 +/- 94 min, respectively.",Pharmacokinetics and pharmacodynamics of propofol/alfentanil infusions for sedation in ICU patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8750122/),l,31.9,43545,DB00818,Propofol
,8750122,Vdss,"For alfentanil: V1: 31.9 +/- 10.1 l; Vdss: 124 +/- 41 l; Cltot: 345 +/- 70 ml/min; t1/2 gamma: 36 +/- 15 min; t1/2 beta: 275 +/- 94 min, respectively.",Pharmacokinetics and pharmacodynamics of propofol/alfentanil infusions for sedation in ICU patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8750122/),l,124,43546,DB00818,Propofol
,8750122,Cltot,"For alfentanil: V1: 31.9 +/- 10.1 l; Vdss: 124 +/- 41 l; Cltot: 345 +/- 70 ml/min; t1/2 gamma: 36 +/- 15 min; t1/2 beta: 275 +/- 94 min, respectively.",Pharmacokinetics and pharmacodynamics of propofol/alfentanil infusions for sedation in ICU patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8750122/),[ml] / [min],345,43547,DB00818,Propofol
,8750122,t1/2 gamma,"For alfentanil: V1: 31.9 +/- 10.1 l; Vdss: 124 +/- 41 l; Cltot: 345 +/- 70 ml/min; t1/2 gamma: 36 +/- 15 min; t1/2 beta: 275 +/- 94 min, respectively.",Pharmacokinetics and pharmacodynamics of propofol/alfentanil infusions for sedation in ICU patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8750122/),min,36,43548,DB00818,Propofol
,8750122,t1/2 beta,"For alfentanil: V1: 31.9 +/- 10.1 l; Vdss: 124 +/- 41 l; Cltot: 345 +/- 70 ml/min; t1/2 gamma: 36 +/- 15 min; t1/2 beta: 275 +/- 94 min, respectively.",Pharmacokinetics and pharmacodynamics of propofol/alfentanil infusions for sedation in ICU patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8750122/),min,275,43549,DB00818,Propofol
,29720751,Ce,"The mean propofol Ce and SE at induction were 2.34 ± 0.24 μg/ml and 52 ± 8, respectively.",Effect site concentration of propofol at induction and recovery of anaesthesia - A correlative dose-response study. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29720751/),[μg] / [ml],2.34,43879,DB00818,Propofol
,29720751,SE,"The mean propofol Ce and SE at induction were 2.34 ± 0.24 μg/ml and 52 ± 8, respectively.",Effect site concentration of propofol at induction and recovery of anaesthesia - A correlative dose-response study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29720751/),,52,43880,DB00818,Propofol
,29720751,Ce,"The mean propofol Ce and SE at recovery were 1.02 ± 0.22 μg/ml and 86.80 ± 2.86, respectively.",Effect site concentration of propofol at induction and recovery of anaesthesia - A correlative dose-response study. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29720751/),[μg] / [ml],1.02,43881,DB00818,Propofol
,29720751,SE,"The mean propofol Ce and SE at recovery were 1.02 ± 0.22 μg/ml and 86.80 ± 2.86, respectively.",Effect site concentration of propofol at induction and recovery of anaesthesia - A correlative dose-response study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29720751/),,86.80,43882,DB00818,Propofol
,22242687,Areas under the curve,"Areas under the curve for anandamide (mean and 95% CI) were 53.3 (47.4, 59.2) nmol l(-1) 60 min with propofol and 48.5 (43.1, 53.8) nmol l(-1) 60 min with thiopental/sevoflurane (P= NS).",Changes of blood endocannabinoids during anaesthesia: a special case for fatty acid amide hydrolase inhibition by propofol? ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22242687/),[nM] / [l],53.3,45543,DB00818,Propofol
,22242687,Areas under the curve,"Areas under the curve for anandamide (mean and 95% CI) were 53.3 (47.4, 59.2) nmol l(-1) 60 min with propofol and 48.5 (43.1, 53.8) nmol l(-1) 60 min with thiopental/sevoflurane (P= NS).",Changes of blood endocannabinoids during anaesthesia: a special case for fatty acid amide hydrolase inhibition by propofol? ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22242687/),[nM] / [l],48.5,45544,DB00818,Propofol
,22242687,K(m),"Enzyme kinetics (mean ± SD) of recombinant human FAAH were K(m) = 16.9 ± 8.8 µmol l(-1) and V(max) = 44.6 ± 15.8 nmol mg(-1) min(-1) FAAH without, and K(m) = 16.6 ± 4.0 µmol l(-1) and V(max) = 44.0 ± 7.6 nmol mg( 1 ) min(-1) FAAH with 50 µmol l(-1) propofol (P= NS for both).",Changes of blood endocannabinoids during anaesthesia: a special case for fatty acid amide hydrolase inhibition by propofol? ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22242687/),[μM] / [l],16.9,45545,DB00818,Propofol
,22242687,V(max),"Enzyme kinetics (mean ± SD) of recombinant human FAAH were K(m) = 16.9 ± 8.8 µmol l(-1) and V(max) = 44.6 ± 15.8 nmol mg(-1) min(-1) FAAH without, and K(m) = 16.6 ± 4.0 µmol l(-1) and V(max) = 44.0 ± 7.6 nmol mg( 1 ) min(-1) FAAH with 50 µmol l(-1) propofol (P= NS for both).",Changes of blood endocannabinoids during anaesthesia: a special case for fatty acid amide hydrolase inhibition by propofol? ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22242687/),[nM] / [mg·min],44.6,45546,DB00818,Propofol
,22242687,K(m),"Enzyme kinetics (mean ± SD) of recombinant human FAAH were K(m) = 16.9 ± 8.8 µmol l(-1) and V(max) = 44.6 ± 15.8 nmol mg(-1) min(-1) FAAH without, and K(m) = 16.6 ± 4.0 µmol l(-1) and V(max) = 44.0 ± 7.6 nmol mg( 1 ) min(-1) FAAH with 50 µmol l(-1) propofol (P= NS for both).",Changes of blood endocannabinoids during anaesthesia: a special case for fatty acid amide hydrolase inhibition by propofol? ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22242687/),[μM] / [l],16.6,45547,DB00818,Propofol
,22242687,V(max),"Enzyme kinetics (mean ± SD) of recombinant human FAAH were K(m) = 16.9 ± 8.8 µmol l(-1) and V(max) = 44.6 ± 15.8 nmol mg(-1) min(-1) FAAH without, and K(m) = 16.6 ± 4.0 µmol l(-1) and V(max) = 44.0 ± 7.6 nmol mg( 1 ) min(-1) FAAH with 50 µmol l(-1) propofol (P= NS for both).",Changes of blood endocannabinoids during anaesthesia: a special case for fatty acid amide hydrolase inhibition by propofol? ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22242687/),[1·mg·nM] / [min],44.0,45548,DB00818,Propofol
,12081155,apparent distribution volumes,"The apparent distribution volumes of patients A and B were 1.43 and 1.62 l/kg, respectively.",Pharmacokinetics of propofol in elderly coronary artery bypass graft patients under total intravenous anesthesia. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12081155/),[l] / [kg],1.43,46489,DB00818,Propofol
,12081155,apparent distribution volumes,"The apparent distribution volumes of patients A and B were 1.43 and 1.62 l/kg, respectively.",Pharmacokinetics of propofol in elderly coronary artery bypass graft patients under total intravenous anesthesia. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12081155/),[l] / [kg],1.62,46490,DB00818,Propofol
,12081155,half-lives,"The half-lives of propofol in the plasma of patients A and B were estimated to be 13.3 and 17.4 min as the a phase, and 10.1 and 10.5 h as the beta phase, respectively.",Pharmacokinetics of propofol in elderly coronary artery bypass graft patients under total intravenous anesthesia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12081155/),min,13.3,46491,DB00818,Propofol
,12081155,half-lives,"The half-lives of propofol in the plasma of patients A and B were estimated to be 13.3 and 17.4 min as the a phase, and 10.1 and 10.5 h as the beta phase, respectively.",Pharmacokinetics of propofol in elderly coronary artery bypass graft patients under total intravenous anesthesia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12081155/),min,17.4,46492,DB00818,Propofol
,12081155,half-lives,"The half-lives of propofol in the plasma of patients A and B were estimated to be 13.3 and 17.4 min as the a phase, and 10.1 and 10.5 h as the beta phase, respectively.",Pharmacokinetics of propofol in elderly coronary artery bypass graft patients under total intravenous anesthesia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12081155/),h,10.1,46493,DB00818,Propofol
,12081155,half-lives,"The half-lives of propofol in the plasma of patients A and B were estimated to be 13.3 and 17.4 min as the a phase, and 10.1 and 10.5 h as the beta phase, respectively.",Pharmacokinetics of propofol in elderly coronary artery bypass graft patients under total intravenous anesthesia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12081155/),h,10.5,46494,DB00818,Propofol
,8880990,t1/2 beta,"The mean (sd) t1/2 beta was 83.9 (14.8) minutes, the mean (SD) residence time was 99.0 (10.8) minutes, the mean body clearance was 34.5 (12.1) ml kg-1 minute-1 and the mean volume of distribution at steady state was 3864 (1647) ml kg-1.",Pharmacokinetics of propofol as an induction agent in geriatric dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8880990/),min,83.9,47554,DB00818,Propofol
,8880990,residence time,"The mean (sd) t1/2 beta was 83.9 (14.8) minutes, the mean (SD) residence time was 99.0 (10.8) minutes, the mean body clearance was 34.5 (12.1) ml kg-1 minute-1 and the mean volume of distribution at steady state was 3864 (1647) ml kg-1.",Pharmacokinetics of propofol as an induction agent in geriatric dogs. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8880990/),min,99.0,47555,DB00818,Propofol
,8880990,body clearance,"The mean (sd) t1/2 beta was 83.9 (14.8) minutes, the mean (SD) residence time was 99.0 (10.8) minutes, the mean body clearance was 34.5 (12.1) ml kg-1 minute-1 and the mean volume of distribution at steady state was 3864 (1647) ml kg-1.",Pharmacokinetics of propofol as an induction agent in geriatric dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8880990/),[ml] / [kg·min],34.5,47556,DB00818,Propofol
,8880990,volume of distribution at steady state,"The mean (sd) t1/2 beta was 83.9 (14.8) minutes, the mean (SD) residence time was 99.0 (10.8) minutes, the mean body clearance was 34.5 (12.1) ml kg-1 minute-1 and the mean volume of distribution at steady state was 3864 (1647) ml kg-1.",Pharmacokinetics of propofol as an induction agent in geriatric dogs. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8880990/),[ml] / [kg],3864,47557,DB00818,Propofol
,30269150,TCI,"Anesthesia, preceding liver transplantation, was induced and maintained with TCI of 3 µg/mL propofol.",Pharmacokinetic Analysis of Propofol Target-Controlled Infusion Models in Chinese Patients with Hepatic Insufficiency. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30269150/),[μg] / [ml],3,47729,DB00818,Propofol
,1466226,concentration,The predicted median alfentanil concentration (289(256-363) ng ml-1) was significantly lower than the measured median plasma concentration of 368(168-666) ng ml-1).,Alfentanil infusion in total intravenous anaesthesia (TIVA). Population pharmacokinetics fails to predict plasma concentration of alfentanil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1466226/),[ng] / [ml],289,47783,DB00818,Propofol
,1466226,plasma concentration,The predicted median alfentanil concentration (289(256-363) ng ml-1) was significantly lower than the measured median plasma concentration of 368(168-666) ng ml-1).,Alfentanil infusion in total intravenous anaesthesia (TIVA). Population pharmacokinetics fails to predict plasma concentration of alfentanil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1466226/),[ng] / [ml],368,47784,DB00818,Propofol
,3500657,t1/2 pi,"Derived pharmacokinetic parameters expressed as mean values +/- SD indicated an initial fast distribution (t1/2 pi; 2.8 +/- 1.2 min), with an intermediate phase (t1/2 alpha; 31.4 +/- 14.7 min), and a long terminal phase (t1/2 beta; 355 +/- 227 min), a large volume of distribution at steady state (Vss, 287 +/- 213 L), and a high blood clearance (Clb, 1.7 +/- 0.3 L/min).",Disposition of propofol administered as constant rate intravenous infusions in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3500657/),min,2.8,48235,DB00818,Propofol
,3500657,t1/2 alpha,"Derived pharmacokinetic parameters expressed as mean values +/- SD indicated an initial fast distribution (t1/2 pi; 2.8 +/- 1.2 min), with an intermediate phase (t1/2 alpha; 31.4 +/- 14.7 min), and a long terminal phase (t1/2 beta; 355 +/- 227 min), a large volume of distribution at steady state (Vss, 287 +/- 213 L), and a high blood clearance (Clb, 1.7 +/- 0.3 L/min).",Disposition of propofol administered as constant rate intravenous infusions in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3500657/),min,31.4,48236,DB00818,Propofol
,3500657,terminal phase (t1/2 beta,"Derived pharmacokinetic parameters expressed as mean values +/- SD indicated an initial fast distribution (t1/2 pi; 2.8 +/- 1.2 min), with an intermediate phase (t1/2 alpha; 31.4 +/- 14.7 min), and a long terminal phase (t1/2 beta; 355 +/- 227 min), a large volume of distribution at steady state (Vss, 287 +/- 213 L), and a high blood clearance (Clb, 1.7 +/- 0.3 L/min).",Disposition of propofol administered as constant rate intravenous infusions in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3500657/),min,355,48237,DB00818,Propofol
,3500657,volume of distribution at steady state (Vss,"Derived pharmacokinetic parameters expressed as mean values +/- SD indicated an initial fast distribution (t1/2 pi; 2.8 +/- 1.2 min), with an intermediate phase (t1/2 alpha; 31.4 +/- 14.7 min), and a long terminal phase (t1/2 beta; 355 +/- 227 min), a large volume of distribution at steady state (Vss, 287 +/- 213 L), and a high blood clearance (Clb, 1.7 +/- 0.3 L/min).",Disposition of propofol administered as constant rate intravenous infusions in humans. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3500657/),l,287,48238,DB00818,Propofol
,3500657,blood clearance (Clb,"Derived pharmacokinetic parameters expressed as mean values +/- SD indicated an initial fast distribution (t1/2 pi; 2.8 +/- 1.2 min), with an intermediate phase (t1/2 alpha; 31.4 +/- 14.7 min), and a long terminal phase (t1/2 beta; 355 +/- 227 min), a large volume of distribution at steady state (Vss, 287 +/- 213 L), and a high blood clearance (Clb, 1.7 +/- 0.3 L/min).",Disposition of propofol administered as constant rate intravenous infusions in humans. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3500657/),[l] / [min],1.7,48239,DB00818,Propofol
,3500657,elimination rate constant (K10,"The elimination rate constant (K10, 0.1190 +/- 0.0351 min-1) was large compared with the other transfer rate constants and was responsible for the large amount of drug eliminated during distribution.",Disposition of propofol administered as constant rate intravenous infusions in humans. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3500657/),1/[min],0.1190,48240,DB00818,Propofol
,3500657,fraction of drug eliminated during the terminal phase,The fraction of drug eliminated during the terminal phase amounted to 0.28.,Disposition of propofol administered as constant rate intravenous infusions in humans. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3500657/),,0.28,48241,DB00818,Propofol
,3500657,K31,"The slow return of drug from remote tissues (K31, 0.0033 +/- 0.0013 min-1) was rate limiting in the ultimate elimination.",Disposition of propofol administered as constant rate intravenous infusions in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3500657/),1/[min],0.0033,48242,DB00818,Propofol
,11025949,dilution rate,"The dilution rate of the plasma from the fractional change in blood hemoglobin increased to 0.08 +/- 0.02, 0.24 +/- 0.03, and 0.36 +/- 0.03, respectively.","[The effect of acetate ringer solution, 6% hydroxyethyl starch saline and 20% mannitol solution on the serum concentration of propofol continuously infused]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11025949/),,0.08,48509,DB00818,Propofol
,11025949,dilution rate,"The dilution rate of the plasma from the fractional change in blood hemoglobin increased to 0.08 +/- 0.02, 0.24 +/- 0.03, and 0.36 +/- 0.03, respectively.","[The effect of acetate ringer solution, 6% hydroxyethyl starch saline and 20% mannitol solution on the serum concentration of propofol continuously infused]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11025949/),,0.24,48510,DB00818,Propofol
,11025949,dilution rate,"The dilution rate of the plasma from the fractional change in blood hemoglobin increased to 0.08 +/- 0.02, 0.24 +/- 0.03, and 0.36 +/- 0.03, respectively.","[The effect of acetate ringer solution, 6% hydroxyethyl starch saline and 20% mannitol solution on the serum concentration of propofol continuously infused]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11025949/),,0.36,48511,DB00818,Propofol
,10631438,sedation score,The sedation score increased from 1 in the first 12 h to values between 2 and 3 for the remaining sedation period.,"[Analgo-sedation in intensive care: a quantitative, EEG-based trial with propofol 1% and 2%]. ",AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10631438/),,1,48719,DB00818,Propofol
,10631438,sedation score,The sedation score increased from 1 in the first 12 h to values between 2 and 3 for the remaining sedation period.,"[Analgo-sedation in intensive care: a quantitative, EEG-based trial with propofol 1% and 2%]. ",AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10631438/),,2 and 3,48720,DB00818,Propofol
,10631438,plasma concentrations,"At the same time, propofol plasma concentrations increased from 0.7 +/- 0.3 microgram/ml to 1.8 +/- 1.3 micrograms/ml.","[Analgo-sedation in intensive care: a quantitative, EEG-based trial with propofol 1% and 2%]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10631438/),[μg] / [ml],0.,48721,DB00818,Propofol
,10631438,plasma concentrations,"At the same time, propofol plasma concentrations increased from 0.7 +/- 0.3 microgram/ml to 1.8 +/- 1.3 micrograms/ml.","[Analgo-sedation in intensive care: a quantitative, EEG-based trial with propofol 1% and 2%]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10631438/),,1,48722,DB00818,Propofol
,10631438,clearance,Alfentanil clearance was found to be reduced with four patients having extremely small clearance values (33 +/- 3 ml/min).,"[Analgo-sedation in intensive care: a quantitative, EEG-based trial with propofol 1% and 2%]. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10631438/),[ml] / [min],33,48723,DB00818,Propofol
,10460064,Michaelis-Menten constant,The mean (+/-SD) Michaelis-Menten constant for midazolam 1'-hydroxylation by human liver microsomes was 5.6 +/- 3.3 micromol/L.,Propofol decreases the clearance of midazolam by inhibiting CYP3A4: an in vivo and in vitro study. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10460064/),[μM] / [l],5.6,48761,DB00818,Propofol
,10460064,inhibition constant,"The formation of 1'-hydroxymidazolam was competitively inhibited by propofol, and the mean inhibition constant was 56.7 +/- 16.6 micromol/L.",Propofol decreases the clearance of midazolam by inhibiting CYP3A4: an in vivo and in vitro study. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10460064/),[μM] / [l],56.7,48762,DB00818,Propofol
,10460064,Michaelis-Menten constant,"The mean Michaelis-Menten constant and mean inhibition constant values for midazolam 1'-hydroxylation by recombinant CYP3A4 were 4.0 micromol/L and 61.0 micromol/L, respectively, consistent with the mean values obtained from human liver microsomes.",Propofol decreases the clearance of midazolam by inhibiting CYP3A4: an in vivo and in vitro study. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10460064/),[μM] / [l],4.0,48763,DB00818,Propofol
,10460064,inhibition constant,"The mean Michaelis-Menten constant and mean inhibition constant values for midazolam 1'-hydroxylation by recombinant CYP3A4 were 4.0 micromol/L and 61.0 micromol/L, respectively, consistent with the mean values obtained from human liver microsomes.",Propofol decreases the clearance of midazolam by inhibiting CYP3A4: an in vivo and in vitro study. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10460064/),[μM] / [l],61.0,48764,DB00818,Propofol
,29755192,plasma concentrations (Cmax),"Maximum bupivacaine plasma concentrations (Cmax) for BE and BD were 1155 ± 168 ng/mL and 1678 ± 364 ng/mL (P = 0.29) at 67 ± 13 min (Tmax) and 123 ± 59 min (P = 0.17), respectively.",Efficacy and pharmacokinetics of bupivacaine with epinephrine or dexmedetomidine after intraperitoneal administration in cats undergoing ovariohysterectomy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29755192/),[ng] / [ml],1155,48784,DB00818,Propofol
,29755192,plasma concentrations (Cmax),"Maximum bupivacaine plasma concentrations (Cmax) for BE and BD were 1155 ± 168 ng/mL and 1678 ± 364 ng/mL (P = 0.29) at 67 ± 13 min (Tmax) and 123 ± 59 min (P = 0.17), respectively.",Efficacy and pharmacokinetics of bupivacaine with epinephrine or dexmedetomidine after intraperitoneal administration in cats undergoing ovariohysterectomy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29755192/),[ng] / [ml],1678,48785,DB00818,Propofol
,29755192,Tmax,"Maximum bupivacaine plasma concentrations (Cmax) for BE and BD were 1155 ± 168 ng/mL and 1678 ± 364 ng/mL (P = 0.29) at 67 ± 13 min (Tmax) and 123 ± 59 min (P = 0.17), respectively.",Efficacy and pharmacokinetics of bupivacaine with epinephrine or dexmedetomidine after intraperitoneal administration in cats undergoing ovariohysterectomy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29755192/),min,67,48786,DB00818,Propofol
,11696118,EC50,The EC50 of propofol during OGD was 3.55 microg.,Determination of the median effective concentration (EC50) of propofol during oesophagogastroduodenoscopy in children. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11696118/),μg,3.55,48810,DB00818,Propofol
,3499160,T1/2 alpha,"The pharmacokinetics of propofol in unpretreated patients who were maintained with nitrous oxide in oxygen only can be described by a three-compartment open mammalian model with very rapid distribution (T1/2 alpha about 3 min), rapid elimination (T1/2 beta 45 min) and a slower final phase (T1/2 gamma about 300 min).",Pharmacokinetics of propofol in female patients. Studies using single bolus injections. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3499160/),min,3,49295,DB00818,Propofol
,3499160,T1/2 beta,"The pharmacokinetics of propofol in unpretreated patients who were maintained with nitrous oxide in oxygen only can be described by a three-compartment open mammalian model with very rapid distribution (T1/2 alpha about 3 min), rapid elimination (T1/2 beta 45 min) and a slower final phase (T1/2 gamma about 300 min).",Pharmacokinetics of propofol in female patients. Studies using single bolus injections. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3499160/),min,45,49296,DB00818,Propofol
,3499160,total body clearance,The total body clearance of propofol was rapid (1.91 litre min-1).,Pharmacokinetics of propofol in female patients. Studies using single bolus injections. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3499160/),[l] / [min],1.91,49297,DB00818,Propofol
,3499160,Vss,Propofol was initially distributed into a relatively large central compartment (41.3 litre) and was extensively redistributed (Vss 305 litre; V gamma 722 litre).,Pharmacokinetics of propofol in female patients. Studies using single bolus injections. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3499160/),l,305,49298,DB00818,Propofol
,3499160,V gamma,Propofol was initially distributed into a relatively large central compartment (41.3 litre) and was extensively redistributed (Vss 305 litre; V gamma 722 litre).,Pharmacokinetics of propofol in female patients. Studies using single bolus injections. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3499160/),l,722,49299,DB00818,Propofol
,12071237,Vm,"Pharmacokinetics were found to be nonlinear and were best described by a two-compartment model with Michaelis-Menten elimination (Vm = 2.17 microg mL(-1) min(-1), Km = 2.65 microg mL(-1), k12 = 0.30 min(-1), k21 0.063 min(-1), Vc = 0.13 L).",Propofol in rats: testing for nonlinear pharmacokinetics and modelling acute tolerance to EEG effects. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12071237/),[μg] / [min·ml],2.17,50203,DB00818,Propofol
,12071237,Km,"Pharmacokinetics were found to be nonlinear and were best described by a two-compartment model with Michaelis-Menten elimination (Vm = 2.17 microg mL(-1) min(-1), Km = 2.65 microg mL(-1), k12 = 0.30 min(-1), k21 0.063 min(-1), Vc = 0.13 L).",Propofol in rats: testing for nonlinear pharmacokinetics and modelling acute tolerance to EEG effects. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12071237/),[μg] / [ml],2.65,50204,DB00818,Propofol
,12071237,k12,"Pharmacokinetics were found to be nonlinear and were best described by a two-compartment model with Michaelis-Menten elimination (Vm = 2.17 microg mL(-1) min(-1), Km = 2.65 microg mL(-1), k12 = 0.30 min(-1), k21 0.063 min(-1), Vc = 0.13 L).",Propofol in rats: testing for nonlinear pharmacokinetics and modelling acute tolerance to EEG effects. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12071237/),1/[min],0.30,50205,DB00818,Propofol
,12071237,k21,"Pharmacokinetics were found to be nonlinear and were best described by a two-compartment model with Michaelis-Menten elimination (Vm = 2.17 microg mL(-1) min(-1), Km = 2.65 microg mL(-1), k12 = 0.30 min(-1), k21 0.063 min(-1), Vc = 0.13 L).",Propofol in rats: testing for nonlinear pharmacokinetics and modelling acute tolerance to EEG effects. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12071237/),1/[min],0.063,50206,DB00818,Propofol
,12071237,Vc,"Pharmacokinetics were found to be nonlinear and were best described by a two-compartment model with Michaelis-Menten elimination (Vm = 2.17 microg mL(-1) min(-1), Km = 2.65 microg mL(-1), k12 = 0.30 min(-1), k21 0.063 min(-1), Vc = 0.13 L).",Propofol in rats: testing for nonlinear pharmacokinetics and modelling acute tolerance to EEG effects. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12071237/),l,0.13,50207,DB00818,Propofol
,12071237,E0,"The hypnotic effect was best described by a sigmoid Emax model (E0 = 17.8 Hz, Emax = 17.7 Hz, EC50 = 4.1 microg mL(-1), gamma = 2.3, ke0 = 0.36 min(-1)) with competitive antagonism of propofol and a hypothetical drug in an additional tolerance compartment.",Propofol in rats: testing for nonlinear pharmacokinetics and modelling acute tolerance to EEG effects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12071237/),hz,17.8,50208,DB00818,Propofol
,12071237,Emax,"The hypnotic effect was best described by a sigmoid Emax model (E0 = 17.8 Hz, Emax = 17.7 Hz, EC50 = 4.1 microg mL(-1), gamma = 2.3, ke0 = 0.36 min(-1)) with competitive antagonism of propofol and a hypothetical drug in an additional tolerance compartment.",Propofol in rats: testing for nonlinear pharmacokinetics and modelling acute tolerance to EEG effects. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12071237/),hz,17.7,50209,DB00818,Propofol
,12071237,EC50,"The hypnotic effect was best described by a sigmoid Emax model (E0 = 17.8 Hz, Emax = 17.7 Hz, EC50 = 4.1 microg mL(-1), gamma = 2.3, ke0 = 0.36 min(-1)) with competitive antagonism of propofol and a hypothetical drug in an additional tolerance compartment.",Propofol in rats: testing for nonlinear pharmacokinetics and modelling acute tolerance to EEG effects. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12071237/),[μg] / [ml],4.1,50210,DB00818,Propofol
,12071237,gamma,"The hypnotic effect was best described by a sigmoid Emax model (E0 = 17.8 Hz, Emax = 17.7 Hz, EC50 = 4.1 microg mL(-1), gamma = 2.3, ke0 = 0.36 min(-1)) with competitive antagonism of propofol and a hypothetical drug in an additional tolerance compartment.",Propofol in rats: testing for nonlinear pharmacokinetics and modelling acute tolerance to EEG effects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12071237/),,2.3,50211,DB00818,Propofol
,12071237,ke0,"The hypnotic effect was best described by a sigmoid Emax model (E0 = 17.8 Hz, Emax = 17.7 Hz, EC50 = 4.1 microg mL(-1), gamma = 2.3, ke0 = 0.36 min(-1)) with competitive antagonism of propofol and a hypothetical drug in an additional tolerance compartment.",Propofol in rats: testing for nonlinear pharmacokinetics and modelling acute tolerance to EEG effects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12071237/),1/[min],0.36,50212,DB00818,Propofol
,11506101,emergence times,"Predicted emergence times in a typical subject after 24 h, 72 h, 7 days, and 14 days of light sedation (sedation score = 3 --> 2) with propofol were 13, 34, 198, and 203 min, respectively.",Propofol dosing regimens for ICU sedation based upon an integrated pharmacokinetic-pharmacodynamic model. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11506101/),min,13,50268,DB00818,Propofol
,11506101,emergence times,"Predicted emergence times in a typical subject after 24 h, 72 h, 7 days, and 14 days of light sedation (sedation score = 3 --> 2) with propofol were 13, 34, 198, and 203 min, respectively.",Propofol dosing regimens for ICU sedation based upon an integrated pharmacokinetic-pharmacodynamic model. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11506101/),min,34,50269,DB00818,Propofol
,11506101,emergence times,"Predicted emergence times in a typical subject after 24 h, 72 h, 7 days, and 14 days of light sedation (sedation score = 3 --> 2) with propofol were 13, 34, 198, and 203 min, respectively.",Propofol dosing regimens for ICU sedation based upon an integrated pharmacokinetic-pharmacodynamic model. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11506101/),min,198,50270,DB00818,Propofol
,11506101,emergence times,"Predicted emergence times in a typical subject after 24 h, 72 h, 7 days, and 14 days of light sedation (sedation score = 3 --> 2) with propofol were 13, 34, 198, and 203 min, respectively.",Propofol dosing regimens for ICU sedation based upon an integrated pharmacokinetic-pharmacodynamic model. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11506101/),min,203,50271,DB00818,Propofol
,11506101,emergence times,"Corresponding emergence times from deep sedation (sedation score = 5 --> 2) with propofol were 25, 59, 71, and 74 h.",Propofol dosing regimens for ICU sedation based upon an integrated pharmacokinetic-pharmacodynamic model. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11506101/),h,25,50272,DB00818,Propofol
,11506101,emergence times,"Corresponding emergence times from deep sedation (sedation score = 5 --> 2) with propofol were 25, 59, 71, and 74 h.",Propofol dosing regimens for ICU sedation based upon an integrated pharmacokinetic-pharmacodynamic model. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11506101/),h,59,50273,DB00818,Propofol
,11506101,emergence times,"Corresponding emergence times from deep sedation (sedation score = 5 --> 2) with propofol were 25, 59, 71, and 74 h.",Propofol dosing regimens for ICU sedation based upon an integrated pharmacokinetic-pharmacodynamic model. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11506101/),h,71,50274,DB00818,Propofol
,11506101,emergence times,"Corresponding emergence times from deep sedation (sedation score = 5 --> 2) with propofol were 25, 59, 71, and 74 h.",Propofol dosing regimens for ICU sedation based upon an integrated pharmacokinetic-pharmacodynamic model. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11506101/),h,74,50275,DB00818,Propofol
,26021605,bioavailability,"In rats, bioavailability of propofol from fospropofol delivered orally was found to be appreciable, in the order of around 20-70%, depending on dose.",Gastrointestinal delivery of propofol from fospropofol: its bioavailability and activity in rodents and human volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26021605/),%,20-70,50279,DB00818,Propofol
,26021605,bioavailability,"Availability was especially marked following fospropofol administration via the intraduodenal route, where bioavailability approximated 100%.",Gastrointestinal delivery of propofol from fospropofol: its bioavailability and activity in rodents and human volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26021605/),%,100,50280,DB00818,Propofol
,9100179,constant rate,"kg-1, 5 min before induction of anesthesia, and infused at a constant rate of 0.5 microgram.",Predictive accuracy of continuous propofol infusions in neurosurgical patients: comparison of pharmacokinetic models. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9100179/),μg,0.5,50314,DB00818,Propofol
,22446000,concentrations,"The plasma propofol concentrations in internal carotid artery and jugular vein were similar in both light anesthesia group (3.00 ± 0.31 and 3.10 ± 0.51 µg/ml, respectively, P>0.05) and deep anesthesia group (6.41 ± 0.05 and 6.40 ± 0.11 µg/ml, respectively, P>0.05).",[Effect of propofol at uptake equilibrium on γ-aminobutyric acid in different cerebral regions in dogs]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22446000/),[μg] / [ml],3.00,50674,DB00818,Propofol
,22446000,concentrations,"The plasma propofol concentrations in internal carotid artery and jugular vein were similar in both light anesthesia group (3.00 ± 0.31 and 3.10 ± 0.51 µg/ml, respectively, P>0.05) and deep anesthesia group (6.41 ± 0.05 and 6.40 ± 0.11 µg/ml, respectively, P>0.05).",[Effect of propofol at uptake equilibrium on γ-aminobutyric acid in different cerebral regions in dogs]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22446000/),[μg] / [ml],3.10,50675,DB00818,Propofol
,22446000,concentrations,"The plasma propofol concentrations in internal carotid artery and jugular vein were similar in both light anesthesia group (3.00 ± 0.31 and 3.10 ± 0.51 µg/ml, respectively, P>0.05) and deep anesthesia group (6.41 ± 0.05 and 6.40 ± 0.11 µg/ml, respectively, P>0.05).",[Effect of propofol at uptake equilibrium on γ-aminobutyric acid in different cerebral regions in dogs]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22446000/),[μg] / [ml],6.41,50676,DB00818,Propofol
,22446000,concentrations,"The plasma propofol concentrations in internal carotid artery and jugular vein were similar in both light anesthesia group (3.00 ± 0.31 and 3.10 ± 0.51 µg/ml, respectively, P>0.05) and deep anesthesia group (6.41 ± 0.05 and 6.40 ± 0.11 µg/ml, respectively, P>0.05).",[Effect of propofol at uptake equilibrium on γ-aminobutyric acid in different cerebral regions in dogs]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22446000/),[μg] / [ml],6.40,50677,DB00818,Propofol
,18179618,plasma concentrations,A previously published pharmacokinetic simulation suggested a simple manual infusion regimen to achieve propofol plasma concentrations of 3 microg.ml(-1).,Clinical adaptation of a pharmacokinetic model of Propofol plasma concentrations in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18179618/),[μg] / [ml],3,51018,DB00818,Propofol
,29728755,effective dose for 50%,"Remifentanil effective dose for 50% was established in 3.04 µg/kg (IC 95% 2.68-3.11, p < 0.05).",ED50 of remifentanil for providing excellent intubating conditions when co-administered with a single standard dose of propofol without the use of muscle relaxants in children: dose-finding clinical trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29728755/),[μg] / [kg],3.04,52049,DB00818,Propofol
,21724003,fast,"The objective of this study was to evaluate the clinical performance of two different ke0 (fast = 1.21 min(-1), and slow = 0.26 min(-1)) in relation to Ce during loss and recovery of consciousness using Marsh pharmacokinetic model.",Clinical evaluation of two Ke0 in the same pharmacokinetic propofol model: study on loss and recovery of consciousness. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21724003/),1/[min],1.21,53611,DB00818,Propofol
,21724003,fast,"The objective of this study was to evaluate the clinical performance of two different ke0 (fast = 1.21 min(-1), and slow = 0.26 min(-1)) in relation to Ce during loss and recovery of consciousness using Marsh pharmacokinetic model.",Clinical evaluation of two Ke0 in the same pharmacokinetic propofol model: study on loss and recovery of consciousness. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21724003/),1/[min],0.26,53612,DB00818,Propofol
,21724003,slow,"The objective of this study was to evaluate the clinical performance of two different ke0 (fast = 1.21 min(-1), and slow = 0.26 min(-1)) in relation to Ce during loss and recovery of consciousness using Marsh pharmacokinetic model.",Clinical evaluation of two Ke0 in the same pharmacokinetic propofol model: study on loss and recovery of consciousness. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21724003/),1/[min],0.26,53613,DB00818,Propofol
,21724003,Ce,"On loss and recovery of consciousness, the Ce for fast ke0 was different (3.64 ± 0.78 and 1.47 ± 0.29 μg.",Clinical evaluation of two Ke0 in the same pharmacokinetic propofol model: study on loss and recovery of consciousness. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21724003/),μg,3.64,53614,DB00818,Propofol
,21724003,Ce,"On loss and recovery of consciousness, the Ce for fast ke0 was different (3.64 ± 0.78 and 1.47 ± 0.29 μg.",Clinical evaluation of two Ke0 in the same pharmacokinetic propofol model: study on loss and recovery of consciousness. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21724003/),μg,1.47,53615,DB00818,Propofol
,21724003,ke0,"mL(-1), respectively, p < 0.0001), while with slow ke0 the Ce was similar (2.20 ± 0.70 and 2.14 ± 0.43 μg.",Clinical evaluation of two Ke0 in the same pharmacokinetic propofol model: study on loss and recovery of consciousness. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21724003/),μg,2.20,53616,DB00818,Propofol
,21724003,ke0,"mL(-1), respectively, p < 0.0001), while with slow ke0 the Ce was similar (2.20 ± 0.70 and 2.14 ± 0.43 μg.",Clinical evaluation of two Ke0 in the same pharmacokinetic propofol model: study on loss and recovery of consciousness. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21724003/),μg,2.14,53617,DB00818,Propofol
,21724003,Ce,"mL(-1), respectively, p < 0.0001), while with slow ke0 the Ce was similar (2.20 ± 0.70 and 2.14 ± 0.43 μg.",Clinical evaluation of two Ke0 in the same pharmacokinetic propofol model: study on loss and recovery of consciousness. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21724003/),μg,2.20,53618,DB00818,Propofol
,21724003,Ce,"mL(-1), respectively, p < 0.0001), while with slow ke0 the Ce was similar (2.20 ± 0.70 and 2.14 ± 0.43 μg.",Clinical evaluation of two Ke0 in the same pharmacokinetic propofol model: study on loss and recovery of consciousness. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21724003/),μg,2.14,53619,DB00818,Propofol
,21724003,ke0,"Clinically, the slow ke0 (0.26 min(-1)) incorporated in the Marsh pharmacokinetic model showed better performance than the fast ke0 (1.21 min(-1)), since the calculated concentration of propofol at the effect site on loss and recovery of consciousness was similar.",Clinical evaluation of two Ke0 in the same pharmacokinetic propofol model: study on loss and recovery of consciousness. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21724003/),1/[min],0.26,53620,DB00818,Propofol
,21724003,ke0,"Clinically, the slow ke0 (0.26 min(-1)) incorporated in the Marsh pharmacokinetic model showed better performance than the fast ke0 (1.21 min(-1)), since the calculated concentration of propofol at the effect site on loss and recovery of consciousness was similar.",Clinical evaluation of two Ke0 in the same pharmacokinetic propofol model: study on loss and recovery of consciousness. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21724003/),1/[min],1.21,53621,DB00818,Propofol
,28258392,Central volume of distribution,"Central volume of distribution, peripheral volume and intercompartmental clearance were 45.2 L, 128 L and 1.75 L/min, respectively, with no predictive covariates identifiable.",Propofol Clearance in Morbidly Obese Children and Adolescents : Influence of Age and Body Size. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28258392/),l,45.2,54327,DB00818,Propofol
,28258392,peripheral volume,"Central volume of distribution, peripheral volume and intercompartmental clearance were 45.2 L, 128 L and 1.75 L/min, respectively, with no predictive covariates identifiable.",Propofol Clearance in Morbidly Obese Children and Adolescents : Influence of Age and Body Size. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28258392/),l,128,54328,DB00818,Propofol
,28258392,intercompartmental clearance,"Central volume of distribution, peripheral volume and intercompartmental clearance were 45.2 L, 128 L and 1.75 L/min, respectively, with no predictive covariates identifiable.",Propofol Clearance in Morbidly Obese Children and Adolescents : Influence of Age and Body Size. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28258392/),[l] / [min],1.75,54329,DB00818,Propofol
,30690713,effect-site concentrations (Ces),"The target effect-site concentrations (Ces) of propofol were 2.5, 3, 3.5, 4, 4.5, and 2 μg/mL.",Predictive performance of a new pharmacokinetic model for propofol in underweight patients during target-controlled infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30690713/),[μg] / [ml],2.5,55434,DB00818,Propofol
,30690713,effect-site concentrations (Ces),"The target effect-site concentrations (Ces) of propofol were 2.5, 3, 3.5, 4, 4.5, and 2 μg/mL.",Predictive performance of a new pharmacokinetic model for propofol in underweight patients during target-controlled infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30690713/),[μg] / [ml],3,55435,DB00818,Propofol
,30690713,effect-site concentrations (Ces),"The target effect-site concentrations (Ces) of propofol were 2.5, 3, 3.5, 4, 4.5, and 2 μg/mL.",Predictive performance of a new pharmacokinetic model for propofol in underweight patients during target-controlled infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30690713/),[μg] / [ml],3.5,55436,DB00818,Propofol
,30690713,effect-site concentrations (Ces),"The target effect-site concentrations (Ces) of propofol were 2.5, 3, 3.5, 4, 4.5, and 2 μg/mL.",Predictive performance of a new pharmacokinetic model for propofol in underweight patients during target-controlled infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30690713/),[μg] / [ml],4,55437,DB00818,Propofol
,30690713,effect-site concentrations (Ces),"The target effect-site concentrations (Ces) of propofol were 2.5, 3, 3.5, 4, 4.5, and 2 μg/mL.",Predictive performance of a new pharmacokinetic model for propofol in underweight patients during target-controlled infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30690713/),[μg] / [ml],4.5,55438,DB00818,Propofol
,30690713,effect-site concentrations (Ces),"The target effect-site concentrations (Ces) of propofol were 2.5, 3, 3.5, 4, 4.5, and 2 μg/mL.",Predictive performance of a new pharmacokinetic model for propofol in underweight patients during target-controlled infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30690713/),[μg] / [ml],2,55439,DB00818,Propofol
≥,30690713,Ce,"In particular, the Schnider model showed greater inaccuracy at a target Ce ≥ 3 µg/mL.",Predictive performance of a new pharmacokinetic model for propofol in underweight patients during target-controlled infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30690713/),[μg] / [ml],3,55440,DB00818,Propofol
,19925493,k(e0),"The blood-brain equilibration rate constants (k(e0), min(-1)) were 0.476 and 0.696 for microemulsion and LCT propofol respectively.",Pharmacokinetics and pharmacodynamics of a new reformulated microemulsion and the long-chain triglyceride emulsion of propofol in beagle dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19925493/),1/[min],0.476,56241,DB00818,Propofol
,19925493,k(e0),"The blood-brain equilibration rate constants (k(e0), min(-1)) were 0.476 and 0.696 for microemulsion and LCT propofol respectively.",Pharmacokinetics and pharmacodynamics of a new reformulated microemulsion and the long-chain triglyceride emulsion of propofol in beagle dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19925493/),1/[min],0.696,56242,DB00818,Propofol
,17965417,clearance (CL(std)),Standardized propofol clearance (CL(std)) at 38 weeks PMA was 0.029 litre min(-1).,Inter-individual variability in propofol pharmacokinetics in preterm and term neonates. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17965417/),[l] / [min],0.029,57088,DB00818,Propofol
,17965417,central volume,"Values for central volume (1.32 litre), peripheral volume 1 (15.4 litre), and peripheral volume 2 (1.29 litre) were not significantly influenced by any of the covariates (P>0.001).",Inter-individual variability in propofol pharmacokinetics in preterm and term neonates. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17965417/),l,1.32,57089,DB00818,Propofol
,17965417,peripheral volume 1,"Values for central volume (1.32 litre), peripheral volume 1 (15.4 litre), and peripheral volume 2 (1.29 litre) were not significantly influenced by any of the covariates (P>0.001).",Inter-individual variability in propofol pharmacokinetics in preterm and term neonates. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17965417/),l,15.4,57090,DB00818,Propofol
,17965417,peripheral volume 2,"Values for central volume (1.32 litre), peripheral volume 1 (15.4 litre), and peripheral volume 2 (1.29 litre) were not significantly influenced by any of the covariates (P>0.001).",Inter-individual variability in propofol pharmacokinetics in preterm and term neonates. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17965417/),l,1.29,57091,DB00818,Propofol
,19627530,clearance,"Remifentanil, a drug cleared by hydrolysis, can be modeled in all age groups by simple application of this model using a standardized clearance of 2790 ml x min(-1) for a 70-kg person.",Pediatric models for adult target-controlled infusion pumps. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19627530/),[ml] / [min],2790,57639,DB00818,Propofol
,19627530,mature,"Propofol maturation has been described with a mature clearance of 1.83 l x min(-1) x 70 kg(-1), a maturation half-time (TM(50)) of 44 weeks and a Hill coefficient of 4.9.",Pediatric models for adult target-controlled infusion pumps. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19627530/),[l] / [70·kg·min],1.83,57640,DB00818,Propofol
,19627530,clearance,"Propofol maturation has been described with a mature clearance of 1.83 l x min(-1) x 70 kg(-1), a maturation half-time (TM(50)) of 44 weeks and a Hill coefficient of 4.9.",Pediatric models for adult target-controlled infusion pumps. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19627530/),[l] / [70·kg·min],1.83,57641,DB00818,Propofol
,19627530,maturation half-time (TM(50)),"Propofol maturation has been described with a mature clearance of 1.83 l x min(-1) x 70 kg(-1), a maturation half-time (TM(50)) of 44 weeks and a Hill coefficient of 4.9.",Pediatric models for adult target-controlled infusion pumps. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19627530/),weeks,44,57642,DB00818,Propofol
,19627530,Hill coefficient,"Propofol maturation has been described with a mature clearance of 1.83 l x min(-1) x 70 kg(-1), a maturation half-time (TM(50)) of 44 weeks and a Hill coefficient of 4.9.",Pediatric models for adult target-controlled infusion pumps. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19627530/),,4.9,57643,DB00818,Propofol
,8659779,total clearance,"Using noncompartmental analysis, total clearance of propofol (+/-SD) was 0.053+/-0.013l.kg(-1).min(-1), volume of distribution at steady state9.5 +/- 3.7l.kg(-1),and residence time 188 +/- 85 min.",Pharmacokinetics of propofol after a single dose in children aged 1-3 years with minor burns. Comparison of three data analysis approaches. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8659779/),[l] / [kg·min],0.053,59843,DB00818,Propofol
,8659779,volume of distribution at steady state,"Using noncompartmental analysis, total clearance of propofol (+/-SD) was 0.053+/-0.013l.kg(-1).min(-1), volume of distribution at steady state9.5 +/- 3.7l.kg(-1),and residence time 188 +/- 85 min.",Pharmacokinetics of propofol after a single dose in children aged 1-3 years with minor burns. Comparison of three data analysis approaches. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8659779/),[l] / [kg],9.5,59844,DB00818,Propofol
,8659779,residence time,"Using noncompartmental analysis, total clearance of propofol (+/-SD) was 0.053+/-0.013l.kg(-1).min(-1), volume of distribution at steady state9.5 +/- 3.7l.kg(-1),and residence time 188 +/- 85 min.",Pharmacokinetics of propofol after a single dose in children aged 1-3 years with minor burns. Comparison of three data analysis approaches. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8659779/),min,188,59845,DB00818,Propofol
,8659779,systemic clearance,"Results of population versus two-stage analysis are as follow: systemic clearance 0.049 versus 0.048 l.kg(-).min(-1), volume of central compartment 1.03 versus 0.95 l.kg(-1), volume of steady state 8.09 versus 8.17 l.kg(-1).",Pharmacokinetics of propofol after a single dose in children aged 1-3 years with minor burns. Comparison of three data analysis approaches. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8659779/),[kg(-·l] / [min],0.049,59846,DB00818,Propofol
,8659779,systemic clearance,"Results of population versus two-stage analysis are as follow: systemic clearance 0.049 versus 0.048 l.kg(-).min(-1), volume of central compartment 1.03 versus 0.95 l.kg(-1), volume of steady state 8.09 versus 8.17 l.kg(-1).",Pharmacokinetics of propofol after a single dose in children aged 1-3 years with minor burns. Comparison of three data analysis approaches. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8659779/),[kg(-·l] / [min],0.048,59847,DB00818,Propofol
,8659779,volume of central compartment,"Results of population versus two-stage analysis are as follow: systemic clearance 0.049 versus 0.048 l.kg(-).min(-1), volume of central compartment 1.03 versus 0.95 l.kg(-1), volume of steady state 8.09 versus 8.17 l.kg(-1).",Pharmacokinetics of propofol after a single dose in children aged 1-3 years with minor burns. Comparison of three data analysis approaches. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8659779/),[l] / [kg],1.03,59848,DB00818,Propofol
,8659779,volume of central compartment,"Results of population versus two-stage analysis are as follow: systemic clearance 0.049 versus 0.048 l.kg(-).min(-1), volume of central compartment 1.03 versus 0.95 l.kg(-1), volume of steady state 8.09 versus 8.17 l.kg(-1).",Pharmacokinetics of propofol after a single dose in children aged 1-3 years with minor burns. Comparison of three data analysis approaches. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8659779/),[l] / [kg],0.95,59849,DB00818,Propofol
,8659779,volume of steady state,"Results of population versus two-stage analysis are as follow: systemic clearance 0.049 versus 0.048 l.kg(-).min(-1), volume of central compartment 1.03 versus 0.95 l.kg(-1), volume of steady state 8.09 versus 8.17 l.kg(-1).",Pharmacokinetics of propofol after a single dose in children aged 1-3 years with minor burns. Comparison of three data analysis approaches. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8659779/),[l] / [kg],8.09,59850,DB00818,Propofol
,8659779,volume of steady state,"Results of population versus two-stage analysis are as follow: systemic clearance 0.049 versus 0.048 l.kg(-).min(-1), volume of central compartment 1.03 versus 0.95 l.kg(-1), volume of steady state 8.09 versus 8.17 l.kg(-1).",Pharmacokinetics of propofol after a single dose in children aged 1-3 years with minor burns. Comparison of three data analysis approaches. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8659779/),[l] / [kg],8.17,59851,DB00818,Propofol
,30115253,V1(L),"The parameter estimates were as follows: V1(L)=2.02, V2(L)=12.9(BMI/18.5), V3(L)=139, Cl (L⋅min-1)=1.66(LBM/40), Q1 (L⋅min-1)=1.44, Q2 (L⋅min-1)=0.87+0.0189×(LBM-40).",Population pharmacokinetic analysis of propofol in underweight patients under general anaesthesia. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30115253/),,2.02,61342,DB00818,Propofol
,30115253,V2(L),"The parameter estimates were as follows: V1(L)=2.02, V2(L)=12.9(BMI/18.5), V3(L)=139, Cl (L⋅min-1)=1.66(LBM/40), Q1 (L⋅min-1)=1.44, Q2 (L⋅min-1)=0.87+0.0189×(LBM-40).",Population pharmacokinetic analysis of propofol in underweight patients under general anaesthesia. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30115253/),,12.9,61343,DB00818,Propofol
,30115253,V3(L),"The parameter estimates were as follows: V1(L)=2.02, V2(L)=12.9(BMI/18.5), V3(L)=139, Cl (L⋅min-1)=1.66(LBM/40), Q1 (L⋅min-1)=1.44, Q2 (L⋅min-1)=0.87+0.0189×(LBM-40).",Population pharmacokinetic analysis of propofol in underweight patients under general anaesthesia. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30115253/),,139,61344,DB00818,Propofol
,30115253,Cl,"The parameter estimates were as follows: V1(L)=2.02, V2(L)=12.9(BMI/18.5), V3(L)=139, Cl (L⋅min-1)=1.66(LBM/40), Q1 (L⋅min-1)=1.44, Q2 (L⋅min-1)=0.87+0.0189×(LBM-40).",Population pharmacokinetic analysis of propofol in underweight patients under general anaesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30115253/),[l] / [min],1.,61345,DB00818,Propofol
,30115253,Q1,"The parameter estimates were as follows: V1(L)=2.02, V2(L)=12.9(BMI/18.5), V3(L)=139, Cl (L⋅min-1)=1.66(LBM/40), Q1 (L⋅min-1)=1.44, Q2 (L⋅min-1)=0.87+0.0189×(LBM-40).",Population pharmacokinetic analysis of propofol in underweight patients under general anaesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30115253/),[l] / [min],1.44,61346,DB00818,Propofol
,30115253,tpeak,The median tpeak of propofol was 1.32 min (n=48).,Population pharmacokinetic analysis of propofol in underweight patients under general anaesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30115253/),min,1.32,61347,DB00818,Propofol
,20510032,central compartment distribution volume [Vc,"During shock phase, comparing with central compartment distribution volume [Vc, (3.1 + or - 1.5) L/kg], area under curve [AUC, (25 + or - 7) mg x min x L(-1)], elimination phase half life [t1/2beta, (113 + or - 93) min], clearance [CLs, (110 + or - 50) mL x kg(-1) x min(-1)] of rabbits in sham injury group, Vc[(8.8 + or - 4.2) L x kg(-1)] and AUC [(44 + or - 10) mg x min x L(-1)] increased significantly (with t value respectively 3.191 and 3.668, and P values both below 0.01); t1/2beta [(339 + or - 258) min] prolonged (t = 2.932, P < 0.05); CLs [(40 + or - 30) mL x kg(-1) x min(-1)] decreased (t = -3.013, P < 0.05) in burn group.",[Pharmacokinetics differences of propofol during different pathological stages of severe burn in rabbits]. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20510032/),[l] / [kg],3.1,61578,DB00818,Propofol
,20510032,area under curve [AUC,"During shock phase, comparing with central compartment distribution volume [Vc, (3.1 + or - 1.5) L/kg], area under curve [AUC, (25 + or - 7) mg x min x L(-1)], elimination phase half life [t1/2beta, (113 + or - 93) min], clearance [CLs, (110 + or - 50) mL x kg(-1) x min(-1)] of rabbits in sham injury group, Vc[(8.8 + or - 4.2) L x kg(-1)] and AUC [(44 + or - 10) mg x min x L(-1)] increased significantly (with t value respectively 3.191 and 3.668, and P values both below 0.01); t1/2beta [(339 + or - 258) min] prolonged (t = 2.932, P < 0.05); CLs [(40 + or - 30) mL x kg(-1) x min(-1)] decreased (t = -3.013, P < 0.05) in burn group.",[Pharmacokinetics differences of propofol during different pathological stages of severe burn in rabbits]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20510032/),[mg·min] / [l],25,61579,DB00818,Propofol
,20510032,elimination phase half life [t1/2beta,"During shock phase, comparing with central compartment distribution volume [Vc, (3.1 + or - 1.5) L/kg], area under curve [AUC, (25 + or - 7) mg x min x L(-1)], elimination phase half life [t1/2beta, (113 + or - 93) min], clearance [CLs, (110 + or - 50) mL x kg(-1) x min(-1)] of rabbits in sham injury group, Vc[(8.8 + or - 4.2) L x kg(-1)] and AUC [(44 + or - 10) mg x min x L(-1)] increased significantly (with t value respectively 3.191 and 3.668, and P values both below 0.01); t1/2beta [(339 + or - 258) min] prolonged (t = 2.932, P < 0.05); CLs [(40 + or - 30) mL x kg(-1) x min(-1)] decreased (t = -3.013, P < 0.05) in burn group.",[Pharmacokinetics differences of propofol during different pathological stages of severe burn in rabbits]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20510032/),min,113,61580,DB00818,Propofol
,20510032,clearance [CLs,"During shock phase, comparing with central compartment distribution volume [Vc, (3.1 + or - 1.5) L/kg], area under curve [AUC, (25 + or - 7) mg x min x L(-1)], elimination phase half life [t1/2beta, (113 + or - 93) min], clearance [CLs, (110 + or - 50) mL x kg(-1) x min(-1)] of rabbits in sham injury group, Vc[(8.8 + or - 4.2) L x kg(-1)] and AUC [(44 + or - 10) mg x min x L(-1)] increased significantly (with t value respectively 3.191 and 3.668, and P values both below 0.01); t1/2beta [(339 + or - 258) min] prolonged (t = 2.932, P < 0.05); CLs [(40 + or - 30) mL x kg(-1) x min(-1)] decreased (t = -3.013, P < 0.05) in burn group.",[Pharmacokinetics differences of propofol during different pathological stages of severe burn in rabbits]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20510032/),[ml] / [kg·min],110,61581,DB00818,Propofol
,20510032,Vc,"During shock phase, comparing with central compartment distribution volume [Vc, (3.1 + or - 1.5) L/kg], area under curve [AUC, (25 + or - 7) mg x min x L(-1)], elimination phase half life [t1/2beta, (113 + or - 93) min], clearance [CLs, (110 + or - 50) mL x kg(-1) x min(-1)] of rabbits in sham injury group, Vc[(8.8 + or - 4.2) L x kg(-1)] and AUC [(44 + or - 10) mg x min x L(-1)] increased significantly (with t value respectively 3.191 and 3.668, and P values both below 0.01); t1/2beta [(339 + or - 258) min] prolonged (t = 2.932, P < 0.05); CLs [(40 + or - 30) mL x kg(-1) x min(-1)] decreased (t = -3.013, P < 0.05) in burn group.",[Pharmacokinetics differences of propofol during different pathological stages of severe burn in rabbits]. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20510032/),[l] / [kg],8.8,61582,DB00818,Propofol
,20510032,AUC,"During shock phase, comparing with central compartment distribution volume [Vc, (3.1 + or - 1.5) L/kg], area under curve [AUC, (25 + or - 7) mg x min x L(-1)], elimination phase half life [t1/2beta, (113 + or - 93) min], clearance [CLs, (110 + or - 50) mL x kg(-1) x min(-1)] of rabbits in sham injury group, Vc[(8.8 + or - 4.2) L x kg(-1)] and AUC [(44 + or - 10) mg x min x L(-1)] increased significantly (with t value respectively 3.191 and 3.668, and P values both below 0.01); t1/2beta [(339 + or - 258) min] prolonged (t = 2.932, P < 0.05); CLs [(40 + or - 30) mL x kg(-1) x min(-1)] decreased (t = -3.013, P < 0.05) in burn group.",[Pharmacokinetics differences of propofol during different pathological stages of severe burn in rabbits]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20510032/),[mg·min] / [l],44,61583,DB00818,Propofol
,20510032,t1/2beta,"During shock phase, comparing with central compartment distribution volume [Vc, (3.1 + or - 1.5) L/kg], area under curve [AUC, (25 + or - 7) mg x min x L(-1)], elimination phase half life [t1/2beta, (113 + or - 93) min], clearance [CLs, (110 + or - 50) mL x kg(-1) x min(-1)] of rabbits in sham injury group, Vc[(8.8 + or - 4.2) L x kg(-1)] and AUC [(44 + or - 10) mg x min x L(-1)] increased significantly (with t value respectively 3.191 and 3.668, and P values both below 0.01); t1/2beta [(339 + or - 258) min] prolonged (t = 2.932, P < 0.05); CLs [(40 + or - 30) mL x kg(-1) x min(-1)] decreased (t = -3.013, P < 0.05) in burn group.",[Pharmacokinetics differences of propofol during different pathological stages of severe burn in rabbits]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20510032/),min,339,61584,DB00818,Propofol
,20510032,CLs,"During shock phase, comparing with central compartment distribution volume [Vc, (3.1 + or - 1.5) L/kg], area under curve [AUC, (25 + or - 7) mg x min x L(-1)], elimination phase half life [t1/2beta, (113 + or - 93) min], clearance [CLs, (110 + or - 50) mL x kg(-1) x min(-1)] of rabbits in sham injury group, Vc[(8.8 + or - 4.2) L x kg(-1)] and AUC [(44 + or - 10) mg x min x L(-1)] increased significantly (with t value respectively 3.191 and 3.668, and P values both below 0.01); t1/2beta [(339 + or - 258) min] prolonged (t = 2.932, P < 0.05); CLs [(40 + or - 30) mL x kg(-1) x min(-1)] decreased (t = -3.013, P < 0.05) in burn group.",[Pharmacokinetics differences of propofol during different pathological stages of severe burn in rabbits]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20510032/),[ml] / [kg·min],40,61585,DB00818,Propofol
,20510032,CLs,"During hypermetabolic phase, CLs [(180 + or - 40) mL x kg(-1) x min(-1)] of rabbits in burn group was significantly higher than that in sham injury group [(90 + or - 30) mL x kg(-1) x min(-1), t = -3.013, P < 0.05].",[Pharmacokinetics differences of propofol during different pathological stages of severe burn in rabbits]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20510032/),[ml] / [kg·min],180,61586,DB00818,Propofol
,20510032,CLs,"During hypermetabolic phase, CLs [(180 + or - 40) mL x kg(-1) x min(-1)] of rabbits in burn group was significantly higher than that in sham injury group [(90 + or - 30) mL x kg(-1) x min(-1), t = -3.013, P < 0.05].",[Pharmacokinetics differences of propofol during different pathological stages of severe burn in rabbits]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20510032/),[ml] / [kg·min],90,61587,DB00818,Propofol
,20510032,Vc,"Comparing with those of rabbits in burn group during shock phase, Vc [(4.1 + or - 1.3) L/g] and AUC [(24 + or - 5) mg x min x L(-1)] decreased significantly (with t value respectively 2.979 and 3.766, and P value both below 0.01); distribution phase half time [t1/2alpha, shock phase (16.1 + or - 13.1) min and hypermetabolic phase (8.3 + or - 2.5) min] and t1/2beta [(55 + or - 19) min] shortened obviously (with t value respectively 9.065 and 8.795, and P values both below 0.01); CLs increased significantly (t = 4.238, P < 0.01) during hypermetabolic phase.",[Pharmacokinetics differences of propofol during different pathological stages of severe burn in rabbits]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20510032/),[l] / [g],4.1,61588,DB00818,Propofol
,20510032,AUC,"Comparing with those of rabbits in burn group during shock phase, Vc [(4.1 + or - 1.3) L/g] and AUC [(24 + or - 5) mg x min x L(-1)] decreased significantly (with t value respectively 2.979 and 3.766, and P value both below 0.01); distribution phase half time [t1/2alpha, shock phase (16.1 + or - 13.1) min and hypermetabolic phase (8.3 + or - 2.5) min] and t1/2beta [(55 + or - 19) min] shortened obviously (with t value respectively 9.065 and 8.795, and P values both below 0.01); CLs increased significantly (t = 4.238, P < 0.01) during hypermetabolic phase.",[Pharmacokinetics differences of propofol during different pathological stages of severe burn in rabbits]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20510032/),[mg·min] / [l],24,61589,DB00818,Propofol
,20510032,distribution phase half time [t1/2alpha,"Comparing with those of rabbits in burn group during shock phase, Vc [(4.1 + or - 1.3) L/g] and AUC [(24 + or - 5) mg x min x L(-1)] decreased significantly (with t value respectively 2.979 and 3.766, and P value both below 0.01); distribution phase half time [t1/2alpha, shock phase (16.1 + or - 13.1) min and hypermetabolic phase (8.3 + or - 2.5) min] and t1/2beta [(55 + or - 19) min] shortened obviously (with t value respectively 9.065 and 8.795, and P values both below 0.01); CLs increased significantly (t = 4.238, P < 0.01) during hypermetabolic phase.",[Pharmacokinetics differences of propofol during different pathological stages of severe burn in rabbits]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20510032/),min,16.1,61590,DB00818,Propofol
,20510032,distribution phase half time [t1/2alpha,"Comparing with those of rabbits in burn group during shock phase, Vc [(4.1 + or - 1.3) L/g] and AUC [(24 + or - 5) mg x min x L(-1)] decreased significantly (with t value respectively 2.979 and 3.766, and P value both below 0.01); distribution phase half time [t1/2alpha, shock phase (16.1 + or - 13.1) min and hypermetabolic phase (8.3 + or - 2.5) min] and t1/2beta [(55 + or - 19) min] shortened obviously (with t value respectively 9.065 and 8.795, and P values both below 0.01); CLs increased significantly (t = 4.238, P < 0.01) during hypermetabolic phase.",[Pharmacokinetics differences of propofol during different pathological stages of severe burn in rabbits]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20510032/),min,8.3,61591,DB00818,Propofol
,20510032,t1/2beta,"Comparing with those of rabbits in burn group during shock phase, Vc [(4.1 + or - 1.3) L/g] and AUC [(24 + or - 5) mg x min x L(-1)] decreased significantly (with t value respectively 2.979 and 3.766, and P value both below 0.01); distribution phase half time [t1/2alpha, shock phase (16.1 + or - 13.1) min and hypermetabolic phase (8.3 + or - 2.5) min] and t1/2beta [(55 + or - 19) min] shortened obviously (with t value respectively 9.065 and 8.795, and P values both below 0.01); CLs increased significantly (t = 4.238, P < 0.01) during hypermetabolic phase.",[Pharmacokinetics differences of propofol during different pathological stages of severe burn in rabbits]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20510032/),min,55,61592,DB00818,Propofol
,21862493,volume,A mean volume of 913 (82) ml of blood was drained before reaching circulatory collapse.,Influence of haemorrhage on the pseudo-steady-state remifentanil concentration in a swine model: a comparison with propofol and the effect of haemorrhagic shock stage. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21862493/),ml,913,63125,DB00818,Propofol
,3264711,apparent elimination half-life,"In the three patients in whom the sampling period exceeded 42 h, apparent elimination half-life (55.6 h) and apparent volume of distribution (1370 l) greatly exceeded previously published estimates and systemic blood clearance (1020 ml min-1) was much less than previous estimates.",Extended blood collection period required to define distribution and elimination kinetics of propofol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3264711/),h,55.6,63358,DB00818,Propofol
,3264711,apparent volume of distribution,"In the three patients in whom the sampling period exceeded 42 h, apparent elimination half-life (55.6 h) and apparent volume of distribution (1370 l) greatly exceeded previously published estimates and systemic blood clearance (1020 ml min-1) was much less than previous estimates.",Extended blood collection period required to define distribution and elimination kinetics of propofol. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3264711/),l,1370,63359,DB00818,Propofol
,3264711,systemic blood clearance,"In the three patients in whom the sampling period exceeded 42 h, apparent elimination half-life (55.6 h) and apparent volume of distribution (1370 l) greatly exceeded previously published estimates and systemic blood clearance (1020 ml min-1) was much less than previous estimates.",Extended blood collection period required to define distribution and elimination kinetics of propofol. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3264711/),[ml] / [min],1020,63360,DB00818,Propofol
,30671895,blood loss,"The median estimated blood loss was 1600 mL (IQR 1000-2300), and the median fluid balance at Tfinal was + 3200 mL (IQR 2320-4715).",Measuring the accuracy of propofol target-controlled infusion (TCI) before and after surgery with major blood loss. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30671895/),ml,1600,63613,DB00818,Propofol
,30671895,bispectral index,The median bispectral index (0-100) was 50 (IQR 42-54) and 49 (IQR 42-56) at the two respective time points.,Measuring the accuracy of propofol target-controlled infusion (TCI) before and after surgery with major blood loss. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30671895/),,50,63614,DB00818,Propofol
,30671895,bispectral index,The median bispectral index (0-100) was 50 (IQR 42-54) and 49 (IQR 42-56) at the two respective time points.,Measuring the accuracy of propofol target-controlled infusion (TCI) before and after surgery with major blood loss. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30671895/),,49,63615,DB00818,Propofol
,30671895,CTCI,"At Tinitial, median CTCI was 2.2 µmol/L (IQR 2-2.45) and Cblood was 2.0 µmol/L (bias 0.3 µmol/L, limits of agreement - 1.1 to 1.3, p = 0.33).",Measuring the accuracy of propofol target-controlled infusion (TCI) before and after surgery with major blood loss. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30671895/),[μM] / [l],2.2,63616,DB00818,Propofol
,30671895,Cblood,"At Tinitial, median CTCI was 2.2 µmol/L (IQR 2-2.45) and Cblood was 2.0 µmol/L (bias 0.3 µmol/L, limits of agreement - 1.1 to 1.3, p = 0.33).",Measuring the accuracy of propofol target-controlled infusion (TCI) before and after surgery with major blood loss. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30671895/),[μM] / [l],2.0,63617,DB00818,Propofol
,30671895,CTCI,"CTCI and Cblood at Tfinal were 2.0 µmol/L (IQR 1.6-2.2) and 1 µmol/L (IQR 0.8-1.4), respectively (bias 0.6 µmol/L, limits of agreement - 0.89 to 1.4, p < 0.0001).",Measuring the accuracy of propofol target-controlled infusion (TCI) before and after surgery with major blood loss. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30671895/),[μM] / [l],2.0,63618,DB00818,Propofol
,30671895,Cblood,"CTCI and Cblood at Tfinal were 2.0 µmol/L (IQR 1.6-2.2) and 1 µmol/L (IQR 0.8-1.4), respectively (bias 0.6 µmol/L, limits of agreement - 0.89 to 1.4, p < 0.0001).",Measuring the accuracy of propofol target-controlled infusion (TCI) before and after surgery with major blood loss. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30671895/),[μM] / [l],1,63619,DB00818,Propofol
,33415524,half-life,"The blood-brain equilibration half-life based on the ke0 estimates for ApEn at 2, 10, 30, 60 s and BIS were 4.31, 3.96, 5.78.",Do epoch lengths of hypnotic depth indicators affect estimated of blood-brain equilibration rate constants of propofol? ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33415524/),,4.31,63923,DB00818,Propofol
,33415524,half-life,"The blood-brain equilibration half-life based on the ke0 estimates for ApEn at 2, 10, 30, 60 s and BIS were 4.31, 3.96, 5.78.",Do epoch lengths of hypnotic depth indicators affect estimated of blood-brain equilibration rate constants of propofol? ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33415524/),,3.96,63924,DB00818,Propofol
,33415524,half-life,"The blood-brain equilibration half-life based on the ke0 estimates for ApEn at 2, 10, 30, 60 s and BIS were 4.31, 3.96, 5.78.",Do epoch lengths of hypnotic depth indicators affect estimated of blood-brain equilibration rate constants of propofol? ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33415524/),,5.78,63925,DB00818,Propofol
,33415524,Ce50,"6.54, 5.09 min, respectively, whereas the Ce50,LOC for ApEn at 2, 10, 30, 60 s and BIS were 1.55, 1.47, 1.28, 1.04, and 1.55 μg·ml-1, respectively.",Do epoch lengths of hypnotic depth indicators affect estimated of blood-brain equilibration rate constants of propofol? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33415524/),[μg] / [ml],1.55,63926,DB00818,Propofol
,33415524,Ce50,"6.54, 5.09 min, respectively, whereas the Ce50,LOC for ApEn at 2, 10, 30, 60 s and BIS were 1.55, 1.47, 1.28, 1.04, and 1.55 μg·ml-1, respectively.",Do epoch lengths of hypnotic depth indicators affect estimated of blood-brain equilibration rate constants of propofol? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33415524/),[μg] / [ml],1.47,63927,DB00818,Propofol
,33415524,Ce50,"6.54, 5.09 min, respectively, whereas the Ce50,LOC for ApEn at 2, 10, 30, 60 s and BIS were 1.55, 1.47, 1.28, 1.04, and 1.55 μg·ml-1, respectively.",Do epoch lengths of hypnotic depth indicators affect estimated of blood-brain equilibration rate constants of propofol? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33415524/),[μg] / [ml],1.28,63928,DB00818,Propofol
,33415524,Ce50,"6.54, 5.09 min, respectively, whereas the Ce50,LOC for ApEn at 2, 10, 30, 60 s and BIS were 1.55, 1.47, 1.28, 1.04, and 1.55 μg·ml-1, respectively.",Do epoch lengths of hypnotic depth indicators affect estimated of blood-brain equilibration rate constants of propofol? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33415524/),[μg] / [ml],1.04,63929,DB00818,Propofol
,23824662,peak sugammadex concentration,"The mean peak sugammadex concentration was 66.5 μg/mL, with exposure similar in the sevoflurane/propofol groups.",Effect of sugammadex on QT/QTc interval prolongation when combined with QTc-prolonging sevoflurane or propofol anaesthesia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23824662/),[μg] / [ml],66.5,65938,DB00818,Propofol
,11314830,peak arterial concentrations,"Under halothane anaesthesia, the peak arterial concentrations of each drug occurred at the end of the two-minute infusion, and was 42.3 mg/l and 12.3 mg/l for thiopentone and propofol, respectively.",The cerebral and systemic kinetics of thiopentone and propofol in halothane anaesthetized sheep. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11314830/),[mg] / [l],42.3,66366,DB00818,Propofol
,11314830,peak arterial concentrations,"Under halothane anaesthesia, the peak arterial concentrations of each drug occurred at the end of the two-minute infusion, and was 42.3 mg/l and 12.3 mg/l for thiopentone and propofol, respectively.",The cerebral and systemic kinetics of thiopentone and propofol in halothane anaesthetized sheep. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11314830/),[mg] / [l],12.3,66367,DB00818,Propofol
,11314830,systemic clearance,Propofol had a significantly larger systemic clearance (3.19 l/min) than thiopentone (0.99 l/min).,The cerebral and systemic kinetics of thiopentone and propofol in halothane anaesthetized sheep. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11314830/),[l] / [min],3.19,66368,DB00818,Propofol
,11314830,systemic clearance,Propofol had a significantly larger systemic clearance (3.19 l/min) than thiopentone (0.99 l/min).,The cerebral and systemic kinetics of thiopentone and propofol in halothane anaesthetized sheep. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11314830/),[l] / [min],0.99,66369,DB00818,Propofol
,11314830,extraction ratio,The extraction ratio across the brain near the end of the infusions (1.5 min) were 0.85 and 0.46 respectively.,The cerebral and systemic kinetics of thiopentone and propofol in halothane anaesthetized sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11314830/),,0.85,66370,DB00818,Propofol
,11314830,extraction ratio,The extraction ratio across the brain near the end of the infusions (1.5 min) were 0.85 and 0.46 respectively.,The cerebral and systemic kinetics of thiopentone and propofol in halothane anaesthetized sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11314830/),,0.46,66371,DB00818,Propofol
,18193918,clearance,The population distribution of propofol clearance was subsequently found to have a Gaussian distribution only in the log domain (mean value equivalent to 26.1 mL/kg/min).,Use of target controlled infusion to derive age and gender covariates for propofol clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18193918/),[ml] / [kg·min],26.1,66480,DB00818,Propofol
,18193918,clearance,"The distribution in the normal domain was consequently asymmetric, with a slight predominance of patients with high values of clearance (5% and 95% confidence limits 17.7 and 42.1 mL/kg/min, respectively).",Use of target controlled infusion to derive age and gender covariates for propofol clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18193918/),[ml] / [kg·min],5,66481,DB00818,Propofol
,18193918,clearance,"The distribution in the normal domain was consequently asymmetric, with a slight predominance of patients with high values of clearance (5% and 95% confidence limits 17.7 and 42.1 mL/kg/min, respectively).",Use of target controlled infusion to derive age and gender covariates for propofol clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18193918/),[ml] / [kg·min],17.7,66482,DB00818,Propofol
,18193918,clearance,"The distribution in the normal domain was consequently asymmetric, with a slight predominance of patients with high values of clearance (5% and 95% confidence limits 17.7 and 42.1 mL/kg/min, respectively).",Use of target controlled infusion to derive age and gender covariates for propofol clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18193918/),[ml] / [kg·min],42.1,66483,DB00818,Propofol
,18641105,Sedation success rates,"Sedation success rates were 88.7% and 27.5%, respectively (p < 0.0001).","A phase 3, randomized, double-blind study to assess the efficacy and safety of fospropofol disodium injection for moderate sedation in patients undergoing flexible bronchoscopy. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18641105/),%,88.7,66682,DB00818,Propofol
,18641105,Sedation success rates,"Sedation success rates were 88.7% and 27.5%, respectively (p < 0.0001).","A phase 3, randomized, double-blind study to assess the efficacy and safety of fospropofol disodium injection for moderate sedation in patients undergoing flexible bronchoscopy. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18641105/),%,27.5,66683,DB00818,Propofol
,18641105,time to full alertness,"The median time to full alertness was slightly longer for the 6.5 mg/kg dose (5.5 vs 3.0 min, respectively).","A phase 3, randomized, double-blind study to assess the efficacy and safety of fospropofol disodium injection for moderate sedation in patients undergoing flexible bronchoscopy. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18641105/),min,5.5,66684,DB00818,Propofol
,18641105,time to full alertness,"The median time to full alertness was slightly longer for the 6.5 mg/kg dose (5.5 vs 3.0 min, respectively).","A phase 3, randomized, double-blind study to assess the efficacy and safety of fospropofol disodium injection for moderate sedation in patients undergoing flexible bronchoscopy. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18641105/),min,3.0,66685,DB00818,Propofol
,2683416,half-lives,"The blood concentration-time profile of propofol after an iv bolus injection follows a three-compartment model with half-lives of 2-4 min, 30-45 min, and 3-63 h, respectively.",Clinical pharmacology of propofol: an intravenous anesthetic agent. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2683416/),min,2-4,68206,DB00818,Propofol
,2683416,half-lives,"The blood concentration-time profile of propofol after an iv bolus injection follows a three-compartment model with half-lives of 2-4 min, 30-45 min, and 3-63 h, respectively.",Clinical pharmacology of propofol: an intravenous anesthetic agent. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2683416/),min,30-45,68207,DB00818,Propofol
,2683416,half-lives,"The blood concentration-time profile of propofol after an iv bolus injection follows a three-compartment model with half-lives of 2-4 min, 30-45 min, and 3-63 h, respectively.",Clinical pharmacology of propofol: an intravenous anesthetic agent. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2683416/),h,3-63,68208,DB00818,Propofol
,22345868,ke0,Forty unpremedicated patients were randomized to group TE1 (Schnider's pharmacokinetic model with ke0 adapted to T(PEAK) = 74s) and TE2 (T(PEAK) = 96s).,The peak bispectral index time cannot predict early phase propofol pharmacodynamics with effect site-controlled infusion algorithm. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22345868/),s,74,68975,DB00818,Propofol
,22345868,ke0,Forty unpremedicated patients were randomized to group TE1 (Schnider's pharmacokinetic model with ke0 adapted to T(PEAK) = 74s) and TE2 (T(PEAK) = 96s).,The peak bispectral index time cannot predict early phase propofol pharmacodynamics with effect site-controlled infusion algorithm. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22345868/),s,96,68976,DB00818,Propofol
,6968566,Half-lives of the distribution phase,Half-lives of the distribution phase were extremely short (1-6 min) and the terminal half-lives were also short (16-55 min).,"Pharmacokinetics in laboratory animals of ICI 35 868, a new i.v. anaesthetic agent. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6968566/),min,1-6,69095,DB00818,Propofol
,6968566,terminal half-lives,Half-lives of the distribution phase were extremely short (1-6 min) and the terminal half-lives were also short (16-55 min).,"Pharmacokinetics in laboratory animals of ICI 35 868, a new i.v. anaesthetic agent. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6968566/),min,16-55,69096,DB00818,Propofol
,18052733,MAC,Isoflurane MAC was 1.32 +/- 0.14%.,Effects of perzinfotel on the minimum alveolar concentration of isoflurane in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18052733/),%,1.32,69482,DB00818,Propofol
,1989737,Vss,"The mean +/- SD Vss = 2.38 +/- 1.16 L.kg-1, Cl = 39.2 +/- 9.75 ml.min-1.kg-1 and t1/2 beta = 126 +/- 68.7 min.",Disposition of propofol infusions for caesarean section. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1989737/),[l] / [kg],2.38,69610,DB00818,Propofol
,1989737,Cl,"The mean +/- SD Vss = 2.38 +/- 1.16 L.kg-1, Cl = 39.2 +/- 9.75 ml.min-1.kg-1 and t1/2 beta = 126 +/- 68.7 min.",Disposition of propofol infusions for caesarean section. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1989737/),[ml] / [kg·min],39.2,69611,DB00818,Propofol
,1989737,t1/2 beta,"The mean +/- SD Vss = 2.38 +/- 1.16 L.kg-1, Cl = 39.2 +/- 9.75 ml.min-1.kg-1 and t1/2 beta = 126 +/- 68.7 min.",Disposition of propofol infusions for caesarean section. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1989737/),min,126,69612,DB00818,Propofol
,1989737,recovery times,"Maternal recovery times did not depend on the total dose of propofol but the concentration of propofol at the time of eye opening was greater in the high group than the low group (1.74 +/- 0.51 vs 1.24 +/- 0.32 micrograms.ml-1, P less than 0.01).",Disposition of propofol infusions for caesarean section. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1989737/),[μg] / [ml],1.74,69613,DB00818,Propofol
,1989737,recovery times,"Maternal recovery times did not depend on the total dose of propofol but the concentration of propofol at the time of eye opening was greater in the high group than the low group (1.74 +/- 0.51 vs 1.24 +/- 0.32 micrograms.ml-1, P less than 0.01).",Disposition of propofol infusions for caesarean section. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1989737/),[μg] / [ml],1.24,69614,DB00818,Propofol
,17529920,effect site concentration,Obese patients were intubated using a flexible fiberoptic bronchoscopic technique facilitated by a target controlled effect site concentration of remifentanil set at 2.5 ng/mL.,Effect of morbid obesity on kinetic of desflurane: wash-in wash-out curves and recovery times. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17529920/),[ng] / [ml],2.5,69936,DB00818,Propofol
,15816565,time to recovery,Clinical duration and the time to recovery of the train-of-four to 70% were prolonged in the renal failure group compared to control; 49 vs.,Pharmacokinetics and pharmacodynamics of rocuronium in patients with and without renal failure. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15816565/),,49,70584,DB00818,Propofol
,12694152,Distribution volume at steady-state,"Distribution volume at steady-state and clearance in the supine position was 180 and 0.92 l min- 1, respectively, and in the prone position 127 and 0.74 l min- 1, respectively, in spite of a continuous infusion of dopamine.",Propofol pharmacokinetics in a dwarfism patient. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12694152/),1·l·min-,180,70900,DB00818,Propofol
,12694152,Distribution volume at steady-state,"Distribution volume at steady-state and clearance in the supine position was 180 and 0.92 l min- 1, respectively, and in the prone position 127 and 0.74 l min- 1, respectively, in spite of a continuous infusion of dopamine.",Propofol pharmacokinetics in a dwarfism patient. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12694152/),1·l·min-,0.92,70901,DB00818,Propofol
,12694152,Distribution volume at steady-state,"Distribution volume at steady-state and clearance in the supine position was 180 and 0.92 l min- 1, respectively, and in the prone position 127 and 0.74 l min- 1, respectively, in spite of a continuous infusion of dopamine.",Propofol pharmacokinetics in a dwarfism patient. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12694152/),1·l·min-,127,70902,DB00818,Propofol
,12694152,clearance,"Distribution volume at steady-state and clearance in the supine position was 180 and 0.92 l min- 1, respectively, and in the prone position 127 and 0.74 l min- 1, respectively, in spite of a continuous infusion of dopamine.",Propofol pharmacokinetics in a dwarfism patient. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12694152/),1·l·min-,0.92,70903,DB00818,Propofol
,12694152,clearance,"Distribution volume at steady-state and clearance in the supine position was 180 and 0.92 l min- 1, respectively, and in the prone position 127 and 0.74 l min- 1, respectively, in spite of a continuous infusion of dopamine.",Propofol pharmacokinetics in a dwarfism patient. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12694152/),1·l·min-,127,70904,DB00818,Propofol
,12694152,clearance,"Distribution volume at steady-state and clearance in the supine position was 180 and 0.92 l min- 1, respectively, and in the prone position 127 and 0.74 l min- 1, respectively, in spite of a continuous infusion of dopamine.",Propofol pharmacokinetics in a dwarfism patient. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12694152/),1·l·min-,0.74,70905,DB00818,Propofol
,10608210,F(I)O2,"After an initial 90 min period of propofol infusion, rabbits were randomly allocated to one of three groups: hypoxia (F(I)O2 = 0.1), normoxia (F(I)O2 = 0.21), and hyperoxia (F(I)O2 = 1.0).",The influence of hypoxia and hyperoxia on the kinetics of propofol emulsion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10608210/),,0,71925,DB00818,Propofol
,10608210,F(I)O2,"After an initial 90 min period of propofol infusion, rabbits were randomly allocated to one of three groups: hypoxia (F(I)O2 = 0.1), normoxia (F(I)O2 = 0.21), and hyperoxia (F(I)O2 = 1.0).",The influence of hypoxia and hyperoxia on the kinetics of propofol emulsion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10608210/),,1.0,71926,DB00818,Propofol
,10608210,arterial propofol concentration,"The mean arterial propofol concentration at the end of infusion was higher in the hypoxia group (15.2 +/- 2.8 microg x mL(-1), mean +/- SD) than in the normoxia (7.4 +/- 1.7) and hyperoxia (8.0 +/- 1.9) groups (P < 0.05).",The influence of hypoxia and hyperoxia on the kinetics of propofol emulsion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10608210/),[μg] / [ml],15.2,71927,DB00818,Propofol
,10608210,arterial propofol concentration,"The mean arterial propofol concentration at the end of infusion was higher in the hypoxia group (15.2 +/- 2.8 microg x mL(-1), mean +/- SD) than in the normoxia (7.4 +/- 1.7) and hyperoxia (8.0 +/- 1.9) groups (P < 0.05).",The influence of hypoxia and hyperoxia on the kinetics of propofol emulsion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10608210/),[μg] / [ml],7.4,71928,DB00818,Propofol
,10608210,arterial propofol concentration,"The mean arterial propofol concentration at the end of infusion was higher in the hypoxia group (15.2 +/- 2.8 microg x mL(-1), mean +/- SD) than in the normoxia (7.4 +/- 1.7) and hyperoxia (8.0 +/- 1.9) groups (P < 0.05).",The influence of hypoxia and hyperoxia on the kinetics of propofol emulsion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10608210/),[μg] / [ml],8.0,71929,DB00818,Propofol
greater,15060510,hepatic extraction ratio,The hepatic extraction ratio of propofol was greater than 0.8 and remained constant throughout surgery.,"Changes in drug plasma concentrations of an extensively bound and highly extracted drug, propofol, in response to altered plasma binding. ",EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15060510/),,0.8,71947,DB00818,Propofol
,9661573,infusion rates,"The mean propofol infusion rates were higher in hyperthyroid than in patients with euthyroidism (median values Group H 10.0 mg.kg-1.h-1, Group E 6.5 mg.kg-1.h-1; P < 0.05), although the reverse was true for average propofol concentrations (Group H 1.8 micrograms/mL, Group E 3.3 micrograms/mL; P < 0.05).",Propofol clearance and distribution volume increase in patients with hyperthyroidism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9661573/),[mg] / [h·kg],10.0,72140,DB00818,Propofol
,9661573,infusion rates,"The mean propofol infusion rates were higher in hyperthyroid than in patients with euthyroidism (median values Group H 10.0 mg.kg-1.h-1, Group E 6.5 mg.kg-1.h-1; P < 0.05), although the reverse was true for average propofol concentrations (Group H 1.8 micrograms/mL, Group E 3.3 micrograms/mL; P < 0.05).",Propofol clearance and distribution volume increase in patients with hyperthyroidism. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9661573/),[mg] / [h·kg],6.5,72141,DB00818,Propofol
,9661573,clearance,Group H also had higher values for propofol clearance (5.1 L/min versus 2.5 L/min; P < 0.05) and distribution volume at steady state (10.0 L/kg versus 2.8 L/kg; P < 0.05).,Propofol clearance and distribution volume increase in patients with hyperthyroidism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9661573/),[l] / [min],5.1,72142,DB00818,Propofol
,9661573,clearance,Group H also had higher values for propofol clearance (5.1 L/min versus 2.5 L/min; P < 0.05) and distribution volume at steady state (10.0 L/kg versus 2.8 L/kg; P < 0.05).,Propofol clearance and distribution volume increase in patients with hyperthyroidism. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9661573/),[l] / [min],2.5,72143,DB00818,Propofol
,9661573,distribution volume at steady state,Group H also had higher values for propofol clearance (5.1 L/min versus 2.5 L/min; P < 0.05) and distribution volume at steady state (10.0 L/kg versus 2.8 L/kg; P < 0.05).,Propofol clearance and distribution volume increase in patients with hyperthyroidism. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9661573/),[l] / [kg],10.0,72144,DB00818,Propofol
,9661573,distribution volume at steady state,Group H also had higher values for propofol clearance (5.1 L/min versus 2.5 L/min; P < 0.05) and distribution volume at steady state (10.0 L/kg versus 2.8 L/kg; P < 0.05).,Propofol clearance and distribution volume increase in patients with hyperthyroidism. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9661573/),[l] / [kg],2.8,72145,DB00818,Propofol
,8198908,Recovery,Recovery was slowest with the propofol infusion (mean 39.8 (SD 12.9) min when eyes opened on command).,"Recovery after propofol infusion anaesthesia in children: comparison with propofol, thiopentone or halothane induction followed by halothane maintenance. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8198908/),min,39.8,72637,DB00818,Propofol
,8198908,recovery times,"The recovery times were significantly shorter with the three other techniques (propofol bolus 21.9 (9.9) min, thiopentone 23.4 (11.3) min, halothane 20.1 (8.9) min), and the choice among these three methods had no significant influence on the recovery profile.","Recovery after propofol infusion anaesthesia in children: comparison with propofol, thiopentone or halothane induction followed by halothane maintenance. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8198908/),min,21.9,72638,DB00818,Propofol
,8198908,recovery times,"The recovery times were significantly shorter with the three other techniques (propofol bolus 21.9 (9.9) min, thiopentone 23.4 (11.3) min, halothane 20.1 (8.9) min), and the choice among these three methods had no significant influence on the recovery profile.","Recovery after propofol infusion anaesthesia in children: comparison with propofol, thiopentone or halothane induction followed by halothane maintenance. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8198908/),min,23.4,72639,DB00818,Propofol
,8198908,recovery times,"The recovery times were significantly shorter with the three other techniques (propofol bolus 21.9 (9.9) min, thiopentone 23.4 (11.3) min, halothane 20.1 (8.9) min), and the choice among these three methods had no significant influence on the recovery profile.","Recovery after propofol infusion anaesthesia in children: comparison with propofol, thiopentone or halothane induction followed by halothane maintenance. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8198908/),min,20.1,72640,DB00818,Propofol
,19330248,Time to extubation,"Time to extubation after the end of propofol infusion was greater in the on-pump coronary artery bypass graft group (334 +/- 117 vs. 216 +/- 85 min, p = 0.04).",Effects of cardiopulmonary bypass on propofol pharmacokinetics and bispectral index during coronary surgery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19330248/),min,334,72893,DB00818,Propofol
,19330248,Time to extubation,"Time to extubation after the end of propofol infusion was greater in the on-pump coronary artery bypass graft group (334 +/- 117 vs. 216 +/- 85 min, p = 0.04).",Effects of cardiopulmonary bypass on propofol pharmacokinetics and bispectral index during coronary surgery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19330248/),min,216,72894,DB00818,Propofol
,19330248,biological,"Patients undergoing cardiopulmonary bypass had shorter biological (1.82 +/- 0.5 vs. 3.67 +/- 1.15 h, p < 0.01) and terminal elimination (6.27 +/- 1.29 vs. 10.5h +/- 2.18, p < 0.01) half-life values, as well as higher total plasma clearance (28.36 +/- 11.40 vs.18.29 +/- 7.67 mL/kg/min, p = 0.03), compared to patients in the off-pump coronary artery bypass graft group.",Effects of cardiopulmonary bypass on propofol pharmacokinetics and bispectral index during coronary surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19330248/),h,1.82,72895,DB00818,Propofol
,19330248,biological,"Patients undergoing cardiopulmonary bypass had shorter biological (1.82 +/- 0.5 vs. 3.67 +/- 1.15 h, p < 0.01) and terminal elimination (6.27 +/- 1.29 vs. 10.5h +/- 2.18, p < 0.01) half-life values, as well as higher total plasma clearance (28.36 +/- 11.40 vs.18.29 +/- 7.67 mL/kg/min, p = 0.03), compared to patients in the off-pump coronary artery bypass graft group.",Effects of cardiopulmonary bypass on propofol pharmacokinetics and bispectral index during coronary surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19330248/),h,3.67,72896,DB00818,Propofol
,19330248,terminal elimination,"Patients undergoing cardiopulmonary bypass had shorter biological (1.82 +/- 0.5 vs. 3.67 +/- 1.15 h, p < 0.01) and terminal elimination (6.27 +/- 1.29 vs. 10.5h +/- 2.18, p < 0.01) half-life values, as well as higher total plasma clearance (28.36 +/- 11.40 vs.18.29 +/- 7.67 mL/kg/min, p = 0.03), compared to patients in the off-pump coronary artery bypass graft group.",Effects of cardiopulmonary bypass on propofol pharmacokinetics and bispectral index during coronary surgery. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19330248/),h,6.27,72897,DB00818,Propofol
,19330248,terminal elimination,"Patients undergoing cardiopulmonary bypass had shorter biological (1.82 +/- 0.5 vs. 3.67 +/- 1.15 h, p < 0.01) and terminal elimination (6.27 +/- 1.29 vs. 10.5h +/- 2.18, p < 0.01) half-life values, as well as higher total plasma clearance (28.36 +/- 11.40 vs.18.29 +/- 7.67 mL/kg/min, p = 0.03), compared to patients in the off-pump coronary artery bypass graft group.",Effects of cardiopulmonary bypass on propofol pharmacokinetics and bispectral index during coronary surgery. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19330248/),h,10.5,72898,DB00818,Propofol
,19330248,total plasma clearance,"Patients undergoing cardiopulmonary bypass had shorter biological (1.82 +/- 0.5 vs. 3.67 +/- 1.15 h, p < 0.01) and terminal elimination (6.27 +/- 1.29 vs. 10.5h +/- 2.18, p < 0.01) half-life values, as well as higher total plasma clearance (28.36 +/- 11.40 vs.18.29 +/- 7.67 mL/kg/min, p = 0.03), compared to patients in the off-pump coronary artery bypass graft group.",Effects of cardiopulmonary bypass on propofol pharmacokinetics and bispectral index during coronary surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19330248/),[ml] / [kg·min],28.36,72899,DB00818,Propofol
,19330248,total plasma clearance,"Patients undergoing cardiopulmonary bypass had shorter biological (1.82 +/- 0.5 vs. 3.67 +/- 1.15 h, p < 0.01) and terminal elimination (6.27 +/- 1.29 vs. 10.5h +/- 2.18, p < 0.01) half-life values, as well as higher total plasma clearance (28.36 +/- 11.40 vs.18.29 +/- 7.67 mL/kg/min, p = 0.03), compared to patients in the off-pump coronary artery bypass graft group.",Effects of cardiopulmonary bypass on propofol pharmacokinetics and bispectral index during coronary surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19330248/),[ml] / [kg·min],18.29,72900,DB00818,Propofol
,10853884,clearance (Cl),"The average pharmacokinetic parameter estimates of clearance (Cl), volume of distribution at steady state (Vd,ss), elimination half-life (t1/2,beta) and distribution half-life (t1/2,alpha) observed in the three groups were 28 +/- 1.1 ml/kg/min, 1.8 +/- 0.12 l/kg, 94 +/- 4.1 min and 3.1 +/- 0.26 min, respectively (mean +/- SEM, n = 24) and no significant differences were noted between the three formulations (P > 0.05).",Pharmacokinetics and pharmacodynamics of propofol 6% SAZN versus propofol 1% SAZN and Diprivan-10 for short-term sedation following coronary artery bypass surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10853884/),[ml] / [kg·min],28,73010,DB00818,Propofol
,10853884,"volume of distribution at steady state (Vd,ss)","The average pharmacokinetic parameter estimates of clearance (Cl), volume of distribution at steady state (Vd,ss), elimination half-life (t1/2,beta) and distribution half-life (t1/2,alpha) observed in the three groups were 28 +/- 1.1 ml/kg/min, 1.8 +/- 0.12 l/kg, 94 +/- 4.1 min and 3.1 +/- 0.26 min, respectively (mean +/- SEM, n = 24) and no significant differences were noted between the three formulations (P > 0.05).",Pharmacokinetics and pharmacodynamics of propofol 6% SAZN versus propofol 1% SAZN and Diprivan-10 for short-term sedation following coronary artery bypass surgery. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10853884/),[l] / [kg],1.8,73011,DB00818,Propofol
,10853884,"volume of distribution at steady state (Vd,ss)","The average pharmacokinetic parameter estimates of clearance (Cl), volume of distribution at steady state (Vd,ss), elimination half-life (t1/2,beta) and distribution half-life (t1/2,alpha) observed in the three groups were 28 +/- 1.1 ml/kg/min, 1.8 +/- 0.12 l/kg, 94 +/- 4.1 min and 3.1 +/- 0.26 min, respectively (mean +/- SEM, n = 24) and no significant differences were noted between the three formulations (P > 0.05).",Pharmacokinetics and pharmacodynamics of propofol 6% SAZN versus propofol 1% SAZN and Diprivan-10 for short-term sedation following coronary artery bypass surgery. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10853884/),min,94,73012,DB00818,Propofol
,10853884,"elimination half-life (t1/2,beta)","The average pharmacokinetic parameter estimates of clearance (Cl), volume of distribution at steady state (Vd,ss), elimination half-life (t1/2,beta) and distribution half-life (t1/2,alpha) observed in the three groups were 28 +/- 1.1 ml/kg/min, 1.8 +/- 0.12 l/kg, 94 +/- 4.1 min and 3.1 +/- 0.26 min, respectively (mean +/- SEM, n = 24) and no significant differences were noted between the three formulations (P > 0.05).",Pharmacokinetics and pharmacodynamics of propofol 6% SAZN versus propofol 1% SAZN and Diprivan-10 for short-term sedation following coronary artery bypass surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10853884/),[l] / [kg],1.8,73013,DB00818,Propofol
,10853884,"elimination half-life (t1/2,beta)","The average pharmacokinetic parameter estimates of clearance (Cl), volume of distribution at steady state (Vd,ss), elimination half-life (t1/2,beta) and distribution half-life (t1/2,alpha) observed in the three groups were 28 +/- 1.1 ml/kg/min, 1.8 +/- 0.12 l/kg, 94 +/- 4.1 min and 3.1 +/- 0.26 min, respectively (mean +/- SEM, n = 24) and no significant differences were noted between the three formulations (P > 0.05).",Pharmacokinetics and pharmacodynamics of propofol 6% SAZN versus propofol 1% SAZN and Diprivan-10 for short-term sedation following coronary artery bypass surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10853884/),min,94,73014,DB00818,Propofol
,10853884,"distribution half-life (t1/2,alpha)","The average pharmacokinetic parameter estimates of clearance (Cl), volume of distribution at steady state (Vd,ss), elimination half-life (t1/2,beta) and distribution half-life (t1/2,alpha) observed in the three groups were 28 +/- 1.1 ml/kg/min, 1.8 +/- 0.12 l/kg, 94 +/- 4.1 min and 3.1 +/- 0.26 min, respectively (mean +/- SEM, n = 24) and no significant differences were noted between the three formulations (P > 0.05).",Pharmacokinetics and pharmacodynamics of propofol 6% SAZN versus propofol 1% SAZN and Diprivan-10 for short-term sedation following coronary artery bypass surgery. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10853884/),min,3.1,73015,DB00818,Propofol
,11512369,mean,"Propofol induction produced a smaller mean arterial pressure increase immediately after intubation than did thiopental induction in adult and elderly groups (101.0 +/- 18.5 and 104.0 +/- 21.1 mmHg in the propofol groups vs. 138.3 +/- 17.1 and 138.9 +/- 16.1 mmHg in the thiopental groups at 1 minute after intubation, p < 0.001 and p = 0.001, respectively).",Hemodynamic responses of thiopental and propofol in different-aged patients during endotracheal intubation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11512369/),mmhg,101.0,73765,DB00818,Propofol
,11512369,mean,"Propofol induction produced a smaller mean arterial pressure increase immediately after intubation than did thiopental induction in adult and elderly groups (101.0 +/- 18.5 and 104.0 +/- 21.1 mmHg in the propofol groups vs. 138.3 +/- 17.1 and 138.9 +/- 16.1 mmHg in the thiopental groups at 1 minute after intubation, p < 0.001 and p = 0.001, respectively).",Hemodynamic responses of thiopental and propofol in different-aged patients during endotracheal intubation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11512369/),mmhg,104.0,73766,DB00818,Propofol
,11512369,heart rate,"Differences in heart rate between propofol and thiopental groups were found in young and adult groups (85.1 +/- 9.2 and 81.7 +/- 10.9 in the propofol groups vs. 94.5 +/- 9.9 and 95.0 +/- 14.0 beats per minute in the thiopental groups at 1 minute after intubation, p = 0.041 and p = 0.029, respectively).",Hemodynamic responses of thiopental and propofol in different-aged patients during endotracheal intubation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11512369/),[beats] / [min],85.1,73767,DB00818,Propofol
,11512369,heart rate,"Differences in heart rate between propofol and thiopental groups were found in young and adult groups (85.1 +/- 9.2 and 81.7 +/- 10.9 in the propofol groups vs. 94.5 +/- 9.9 and 95.0 +/- 14.0 beats per minute in the thiopental groups at 1 minute after intubation, p = 0.041 and p = 0.029, respectively).",Hemodynamic responses of thiopental and propofol in different-aged patients during endotracheal intubation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11512369/),[beats] / [min],81.7,73768,DB00818,Propofol
,11512369,heart rate,"Differences in heart rate between propofol and thiopental groups were found in young and adult groups (85.1 +/- 9.2 and 81.7 +/- 10.9 in the propofol groups vs. 94.5 +/- 9.9 and 95.0 +/- 14.0 beats per minute in the thiopental groups at 1 minute after intubation, p = 0.041 and p = 0.029, respectively).",Hemodynamic responses of thiopental and propofol in different-aged patients during endotracheal intubation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11512369/),[beats] / [min],94.5,73769,DB00818,Propofol
,11512369,heart rate,"Differences in heart rate between propofol and thiopental groups were found in young and adult groups (85.1 +/- 9.2 and 81.7 +/- 10.9 in the propofol groups vs. 94.5 +/- 9.9 and 95.0 +/- 14.0 beats per minute in the thiopental groups at 1 minute after intubation, p = 0.041 and p = 0.029, respectively).",Hemodynamic responses of thiopental and propofol in different-aged patients during endotracheal intubation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11512369/),[beats] / [min],95.0,73770,DB00818,Propofol
,27088998,Peak plasma concentrations,Peak plasma concentrations were larger using the mucosal atomization device (median [range]: 1.9 [1.4-3.2] μg/mL) than the spray tube (1.1 [0.6-2.0] μg/mL; P = 0.0021).,The Pharmacokinetics of Atomized Lidocaine Administered via the Trachea: A Randomized Trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27088998/),[μg] / [ml],1.9,75318,DB00818,Propofol
,27088998,Peak plasma concentrations,Peak plasma concentrations were larger using the mucosal atomization device (median [range]: 1.9 [1.4-3.2] μg/mL) than the spray tube (1.1 [0.6-2.0] μg/mL; P = 0.0021).,The Pharmacokinetics of Atomized Lidocaine Administered via the Trachea: A Randomized Trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27088998/),[μg] / [ml],1.1,75319,DB00818,Propofol
,27088998,bioavailability,"Our pharmacokinetic model estimated a difference of bioavailability between the atomized and the nonatomized lidocaine (0.801 and 0.559 respectively, P = 0.0005), whereas our model estimated no difference in the absorption rate constant (0.00688/min).",The Pharmacokinetics of Atomized Lidocaine Administered via the Trachea: A Randomized Trial. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27088998/),,0.801,75320,DB00818,Propofol
,27088998,bioavailability,"Our pharmacokinetic model estimated a difference of bioavailability between the atomized and the nonatomized lidocaine (0.801 and 0.559 respectively, P = 0.0005), whereas our model estimated no difference in the absorption rate constant (0.00688/min).",The Pharmacokinetics of Atomized Lidocaine Administered via the Trachea: A Randomized Trial. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27088998/),,0.559,75321,DB00818,Propofol
,27088998,absorption rate constant,"Our pharmacokinetic model estimated a difference of bioavailability between the atomized and the nonatomized lidocaine (0.801 and 0.559 respectively, P = 0.0005), whereas our model estimated no difference in the absorption rate constant (0.00688/min).",The Pharmacokinetics of Atomized Lidocaine Administered via the Trachea: A Randomized Trial. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27088998/),1/[min],0.00688,75322,DB00818,Propofol
more,10618958,blood loss,We report a patient who underwent repeat orthotopic liver transplantation complicated by intraoperative blood loss of more than 59 litre.,Effect of haemorrhage on plasma propofol concentrations in a patient undergoing orthotopic liver transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10618958/),l,59,75856,DB00818,Propofol
,1859759,total body clearance,"The Caesarean section group had a total body clearance of (median) 31.5 (range 24.4-53.3) ml min-1 kg-1, apparent volume of distribution at steady state 5.10 (2.46-6.61) litre kg-1 and mean residence time 161 (52.3-251) min; values for the post-partum group were 33.8 (21.5-47.2) ml min-1 kg-1, 5.17 (3.47-8.09) litre kg-1 and 163 (92.3-238) min, respectively.",Disposition of propofol at caesarean section and in the postpartum period. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1859759/),[ml] / [kg·min],31.5,76535,DB00818,Propofol
,1859759,apparent volume of distribution at steady state,"The Caesarean section group had a total body clearance of (median) 31.5 (range 24.4-53.3) ml min-1 kg-1, apparent volume of distribution at steady state 5.10 (2.46-6.61) litre kg-1 and mean residence time 161 (52.3-251) min; values for the post-partum group were 33.8 (21.5-47.2) ml min-1 kg-1, 5.17 (3.47-8.09) litre kg-1 and 163 (92.3-238) min, respectively.",Disposition of propofol at caesarean section and in the postpartum period. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1859759/),[l] / [kg],5.10,76536,DB00818,Propofol
,1859759,mean residence time,"The Caesarean section group had a total body clearance of (median) 31.5 (range 24.4-53.3) ml min-1 kg-1, apparent volume of distribution at steady state 5.10 (2.46-6.61) litre kg-1 and mean residence time 161 (52.3-251) min; values for the post-partum group were 33.8 (21.5-47.2) ml min-1 kg-1, 5.17 (3.47-8.09) litre kg-1 and 163 (92.3-238) min, respectively.",Disposition of propofol at caesarean section and in the postpartum period. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1859759/),min,161,76537,DB00818,Propofol
,1859759,mean residence time,"The Caesarean section group had a total body clearance of (median) 31.5 (range 24.4-53.3) ml min-1 kg-1, apparent volume of distribution at steady state 5.10 (2.46-6.61) litre kg-1 and mean residence time 161 (52.3-251) min; values for the post-partum group were 33.8 (21.5-47.2) ml min-1 kg-1, 5.17 (3.47-8.09) litre kg-1 and 163 (92.3-238) min, respectively.",Disposition of propofol at caesarean section and in the postpartum period. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1859759/),[ml] / [kg·min],33.8,76538,DB00818,Propofol
,2390424,elimination half-life,"Values of elimination half-life ranged from 13.1 to 44.7 h, systemic clearance from 1.02 to 1.63 l h-1 and volume of distribution from 1390 to 3940 l and these were similar to those obtained with bolus administration.",Pharmacokinetics of propofol when given by intravenous infusion. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2390424/),h,13.1 to 44.7,76761,DB00818,Propofol
,2390424,systemic clearance,"Values of elimination half-life ranged from 13.1 to 44.7 h, systemic clearance from 1.02 to 1.63 l h-1 and volume of distribution from 1390 to 3940 l and these were similar to those obtained with bolus administration.",Pharmacokinetics of propofol when given by intravenous infusion. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2390424/),[l] / [h],1.02 to 1.63,76762,DB00818,Propofol
,2390424,volume of distribution,"Values of elimination half-life ranged from 13.1 to 44.7 h, systemic clearance from 1.02 to 1.63 l h-1 and volume of distribution from 1390 to 3940 l and these were similar to those obtained with bolus administration.",Pharmacokinetics of propofol when given by intravenous infusion. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2390424/),l,1390 to 3940,76763,DB00818,Propofol
,2390424,o,"The large volume of distribution is consistent with the high octanol/blood partition coefficient, which was found to be 72.0.",Pharmacokinetics of propofol when given by intravenous infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2390424/),,72.0,76764,DB00818,Propofol
,20003124,ke0,"The Ce estimated with Schnider (ke0=0.45/min), Marsh (ke0=1.21/min) and Marsh (ke0=0.26/min) at LOC were 4.40 +/- 1.45, 3.55 +/- 0.64 and 1.28 +/- 0.44 microg/ml during the bolus dose and 2.81 +/- 0.61, 2.50 +/- 0.39 and 1.72 +/- 0.41 microg/ml, during the infusion scheme (P<0.05).",Predictive ability of propofol effect-site concentrations during fast and slow infusion rates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20003124/),1/[min],0.45,76914,DB00818,Propofol
,20003124,ke0,"The Ce estimated with Schnider (ke0=0.45/min), Marsh (ke0=1.21/min) and Marsh (ke0=0.26/min) at LOC were 4.40 +/- 1.45, 3.55 +/- 0.64 and 1.28 +/- 0.44 microg/ml during the bolus dose and 2.81 +/- 0.61, 2.50 +/- 0.39 and 1.72 +/- 0.41 microg/ml, during the infusion scheme (P<0.05).",Predictive ability of propofol effect-site concentrations during fast and slow infusion rates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20003124/),1/[min],1.21,76915,DB00818,Propofol
,20003124,ke0,"The Ce estimated with Schnider (ke0=0.45/min), Marsh (ke0=1.21/min) and Marsh (ke0=0.26/min) at LOC were 4.40 +/- 1.45, 3.55 +/- 0.64 and 1.28 +/- 0.44 microg/ml during the bolus dose and 2.81 +/- 0.61, 2.50 +/- 0.39 and 1.72 +/- 0.41 microg/ml, during the infusion scheme (P<0.05).",Predictive ability of propofol effect-site concentrations during fast and slow infusion rates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20003124/),[μg] / [ml],0.26,76916,DB00818,Propofol
,20003124,ke0,"The Ce estimated with Schnider (ke0=0.45/min), Marsh (ke0=1.21/min) and Marsh (ke0=0.26/min) at LOC were 4.40 +/- 1.45, 3.55 +/- 0.64 and 1.28 +/- 0.44 microg/ml during the bolus dose and 2.81 +/- 0.61, 2.50 +/- 0.39 and 1.72 +/- 0.41 microg/ml, during the infusion scheme (P<0.05).",Predictive ability of propofol effect-site concentrations during fast and slow infusion rates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20003124/),[μg] / [ml],4.40,76917,DB00818,Propofol
,20003124,ke0,"The Ce estimated with Schnider (ke0=0.45/min), Marsh (ke0=1.21/min) and Marsh (ke0=0.26/min) at LOC were 4.40 +/- 1.45, 3.55 +/- 0.64 and 1.28 +/- 0.44 microg/ml during the bolus dose and 2.81 +/- 0.61, 2.50 +/- 0.39 and 1.72 +/- 0.41 microg/ml, during the infusion scheme (P<0.05).",Predictive ability of propofol effect-site concentrations during fast and slow infusion rates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20003124/),[μg] / [ml],3.55,76918,DB00818,Propofol
,20003124,ke0,"The Ce estimated with Schnider (ke0=0.45/min), Marsh (ke0=1.21/min) and Marsh (ke0=0.26/min) at LOC were 4.40 +/- 1.45, 3.55 +/- 0.64 and 1.28 +/- 0.44 microg/ml during the bolus dose and 2.81 +/- 0.61, 2.50 +/- 0.39 and 1.72 +/- 0.41 microg/ml, during the infusion scheme (P<0.05).",Predictive ability of propofol effect-site concentrations during fast and slow infusion rates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20003124/),[μg] / [ml],1.28,76919,DB00818,Propofol
,20003124,ke0,"The Ce estimated with Schnider (ke0=0.45/min), Marsh (ke0=1.21/min) and Marsh (ke0=0.26/min) at LOC were 4.40 +/- 1.45, 3.55 +/- 0.64 and 1.28 +/- 0.44 microg/ml during the bolus dose and 2.81 +/- 0.61, 2.50 +/- 0.39 and 1.72 +/- 0.41 microg/ml, during the infusion scheme (P<0.05).",Predictive ability of propofol effect-site concentrations during fast and slow infusion rates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20003124/),[μg] / [ml],2.81,76920,DB00818,Propofol
,20003124,ke0,"The Ce estimated with Schnider (ke0=0.45/min), Marsh (ke0=1.21/min) and Marsh (ke0=0.26/min) at LOC were 4.40 +/- 1.45, 3.55 +/- 0.64 and 1.28 +/- 0.44 microg/ml during the bolus dose and 2.81 +/- 0.61, 2.50 +/- 0.39 and 1.72 +/- 0.41 microg/ml, during the infusion scheme (P<0.05).",Predictive ability of propofol effect-site concentrations during fast and slow infusion rates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20003124/),[μg] / [ml],2.50,76921,DB00818,Propofol
,20003124,CSI,The CSI values observed at LOC were 70 +/- 4 during the bolus dose and 71 +/- 2 during the infusion scheme (NS).,Predictive ability of propofol effect-site concentrations during fast and slow infusion rates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20003124/),,70,76922,DB00818,Propofol
,20003124,CSI,The CSI values observed at LOC were 70 +/- 4 during the bolus dose and 71 +/- 2 during the infusion scheme (NS).,Predictive ability of propofol effect-site concentrations during fast and slow infusion rates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20003124/),,71,76923,DB00818,Propofol
,3257879,clearance,The clearance of propofol was significantly lower in the elderly (1.44 +/- 0.10 (SE) litre min-1) than in the younger patients (1.79 +/- 0.12 litre min-1).,Pharmacokinetics of propofol (diprivan) in elderly patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3257879/),[l] / [min],1.44,77947,DB00818,Propofol
,3257879,clearance,The clearance of propofol was significantly lower in the elderly (1.44 +/- 0.10 (SE) litre min-1) than in the younger patients (1.79 +/- 0.12 litre min-1).,Pharmacokinetics of propofol (diprivan) in elderly patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3257879/),[l] / [min],1.79,77948,DB00818,Propofol
,3257879,volume of the central compartment,The volume of the central compartment in the elderly patients was significantly smaller (19.6 +/- 5.2 litre) than that in the young (26.3 +/- 2.9 litre).,Pharmacokinetics of propofol (diprivan) in elderly patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3257879/),l,19.6,77949,DB00818,Propofol
,3257879,volume of the central compartment,The volume of the central compartment in the elderly patients was significantly smaller (19.6 +/- 5.2 litre) than that in the young (26.3 +/- 2.9 litre).,Pharmacokinetics of propofol (diprivan) in elderly patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3257879/),l,26.3,77950,DB00818,Propofol
,3257879,volume of distribution at equilibrium,"There was no difference in the volume of distribution at equilibrium (1608 +/- 246 litre in the elderly and 1757 +/- 360 litre in the young), in the volume of distribution at steady state (691 +/- 139 litre in the elderly and 771 +/- 236 litre in the young) or in the half-lives of distribution and elimination.",Pharmacokinetics of propofol (diprivan) in elderly patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3257879/),l,1608,77951,DB00818,Propofol
,3257879,volume of distribution at equilibrium,"There was no difference in the volume of distribution at equilibrium (1608 +/- 246 litre in the elderly and 1757 +/- 360 litre in the young), in the volume of distribution at steady state (691 +/- 139 litre in the elderly and 771 +/- 236 litre in the young) or in the half-lives of distribution and elimination.",Pharmacokinetics of propofol (diprivan) in elderly patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3257879/),l,1757,77952,DB00818,Propofol
,3257879,volume of distribution at steady state,"There was no difference in the volume of distribution at equilibrium (1608 +/- 246 litre in the elderly and 1757 +/- 360 litre in the young), in the volume of distribution at steady state (691 +/- 139 litre in the elderly and 771 +/- 236 litre in the young) or in the half-lives of distribution and elimination.",Pharmacokinetics of propofol (diprivan) in elderly patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3257879/),l,691,77953,DB00818,Propofol
,3257879,volume of distribution at steady state,"There was no difference in the volume of distribution at equilibrium (1608 +/- 246 litre in the elderly and 1757 +/- 360 litre in the young), in the volume of distribution at steady state (691 +/- 139 litre in the elderly and 771 +/- 236 litre in the young) or in the half-lives of distribution and elimination.",Pharmacokinetics of propofol (diprivan) in elderly patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3257879/),l,771,77954,DB00818,Propofol
,14766712,CL(cr),Forty adult ICU patients with normal/mildly impaired renal function (creatinine clearance [CL(cr)] 62.9 (sd) 14.5 ml min(-1); n=10) or moderate/severe renal impairment (CL(cr) 14.7 (15.7) ml min(-1); n=30) were included.,"Pharmacokinetics of remifentanil and its major metabolite, remifentanil acid, in ICU patients with renal impairment. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14766712/),[ml] / [min],14.7,78207,DB00818,Propofol
,14766712,clearance,"RA clearance in the moderate/severe group was reduced to about 25% that of the normal/mild group (41 (29) vs 176 (49) ml kg(-1) h(-1), P<0.0001).","Pharmacokinetics of remifentanil and its major metabolite, remifentanil acid, in ICU patients with renal impairment. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14766712/),[ml] / [h·kg],41,78208,DB00818,Propofol
,14766712,clearance,"RA clearance in the moderate/severe group was reduced to about 25% that of the normal/mild group (41 (29) vs 176 (49) ml kg(-1) h(-1), P<0.0001).","Pharmacokinetics of remifentanil and its major metabolite, remifentanil acid, in ICU patients with renal impairment. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14766712/),[ml] / [h·kg],176,78209,DB00818,Propofol
,14766712,Metabolic ratio,"Metabolic ratio, a predictor of the ratio of RA to remifentanil concentrations at steady state, was approximately eight-fold higher in the moderate/severe group relative to the normal/mild group (116 (110) vs 15 (4), P<0.0001).","Pharmacokinetics of remifentanil and its major metabolite, remifentanil acid, in ICU patients with renal impairment. ",Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14766712/),,116,78210,DB00818,Propofol
,14766712,Metabolic ratio,"Metabolic ratio, a predictor of the ratio of RA to remifentanil concentrations at steady state, was approximately eight-fold higher in the moderate/severe group relative to the normal/mild group (116 (110) vs 15 (4), P<0.0001).","Pharmacokinetics of remifentanil and its major metabolite, remifentanil acid, in ICU patients with renal impairment. ",Metabolic ratio-Q4,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14766712/),,15,78211,DB00818,Propofol
,14766712,Maximum RA levels,Maximum RA levels approached 700 ng ml(-1) in the moderate/severe group.,"Pharmacokinetics of remifentanil and its major metabolite, remifentanil acid, in ICU patients with renal impairment. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14766712/),[ng] / [ml],700,78212,DB00818,Propofol
,7784724,FiO2,"Anesthesia was induced with propofol (2 mg/kg), sufentanil (0.5 micrograms/kg), and vecuronium (0.08 mg/kg) and continued as total intravenous anesthesia with propofol (8 mg/kg/h) and oxygen in air (FiO2 = 0.33).",The technique of endobronchial lidocaine administration does not influence plasma concentration profiles and pharmacokinetic parameters in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7784724/),,0.,78336,DB00818,Propofol
,7784724,maximal mean plasma concentrations,Asorption of lidocaine in groups 1-3 resulted in maximal mean plasma concentrations ranging from 0.78 to 0.85 micrograms/ml after 16.9 to 22.4 min.,The technique of endobronchial lidocaine administration does not influence plasma concentration profiles and pharmacokinetic parameters in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7784724/),[μg] / [ml],0.78 to 0.85,78337,DB00818,Propofol
,20510522,volume of distribution of the central compartment (V(1)),"The volume of distribution of the central compartment (V(1)) was considerably greater in the burned than non-burned group (48.4 L vs. 27.6 L, respectively).",Population pharmacokinetics of a propofol bolus administered in patients with major burns. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20510522/),l,48.4,79097,DB00818,Propofol
,20510522,volume of distribution of the central compartment (V(1)),"The volume of distribution of the central compartment (V(1)) was considerably greater in the burned than non-burned group (48.4 L vs. 27.6 L, respectively).",Population pharmacokinetics of a propofol bolus administered in patients with major burns. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20510522/),l,27.6,79098,DB00818,Propofol
,20510522,clearances of the central (CL(1),"The clearances of the central (CL(1)) and slow peripheral (CL(3)) compartments were higher in burn patients (4.2 L/min vs. 1.7 L/min and 3.6 L/min vs. 1.1 L/min, respectively).",Population pharmacokinetics of a propofol bolus administered in patients with major burns. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20510522/),[l] / [min],4.2,79099,DB00818,Propofol
,20510522,clearances of the central (CL(1),"The clearances of the central (CL(1)) and slow peripheral (CL(3)) compartments were higher in burn patients (4.2 L/min vs. 1.7 L/min and 3.6 L/min vs. 1.1 L/min, respectively).",Population pharmacokinetics of a propofol bolus administered in patients with major burns. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20510522/),[l] / [min],1.7,79100,DB00818,Propofol
,20510522,clearances of the central (CL(1),"The clearances of the central (CL(1)) and slow peripheral (CL(3)) compartments were higher in burn patients (4.2 L/min vs. 1.7 L/min and 3.6 L/min vs. 1.1 L/min, respectively).",Population pharmacokinetics of a propofol bolus administered in patients with major burns. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20510522/),[l] / [min],3.6,79101,DB00818,Propofol
,17592350,effect-site concentrations,"At LOC1, predicted effect-site concentrations of propofol and remifentanil were, respectively, 3.6+/-1.2 microg/mL and 2.4+/-0.4 etag/mL.",Propofol and remifentanil effect-site concentrations estimated by pharmacokinetic simulation and bispectral index monitoring during craniotomy with intraoperative awakening for brain tumor resection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17592350/),[μg] / [ml],3.6,79380,DB00818,Propofol
,17592350,effect-site concentrations,"At LOC1, predicted effect-site concentrations of propofol and remifentanil were, respectively, 3.6+/-1.2 microg/mL and 2.4+/-0.4 etag/mL.",Propofol and remifentanil effect-site concentrations estimated by pharmacokinetic simulation and bispectral index monitoring during craniotomy with intraoperative awakening for brain tumor resection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17592350/),[etag] / [ml],2.4,79381,DB00818,Propofol
,17592350,effect-site concentrations,"At ROC1, predicted effect-site concentrations of propofol and remifentanil were, respectively, 2.1+/-0.3 microg/mL and 1.8+/-0.3 etag/mL.",Propofol and remifentanil effect-site concentrations estimated by pharmacokinetic simulation and bispectral index monitoring during craniotomy with intraoperative awakening for brain tumor resection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17592350/),[μg] / [ml],2.1,79382,DB00818,Propofol
,17592350,effect-site concentrations,"At ROC1, predicted effect-site concentrations of propofol and remifentanil were, respectively, 2.1+/-0.3 microg/mL and 1.8+/-0.3 etag/mL.",Propofol and remifentanil effect-site concentrations estimated by pharmacokinetic simulation and bispectral index monitoring during craniotomy with intraoperative awakening for brain tumor resection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17592350/),[etag] / [ml],1.8,79383,DB00818,Propofol
,17592350,effect-site concentrations,"At NT, predicted effect-site concentrations of propofol and remifentanil were, respectively, 0.9+/-0.3 microg/mL and 1.8+/-0.2 etag/mL.",Propofol and remifentanil effect-site concentrations estimated by pharmacokinetic simulation and bispectral index monitoring during craniotomy with intraoperative awakening for brain tumor resection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17592350/),[μg] / [ml],0.9,79384,DB00818,Propofol
,17592350,effect-site concentrations,"At NT, predicted effect-site concentrations of propofol and remifentanil were, respectively, 0.9+/-0.3 microg/mL and 1.8+/-0.2 etag/mL.",Propofol and remifentanil effect-site concentrations estimated by pharmacokinetic simulation and bispectral index monitoring during craniotomy with intraoperative awakening for brain tumor resection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17592350/),[etag] / [ml],1.8,79385,DB00818,Propofol
,17592350,effect-site concentrations,"At LOC2, predicted effect-site concentrations of propofol and remifentanil were, respectively, 2.1+/-0.2 microg/mL and 2.5+/-0.2 etag/mL.",Propofol and remifentanil effect-site concentrations estimated by pharmacokinetic simulation and bispectral index monitoring during craniotomy with intraoperative awakening for brain tumor resection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17592350/),[μg] / [ml],2.1,79386,DB00818,Propofol
,17592350,effect-site concentrations,"At LOC2, predicted effect-site concentrations of propofol and remifentanil were, respectively, 2.1+/-0.2 microg/mL and 2.5+/-0.2 etag/mL.",Propofol and remifentanil effect-site concentrations estimated by pharmacokinetic simulation and bispectral index monitoring during craniotomy with intraoperative awakening for brain tumor resection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17592350/),[etag] / [ml],2.5,79387,DB00818,Propofol
,17592350,effect-site concentrations,"At ROC2, predicted effect-site concentrations of propofol and remifentanil were, respectively, 1.2+/-0.5 microg/mL and 1.4+/-0.2 etag/mL (data are mean+/-SE).",Propofol and remifentanil effect-site concentrations estimated by pharmacokinetic simulation and bispectral index monitoring during craniotomy with intraoperative awakening for brain tumor resection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17592350/),[μg] / [ml],1.2,79388,DB00818,Propofol
,17592350,effect-site concentrations,"At ROC2, predicted effect-site concentrations of propofol and remifentanil were, respectively, 1.2+/-0.5 microg/mL and 1.4+/-0.2 etag/mL (data are mean+/-SE).",Propofol and remifentanil effect-site concentrations estimated by pharmacokinetic simulation and bispectral index monitoring during craniotomy with intraoperative awakening for brain tumor resection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17592350/),[etag] / [ml],1.4,79389,DB00818,Propofol
,8669668,central compartment volume,Optimal pharmacokinetic parameters were: central compartment volume = 6.0 l; second compartment volume = 49.5 l; third compartment volume = 429.3 l; Cl1 (elimination clearance) = 0.68 l/min; Cl2 (distribution clearance) = 1.97 l/min1; and Cl3 (distribution clearance) = 0.70 l/min.,Pharmacokinetics of propofol in adult patients undergoing coronary revascularization. The Multicenter Study of Perioperative Ischemia Research Group. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8669668/),l,6.0,79392,DB00818,Propofol
,8669668,second compartment volume,Optimal pharmacokinetic parameters were: central compartment volume = 6.0 l; second compartment volume = 49.5 l; third compartment volume = 429.3 l; Cl1 (elimination clearance) = 0.68 l/min; Cl2 (distribution clearance) = 1.97 l/min1; and Cl3 (distribution clearance) = 0.70 l/min.,Pharmacokinetics of propofol in adult patients undergoing coronary revascularization. The Multicenter Study of Perioperative Ischemia Research Group. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8669668/),l,49.5,79393,DB00818,Propofol
,8669668,third compartment volume,Optimal pharmacokinetic parameters were: central compartment volume = 6.0 l; second compartment volume = 49.5 l; third compartment volume = 429.3 l; Cl1 (elimination clearance) = 0.68 l/min; Cl2 (distribution clearance) = 1.97 l/min1; and Cl3 (distribution clearance) = 0.70 l/min.,Pharmacokinetics of propofol in adult patients undergoing coronary revascularization. The Multicenter Study of Perioperative Ischemia Research Group. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8669668/),l,429.3,79394,DB00818,Propofol
,8669668,Cl1 (elimination clearance),Optimal pharmacokinetic parameters were: central compartment volume = 6.0 l; second compartment volume = 49.5 l; third compartment volume = 429.3 l; Cl1 (elimination clearance) = 0.68 l/min; Cl2 (distribution clearance) = 1.97 l/min1; and Cl3 (distribution clearance) = 0.70 l/min.,Pharmacokinetics of propofol in adult patients undergoing coronary revascularization. The Multicenter Study of Perioperative Ischemia Research Group. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8669668/),[l] / [min],0.68,79395,DB00818,Propofol
,8669668,Cl2 (distribution clearance),Optimal pharmacokinetic parameters were: central compartment volume = 6.0 l; second compartment volume = 49.5 l; third compartment volume = 429.3 l; Cl1 (elimination clearance) = 0.68 l/min; Cl2 (distribution clearance) = 1.97 l/min1; and Cl3 (distribution clearance) = 0.70 l/min.,Pharmacokinetics of propofol in adult patients undergoing coronary revascularization. The Multicenter Study of Perioperative Ischemia Research Group. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8669668/),[l] / [min1],1.97,79396,DB00818,Propofol
,8669668,Cl3 (distribution clearance),Optimal pharmacokinetic parameters were: central compartment volume = 6.0 l; second compartment volume = 49.5 l; third compartment volume = 429.3 l; Cl1 (elimination clearance) = 0.68 l/min; Cl2 (distribution clearance) = 1.97 l/min1; and Cl3 (distribution clearance) = 0.70 l/min.,Pharmacokinetics of propofol in adult patients undergoing coronary revascularization. The Multicenter Study of Perioperative Ischemia Research Group. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8669668/),[l] / [min],0.70,79397,DB00818,Propofol
,8669668,V1,"The effects of CPB were optimally modeled by step changes in V1 and Cl1 to values of 15.9 and 1.95, respectively, with the institution of CPB.",Pharmacokinetics of propofol in adult patients undergoing coronary revascularization. The Multicenter Study of Perioperative Ischemia Research Group. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8669668/),,15.9,79398,DB00818,Propofol
,8669668,Cl1,"The effects of CPB were optimally modeled by step changes in V1 and Cl1 to values of 15.9 and 1.95, respectively, with the institution of CPB.",Pharmacokinetics of propofol in adult patients undergoing coronary revascularization. The Multicenter Study of Perioperative Ischemia Research Group. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8669668/),,1.95,79399,DB00818,Propofol
,17006727,BIS,General anesthesia was administered to 15 ASA I-II patients with a continuous infusion of propofol to maintain a BIS value of 45 +/- 5.,"The influence of sevoflurane on the bispectral index, regional cerebral oxygen saturation, and propofol concentration during propofol/N2O anesthesia. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17006727/),,45,79653,DB00818,Propofol
,17006727,concentration,"Propofol concentration was increased from 2.71 +/- 0.51 microg/ml to 3.30 +/- 0.57 microg/ml (P < 0.05) after sevoflurane application, and was returned to baseline after sevoflurane washout.","The influence of sevoflurane on the bispectral index, regional cerebral oxygen saturation, and propofol concentration during propofol/N2O anesthesia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17006727/),[μg] / [ml],2.71,79654,DB00818,Propofol
,17006727,concentration,"Propofol concentration was increased from 2.71 +/- 0.51 microg/ml to 3.30 +/- 0.57 microg/ml (P < 0.05) after sevoflurane application, and was returned to baseline after sevoflurane washout.","The influence of sevoflurane on the bispectral index, regional cerebral oxygen saturation, and propofol concentration during propofol/N2O anesthesia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17006727/),[μg] / [ml],3.30,79655,DB00818,Propofol
,29436891,intrinsic clearance (CLint = Vmax/Km,"Of 12 test UGT enzymes, UGT1A3 was the most active one toward alpinetin with an intrinsic clearance (CLint = Vmax/Km) value of 66.5 μl/min/nmol, followed by UGT1A1 (CLint = 48.6 μl/min/nmol), UGT1A9 (CLint = 21.0 μl/min/nmol), UGT2B15 (CLint = 16.7 μl/min/nmol) and UGT1A10 (CLint = 1.60 μl/min/nmol).",Identification of UGTs and BCRP as potential pharmacokinetic determinants of the natural flavonoid alpinetin. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29436891/),[μl] / [min·nM],66.5,79738,DB00818,Propofol
,29436891,CLint,"Of 12 test UGT enzymes, UGT1A3 was the most active one toward alpinetin with an intrinsic clearance (CLint = Vmax/Km) value of 66.5 μl/min/nmol, followed by UGT1A1 (CLint = 48.6 μl/min/nmol), UGT1A9 (CLint = 21.0 μl/min/nmol), UGT2B15 (CLint = 16.7 μl/min/nmol) and UGT1A10 (CLint = 1.60 μl/min/nmol).",Identification of UGTs and BCRP as potential pharmacokinetic determinants of the natural flavonoid alpinetin. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29436891/),[μl] / [min·nM],48.6,79739,DB00818,Propofol
,29436891,CLint,"Of 12 test UGT enzymes, UGT1A3 was the most active one toward alpinetin with an intrinsic clearance (CLint = Vmax/Km) value of 66.5 μl/min/nmol, followed by UGT1A1 (CLint = 48.6 μl/min/nmol), UGT1A9 (CLint = 21.0 μl/min/nmol), UGT2B15 (CLint = 16.7 μl/min/nmol) and UGT1A10 (CLint = 1.60 μl/min/nmol).",Identification of UGTs and BCRP as potential pharmacokinetic determinants of the natural flavonoid alpinetin. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29436891/),[μl] / [min·nM],21.0,79740,DB00818,Propofol
,29436891,CLint,"Of 12 test UGT enzymes, UGT1A3 was the most active one toward alpinetin with an intrinsic clearance (CLint = Vmax/Km) value of 66.5 μl/min/nmol, followed by UGT1A1 (CLint = 48.6 μl/min/nmol), UGT1A9 (CLint = 21.0 μl/min/nmol), UGT2B15 (CLint = 16.7 μl/min/nmol) and UGT1A10 (CLint = 1.60 μl/min/nmol).",Identification of UGTs and BCRP as potential pharmacokinetic determinants of the natural flavonoid alpinetin. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29436891/),[μl] / [min·nM],16.7,79741,DB00818,Propofol
,29436891,CLint,"Of 12 test UGT enzymes, UGT1A3 was the most active one toward alpinetin with an intrinsic clearance (CLint = Vmax/Km) value of 66.5 μl/min/nmol, followed by UGT1A1 (CLint = 48.6 μl/min/nmol), UGT1A9 (CLint = 21.0 μl/min/nmol), UGT2B15 (CLint = 16.7 μl/min/nmol) and UGT1A10 (CLint = 1.60 μl/min/nmol).",Identification of UGTs and BCRP as potential pharmacokinetic determinants of the natural flavonoid alpinetin. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29436891/),[μl] / [min·nM],1.60,79742,DB00818,Propofol
,24722258,V1,"Parameter estimates for a 35-year, 70-kg male patient were: 9.77, 29.0, 134 L, 1.53, 1.42, and 0.608 L/min for V1, V2, V3, CL, Q2, and Q3, respectively.",A general purpose pharmacokinetic model for propofol. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24722258/),l,9.77,80456,DB00818,Propofol
,24722258,V1,"Parameter estimates for a 35-year, 70-kg male patient were: 9.77, 29.0, 134 L, 1.53, 1.42, and 0.608 L/min for V1, V2, V3, CL, Q2, and Q3, respectively.",A general purpose pharmacokinetic model for propofol. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24722258/),l,29.0,80457,DB00818,Propofol
,24722258,V1,"Parameter estimates for a 35-year, 70-kg male patient were: 9.77, 29.0, 134 L, 1.53, 1.42, and 0.608 L/min for V1, V2, V3, CL, Q2, and Q3, respectively.",A general purpose pharmacokinetic model for propofol. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24722258/),l,134,80458,DB00818,Propofol
,24722258,V1,"Parameter estimates for a 35-year, 70-kg male patient were: 9.77, 29.0, 134 L, 1.53, 1.42, and 0.608 L/min for V1, V2, V3, CL, Q2, and Q3, respectively.",A general purpose pharmacokinetic model for propofol. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24722258/),[l] / [min],1.53,80459,DB00818,Propofol
,24722258,V1,"Parameter estimates for a 35-year, 70-kg male patient were: 9.77, 29.0, 134 L, 1.53, 1.42, and 0.608 L/min for V1, V2, V3, CL, Q2, and Q3, respectively.",A general purpose pharmacokinetic model for propofol. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24722258/),[l] / [min],1.42,80460,DB00818,Propofol
,24722258,V2,"Parameter estimates for a 35-year, 70-kg male patient were: 9.77, 29.0, 134 L, 1.53, 1.42, and 0.608 L/min for V1, V2, V3, CL, Q2, and Q3, respectively.",A general purpose pharmacokinetic model for propofol. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24722258/),[l] / [min],0.608,80461,DB00818,Propofol
,34281773,Fe',Anaesthesia was maintained with isoflurane in 50% oxygen (Fe'Iso 1.3-1.5%).,Influence of general anaesthesia on the intravenous acetaminophen pharmacokinetics in Beagle dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34281773/),%,1.3-1.5,81318,DB00818,Propofol
,34281773,volume of distribution,"No significant differences were found for volume of distribution values 1.41 (0.94-3.65) and 1.72 (0.89-2.60) L kg-1, clearance values 1.52 (0.71-2.30) and 1.60 (0.91-1.78) L kg-1 hour-1 or terminal elimination half-life values 2.45 (1.45-8.71) and 3.57 (1.96-6.35) hours between conscious and anaesthetized dogs, respectively.",Influence of general anaesthesia on the intravenous acetaminophen pharmacokinetics in Beagle dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34281773/),[l] / [kg],1.41,81319,DB00818,Propofol
,34281773,volume of distribution,"No significant differences were found for volume of distribution values 1.41 (0.94-3.65) and 1.72 (0.89-2.60) L kg-1, clearance values 1.52 (0.71-2.30) and 1.60 (0.91-1.78) L kg-1 hour-1 or terminal elimination half-life values 2.45 (1.45-8.71) and 3.57 (1.96-6.35) hours between conscious and anaesthetized dogs, respectively.",Influence of general anaesthesia on the intravenous acetaminophen pharmacokinetics in Beagle dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34281773/),[l] / [kg],1.72,81320,DB00818,Propofol
,34281773,clearance,"No significant differences were found for volume of distribution values 1.41 (0.94-3.65) and 1.72 (0.89-2.60) L kg-1, clearance values 1.52 (0.71-2.30) and 1.60 (0.91-1.78) L kg-1 hour-1 or terminal elimination half-life values 2.45 (1.45-8.71) and 3.57 (1.96-6.35) hours between conscious and anaesthetized dogs, respectively.",Influence of general anaesthesia on the intravenous acetaminophen pharmacokinetics in Beagle dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34281773/),[l] / [h·kg],1.52,81321,DB00818,Propofol
,34281773,clearance,"No significant differences were found for volume of distribution values 1.41 (0.94-3.65) and 1.72 (0.89-2.60) L kg-1, clearance values 1.52 (0.71-2.30) and 1.60 (0.91-1.78) L kg-1 hour-1 or terminal elimination half-life values 2.45 (1.45-8.71) and 3.57 (1.96-6.35) hours between conscious and anaesthetized dogs, respectively.",Influence of general anaesthesia on the intravenous acetaminophen pharmacokinetics in Beagle dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34281773/),[l] / [h·kg],1.60,81322,DB00818,Propofol
,34281773,terminal elimination half-life,"No significant differences were found for volume of distribution values 1.41 (0.94-3.65) and 1.72 (0.89-2.60) L kg-1, clearance values 1.52 (0.71-2.30) and 1.60 (0.91-1.78) L kg-1 hour-1 or terminal elimination half-life values 2.45 (1.45-8.71) and 3.57 (1.96-6.35) hours between conscious and anaesthetized dogs, respectively.",Influence of general anaesthesia on the intravenous acetaminophen pharmacokinetics in Beagle dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/34281773/),h,2.45,81323,DB00818,Propofol
,34281773,terminal elimination half-life,"No significant differences were found for volume of distribution values 1.41 (0.94-3.65) and 1.72 (0.89-2.60) L kg-1, clearance values 1.52 (0.71-2.30) and 1.60 (0.91-1.78) L kg-1 hour-1 or terminal elimination half-life values 2.45 (1.45-8.71) and 3.57 (1.96-6.35) hours between conscious and anaesthetized dogs, respectively.",Influence of general anaesthesia on the intravenous acetaminophen pharmacokinetics in Beagle dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/34281773/),h,3.57,81324,DB00818,Propofol
,23115086,t(1/2),"During TH, morphine elimination half-life (t(1/2)) was significantly higher, while total clearance (CL(tot)) was significantly lower (median [semi-interquartile range (s-iqr)]): t(1/2), 266 (43) versus 168 (11) minutes, P < 0.01; CL(tot), 1201 (283) versus 1687 (200) ml/min, P < 0.01.","Effects of hypothermia on the disposition of morphine, midazolam, fentanyl, and propofol in intensive care unit patients. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23115086/),min,266,81576,DB00818,Propofol
,23115086,t(1/2),"During TH, morphine elimination half-life (t(1/2)) was significantly higher, while total clearance (CL(tot)) was significantly lower (median [semi-interquartile range (s-iqr)]): t(1/2), 266 (43) versus 168 (11) minutes, P < 0.01; CL(tot), 1201 (283) versus 1687 (200) ml/min, P < 0.01.","Effects of hypothermia on the disposition of morphine, midazolam, fentanyl, and propofol in intensive care unit patients. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23115086/),min,168,81577,DB00818,Propofol
,23115086,CL(tot),"During TH, morphine elimination half-life (t(1/2)) was significantly higher, while total clearance (CL(tot)) was significantly lower (median [semi-interquartile range (s-iqr)]): t(1/2), 266 (43) versus 168 (11) minutes, P < 0.01; CL(tot), 1201 (283) versus 1687 (200) ml/min, P < 0.01.","Effects of hypothermia on the disposition of morphine, midazolam, fentanyl, and propofol in intensive care unit patients. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23115086/),[ml] / [min],1201,81578,DB00818,Propofol
,23115086,CL(tot),"During TH, morphine elimination half-life (t(1/2)) was significantly higher, while total clearance (CL(tot)) was significantly lower (median [semi-interquartile range (s-iqr)]): t(1/2), 266 (43) versus 168 (11) minutes, P < 0.01; CL(tot), 1201 (283) versus 1687 (200) ml/min, P < 0.01.","Effects of hypothermia on the disposition of morphine, midazolam, fentanyl, and propofol in intensive care unit patients. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23115086/),[ml] / [min],1687,81579,DB00818,Propofol
,23115086,CL(tot),"CL(tot) of fentanyl and propofol was significantly lower in hypothermic patients [median (s-iqr)]: fentanyl, 726 (230) versus 1331 (678) ml/min, P < 0.05; propofol, 2046 (305) versus 2665 (223) ml/min, P < 0.05.","Effects of hypothermia on the disposition of morphine, midazolam, fentanyl, and propofol in intensive care unit patients. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23115086/),[ml] / [min],726,81580,DB00818,Propofol
,23115086,CL(tot),"CL(tot) of fentanyl and propofol was significantly lower in hypothermic patients [median (s-iqr)]: fentanyl, 726 (230) versus 1331 (678) ml/min, P < 0.05; propofol, 2046 (305) versus 2665 (223) ml/min, P < 0.05.","Effects of hypothermia on the disposition of morphine, midazolam, fentanyl, and propofol in intensive care unit patients. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23115086/),[ml] / [min],1331,81581,DB00818,Propofol
,23115086,CL(tot),"CL(tot) of fentanyl and propofol was significantly lower in hypothermic patients [median (s-iqr)]: fentanyl, 726 (230) versus 1331 (678) ml/min, P < 0.05; propofol, 2046 (305) versus 2665 (223) ml/min, P < 0.05.","Effects of hypothermia on the disposition of morphine, midazolam, fentanyl, and propofol in intensive care unit patients. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23115086/),[ml] / [min],2046,81582,DB00818,Propofol
,23115086,CL(tot),"CL(tot) of fentanyl and propofol was significantly lower in hypothermic patients [median (s-iqr)]: fentanyl, 726 (230) versus 1331 (678) ml/min, P < 0.05; propofol, 2046 (305) versus 2665 (223) ml/min, P < 0.05.","Effects of hypothermia on the disposition of morphine, midazolam, fentanyl, and propofol in intensive care unit patients. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23115086/),[ml] / [min],2665,81583,DB00818,Propofol
,16394686,Clearance,"Clearance was 0.185 l/min, the volume of distribution of the central compartment was 7.41 l, the peripheral volumes of distribution were 54.6 and 7.2 l, and the intercompartmental clearances were 0.614 and 0.692 l/min for a child of the average weight of 13.7 kg.",Pharmacokinetics of a single bolus of propofol in chinese children of different ages. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16394686/),[l] / [min],0.185,82277,DB00818,Propofol
,16394686,volume of distribution of the central compartment,"Clearance was 0.185 l/min, the volume of distribution of the central compartment was 7.41 l, the peripheral volumes of distribution were 54.6 and 7.2 l, and the intercompartmental clearances were 0.614 and 0.692 l/min for a child of the average weight of 13.7 kg.",Pharmacokinetics of a single bolus of propofol in chinese children of different ages. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16394686/),l,7.41,82278,DB00818,Propofol
,16394686,peripheral volumes of distribution,"Clearance was 0.185 l/min, the volume of distribution of the central compartment was 7.41 l, the peripheral volumes of distribution were 54.6 and 7.2 l, and the intercompartmental clearances were 0.614 and 0.692 l/min for a child of the average weight of 13.7 kg.",Pharmacokinetics of a single bolus of propofol in chinese children of different ages. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16394686/),l,54.6,82279,DB00818,Propofol
,16394686,peripheral volumes of distribution,"Clearance was 0.185 l/min, the volume of distribution of the central compartment was 7.41 l, the peripheral volumes of distribution were 54.6 and 7.2 l, and the intercompartmental clearances were 0.614 and 0.692 l/min for a child of the average weight of 13.7 kg.",Pharmacokinetics of a single bolus of propofol in chinese children of different ages. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16394686/),l,7.2,82280,DB00818,Propofol
,16394686,intercompartmental clearances,"Clearance was 0.185 l/min, the volume of distribution of the central compartment was 7.41 l, the peripheral volumes of distribution were 54.6 and 7.2 l, and the intercompartmental clearances were 0.614 and 0.692 l/min for a child of the average weight of 13.7 kg.",Pharmacokinetics of a single bolus of propofol in chinese children of different ages. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16394686/),[l] / [min],0.614,82281,DB00818,Propofol
,16394686,intercompartmental clearances,"Clearance was 0.185 l/min, the volume of distribution of the central compartment was 7.41 l, the peripheral volumes of distribution were 54.6 and 7.2 l, and the intercompartmental clearances were 0.614 and 0.692 l/min for a child of the average weight of 13.7 kg.",Pharmacokinetics of a single bolus of propofol in chinese children of different ages. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16394686/),[l] / [min],0.692,82282,DB00818,Propofol
,16394686,half-lives,"The half-lives were 2.67, 14.89, and 310.60 min.",Pharmacokinetics of a single bolus of propofol in chinese children of different ages. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16394686/),min,2.67,82283,DB00818,Propofol
,16394686,half-lives,"The half-lives were 2.67, 14.89, and 310.60 min.",Pharmacokinetics of a single bolus of propofol in chinese children of different ages. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16394686/),min,14.89,82284,DB00818,Propofol
,16394686,half-lives,"The half-lives were 2.67, 14.89, and 310.60 min.",Pharmacokinetics of a single bolus of propofol in chinese children of different ages. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16394686/),min,310.60,82285,DB00818,Propofol
,12459662,initial steady state concentration,Twenty-one patients with advanced Parkinson disease undergoing functional stereotactic surgery were included in the study and received propofol target-controlled infusion to achieve an initial steady state concentration of 1 microg/ml.,Modeling of the sedative and airway obstruction effects of propofol in patients with Parkinson disease undergoing stereotactic surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12459662/),[μg] / [ml],1,82503,DB00818,Propofol
,12459662,C(50),"The estimates of C(50) for Ramsay scores 3, 4, and 5 were 0.1, 1.02, and 2.28 microg/ml, respectively.",Modeling of the sedative and airway obstruction effects of propofol in patients with Parkinson disease undergoing stereotactic surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12459662/),[μg] / [ml],0.1,82504,DB00818,Propofol
,12459662,C(50),"The estimates of C(50) for Ramsay scores 3, 4, and 5 were 0.1, 1.02, and 2.28 microg/ml, respectively.",Modeling of the sedative and airway obstruction effects of propofol in patients with Parkinson disease undergoing stereotactic surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12459662/),[μg] / [ml],1.02,82505,DB00818,Propofol
,12459662,C(50),"The estimates of C(50) for Ramsay scores 3, 4, and 5 were 0.1, 1.02, and 2.28 microg/ml, respectively.",Modeling of the sedative and airway obstruction effects of propofol in patients with Parkinson disease undergoing stereotactic surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12459662/),[μg] / [ml],2.28,82506,DB00818,Propofol
,12459662,C(50),"For airway obstruction scores 2 and 3, the estimates of C(50) were 0.32 and 2.98 microg/ml, respectively.",Modeling of the sedative and airway obstruction effects of propofol in patients with Parkinson disease undergoing stereotactic surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12459662/),[μg] / [ml],0.32,82507,DB00818,Propofol
,12459662,C(50),"For airway obstruction scores 2 and 3, the estimates of C(50) were 0.32 and 2.98 microg/ml, respectively.",Modeling of the sedative and airway obstruction effects of propofol in patients with Parkinson disease undergoing stereotactic surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12459662/),[μg] / [ml],2.98,82508,DB00818,Propofol
,12459662,k(e0),"Estimates of k(e0) were 0.24 and 0.5 1/min for the sedation and respiratory effects, respectively.",Modeling of the sedative and airway obstruction effects of propofol in patients with Parkinson disease undergoing stereotactic surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12459662/),[1] / [min],0.24,82509,DB00818,Propofol
,12459662,k(e0),"Estimates of k(e0) were 0.24 and 0.5 1/min for the sedation and respiratory effects, respectively.",Modeling of the sedative and airway obstruction effects of propofol in patients with Parkinson disease undergoing stereotactic surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12459662/),[1] / [min],0.5,82510,DB00818,Propofol
,12459662,steady state plasma propofol concentration,"Based on the results from the final models, a typical steady state plasma propofol concentration of 0.35 microg/ml eliciting a sedation score of 3 with only minimal, if any, airway obstruction has been defined as the therapeutic target.",Modeling of the sedative and airway obstruction effects of propofol in patients with Parkinson disease undergoing stereotactic surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12459662/),[μg] / [ml],0.35,82511,DB00818,Propofol
,10691226,half-life,"In group II, the effect site was computed using a half-life for plasma effect-site equilibration (t1/2k(eo)) of 3.5 min.",Comparison of plasma compartment versus two methods for effect compartment--controlled target-controlled infusion for propofol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10691226/),min,3.5,82558,DB00818,Propofol
,10691226,t1/2k(eo)),"In group II, the effect site was computed using a half-life for plasma effect-site equilibration (t1/2k(eo)) of 3.5 min.",Comparison of plasma compartment versus two methods for effect compartment--controlled target-controlled infusion for propofol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10691226/),min,3.5,82559,DB00818,Propofol
,10691226,time to peak effect,"In group III, plasma effect-site equilibration rate constant (k(eo)) was computed to yield a time to peak effect of 1.6 min after bolus injection, yielding a t1/2keo of 34 s.",Comparison of plasma compartment versus two methods for effect compartment--controlled target-controlled infusion for propofol. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10691226/),min,1.6,82560,DB00818,Propofol
,10691226,t1/2keo,"In group III, plasma effect-site equilibration rate constant (k(eo)) was computed to yield a time to peak effect of 1.6 min after bolus injection, yielding a t1/2keo of 34 s.",Comparison of plasma compartment versus two methods for effect compartment--controlled target-controlled infusion for propofol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10691226/),s,34,82561,DB00818,Propofol
,10691226,time to peak effect,A biophase model combining the Marsh kinetics and a time to peak effect of 1.6 min accurately predicted the time course of propofol drug effect.,Comparison of plasma compartment versus two methods for effect compartment--controlled target-controlled infusion for propofol. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10691226/),min,1.6,82562,DB00818,Propofol
,7880705,CI,"Propofol CI and Vss, normalized for body weight, were similar in children with biliary atresia (mean 37.5 (SD 8.3) ml min-1 kg-1 and 3.5 (1.6) litre kg-1, respectively) compared with control children (38.7 (6.8) ml min-1 kg-1 and 2.4 (0.8) litre-1 kg-1, respectively).",Propofol pharmacokinetics in children with biliary atresia. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7880705/),[ml] / [kg·min],37.5,83101,DB00818,Propofol
,7880705,CI,"Propofol CI and Vss, normalized for body weight, were similar in children with biliary atresia (mean 37.5 (SD 8.3) ml min-1 kg-1 and 3.5 (1.6) litre kg-1, respectively) compared with control children (38.7 (6.8) ml min-1 kg-1 and 2.4 (0.8) litre-1 kg-1, respectively).",Propofol pharmacokinetics in children with biliary atresia. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7880705/),[ml] / [kg·min],38.7,83102,DB00818,Propofol
,7880705,Vss,"Propofol CI and Vss, normalized for body weight, were similar in children with biliary atresia (mean 37.5 (SD 8.3) ml min-1 kg-1 and 3.5 (1.6) litre kg-1, respectively) compared with control children (38.7 (6.8) ml min-1 kg-1 and 2.4 (0.8) litre-1 kg-1, respectively).",Propofol pharmacokinetics in children with biliary atresia. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7880705/),[l] / [kg],3.5,83103,DB00818,Propofol
,7880705,Vss,"Propofol CI and Vss, normalized for body weight, were similar in children with biliary atresia (mean 37.5 (SD 8.3) ml min-1 kg-1 and 3.5 (1.6) litre kg-1, respectively) compared with control children (38.7 (6.8) ml min-1 kg-1 and 2.4 (0.8) litre-1 kg-1, respectively).",Propofol pharmacokinetics in children with biliary atresia. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7880705/),1/[kg·l],2.4,83104,DB00818,Propofol
,16169890,Apparent systemic clearances,"Apparent systemic clearances in the dissection, anhepatic and reperfusion phases were 1.89 (sd 0.48) litre min(-1), 1.08 (0.25) litre min(-1) and 1.53 (0.51) litre min(-1), respectively.",Changes in apparent systemic clearance of propofol during transplantation of living related donor liver. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16169890/),[l] / [min],1.89,85040,DB00818,Propofol
,16169890,Apparent systemic clearances,"Apparent systemic clearances in the dissection, anhepatic and reperfusion phases were 1.89 (sd 0.48) litre min(-1), 1.08 (0.25) litre min(-1) and 1.53 (0.51) litre min(-1), respectively.",Changes in apparent systemic clearance of propofol during transplantation of living related donor liver. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16169890/),[l] / [min],1.08,85041,DB00818,Propofol
,16169890,Apparent systemic clearances,"Apparent systemic clearances in the dissection, anhepatic and reperfusion phases were 1.89 (sd 0.48) litre min(-1), 1.08 (0.25) litre min(-1) and 1.53 (0.51) litre min(-1), respectively.",Changes in apparent systemic clearance of propofol during transplantation of living related donor liver. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16169890/),[l] / [min],1.53,85042,DB00818,Propofol
,16169890,intestinal extraction ratio,The intestinal extraction ratio calculated from the concentration in the radial artery and portal vein was 0.24 (0.12).,Changes in apparent systemic clearance of propofol during transplantation of living related donor liver. ,E-Q38,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16169890/),,0.24,85043,DB00818,Propofol
,19290949,t(peak),Average t(peak) was 3.1 min resulting in a k(e0) of 0.7230 min(-1).,A step towards effect-site target-controlled infusion with propofol in dogs: a k(e0) for propofol. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19290949/),min,3.1,85578,DB00818,Propofol
,19290949,k(e0),Average t(peak) was 3.1 min resulting in a k(e0) of 0.7230 min(-1).,A step towards effect-site target-controlled infusion with propofol in dogs: a k(e0) for propofol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19290949/),1/[min],0.7230,85579,DB00818,Propofol
,10589629,plasma concentrations,"Unbound ropivacaine plasma concentrations peaked after 15 min at 0.08+/-0.09 microg/mL; the maximum was 0.30 microg/mL, compared with a toxic threshold of 0.6 microg/mL.",Wound infiltration and drain lavage with ropivacaine after major shoulder surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589629/),[μg] / [ml],0.08,85621,DB00818,Propofol
,10589629,maximum,"Unbound ropivacaine plasma concentrations peaked after 15 min at 0.08+/-0.09 microg/mL; the maximum was 0.30 microg/mL, compared with a toxic threshold of 0.6 microg/mL.",Wound infiltration and drain lavage with ropivacaine after major shoulder surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10589629/),[μg] / [ml],0.30,85622,DB00818,Propofol
,11799580,target concentrations,"In general, optimal propofol target concentrations to assure this are 5 micrograms/ml in the presence of fentanyl, 3.5 micrograms/ml in the presence of alfentanil and sufentanil and 2.5 micrograms/ml in the presence of remifentanil.",Clinical interpretation of pharmacokinetic and pharmacodynamic propofol-opioid interactions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11799580/),[μg] / [ml],5,86024,DB00818,Propofol
,11799580,target concentrations,"In general, optimal propofol target concentrations to assure this are 5 micrograms/ml in the presence of fentanyl, 3.5 micrograms/ml in the presence of alfentanil and sufentanil and 2.5 micrograms/ml in the presence of remifentanil.",Clinical interpretation of pharmacokinetic and pharmacodynamic propofol-opioid interactions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11799580/),[μg] / [ml],3.5,86025,DB00818,Propofol
,11799580,target concentrations,"In general, optimal propofol target concentrations to assure this are 5 micrograms/ml in the presence of fentanyl, 3.5 micrograms/ml in the presence of alfentanil and sufentanil and 2.5 micrograms/ml in the presence of remifentanil.",Clinical interpretation of pharmacokinetic and pharmacodynamic propofol-opioid interactions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11799580/),[μg] / [ml],2.5,86026,DB00818,Propofol
,22337791,flow rate,"The mobile phase was a mixture of water (pH 4.0) and acetonitrile, with a flow rate of 1.5 mL/min.",Determination of propofol using high performance liquid chromatography in whole blood with fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22337791/),[ml] / [min],1.5,86154,DB00818,Propofol
,22337791,standard curve,The standard curve ranged from 5-2000 ng/mL.,Determination of propofol using high performance liquid chromatography in whole blood with fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22337791/),[ng] / [ml],5-2000,86155,DB00818,Propofol
,9054254,Cp50,The propofol Cp50 with nitrous oxide was 3.85 micrograms/ ml.,Esmolol reduces anesthetic requirement for skin incision during propofol/nitrous oxide/morphine anesthesia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9054254/),[μg] / [ml],3.85,86430,DB00818,Propofol
,9054254,Cp50,High-dose esmolol infusion was associated with a significant reduction in the Cp50 to 2.80 micrograms/ml (P < 0.04).,Esmolol reduces anesthetic requirement for skin incision during propofol/nitrous oxide/morphine anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9054254/),[μg] / [ml],2.80,86431,DB00818,Propofol
,22558495,C(p),"Sixty female patients were randomly assigned to TCI using Marsh PK (Group M) and TCI using Schnider PK (Group S) targeting 6.0 µg/ml of C(p) of propofol for induction of anesthesia, and loss of responsiveness (LOR) was evaluated.",Cross-simulation between two pharmacokinetic models for the target-controlled infusion of propofol. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22558495/),[μg] / [ml],6.0,88690,DB00818,Propofol
over,8340465,absolute recoveries,The absolute recoveries were over 96% (n = 3).,Quantitation of propofol in plasma by capillary gas chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8340465/),%,96,90781,DB00818,Propofol
,9504432,half-life (t1/2kE0),This formulation is characterized by rapid onset and offset of effect after rapid intravenous administration and an effect-site equilibration half-life (t1/2kE0) of 1.7 min in rats.,Formulation-dependent pharmacokinetics and pharmacodynamics of propofol in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9504432/),min,1.7,91048,DB00818,Propofol
,9504432,t1/2kE0,Compared with the emulsion formulation the distribution volumes (VdC and VdSS) were significantly higher but the t1/2kE0 (2.0 min) was similar for the lipid-free formulation.,Formulation-dependent pharmacokinetics and pharmacodynamics of propofol in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9504432/),min,2.0,91049,DB00818,Propofol
,22690673,Central volume of distribution,"Central volume of distribution, peripheral volume and intercompartmental clearance were 45.2 L, 128 L and 1.75 L/min, respectively, with no predictive covariates identifiable.",Propofol clearance in morbidly obese children and adolescents: influence of age and body size. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22690673/),l,45.2,91518,DB00818,Propofol
,22690673,peripheral volume,"Central volume of distribution, peripheral volume and intercompartmental clearance were 45.2 L, 128 L and 1.75 L/min, respectively, with no predictive covariates identifiable.",Propofol clearance in morbidly obese children and adolescents: influence of age and body size. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22690673/),l,128,91519,DB00818,Propofol
,22690673,intercompartmental clearance,"Central volume of distribution, peripheral volume and intercompartmental clearance were 45.2 L, 128 L and 1.75 L/min, respectively, with no predictive covariates identifiable.",Propofol clearance in morbidly obese children and adolescents: influence of age and body size. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22690673/),[l] / [min],1.75,91520,DB00818,Propofol
,8466066,Total body clearance increase,"Total body clearance increase was correlated to body weight (R = 0.76, 25.4 +/- 6.5 ml.kg-1.min-1, mean +/- SD).",Propofol infusion for maintenance of anesthesia in morbidly obese patients receiving nitrous oxide. A clinical and pharmacokinetic study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8466066/),[ml] / [kg·min],25.4,92464,DB00818,Propofol
,8466066,Volume of distribution at steady state,"Volume of distribution at steady state was also correlated to body weight (R = 0.61, 1.63 +/- 0.54 l.kg-1, mean +/- SD).",Propofol infusion for maintenance of anesthesia in morbidly obese patients receiving nitrous oxide. A clinical and pharmacokinetic study. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8466066/),[l] / [kg],1.63,92465,DB00818,Propofol
,9002457,half-time (T1/2 kE0),"However, a preliminary study in humans has reported a rapid blood-brain equilibration half-time (T1/2 kE0) of only 2.9 min.",Concentration-EEG effect relationship of propofol in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9002457/),min,2.9,94474,DB00818,Propofol
,9002457,duration of,The duration of EEG sleep was 26 (+/- 44% CV) min following 11-15 mg/kg doses of propofol.,Concentration-EEG effect relationship of propofol in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9002457/),min,26,94475,DB00818,Propofol
,9002457,T1/2 kE0,The T1/2 kE0 was 1.7 (+/- 32%) min.,Concentration-EEG effect relationship of propofol in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9002457/),min,1.7,94476,DB00818,Propofol
,9002457,Apparent effect-site concentrations,Apparent effect-site concentrations of 0.5-1 microg/mL were required to maintain sleep in rats.,Concentration-EEG effect relationship of propofol in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9002457/),[μg] / [ml],0.5-1,94477,DB00818,Propofol
,28968087,oral bioavailability,"On the basis of plasma concentrations of compound 1 and SN38 (14), the oral bioavailability of compound 3a and 15 in beagle dogs was found to be 97.6% and 34.1%, respectively.",Oral Delivery of Propofol with Methoxymethylphosphonic Acid as the Delivery Vehicle. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28968087/),%,97.6,94663,DB00818,Propofol
,28968087,oral bioavailability,"On the basis of plasma concentrations of compound 1 and SN38 (14), the oral bioavailability of compound 3a and 15 in beagle dogs was found to be 97.6% and 34.1%, respectively.",Oral Delivery of Propofol with Methoxymethylphosphonic Acid as the Delivery Vehicle. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28968087/),%,34.1,94664,DB00818,Propofol
,27027704,MACBAR,"Mean ± SD isoflurane MACBAR of the fentanyl and control treatments was 1.70 ± 0.28% and 1.79 ± 0.35%, respectively; no significant difference was found between the 2 treatments.",Determination of the minimum alveolar concentration of isoflurane that blunts adrenergic responses in sheep and evaluation of the effects of fentanyl. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27027704/),%,1.70,94698,DB00818,Propofol
,27027704,MACBAR,"Mean ± SD isoflurane MACBAR of the fentanyl and control treatments was 1.70 ± 0.28% and 1.79 ± 0.35%, respectively; no significant difference was found between the 2 treatments.",Determination of the minimum alveolar concentration of isoflurane that blunts adrenergic responses in sheep and evaluation of the effects of fentanyl. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27027704/),%,1.79,94699,DB00818,Propofol
,27027704,steady-state concentration,"Plasma concentration of fentanyl reached a median steady-state concentration of 1.69 ng/mL (interquartile range [25th to 75th percentile], 1.47 to 1.79 ng/mL), which was maintained throughout the study.",Determination of the minimum alveolar concentration of isoflurane that blunts adrenergic responses in sheep and evaluation of the effects of fentanyl. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27027704/),[ng] / [ml],1.69,94700,DB00818,Propofol
,29705687,PPCs,"In phase I, mean PPCs at induction (20.12 μg mL-1) and recovery (11.62 μg mL-1) were different (p < 0.001).",Pharmacokinetics and pharmacodynamic effects in koi carp (Cyprinus carpio) following immersion in propofol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29705687/),[μg] / [ml],20.12,96152,DB00818,Propofol
,29705687,PPCs,"In phase I, mean PPCs at induction (20.12 μg mL-1) and recovery (11.62 μg mL-1) were different (p < 0.001).",Pharmacokinetics and pharmacodynamic effects in koi carp (Cyprinus carpio) following immersion in propofol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29705687/),[μg] / [ml],11.62,96153,DB00818,Propofol
,29705687,PPCs,"In phase II, only mean PPCs at induction (17.92 μg mL-1) and 10 minutes (21.50 μg mL-1) were different (p = 0.013).",Pharmacokinetics and pharmacodynamic effects in koi carp (Cyprinus carpio) following immersion in propofol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29705687/),[μg] / [ml],17.92,96154,DB00818,Propofol
,29705687,PPCs,"In phase II, only mean PPCs at induction (17.92 μg mL-1) and 10 minutes (21.50 μg mL-1) were different (p = 0.013).",Pharmacokinetics and pharmacodynamic effects in koi carp (Cyprinus carpio) following immersion in propofol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29705687/),[μg] / [ml],21.50,96155,DB00818,Propofol
,29705687,Absorption rate constant,"Absorption rate constant, elimination rate constant and intercompartmental rate constant were 0.48, 0.006 and 0.02 minute-1, respectively.",Pharmacokinetics and pharmacodynamic effects in koi carp (Cyprinus carpio) following immersion in propofol. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29705687/),1/[min],0.48,96156,DB00818,Propofol
,29705687,elimination rate constant,"Absorption rate constant, elimination rate constant and intercompartmental rate constant were 0.48, 0.006 and 0.02 minute-1, respectively.",Pharmacokinetics and pharmacodynamic effects in koi carp (Cyprinus carpio) following immersion in propofol. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29705687/),1/[min],0.006,96157,DB00818,Propofol
,29705687,intercompartmental rate constant,"Absorption rate constant, elimination rate constant and intercompartmental rate constant were 0.48, 0.006 and 0.02 minute-1, respectively.",Pharmacokinetics and pharmacodynamic effects in koi carp (Cyprinus carpio) following immersion in propofol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29705687/),1/[min],0.02,96158,DB00818,Propofol
,2354095,Total clearance,"Total clearance of the drug was 2390 (SD 340) ml min-1, hepatic extraction 82% and hepatic clearance 1060 (260) ml min-1.",Hepatic and extrahepatic disposition of propofol in patients undergoing coronary bypass surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2354095/),[ml] / [min],2390,97428,DB00818,Propofol
,2354095,hepatic extraction,"Total clearance of the drug was 2390 (SD 340) ml min-1, hepatic extraction 82% and hepatic clearance 1060 (260) ml min-1.",Hepatic and extrahepatic disposition of propofol in patients undergoing coronary bypass surgery. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2354095/),%,82,97429,DB00818,Propofol
,2354095,hepatic clearance,"Total clearance of the drug was 2390 (SD 340) ml min-1, hepatic extraction 82% and hepatic clearance 1060 (260) ml min-1.",Hepatic and extrahepatic disposition of propofol in patients undergoing coronary bypass surgery. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2354095/),[ml] / [min],1060,97430,DB00818,Propofol
,22492655,maximal enzyme activity,"Modeled maximal enzyme activity was 27.9 nmol · min(-1) · mg protein(-1) at 4 months of age, which had high concordance with the average V(max) in 45 individual adult (>20 years) livers of 29.0 nmol · min(-1) · mg protein(-1).",Neonatal development of hepatic UGT1A9: implications of pediatric pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22492655/),[-1·mg·nM] / [min],27.9,98333,DB00818,Propofol
,22492655,V(max),"Modeled maximal enzyme activity was 27.9 nmol · min(-1) · mg protein(-1) at 4 months of age, which had high concordance with the average V(max) in 45 individual adult (>20 years) livers of 29.0 nmol · min(-1) · mg protein(-1).",Neonatal development of hepatic UGT1A9: implications of pediatric pharmacokinetics. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22492655/),[-1·mg·nM] / [min],29.0,98334,DB00818,Propofol
,22492655,activity,The activity of UGT1A9 ranged 7.5-fold in the adult population (4.1-54.5 nmol · min(-1) · mg protein(-1)).,Neonatal development of hepatic UGT1A9: implications of pediatric pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22492655/),[-1·mg·nM] / [min],4.1-54.5,98335,DB00818,Propofol
,22492655,intrinsic hepatic clearance,"Furthermore, scaling intrinsic hepatic clearance of 4MU with an allometric PK model yielded a high clearance at birth and then fell to adult levels (1.3 l · h(-1) · kg(-1) at 18.1 years for well stirred or 1.4 l · h(-1) · kg(-1) at 18.7 years for parallel tube).",Neonatal development of hepatic UGT1A9: implications of pediatric pharmacokinetics. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22492655/),[l] / [h·kg],1.3,98336,DB00818,Propofol
,22492655,intrinsic hepatic clearance,"Furthermore, scaling intrinsic hepatic clearance of 4MU with an allometric PK model yielded a high clearance at birth and then fell to adult levels (1.3 l · h(-1) · kg(-1) at 18.1 years for well stirred or 1.4 l · h(-1) · kg(-1) at 18.7 years for parallel tube).",Neonatal development of hepatic UGT1A9: implications of pediatric pharmacokinetics. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22492655/),[l] / [h·kg],1.4,98337,DB00818,Propofol
,12790210,target plasma concentration,The propofol target plasma concentration was 1.2 microg mL(-1) throughout the procedure.,Pharmacokinetic-based total intravenous anaesthesia using remifentanil and propofol for surgical myocardial revascularization. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12790210/),[μg] / [ml],1.2,100789,DB00818,Propofol
,12790210,target plasma concentration,A remifentanil target plasma concentration of 8 ng mL(-1) was achieved over 2 min for induction.,Pharmacokinetic-based total intravenous anaesthesia using remifentanil and propofol for surgical myocardial revascularization. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12790210/),[ng] / [ml],8,100790,DB00818,Propofol
,12790210,time to extubation,The duration of postoperative mechanical ventilation of the lungs was 95 +/- 13 min and the time to extubation was 150 +/- 18 min.,Pharmacokinetic-based total intravenous anaesthesia using remifentanil and propofol for surgical myocardial revascularization. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12790210/),min,150,100791,DB00818,Propofol
,12650488,maximum propofol concentration,A maximum propofol concentration of 7.1 +/- 1.7 microg mL(-1) was reached 3.7 +/- 0.2 min after bolus administration.,Pharmacokinetics and pharmacodynamics of the new propofol prodrug GPI 15715 in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12650488/),[μg] / [ml],7.1,101316,DB00818,Propofol
,12650488,half-life,"GPI 15715 showed a short half-life (2.9 +/- 0.2 and 23.9 +/- 9.9 min), an elimination rate constant of 0.18 +/- 0.01 min(-1) and a central volume of distribution of 0.25 +/- 0.02 L kg(-1).",Pharmacokinetics and pharmacodynamics of the new propofol prodrug GPI 15715 in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12650488/),min,2.9,101317,DB00818,Propofol
,12650488,half-life,"GPI 15715 showed a short half-life (2.9 +/- 0.2 and 23.9 +/- 9.9 min), an elimination rate constant of 0.18 +/- 0.01 min(-1) and a central volume of distribution of 0.25 +/- 0.02 L kg(-1).",Pharmacokinetics and pharmacodynamics of the new propofol prodrug GPI 15715 in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12650488/),min,23.9,101318,DB00818,Propofol
,12650488,elimination rate constant,"GPI 15715 showed a short half-life (2.9 +/- 0.2 and 23.9 +/- 9.9 min), an elimination rate constant of 0.18 +/- 0.01 min(-1) and a central volume of distribution of 0.25 +/- 0.02 L kg(-1).",Pharmacokinetics and pharmacodynamics of the new propofol prodrug GPI 15715 in rats. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12650488/),1/[min],0.18,101319,DB00818,Propofol
,12650488,central volume of distribution,"GPI 15715 showed a short half-life (2.9 +/- 0.2 and 23.9 +/- 9.9 min), an elimination rate constant of 0.18 +/- 0.01 min(-1) and a central volume of distribution of 0.25 +/- 0.02 L kg(-1).",Pharmacokinetics and pharmacodynamics of the new propofol prodrug GPI 15715 in rats. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12650488/),[l] / [kg],0.25,101320,DB00818,Propofol
,12650488,half-life,"For propofol, the half-life was 1.9 +/- 0.1 and 45 +/- 7 min, the elimination rate constant was 0.15 +/- 0.02 min(-1) and the central volume of distribution was 2.3 +/- 0.6 L kg(-1).",Pharmacokinetics and pharmacodynamics of the new propofol prodrug GPI 15715 in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12650488/),min,1.9,101321,DB00818,Propofol
,12650488,half-life,"For propofol, the half-life was 1.9 +/- 0.1 and 45 +/- 7 min, the elimination rate constant was 0.15 +/- 0.02 min(-1) and the central volume of distribution was 2.3 +/- 0.6 L kg(-1).",Pharmacokinetics and pharmacodynamics of the new propofol prodrug GPI 15715 in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12650488/),min,45,101322,DB00818,Propofol
,12650488,elimination rate constant,"For propofol, the half-life was 1.9 +/- 0.1 and 45 +/- 7 min, the elimination rate constant was 0.15 +/- 0.02 min(-1) and the central volume of distribution was 2.3 +/- 0.6 L kg(-1).",Pharmacokinetics and pharmacodynamics of the new propofol prodrug GPI 15715 in rats. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12650488/),1/[min],0.15,101323,DB00818,Propofol
,12650488,central volume of distribution,"For propofol, the half-life was 1.9 +/- 0.1 and 45 +/- 7 min, the elimination rate constant was 0.15 +/- 0.02 min(-1) and the central volume of distribution was 2.3 +/- 0.6 L kg(-1).",Pharmacokinetics and pharmacodynamics of the new propofol prodrug GPI 15715 in rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12650488/),[l] / [kg],2.3,101324,DB00818,Propofol
,12650488,E0,"The EEG effect could be described by a sigmoid Emax model including an effect compartment (E0 = 16.9 +/- 7.9 Hz, EC50 = 2.6 +/- 0.8 microg mL(-1), ke0 = 0.35 +/- 0.04 min(-1)).",Pharmacokinetics and pharmacodynamics of the new propofol prodrug GPI 15715 in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12650488/),hz,16.9,101325,DB00818,Propofol
,12650488,EC50,"The EEG effect could be described by a sigmoid Emax model including an effect compartment (E0 = 16.9 +/- 7.9 Hz, EC50 = 2.6 +/- 0.8 microg mL(-1), ke0 = 0.35 +/- 0.04 min(-1)).",Pharmacokinetics and pharmacodynamics of the new propofol prodrug GPI 15715 in rats. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12650488/),[μg] / [ml],2.6,101326,DB00818,Propofol
,12650488,ke0,"The EEG effect could be described by a sigmoid Emax model including an effect compartment (E0 = 16.9 +/- 7.9 Hz, EC50 = 2.6 +/- 0.8 microg mL(-1), ke0 = 0.35 +/- 0.04 min(-1)).",Pharmacokinetics and pharmacodynamics of the new propofol prodrug GPI 15715 in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12650488/),1/[min],0.35,101327,DB00818,Propofol
,2325255,half time of distribution phase,"The half time of distribution phase, 2.6 min, was short, and total clearance, 1.68 l.min-1, was high.",[Clinical study of propofol in male volunteers]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2325255/),min,2.6,102830,DB00818,Propofol
,2325255,total clearance,"The half time of distribution phase, 2.6 min, was short, and total clearance, 1.68 l.min-1, was high.",[Clinical study of propofol in male volunteers]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2325255/),[l] / [min],1.68,102831,DB00818,Propofol
,25600619,bispectral index,A propofol target controlled infusion was started to achieve and maintain a bispectral index value between 35 and 55.,Comparison of the hemodynamic response to induction and intubation during a target-controlled infusion of propofol with 2 different pharmacokinetic models. A prospective ramdomized trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25600619/),,35 and 55,102922,DB00818,Propofol
,23175436,passive transdermal flux,"Among all the CPEs screened, 0.1% sodium dodecyl sulfate (SDS) increased the passive transdermal flux to 13.43 ± 0.73 μg/(cm(2) h) from 8.52 ± 0.82 μg/(cm(2) h) (control).",Transdermal iontophoretic delivery of propofol: a general anaesthetic in the form of its phosphate salt. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23175436/),[μg] / [cm(2)·h],13.43,103663,DB00818,Propofol
,23175436,passive transdermal flux,"Among all the CPEs screened, 0.1% sodium dodecyl sulfate (SDS) increased the passive transdermal flux to 13.43 ± 0.73 μg/(cm(2) h) from 8.52 ± 0.82 μg/(cm(2) h) (control).",Transdermal iontophoretic delivery of propofol: a general anaesthetic in the form of its phosphate salt. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23175436/),[μg] / [cm(2)·h],8.52,103664,DB00818,Propofol
,23175436,flux,Cathodal iontophoresis in combination with 0.1% SDS synergistically enhanced the flux [249.24 ± 6.12 μg/(cm(2) h)] of PP.,Transdermal iontophoretic delivery of propofol: a general anaesthetic in the form of its phosphate salt. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23175436/),[μg] / [cm(2)·h],249.24,103665,DB00818,Propofol
,2223333,Total body clearance,Total body clearance was not reduced significantly in cirrhotic (1.56 (SD 0.48) litre min-1) compared with control (1.75 (0.32) litre min-1) patients.,Pharmacokinetics of propofol infusions in patients with cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2223333/),[l] / [min],1.56,104398,DB00818,Propofol
,2223333,Total body clearance,Total body clearance was not reduced significantly in cirrhotic (1.56 (SD 0.48) litre min-1) compared with control (1.75 (0.32) litre min-1) patients.,Pharmacokinetics of propofol infusions in patients with cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2223333/),[l] / [min],1.75,104399,DB00818,Propofol
,2223333,volume of distribution at steady state,The volume of distribution at steady state was significantly greater in patients with cirrhosis than in control patients (202 (82) litre vs 121 (49) litre).,Pharmacokinetics of propofol infusions in patients with cirrhosis. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2223333/),l,202,104400,DB00818,Propofol
,2223333,volume of distribution at steady state,The volume of distribution at steady state was significantly greater in patients with cirrhosis than in control patients (202 (82) litre vs 121 (49) litre).,Pharmacokinetics of propofol infusions in patients with cirrhosis. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2223333/),l,121,104401,DB00818,Propofol
,11244780,clearance,"Although the clearance of propofol was high (2.8 l.min-1) because of the thyrotoxic state, the patient showed delayed recovery from anesthesia.",[Propofol pharmacokinetics in a patient with TSH producing pituitary adenoma]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11244780/),[l] / [min],2.8,104421,DB00818,Propofol
exceeded,11244780,half-life,The half-life of blood propofol after the termination of infusion exceeded 30 minutes (normal: 10-15 minutes).,[Propofol pharmacokinetics in a patient with TSH producing pituitary adenoma]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11244780/),min,30,104422,DB00818,Propofol
,24977639,lag time,A lag time parameter of 0.44 minutes (SE = 0.04 minutes) to account for the delay in BIS response improved the fit.,Performance of propofol target-controlled infusion models in the obese: pharmacokinetic and pharmacodynamic analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24977639/),min,0.44,105854,DB00818,Propofol
,24977639,effect-site target,"A simulated effect-site target of 3.2 μg/mL (SE = 0.17 μg/mL) was estimated to obtain BIS of 50, in the presence of remifentanil, for a typical patient in our study.",Performance of propofol target-controlled infusion models in the obese: pharmacokinetic and pharmacodynamic analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24977639/),[μg] / [ml],3.2,105855,DB00818,Propofol
,24977639,BIS,"A simulated effect-site target of 3.2 μg/mL (SE = 0.17 μg/mL) was estimated to obtain BIS of 50, in the presence of remifentanil, for a typical patient in our study.",Performance of propofol target-controlled infusion models in the obese: pharmacokinetic and pharmacodynamic analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24977639/),,50,105856,DB00818,Propofol
,10211008,total body clearance,Mean total body clearance was not reduced significantly in the ESRD group (30.66 (SD 8.47) ml kg-1 min-1) compared with the control group (33.75 (7.8) ml kg-1 min-1).,Propofol infusion for induction and maintenance of anaesthesia in patients with end-stage renal disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10211008/),[ml] / [kg·min],30.66,106219,DB00818,Propofol
,10211008,total body clearance,Mean total body clearance was not reduced significantly in the ESRD group (30.66 (SD 8.47) ml kg-1 min-1) compared with the control group (33.75 (7.8) ml kg-1 min-1).,Propofol infusion for induction and maintenance of anaesthesia in patients with end-stage renal disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10211008/),[ml] / [kg·min],33.75,106220,DB00818,Propofol
,10211008,volume of distribution at steady state,"ESRD patients exhibited a greater, but not statistically significant, volume of distribution at steady state compared with patients in the control group (11.25 (8.86) vs 5.79 (2.14) litre kg-1, respectively).",Propofol infusion for induction and maintenance of anaesthesia in patients with end-stage renal disease. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10211008/),[l] / [kg],11.25,106221,DB00818,Propofol
,10211008,volume of distribution at steady state,"ESRD patients exhibited a greater, but not statistically significant, volume of distribution at steady state compared with patients in the control group (11.25 (8.86) vs 5.79 (2.14) litre kg-1, respectively).",Propofol infusion for induction and maintenance of anaesthesia in patients with end-stage renal disease. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10211008/),[l] / [kg],5.79,106222,DB00818,Propofol
,10211008,times to induction of an,"Mean times to induction of anaesthesia were similar in both groups: 177 (SD 57) and 167 (58) s for the ESRD and control groups, respectively.",Propofol infusion for induction and maintenance of anaesthesia in patients with end-stage renal disease. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10211008/),s,177,106223,DB00818,Propofol
,10211008,times to induction of an,"Mean times to induction of anaesthesia were similar in both groups: 177 (SD 57) and 167 (58) s for the ESRD and control groups, respectively.",Propofol infusion for induction and maintenance of anaesthesia in patients with end-stage renal disease. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10211008/),s,167,106224,DB00818,Propofol
,10211008,Waking time,Waking time after cessation of propofol infusion was significantly shorter in the ESRD group (474 (156) s) compared with the control group (714 (240) s) (P < 0.05).,Propofol infusion for induction and maintenance of anaesthesia in patients with end-stage renal disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10211008/),s,474,106225,DB00818,Propofol
,10211008,Waking time,Waking time after cessation of propofol infusion was significantly shorter in the ESRD group (474 (156) s) compared with the control group (714 (240) s) (P < 0.05).,Propofol infusion for induction and maintenance of anaesthesia in patients with end-stage renal disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10211008/),s,714,106226,DB00818,Propofol
,22935955,effect-site concentration,"No differences were observed between Marsh and Schnider models in required propofol dose (0.99 ± 0.26 vs. 0.93 ± 0.31 mg kg(-1), P = 0.322), decrease in mean blood pressure (25 ± 13 vs. 22 ± 14%, P = 0.192) or the need for vasopressors (20 vs. 24%, P = 0.800), but the use of the Marsh model resulted in a lower predicted effect-site concentration (2.3 ± 0.4 vs. 2.7 ± 0.6 μg ml(-1), P = 0.006) and shorter time to induction (296 ± 59 vs. 338 ± 87 s, P = 0.024).",Prospective randomised comparison of Marsh and Schnider pharmacokinetic models for propofol during induction of anaesthesia in elective cardiac surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22935955/),[μg] / [ml],2.3,107205,DB00818,Propofol
,22935955,effect-site concentration,"No differences were observed between Marsh and Schnider models in required propofol dose (0.99 ± 0.26 vs. 0.93 ± 0.31 mg kg(-1), P = 0.322), decrease in mean blood pressure (25 ± 13 vs. 22 ± 14%, P = 0.192) or the need for vasopressors (20 vs. 24%, P = 0.800), but the use of the Marsh model resulted in a lower predicted effect-site concentration (2.3 ± 0.4 vs. 2.7 ± 0.6 μg ml(-1), P = 0.006) and shorter time to induction (296 ± 59 vs. 338 ± 87 s, P = 0.024).",Prospective randomised comparison of Marsh and Schnider pharmacokinetic models for propofol during induction of anaesthesia in elective cardiac surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22935955/),[μg] / [ml],2.7,107206,DB00818,Propofol
,22935955,time to induction,"No differences were observed between Marsh and Schnider models in required propofol dose (0.99 ± 0.26 vs. 0.93 ± 0.31 mg kg(-1), P = 0.322), decrease in mean blood pressure (25 ± 13 vs. 22 ± 14%, P = 0.192) or the need for vasopressors (20 vs. 24%, P = 0.800), but the use of the Marsh model resulted in a lower predicted effect-site concentration (2.3 ± 0.4 vs. 2.7 ± 0.6 μg ml(-1), P = 0.006) and shorter time to induction (296 ± 59 vs. 338 ± 87 s, P = 0.024).",Prospective randomised comparison of Marsh and Schnider pharmacokinetic models for propofol during induction of anaesthesia in elective cardiac surgery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22935955/),s,296,107207,DB00818,Propofol
,22935955,time to induction,"No differences were observed between Marsh and Schnider models in required propofol dose (0.99 ± 0.26 vs. 0.93 ± 0.31 mg kg(-1), P = 0.322), decrease in mean blood pressure (25 ± 13 vs. 22 ± 14%, P = 0.192) or the need for vasopressors (20 vs. 24%, P = 0.800), but the use of the Marsh model resulted in a lower predicted effect-site concentration (2.3 ± 0.4 vs. 2.7 ± 0.6 μg ml(-1), P = 0.006) and shorter time to induction (296 ± 59 vs. 338 ± 87 s, P = 0.024).",Prospective randomised comparison of Marsh and Schnider pharmacokinetic models for propofol during induction of anaesthesia in elective cardiac surgery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22935955/),s,338,107208,DB00818,Propofol
,8792428,fG,"Values for fG, fH and fL were the following: 0.21 +/- 0.07, 0.61 +/- 0.13, and 0.82 +/- 0.09, respectively.","In vivo assessment of intestinal, hepatic, and pulmonary first pass metabolism of propofol in the rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8792428/),,0.21,107638,DB00818,Propofol
,8792428,fH,"Values for fG, fH and fL were the following: 0.21 +/- 0.07, 0.61 +/- 0.13, and 0.82 +/- 0.09, respectively.","In vivo assessment of intestinal, hepatic, and pulmonary first pass metabolism of propofol in the rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8792428/),,0.61,107639,DB00818,Propofol
,8792428,fL,"Values for fG, fH and fL were the following: 0.21 +/- 0.07, 0.61 +/- 0.13, and 0.82 +/- 0.09, respectively.","In vivo assessment of intestinal, hepatic, and pulmonary first pass metabolism of propofol in the rat. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8792428/),,0.82,107640,DB00818,Propofol
,8792428,apparent permeability coefficient,"The apparent permeability coefficient of propofol across Caco-2 cell monolayers was 24.2 +/- 0.3 x 10(-6) cm.sec-1, which is similar to the apparent permeability coefficient obtained for propranolol (30.7 +/- 1.7 x 10(-6) cm.sec-1), a compound known to easily cross the intestinal epithelial membranes.","In vivo assessment of intestinal, hepatic, and pulmonary first pass metabolism of propofol in the rat. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8792428/),[cm] / [s],24.2,107641,DB00818,Propofol
,8792428,apparent permeability coefficient,"The apparent permeability coefficient of propofol across Caco-2 cell monolayers was 24.2 +/- 0.3 x 10(-6) cm.sec-1, which is similar to the apparent permeability coefficient obtained for propranolol (30.7 +/- 1.7 x 10(-6) cm.sec-1), a compound known to easily cross the intestinal epithelial membranes.","In vivo assessment of intestinal, hepatic, and pulmonary first pass metabolism of propofol in the rat. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8792428/),[cm] / [s],30.7,107642,DB00818,Propofol
,2684471,half-life,"On the basis of pharmacokinetic-pharmacodynamic modelling, a mean blood-brain equilibration half-life of only 2.9 minutes has been calculated.",Pharmacokinetic implications for the clinical use of propofol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2684471/),min,2.9,108966,DB00818,Propofol
,2684471,first exponential phase half-life,"The first exponential phase half-life of 2 to 3 minutes mirrors the rapid onset of action, the second (34 to 56 minutes) that of the high metabolic clearance, whereas the long third exponential phase half-life of 184 to 480 minutes describes the slow elimination of a small proportion of the drug remaining in poorly perfused tissues.",Pharmacokinetic implications for the clinical use of propofol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2684471/),min,2 to 3,108967,DB00818,Propofol
,2684471,first exponential phase half-life,"The first exponential phase half-life of 2 to 3 minutes mirrors the rapid onset of action, the second (34 to 56 minutes) that of the high metabolic clearance, whereas the long third exponential phase half-life of 184 to 480 minutes describes the slow elimination of a small proportion of the drug remaining in poorly perfused tissues.",Pharmacokinetic implications for the clinical use of propofol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2684471/),,34,108968,DB00818,Propofol
,2684471,third exponential phase half-life,"The first exponential phase half-life of 2 to 3 minutes mirrors the rapid onset of action, the second (34 to 56 minutes) that of the high metabolic clearance, whereas the long third exponential phase half-life of 184 to 480 minutes describes the slow elimination of a small proportion of the drug remaining in poorly perfused tissues.",Pharmacokinetic implications for the clinical use of propofol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2684471/),min,184 to 480,108969,DB00818,Propofol
,19553403,clearance,"The following indices were higher in burns than controls: propofol clearance (64+/-17 vs 29+/-4 mL/kg/min, P<.001) and volume of distribution (8+/-3 vs 4+/-1 L/kg, P<.001).",Propofol clearance and volume of distribution are increased in patients with major burns. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19553403/),[ml] / [kg·min],64,109663,DB00818,Propofol
,19553403,clearance,"The following indices were higher in burns than controls: propofol clearance (64+/-17 vs 29+/-4 mL/kg/min, P<.001) and volume of distribution (8+/-3 vs 4+/-1 L/kg, P<.001).",Propofol clearance and volume of distribution are increased in patients with major burns. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19553403/),[ml] / [kg·min],29,109664,DB00818,Propofol
,19553403,volume of distribution,"The following indices were higher in burns than controls: propofol clearance (64+/-17 vs 29+/-4 mL/kg/min, P<.001) and volume of distribution (8+/-3 vs 4+/-1 L/kg, P<.001).",Propofol clearance and volume of distribution are increased in patients with major burns. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19553403/),[l] / [kg],8,109665,DB00818,Propofol
,19553403,volume of distribution,"The following indices were higher in burns than controls: propofol clearance (64+/-17 vs 29+/-4 mL/kg/min, P<.001) and volume of distribution (8+/-3 vs 4+/-1 L/kg, P<.001).",Propofol clearance and volume of distribution are increased in patients with major burns. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19553403/),[l] / [kg],4,109666,DB00818,Propofol
,19553403,area under the curve,"The area under the curve was smaller in burns (556+/-152 vs 1193+/-183 microg/mL h, P<.001).",Propofol clearance and volume of distribution are increased in patients with major burns. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19553403/),[μg] / [h·ml],556,109667,DB00818,Propofol
,19553403,area under the curve,"The area under the curve was smaller in burns (556+/-152 vs 1193+/-183 microg/mL h, P<.001).",Propofol clearance and volume of distribution are increased in patients with major burns. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19553403/),[μg] / [h·ml],1193,109668,DB00818,Propofol
,19781381,effect-site concentration,"Anesthesia was induced with propofol, rocuronium and sufentanil administered by TCI lasting for 30 minutes, with target effect-site concentration of sufentanil 4 or 6 ng/ml.",Two-stage analysis of pharmacokinetics of sufentanil administered by target-controlled infusion in Chinese patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19781381/),[ng] / [ml],4,109705,DB00818,Propofol
,19781381,effect-site concentration,"Anesthesia was induced with propofol, rocuronium and sufentanil administered by TCI lasting for 30 minutes, with target effect-site concentration of sufentanil 4 or 6 ng/ml.",Two-stage analysis of pharmacokinetics of sufentanil administered by target-controlled infusion in Chinese patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19781381/),[ng] / [ml],6,109706,DB00818,Propofol
,19781381,volume of central compartment (V(1)),"The variables were derived as follows: the volume of central compartment (V(1)) was 5.4 L, volume of distribution at steady-state (Vdss) was 222.6 L, metabolic clearance (Cl(1)) was 0.84 L/min and elimination half-life (t(1/2Y)) was 389 minutes.",Two-stage analysis of pharmacokinetics of sufentanil administered by target-controlled infusion in Chinese patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19781381/),l,5.4,109707,DB00818,Propofol
,19781381,volume of distribution at steady-state (Vdss),"The variables were derived as follows: the volume of central compartment (V(1)) was 5.4 L, volume of distribution at steady-state (Vdss) was 222.6 L, metabolic clearance (Cl(1)) was 0.84 L/min and elimination half-life (t(1/2Y)) was 389 minutes.",Two-stage analysis of pharmacokinetics of sufentanil administered by target-controlled infusion in Chinese patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19781381/),l,222.6,109708,DB00818,Propofol
,19781381,metabolic clearance (Cl(1)),"The variables were derived as follows: the volume of central compartment (V(1)) was 5.4 L, volume of distribution at steady-state (Vdss) was 222.6 L, metabolic clearance (Cl(1)) was 0.84 L/min and elimination half-life (t(1/2Y)) was 389 minutes.",Two-stage analysis of pharmacokinetics of sufentanil administered by target-controlled infusion in Chinese patients. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19781381/),[l] / [min],0.84,109709,DB00818,Propofol
,19781381,elimination half-life (t(1/2Y)),"The variables were derived as follows: the volume of central compartment (V(1)) was 5.4 L, volume of distribution at steady-state (Vdss) was 222.6 L, metabolic clearance (Cl(1)) was 0.84 L/min and elimination half-life (t(1/2Y)) was 389 minutes.",Two-stage analysis of pharmacokinetics of sufentanil administered by target-controlled infusion in Chinese patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19781381/),min,389,109710,DB00818,Propofol
,15329587,effect site concentration for half maximum effect,The propofol effect site concentration for half maximum effect was 2.0 +/- 0.5 microg/ml for GPI 15715 and 3.0 +/- 0.7 microg/ml for propofol emulsion (P < 0.05).,Comparative pharmacokinetics and pharmacodynamics of the new propofol prodrug GPI 15715 and propofol emulsion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15329587/),[μg] / [ml],2.0,112598,DB00818,Propofol
,15329587,effect site concentration for half maximum effect,The propofol effect site concentration for half maximum effect was 2.0 +/- 0.5 microg/ml for GPI 15715 and 3.0 +/- 0.7 microg/ml for propofol emulsion (P < 0.05).,Comparative pharmacokinetics and pharmacodynamics of the new propofol prodrug GPI 15715 and propofol emulsion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15329587/),[μg] / [ml],3.0,112599,DB00818,Propofol
,15681947,renal extraction ratio,The renal extraction ratio of propofol was 0.58 +/- 0.15 (mean +/- SD).,Human kidneys play an important role in the elimination of propofol. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15681947/),,0.58,112897,DB00818,Propofol
,15681947,renal clearance,"The renal clearance of propofol was 0.41 +/- 0.15 l/min (mean +/- SD), or 27 +/- 9.9% (mean +/- SD) of total body clearance.",Human kidneys play an important role in the elimination of propofol. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15681947/),[l] / [min],0.41,112898,DB00818,Propofol
,15681947,renal clearance,"The renal clearance of propofol was 0.41 +/- 0.15 l/min (mean +/- SD), or 27 +/- 9.9% (mean +/- SD) of total body clearance.",Human kidneys play an important role in the elimination of propofol. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15681947/),%,27,112899,DB00818,Propofol
,11064610,total doses,"Mean total doses of alfentanil, fentanyl and sufentanil were 443, 45 and 4.4 micrograms kg-1, respectively.","Comparison of alfentanil, fentanyl and sufentanil for total intravenous anaesthesia with propofol in patients undergoing coronary artery bypass surgery. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11064610/),,45,113314,DB00818,Propofol
,11064610,total doses,"Mean total doses of alfentanil, fentanyl and sufentanil were 443, 45 and 4.4 micrograms kg-1, respectively.","Comparison of alfentanil, fentanyl and sufentanil for total intravenous anaesthesia with propofol in patients undergoing coronary artery bypass surgery. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11064610/),,4.4,113315,DB00818,Propofol
,2223366,extraction ratios,"Before anaesthesia, the overall mean respective regional pethidine extraction ratios were 0.98 (SD 0.01), 0.20 (0.06) and 0.44 (0.13), the corresponding net fluxes were 47 (7), 5 (2) and 20 (10)% dose min-1 and the clearances 1.44 (0.22), 0.17 (0.07) and 0.80 (0.39) litre min-1.",Effects of propofol and of thiopentone anaesthesia on the regional kinetics of pethidine in the sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2223366/),,0.98,114624,DB00818,Propofol
,2223366,extraction ratios,"Before anaesthesia, the overall mean respective regional pethidine extraction ratios were 0.98 (SD 0.01), 0.20 (0.06) and 0.44 (0.13), the corresponding net fluxes were 47 (7), 5 (2) and 20 (10)% dose min-1 and the clearances 1.44 (0.22), 0.17 (0.07) and 0.80 (0.39) litre min-1.",Effects of propofol and of thiopentone anaesthesia on the regional kinetics of pethidine in the sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2223366/),,0.20,114625,DB00818,Propofol
,2223366,extraction ratios,"Before anaesthesia, the overall mean respective regional pethidine extraction ratios were 0.98 (SD 0.01), 0.20 (0.06) and 0.44 (0.13), the corresponding net fluxes were 47 (7), 5 (2) and 20 (10)% dose min-1 and the clearances 1.44 (0.22), 0.17 (0.07) and 0.80 (0.39) litre min-1.",Effects of propofol and of thiopentone anaesthesia on the regional kinetics of pethidine in the sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2223366/),,0.44,114626,DB00818,Propofol
,2223366,net fluxes,"Before anaesthesia, the overall mean respective regional pethidine extraction ratios were 0.98 (SD 0.01), 0.20 (0.06) and 0.44 (0.13), the corresponding net fluxes were 47 (7), 5 (2) and 20 (10)% dose min-1 and the clearances 1.44 (0.22), 0.17 (0.07) and 0.80 (0.39) litre min-1.",Effects of propofol and of thiopentone anaesthesia on the regional kinetics of pethidine in the sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2223366/),[%·dose] / [min],47,114627,DB00818,Propofol
,2223366,net fluxes,"Before anaesthesia, the overall mean respective regional pethidine extraction ratios were 0.98 (SD 0.01), 0.20 (0.06) and 0.44 (0.13), the corresponding net fluxes were 47 (7), 5 (2) and 20 (10)% dose min-1 and the clearances 1.44 (0.22), 0.17 (0.07) and 0.80 (0.39) litre min-1.",Effects of propofol and of thiopentone anaesthesia on the regional kinetics of pethidine in the sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2223366/),[%·dose] / [min],5,114628,DB00818,Propofol
,2223366,net fluxes,"Before anaesthesia, the overall mean respective regional pethidine extraction ratios were 0.98 (SD 0.01), 0.20 (0.06) and 0.44 (0.13), the corresponding net fluxes were 47 (7), 5 (2) and 20 (10)% dose min-1 and the clearances 1.44 (0.22), 0.17 (0.07) and 0.80 (0.39) litre min-1.",Effects of propofol and of thiopentone anaesthesia on the regional kinetics of pethidine in the sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2223366/),[%·dose] / [min],20,114629,DB00818,Propofol
,2223366,clearances,"Before anaesthesia, the overall mean respective regional pethidine extraction ratios were 0.98 (SD 0.01), 0.20 (0.06) and 0.44 (0.13), the corresponding net fluxes were 47 (7), 5 (2) and 20 (10)% dose min-1 and the clearances 1.44 (0.22), 0.17 (0.07) and 0.80 (0.39) litre min-1.",Effects of propofol and of thiopentone anaesthesia on the regional kinetics of pethidine in the sheep. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2223366/),[l] / [min],1.44,114630,DB00818,Propofol
,2223366,clearances,"Before anaesthesia, the overall mean respective regional pethidine extraction ratios were 0.98 (SD 0.01), 0.20 (0.06) and 0.44 (0.13), the corresponding net fluxes were 47 (7), 5 (2) and 20 (10)% dose min-1 and the clearances 1.44 (0.22), 0.17 (0.07) and 0.80 (0.39) litre min-1.",Effects of propofol and of thiopentone anaesthesia on the regional kinetics of pethidine in the sheep. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2223366/),[l] / [min],0.17,114631,DB00818,Propofol
,2223366,clearances,"Before anaesthesia, the overall mean respective regional pethidine extraction ratios were 0.98 (SD 0.01), 0.20 (0.06) and 0.44 (0.13), the corresponding net fluxes were 47 (7), 5 (2) and 20 (10)% dose min-1 and the clearances 1.44 (0.22), 0.17 (0.07) and 0.80 (0.39) litre min-1.",Effects of propofol and of thiopentone anaesthesia on the regional kinetics of pethidine in the sheep. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2223366/),[l] / [min],0.80,114632,DB00818,Propofol
,2223366,renal extraction ratio,"During propofol anaesthesia, arterial blood concentrations of pethidine approximately doubled (P less than 0.05), mean pethidine hepatic extraction ratio was unchanged, flux was increased to 145 (20)% and clearance decreased to 79 (10)% (P less than 0.05) of baseline values; mean pethidine renal extraction ratio, flux and clearance were 73 (34), 112 (43) and 69 (31)% of baseline values; mean hindquarter pethidine extraction ratio decreased to 65 (25)% (P less than 0.05) of baseline values.",Effects of propofol and of thiopentone anaesthesia on the regional kinetics of pethidine in the sheep. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2223366/),,73,114633,DB00818,Propofol
,11116752,i-,"Of the 11 compounds examined, only propofol had an i-value of 6.6; for all other compounds i-values were lower than 2.1.","Identification of UDP-glucuronosyltransferases involved in the human hepatic metabolism of GV150526, a novel glycine antagonist. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11116752/),,6.6,115760,DB00818,Propofol
lower,11116752,i-,"Of the 11 compounds examined, only propofol had an i-value of 6.6; for all other compounds i-values were lower than 2.1.","Identification of UDP-glucuronosyltransferases involved in the human hepatic metabolism of GV150526, a novel glycine antagonist. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11116752/),,2.1,115761,DB00818,Propofol
,25192266,blood concentration (Cp),The purpose of this study was to assess the optimal predicted blood concentration (Cp) of 4.0 μg ml of propofol using a correction formula including BMI and to evaluate the influences on propofol concentration in obese patients.,Evaluation of bias in predicted and measured propofol concentrations during target-controlled infusions in obese Japanese patients: an open-label comparative study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25192266/),ml·μg,4.0,118811,DB00818,Propofol
,25192266,Cp,Propofol was administered and maintained at a Cp of 4.0 μg ml using a TCI device programmed with the Marsh pharmacokinetic model.,Evaluation of bias in predicted and measured propofol concentrations during target-controlled infusions in obese Japanese patients: an open-label comparative study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25192266/),ml·μg,4.0,118812,DB00818,Propofol
,31326349,Induction targets,Induction targets between 4.0 and 6.5 μg mL-1 allowed intubation within 5.0 ± 0.9 minutes.,A pharmacokinetic model optimized by covariates for propofol target-controlled infusion in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31326349/),[μg] / [ml],4.0 and 6.5,119515,DB00818,Propofol
,31326349,time to extubation,Mean time to extubation was 9.7 ± 2.6 minutes.,A pharmacokinetic model optimized by covariates for propofol target-controlled infusion in dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31326349/),min,9.7,119516,DB00818,Propofol
,2618085,total body clearance,"3. A mean total body clearance of propofol of 3.15 l/min, (SD 0.87 l/min; n = 8) was found, consistent with a high hepatic extraction ratio (overall mean 0.87, SD 0.19; n = 8) and clearance (overall mean 1.12, SD 0.25 l/min; n = 7).",Propofol: assay and regional mass balance in the sheep. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2618085/),[l] / [min],3.15,120187,DB00818,Propofol
,2618085,hepatic extraction ratio,"3. A mean total body clearance of propofol of 3.15 l/min, (SD 0.87 l/min; n = 8) was found, consistent with a high hepatic extraction ratio (overall mean 0.87, SD 0.19; n = 8) and clearance (overall mean 1.12, SD 0.25 l/min; n = 7).",Propofol: assay and regional mass balance in the sheep. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2618085/),,0.87,120188,DB00818,Propofol
,2618085,clearance,"3. A mean total body clearance of propofol of 3.15 l/min, (SD 0.87 l/min; n = 8) was found, consistent with a high hepatic extraction ratio (overall mean 0.87, SD 0.19; n = 8) and clearance (overall mean 1.12, SD 0.25 l/min; n = 7).",Propofol: assay and regional mass balance in the sheep. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2618085/),[l] / [min],1.12,120189,DB00818,Propofol
,17973935,clearance,"3. The systemic kinetics of indomethacin could be described by a two-compartment model, with small distribution volumes and a clearance of 0.68 L/min.",Pharmacokinetics and pharmacodynamics of indomethacin: effects on cerebral blood flow in anaesthetized sheep. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17973935/),[l] / [min],0.68,121513,DB00818,Propofol
,17973935,cerebral distribution volume,"The cerebral kinetics of indomethacin could be described using a model with a cerebral distribution volume between 5 and 8 mL and a loss term of 3.3 mL/min, the latter probably representing slow diffusion across the blood-brain barrier.",Pharmacokinetics and pharmacodynamics of indomethacin: effects on cerebral blood flow in anaesthetized sheep. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17973935/),ml,5 and 8,121514,DB00818,Propofol
,17973935,loss term,"The cerebral kinetics of indomethacin could be described using a model with a cerebral distribution volume between 5 and 8 mL and a loss term of 3.3 mL/min, the latter probably representing slow diffusion across the blood-brain barrier.",Pharmacokinetics and pharmacodynamics of indomethacin: effects on cerebral blood flow in anaesthetized sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17973935/),[ml] / [min],3.3,121515,DB00818,Propofol
,17973935,turnover times,Indirect response models with turnover times of 1.70-4.08 min were generally better able to describe the effect of indomethacin on CBF than effect compartment models.,Pharmacokinetics and pharmacodynamics of indomethacin: effects on cerebral blood flow in anaesthetized sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17973935/),min,1.70-4.08,121516,DB00818,Propofol
,19034110,total body clearance rate,"The propofol mean total body clearance rate was 2.09 +/- 0.65 l/min (mean +/- SD), the volume of distribution at steady state was 159 +/- 57 l, and the elimination half-life was 116 +/- 34 min.",Propofol: its role in changing the practice of anesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19034110/),[l] / [min],2.09,124239,DB00818,Propofol
,19034110,volume of distribution at steady state,"The propofol mean total body clearance rate was 2.09 +/- 0.65 l/min (mean +/- SD), the volume of distribution at steady state was 159 +/- 57 l, and the elimination half-life was 116 +/- 34 min.",Propofol: its role in changing the practice of anesthesia. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19034110/),l,159,124240,DB00818,Propofol
,19034110,elimination half-life,"The propofol mean total body clearance rate was 2.09 +/- 0.65 l/min (mean +/- SD), the volume of distribution at steady state was 159 +/- 57 l, and the elimination half-life was 116 +/- 34 min.",Propofol: its role in changing the practice of anesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19034110/),min,116,124241,DB00818,Propofol
,19034110,clearance rates,"Elderly patients (patients older than 60 yr vs. those younger than 60 yr) had significantly decreased clearance rates (1.58 +/- 0.42 vs. 2.19 +/- 0.64 l/min), whereas women (vs. men) had greater clearance rates (33 +/- 8 vs. 26 +/- 7 ml x kg x min ) and volumes of distribution (2.50 +/- 0.81 vs. 2.05 +/- 0.65 l/kg).",Propofol: its role in changing the practice of anesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19034110/),[l] / [min],1.58,124242,DB00818,Propofol
,19034110,clearance rates,"Elderly patients (patients older than 60 yr vs. those younger than 60 yr) had significantly decreased clearance rates (1.58 +/- 0.42 vs. 2.19 +/- 0.64 l/min), whereas women (vs. men) had greater clearance rates (33 +/- 8 vs. 26 +/- 7 ml x kg x min ) and volumes of distribution (2.50 +/- 0.81 vs. 2.05 +/- 0.65 l/kg).",Propofol: its role in changing the practice of anesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19034110/),[l] / [min],2.19,124243,DB00818,Propofol
,19034110,clearance rates,"Elderly patients (patients older than 60 yr vs. those younger than 60 yr) had significantly decreased clearance rates (1.58 +/- 0.42 vs. 2.19 +/- 0.64 l/min), whereas women (vs. men) had greater clearance rates (33 +/- 8 vs. 26 +/- 7 ml x kg x min ) and volumes of distribution (2.50 +/- 0.81 vs. 2.05 +/- 0.65 l/kg).",Propofol: its role in changing the practice of anesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19034110/),kg·min·ml,33,124244,DB00818,Propofol
,19034110,clearance rates,"Elderly patients (patients older than 60 yr vs. those younger than 60 yr) had significantly decreased clearance rates (1.58 +/- 0.42 vs. 2.19 +/- 0.64 l/min), whereas women (vs. men) had greater clearance rates (33 +/- 8 vs. 26 +/- 7 ml x kg x min ) and volumes of distribution (2.50 +/- 0.81 vs. 2.05 +/- 0.65 l/kg).",Propofol: its role in changing the practice of anesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19034110/),kg·min·ml,26,124245,DB00818,Propofol
,19034110,volumes of distribution,"Elderly patients (patients older than 60 yr vs. those younger than 60 yr) had significantly decreased clearance rates (1.58 +/- 0.42 vs. 2.19 +/- 0.64 l/min), whereas women (vs. men) had greater clearance rates (33 +/- 8 vs. 26 +/- 7 ml x kg x min ) and volumes of distribution (2.50 +/- 0.81 vs. 2.05 +/- 0.65 l/kg).",Propofol: its role in changing the practice of anesthesia. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19034110/),[l] / [kg],2.50,124246,DB00818,Propofol
,19034110,volumes of distribution,"Elderly patients (patients older than 60 yr vs. those younger than 60 yr) had significantly decreased clearance rates (1.58 +/- 0.42 vs. 2.19 +/- 0.64 l/min), whereas women (vs. men) had greater clearance rates (33 +/- 8 vs. 26 +/- 7 ml x kg x min ) and volumes of distribution (2.50 +/- 0.81 vs. 2.05 +/- 0.65 l/kg).",Propofol: its role in changing the practice of anesthesia. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19034110/),[l] / [kg],2.05,124247,DB00818,Propofol
,19034110,elimination half-life,Patients undergoing major (intraabdominal) surgery had longer elimination half-life values (136 +/- 40 vs. 108 +/- 29 min).,Propofol: its role in changing the practice of anesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19034110/),min,136,124248,DB00818,Propofol
,19034110,elimination half-life,Patients undergoing major (intraabdominal) surgery had longer elimination half-life values (136 +/- 40 vs. 108 +/- 29 min).,Propofol: its role in changing the practice of anesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19034110/),min,108,124249,DB00818,Propofol
,19034110,EC50),"Blood propofol concentrations at which 50% of patients (EC50) were awake and oriented after surgery were 1.07 and 0.95 microgram/ml, respectively.",Propofol: its role in changing the practice of anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19034110/),[μg] / [ml],1.07,124250,DB00818,Propofol
,19034110,EC50),"Blood propofol concentrations at which 50% of patients (EC50) were awake and oriented after surgery were 1.07 and 0.95 microgram/ml, respectively.",Propofol: its role in changing the practice of anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19034110/),[μg] / [ml],0.95,124251,DB00818,Propofol
,8785421,loss rate,The best estimate of the overall mean loss rate was 0.7% per day with 95% confidence limits of 0.3% to 1.2% per day.,Measurement of propofol concentration in sheep blood and plasma: effect of storage at different temperatures. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8785421/),[%] / [d],0.7,124580,DB00818,Propofol
,8785421,loss rate,The best estimate of the overall mean loss rate was 0.7% per day with 95% confidence limits of 0.3% to 1.2% per day.,Measurement of propofol concentration in sheep blood and plasma: effect of storage at different temperatures. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8785421/),[%] / [d],1.2,124581,DB00818,Propofol
,8785421,loss rate,There were significant differences of loss rate between sheep--up to about 2% per day in blood or plasma from any one sheep.,Measurement of propofol concentration in sheep blood and plasma: effect of storage at different temperatures. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8785421/),[%] / [d],2,124582,DB00818,Propofol
,22831891,plasma concentrations,"Anaesthesia was managed with propofol and TCI of sufentanil, using the Gepts model, targeting plasma concentrations of 0.4 (n=18) or 0.8 ng ml(-1) (n=20).",Changes in total and unbound concentrations of sufentanil during target controlled infusion for cardiac surgery with cardiopulmonary bypass. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22831891/),[ng] / [ml],0.4,125739,DB00818,Propofol
,22831891,plasma concentrations,"Anaesthesia was managed with propofol and TCI of sufentanil, using the Gepts model, targeting plasma concentrations of 0.4 (n=18) or 0.8 ng ml(-1) (n=20).",Changes in total and unbound concentrations of sufentanil during target controlled infusion for cardiac surgery with cardiopulmonary bypass. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22831891/),[ng] / [ml],0.8,125740,DB00818,Propofol
,11093399,peak venous plasma concentration,"The aqueous solution was absorbed rapidly and the mean (sd) peak venous plasma concentration of bupivacaine, 1.4 (0.4) microg/ml, was detected after five minutes.",Prolongation of epidural anaesthesia in dogs with bupivacaine in a lipid emulsion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11093399/),[μg] / [ml],1.4,126848,DB00818,Propofol
,11093399,peak plasma concentration,"After administration of the lipid emulsion, the peak plasma concentration of bupivacaine, 0.6 (0.2) microg/ml, was detected after 30 minutes.",Prolongation of epidural anaesthesia in dogs with bupivacaine in a lipid emulsion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11093399/),[μg] / [ml],0.6,126849,DB00818,Propofol
,11093399,t1/2beta,"The mean (sd) t1/2beta of the aqueous preparation was 149.1 (32.6) minutes, and of the lipid emulsion 119.2 (34.0) minutes.",Prolongation of epidural anaesthesia in dogs with bupivacaine in a lipid emulsion. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11093399/),min,149.1,126850,DB00818,Propofol
,11093399,t1/2beta,"The mean (sd) t1/2beta of the aqueous preparation was 149.1 (32.6) minutes, and of the lipid emulsion 119.2 (34.0) minutes.",Prolongation of epidural anaesthesia in dogs with bupivacaine in a lipid emulsion. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11093399/),min,119.2,126851,DB00818,Propofol
,11093399,time to the onset of motor block,"The mean time to the onset of motor block after the administration of the aqueous solution, 2.3 (2.2) minutes, was significantly shorter (P=0.028) than after the administration of the lipid emulsion, 9.4 (1.9) minutes, and the duration of the motor block induced by the lipid emulsion, 217.6 (26.2) minutes, was significantly longer (P=0.043) than for the aqueous solution, 158 (48.8) minutes.",Prolongation of epidural anaesthesia in dogs with bupivacaine in a lipid emulsion. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11093399/),min,2.3,126852,DB00818,Propofol
,11093399,time to the onset of motor block,"The mean time to the onset of motor block after the administration of the aqueous solution, 2.3 (2.2) minutes, was significantly shorter (P=0.028) than after the administration of the lipid emulsion, 9.4 (1.9) minutes, and the duration of the motor block induced by the lipid emulsion, 217.6 (26.2) minutes, was significantly longer (P=0.043) than for the aqueous solution, 158 (48.8) minutes.",Prolongation of epidural anaesthesia in dogs with bupivacaine in a lipid emulsion. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11093399/),min,9.4,126853,DB00818,Propofol
,11093399,duration of the motor block,"The mean time to the onset of motor block after the administration of the aqueous solution, 2.3 (2.2) minutes, was significantly shorter (P=0.028) than after the administration of the lipid emulsion, 9.4 (1.9) minutes, and the duration of the motor block induced by the lipid emulsion, 217.6 (26.2) minutes, was significantly longer (P=0.043) than for the aqueous solution, 158 (48.8) minutes.",Prolongation of epidural anaesthesia in dogs with bupivacaine in a lipid emulsion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11093399/),min,217.6,126854,DB00818,Propofol
,11093399,duration of the motor block,"The mean time to the onset of motor block after the administration of the aqueous solution, 2.3 (2.2) minutes, was significantly shorter (P=0.028) than after the administration of the lipid emulsion, 9.4 (1.9) minutes, and the duration of the motor block induced by the lipid emulsion, 217.6 (26.2) minutes, was significantly longer (P=0.043) than for the aqueous solution, 158 (48.8) minutes.",Prolongation of epidural anaesthesia in dogs with bupivacaine in a lipid emulsion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11093399/),min,158,126855,DB00818,Propofol
,8797618,Recovery from sedation,"Recovery from sedation (COMFORT score of > or = 27) after stopping the propofol infusion was rapid, averaging 15.5 mins in 23 of 24 evaluable patients.","A pharmacokinetically based propofol dosing strategy for sedation of the critically ill, mechanically ventilated pediatric patient. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8797618/),min,15.5,127350,DB00818,Propofol
,8797618,time to extubation,"In 13 patients who were extubated after stopping the propofol infusion, the time to extubation was also rapid, averaging 44.5 mins.","A pharmacokinetically based propofol dosing strategy for sedation of the critically ill, mechanically ventilated pediatric patient. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8797618/),min,44.5,127351,DB00818,Propofol
,12411808,EC50,There was no significant difference either in the distribution from the plasma to the brain (k(e0)) or in the end organ sensitivity (EC50 = 335 +/- 76 microg/ml in control vs. 341 +/- 89 microg/ml in hypovolemic rats).,Influence of hypovolemia on the pharmacokinetics and electroencephalographic effect of gamma-hydroxybutyrate in the rat. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12411808/),[μg] / [ml],335,127729,DB00818,Propofol
,12411808,EC50,There was no significant difference either in the distribution from the plasma to the brain (k(e0)) or in the end organ sensitivity (EC50 = 335 +/- 76 microg/ml in control vs. 341 +/- 89 microg/ml in hypovolemic rats).,Influence of hypovolemia on the pharmacokinetics and electroencephalographic effect of gamma-hydroxybutyrate in the rat. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12411808/),[μg] / [ml],341,127730,DB00818,Propofol
,10638903,rate constant,"Decreasing core temperature over 38.0-34.0 degrees C decreases the plasma clearance of vecuronium (11.3% per degrees C), decreases the rate constant for drug equilibration between plasma and effect site (0.023 min(-1) per degrees C), and increases the slope of the concentration-response relationship (0.43 per degrees C).",Temperature-dependent pharmacokinetics and pharmacodynamics of vecuronium. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10638903/),1/[c·degrees·min],0.023,128475,DB00818,Propofol
,18370558,infusion rate,The mean propofol infusion rate was 1.42 +/- 0.4 mg/kg/h.,Postoperative sedation with propofol infusion: haemodynamics and pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18370558/),[mg] / [h·kg],1.42,128538,DB00818,Propofol
,18370558,clinical recovery time (postsedation responsiveness),"The clinical recovery time (postsedation responsiveness) was 15.7 +/- 6.2 minutes, after infusion suspension.",Postoperative sedation with propofol infusion: haemodynamics and pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18370558/),min,15.7,128539,DB00818,Propofol
,18370558,steady-state plasma concentrations,Sedation was quickly obtained without a propofol loading dose; steady-state plasma concentrations of 0.6 to 0.8 mg/L were rapidly achieved.,Postoperative sedation with propofol infusion: haemodynamics and pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18370558/),[mg] / [l],0.6 to 0.8,128540,DB00818,Propofol
,2100757,total body clearance,The pharmacokinetics of propofol in pregnant women (n = 8) were described by a high value for total body clearance (mean 2189.6 ml/min) and a short elimination half-life (mean 24.1 min).,Propofol in cesarean section. A pharmacokinetic and pharmacodynamic study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2100757/),[ml] / [min],2189.6,129347,DB00818,Propofol
,2100757,elimination half-life,The pharmacokinetics of propofol in pregnant women (n = 8) were described by a high value for total body clearance (mean 2189.6 ml/min) and a short elimination half-life (mean 24.1 min).,Propofol in cesarean section. A pharmacokinetic and pharmacodynamic study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2100757/),min,24.1,129348,DB00818,Propofol
,23641955,total body metabolic clearance,The total body metabolic clearance of laropiprant determined using this approach (5.0 L/hr) agreed well with the value determined in vivo following intravenous administration to healthy human volunteers (5.1 L/hr).,Using human recombinant UDP-glucuronosyltransferase isoforms and a relative activity factor approach to model total body clearance of laropiprant (MK-0524) in humans. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23641955/),[l] / [h],5.0,129817,DB00818,Propofol
,23641955,total body metabolic clearance,The total body metabolic clearance of laropiprant determined using this approach (5.0 L/hr) agreed well with the value determined in vivo following intravenous administration to healthy human volunteers (5.1 L/hr).,Using human recombinant UDP-glucuronosyltransferase isoforms and a relative activity factor approach to model total body clearance of laropiprant (MK-0524) in humans. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23641955/),[l] / [h],5.1,129818,DB00818,Propofol
,10365202,maximal VAS,The median of the higher sedation scores was 2 (drowsy) and mean maximal VAS was 40 +/- 20 mm (10-70).,[Patient-controlled sedation with propofol for extracorporeal shock wave lithotripsy]. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10365202/),mm,40,129908,DB00818,Propofol
,20435936,constant C(T),"During session B, in addition to this midazolam infusion scheme, a target-controlled infusion of propofol (constant C(T): 0.6 or 1.0 microg x mL(-1)) was given from 15 minutes before the start until 6 hours after termination of the midazolam infusion.",Propofol reduces the distribution and clearance of midazolam. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20435936/),[μg] / [ml],0.6,130087,DB00818,Propofol
,20435936,constant C(T),"During session B, in addition to this midazolam infusion scheme, a target-controlled infusion of propofol (constant C(T): 0.6 or 1.0 microg x mL(-1)) was given from 15 minutes before the start until 6 hours after termination of the midazolam infusion.",Propofol reduces the distribution and clearance of midazolam. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20435936/),[μg] / [ml],1.0,130088,DB00818,Propofol
,20435936,C(blood),"Propofol (C(blood): 1.2 microg x mL(-1)) reduced midazolam central volume of distribution from 5.37 to 2.98 L, elimination clearance from 0.39 to 0.31 L x min(-1), and rapid distribution clearance from 2.77 to 2.11 L x min(-1).",Propofol reduces the distribution and clearance of midazolam. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20435936/),[μg] / [ml],1.2,130089,DB00818,Propofol
,20435936,central volume of distribution,"Propofol (C(blood): 1.2 microg x mL(-1)) reduced midazolam central volume of distribution from 5.37 to 2.98 L, elimination clearance from 0.39 to 0.31 L x min(-1), and rapid distribution clearance from 2.77 to 2.11 L x min(-1).",Propofol reduces the distribution and clearance of midazolam. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20435936/),l,5.37 to 2.98,130090,DB00818,Propofol
,20435936,elimination clearance,"Propofol (C(blood): 1.2 microg x mL(-1)) reduced midazolam central volume of distribution from 5.37 to 2.98 L, elimination clearance from 0.39 to 0.31 L x min(-1), and rapid distribution clearance from 2.77 to 2.11 L x min(-1).",Propofol reduces the distribution and clearance of midazolam. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20435936/),[l] / [min],0.39 to 0.31,130091,DB00818,Propofol
,20435936,distribution clearance,"Propofol (C(blood): 1.2 microg x mL(-1)) reduced midazolam central volume of distribution from 5.37 to 2.98 L, elimination clearance from 0.39 to 0.31 L x min(-1), and rapid distribution clearance from 2.77 to 2.11 L x min(-1).",Propofol reduces the distribution and clearance of midazolam. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20435936/),[l] / [min],2.77 to 2.11,130092,DB00818,Propofol
,1997061,volume of distribution (Vss),Propofol produced marked changes in drug distribution; volume of distribution (Vss) of propranolol increased 54% from 82.5 (SEM 7.3) litre awake to 127.3 (27) litre during propofol anaesthesia (P less than 0.05).,Effect of i.v. anaesthesia with propofol on drug distribution and metabolism in the dog. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1997061/),awake·l,82.5,130808,DB00818,Propofol
,1997061,volume of distribution (Vss),Propofol produced marked changes in drug distribution; volume of distribution (Vss) of propranolol increased 54% from 82.5 (SEM 7.3) litre awake to 127.3 (27) litre during propofol anaesthesia (P less than 0.05).,Effect of i.v. anaesthesia with propofol on drug distribution and metabolism in the dog. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1997061/),l,127.3,130809,DB00818,Propofol
,1997061,free fraction,This change was accompanied by an increase (P less than 0.05) in the free fraction of propranolol from 8.5 (0.7) % in awake to 14.0 (0.7) % in propofol-anaesthetized dogs.,Effect of i.v. anaesthesia with propofol on drug distribution and metabolism in the dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1997061/),%,8.5,130810,DB00818,Propofol
,1997061,free fraction,This change was accompanied by an increase (P less than 0.05) in the free fraction of propranolol from 8.5 (0.7) % in awake to 14.0 (0.7) % in propofol-anaesthetized dogs.,Effect of i.v. anaesthesia with propofol on drug distribution and metabolism in the dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1997061/),,14.0,130811,DB00818,Propofol
,12535035,steady-state serum concentration,Anaesthesia comprized propofol aimed at producing an estimated steady-state serum concentration of 3 microg x ml-1 and a caudal epidural block.,Cerebrovascular carbon dioxide reactivity in children anaesthetized with propofol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12535035/),[μg] / [ml],3,130824,DB00818,Propofol
,12535035,Cerebral blood flow velocity,Cerebral blood flow velocity increased as PECO2 increased from 3.3 to 5.2 kPa (25-40 mmHg) (P < 0.001) and from 5.2 to 7.2 kPa (40-55 mmHg) (P < 0.001).,Cerebrovascular carbon dioxide reactivity in children anaesthetized with propofol. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12535035/),kpa,3.3 to 5.2,130825,DB00818,Propofol
,12535035,Cerebral blood flow velocity,Cerebral blood flow velocity increased as PECO2 increased from 3.3 to 5.2 kPa (25-40 mmHg) (P < 0.001) and from 5.2 to 7.2 kPa (40-55 mmHg) (P < 0.001).,Cerebrovascular carbon dioxide reactivity in children anaesthetized with propofol. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12535035/),kpa,5.2 to 7.2,130826,DB00818,Propofol
,12641683,CPRED50,The CPRED50 and CPRED90 were 7.86 microg.,Target concentration of propofol required to insert the laryngeal mask airway in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12641683/),μg,7.86,131526,DB00818,Propofol
,10434811,keo,"In the non-parametric analysis, keo was found to have a mean value of 0.2 (range 0.1-0.36) min-1.",Effect-site modelling of propofol using auditory evoked potentials. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10434811/),1/[min],0.2,132627,DB00818,Propofol
,10434811,effect-site concentration (Ce50),Estimation of keo allowed calculation of the effect-site concentration (Ce50) associated with 50% of AEP effect for the population (2.08 micrograms ml-1; 95% confidence limits 1.7-2.45).,Effect-site modelling of propofol using auditory evoked potentials. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10434811/),[μg] / [ml],2.08,132628,DB00818,Propofol
,10434811,effect-site concentration,"During recovery, 50% of patients demonstrated evidence of waking at an effect-site concentration of 2.28 micrograms ml-1.",Effect-site modelling of propofol using auditory evoked potentials. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10434811/),[μg] / [ml],2.28,132629,DB00818,Propofol
,8110554,Free plasma concentration,Free plasma concentration of midazolam increased from 2.0 (SD 1.5) ng ml-1 to 2.2 (1.9) ng ml-1 after introduction of the propofol infusion (P = 0.32).,Pharmacokinetic interactions between midazolam and propofol: an infusion study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8110554/),[ng] / [ml],2.0,133827,DB00818,Propofol
,8110554,Free plasma concentration,Free plasma concentration of midazolam increased from 2.0 (SD 1.5) ng ml-1 to 2.2 (1.9) ng ml-1 after introduction of the propofol infusion (P = 0.32).,Pharmacokinetic interactions between midazolam and propofol: an infusion study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8110554/),[ng] / [ml],2.2,133828,DB00818,Propofol
,8110554,plasma concentration,Free propofol plasma concentration was unchanged at 18.5 (5.3) ng ml-1 before and 18.7 (7.8) ng ml-1 after introduction of the midazolam infusion (P = 0.94).,Pharmacokinetic interactions between midazolam and propofol: an infusion study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8110554/),[ng] / [ml],18.5,133829,DB00818,Propofol
,8110554,plasma concentration,Free propofol plasma concentration was unchanged at 18.5 (5.3) ng ml-1 before and 18.7 (7.8) ng ml-1 after introduction of the midazolam infusion (P = 0.94).,Pharmacokinetic interactions between midazolam and propofol: an infusion study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8110554/),[ng] / [ml],18.7,133830,DB00818,Propofol
,7593899,peak paracetamol concentration,"There were no differences in median peak paracetamol concentration (M, 18.5 versus P, 20.8 mg/l), median time to peak concentration (M, 20 versus P, 25 min), median area under the concentration-time curve (AUC), or in the median residual volumes at 1 h (M, 14 versus P, 10.5 ml) and 2 h (M, 5 versus P, 3 ml).",Gastric emptying following brain injury: effects of choice of sedation and intracranial pressure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7593899/),[mg] / [l],18.5,134403,DB00818,Propofol
,7593899,peak paracetamol concentration,"There were no differences in median peak paracetamol concentration (M, 18.5 versus P, 20.8 mg/l), median time to peak concentration (M, 20 versus P, 25 min), median area under the concentration-time curve (AUC), or in the median residual volumes at 1 h (M, 14 versus P, 10.5 ml) and 2 h (M, 5 versus P, 3 ml).",Gastric emptying following brain injury: effects of choice of sedation and intracranial pressure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7593899/),[mg] / [l],20.8,134404,DB00818,Propofol
,7593899,time to peak concentration,"There were no differences in median peak paracetamol concentration (M, 18.5 versus P, 20.8 mg/l), median time to peak concentration (M, 20 versus P, 25 min), median area under the concentration-time curve (AUC), or in the median residual volumes at 1 h (M, 14 versus P, 10.5 ml) and 2 h (M, 5 versus P, 3 ml).",Gastric emptying following brain injury: effects of choice of sedation and intracranial pressure. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7593899/),min,20,134405,DB00818,Propofol
,7593899,time to peak concentration,"There were no differences in median peak paracetamol concentration (M, 18.5 versus P, 20.8 mg/l), median time to peak concentration (M, 20 versus P, 25 min), median area under the concentration-time curve (AUC), or in the median residual volumes at 1 h (M, 14 versus P, 10.5 ml) and 2 h (M, 5 versus P, 3 ml).",Gastric emptying following brain injury: effects of choice of sedation and intracranial pressure. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7593899/),min,25,134406,DB00818,Propofol
,7593899,residual volumes,"There were no differences in median peak paracetamol concentration (M, 18.5 versus P, 20.8 mg/l), median time to peak concentration (M, 20 versus P, 25 min), median area under the concentration-time curve (AUC), or in the median residual volumes at 1 h (M, 14 versus P, 10.5 ml) and 2 h (M, 5 versus P, 3 ml).",Gastric emptying following brain injury: effects of choice of sedation and intracranial pressure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7593899/),ml,14,134407,DB00818,Propofol
,7593899,residual volumes,"There were no differences in median peak paracetamol concentration (M, 18.5 versus P, 20.8 mg/l), median time to peak concentration (M, 20 versus P, 25 min), median area under the concentration-time curve (AUC), or in the median residual volumes at 1 h (M, 14 versus P, 10.5 ml) and 2 h (M, 5 versus P, 3 ml).",Gastric emptying following brain injury: effects of choice of sedation and intracranial pressure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7593899/),ml,10.5,134408,DB00818,Propofol
,7593899,residual volumes,"There were no differences in median peak paracetamol concentration (M, 18.5 versus P, 20.8 mg/l), median time to peak concentration (M, 20 versus P, 25 min), median area under the concentration-time curve (AUC), or in the median residual volumes at 1 h (M, 14 versus P, 10.5 ml) and 2 h (M, 5 versus P, 3 ml).",Gastric emptying following brain injury: effects of choice of sedation and intracranial pressure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7593899/),ml,5,134409,DB00818,Propofol
,7593899,residual volumes,"There were no differences in median peak paracetamol concentration (M, 18.5 versus P, 20.8 mg/l), median time to peak concentration (M, 20 versus P, 25 min), median area under the concentration-time curve (AUC), or in the median residual volumes at 1 h (M, 14 versus P, 10.5 ml) and 2 h (M, 5 versus P, 3 ml).",Gastric emptying following brain injury: effects of choice of sedation and intracranial pressure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7593899/),ml,3,134410,DB00818,Propofol
,7593899,AUC,"In patients with ICP > 20 mmHg, paracetamol concentrations were lower (p < 0.05), and AUC after 30 min was lower (165 mg.min/l versus 411 mg.min/l, p = 0.023).",Gastric emptying following brain injury: effects of choice of sedation and intracranial pressure. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7593899/),[mg·min] / [l],165,134411,DB00818,Propofol
,7593899,AUC,"In patients with ICP > 20 mmHg, paracetamol concentrations were lower (p < 0.05), and AUC after 30 min was lower (165 mg.min/l versus 411 mg.min/l, p = 0.023).",Gastric emptying following brain injury: effects of choice of sedation and intracranial pressure. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7593899/),[mg·min] / [l],411,134412,DB00818,Propofol
,1492419,t 1/2,"3. In dog, PG was distributed from plasma (t 1/2 4 min) into a volume equivalent to extracellular water and eliminated with t 1/2 80 min.",Disposition and pharmacology of propofol glucuronide administered intravenously to animals. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1492419/),min,4,136148,DB00818,Propofol
,1492419,t 1/2,"3. In dog, PG was distributed from plasma (t 1/2 4 min) into a volume equivalent to extracellular water and eliminated with t 1/2 80 min.",Disposition and pharmacology of propofol glucuronide administered intravenously to animals. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1492419/),min,80,136149,DB00818,Propofol
,1492419,Total body clearance,"Total body clearance was 1.8 ml/min per kg, and renal clearance about 20% GFR.",Disposition and pharmacology of propofol glucuronide administered intravenously to animals. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1492419/),[ml] / [kg·min],1.8,136150,DB00818,Propofol
,27480084,total sedation-related adverse event rate,The total sedation-related adverse event rate was 5.8 % (25/431).,Safety of Target-Controlled Propofol Infusion by Gastroenterologists in Patients Undergoing Endoscopic Resection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27480084/),%,5.8,136264,DB00818,Propofol
,27480084,infusion time,"In univariate analysis, the propofol infusion time was significantly associated with adverse events (94.88 vs. 59.45 min, P = 0.017).",Safety of Target-Controlled Propofol Infusion by Gastroenterologists in Patients Undergoing Endoscopic Resection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27480084/),min,94.88,136265,DB00818,Propofol
,27480084,infusion time,"In univariate analysis, the propofol infusion time was significantly associated with adverse events (94.88 vs. 59.45 min, P = 0.017).",Safety of Target-Controlled Propofol Infusion by Gastroenterologists in Patients Undergoing Endoscopic Resection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27480084/),min,59.45,136266,DB00818,Propofol
,7925209,clearance,"Mean clearance was 5.2 ml kg-1 min-1, the terminal half-life was 69 min and distribution volume at steady state was 0.22 litre kg-1.",Pharmacokinetics and pharmacodynamics of rocuronium bromide in adult patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7925209/),[ml] / [kg·min],5.2,136530,DB00818,Propofol
,7925209,terminal half-life,"Mean clearance was 5.2 ml kg-1 min-1, the terminal half-life was 69 min and distribution volume at steady state was 0.22 litre kg-1.",Pharmacokinetics and pharmacodynamics of rocuronium bromide in adult patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7925209/),min,69,136531,DB00818,Propofol
,7925209,distribution volume at steady state,"Mean clearance was 5.2 ml kg-1 min-1, the terminal half-life was 69 min and distribution volume at steady state was 0.22 litre kg-1.",Pharmacokinetics and pharmacodynamics of rocuronium bromide in adult patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7925209/),[l] / [kg],0.22,136532,DB00818,Propofol
,7925209,Cumulative urinary excretion,Cumulative urinary excretion was around 18% within 24 h.,Pharmacokinetics and pharmacodynamics of rocuronium bromide in adult patients. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7925209/),%,18,136533,DB00818,Propofol
,12502981,target concentration,The effect-site sufentanil target concentration was initially 0.4 ng/ml but was modified during surgery as a function of blood pressure and heart rate.,Performance of target-controlled sufentanil infusion in obese patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12502981/),[ng] / [ml],0.4,137589,DB00818,Propofol
,12502981,target concentrations,Applied sufentanil target concentrations ranged from 0.3 to 0.65 ng/ml.,Performance of target-controlled sufentanil infusion in obese patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12502981/),[ng] / [ml],0.3 to 0.65,137590,DB00818,Propofol
,12502981,plasma sufentanil concentration,The mean +/- SD plasma sufentanil concentration measured during spontaneous ventilation was 0.13 +/- 0.03 ng/ml.,Performance of target-controlled sufentanil infusion in obese patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12502981/),[ng] / [ml],0.13,137591,DB00818,Propofol
,12502981,Clearance,"Clearance, central volume of distribution, intercompartmental clearance, and peripheral volume of distribution (coefficient of variation) were 1.27 l/min (23%), 37.1 l (20%), 0.87 l/min (44%), and 92.7 l (22%), respectively.",Performance of target-controlled sufentanil infusion in obese patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12502981/),[l] / [min],1.27,137592,DB00818,Propofol
,12502981,peripheral volume of distribution,"Clearance, central volume of distribution, intercompartmental clearance, and peripheral volume of distribution (coefficient of variation) were 1.27 l/min (23%), 37.1 l (20%), 0.87 l/min (44%), and 92.7 l (22%), respectively.",Performance of target-controlled sufentanil infusion in obese patients. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12502981/),l,92.7,137593,DB00818,Propofol
,11140564,infusion rate,The initial propofol infusion rate was 200 mg/h (20 ml/h) for 21 of the 23 implant surgery treatments.,A sedation technique for implant and periodontal surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11140564/),[mg] / [h],200,137733,DB00818,Propofol
,12413256,BIS,"Propofol dose required to achieve a BIS of 50 (5) was also higher in end-stage renal disease patients (2.03 (0.4) mg/kg versus 1.39 (0.43) mg/kg in normal renal function patients, P<0.05).",Evaluation of induction doses of propofol: comparison between endstage renal disease and normal renal function patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12413256/),,50,138290,DB00818,Propofol
,12413256,BIS,"Propofol dose required to achieve a BIS of 50 (5) was also higher in end-stage renal disease patients (2.03 (0.4) mg/kg versus 1.39 (0.43) mg/kg in normal renal function patients, P<0.05).",Evaluation of induction doses of propofol: comparison between endstage renal disease and normal renal function patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12413256/),,2.03,138291,DB00818,Propofol
,12413256,BIS,"Propofol dose required to achieve a BIS of 50 (5) was also higher in end-stage renal disease patients (2.03 (0.4) mg/kg versus 1.39 (0.43) mg/kg in normal renal function patients, P<0.05).",Evaluation of induction doses of propofol: comparison between endstage renal disease and normal renal function patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12413256/),mg,1.39,138292,DB00818,Propofol
,3261954,total body clearance rate,"The propofol mean total body clearance rate was 2.09 +/- 0.65 1/min (mean +/- SD), the volume of distribution at steady state was 159 +/- 57 l, and the elimination half-life was 116 +/- 34 min.",Pharmacokinetics and pharmacodynamics of propofol infusions during general anesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3261954/),[1] / [min],2.09,139207,DB00818,Propofol
,3261954,volume of distribution at steady state,"The propofol mean total body clearance rate was 2.09 +/- 0.65 1/min (mean +/- SD), the volume of distribution at steady state was 159 +/- 57 l, and the elimination half-life was 116 +/- 34 min.",Pharmacokinetics and pharmacodynamics of propofol infusions during general anesthesia. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3261954/),l,159,139208,DB00818,Propofol
,3261954,elimination half-life,"The propofol mean total body clearance rate was 2.09 +/- 0.65 1/min (mean +/- SD), the volume of distribution at steady state was 159 +/- 57 l, and the elimination half-life was 116 +/- 34 min.",Pharmacokinetics and pharmacodynamics of propofol infusions during general anesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3261954/),min,116,139209,DB00818,Propofol
,3261954,clearance rates,"Elderly patients (patients older than 60 yr vs. those younger than 60 yr) had significantly decreased clearance rates (1.58 +/- 0.42 vs. 2.19 +/- 0.64 l/min), whereas women (vs. men) had greater clearance rates (33 +/- 8 vs. 26 +/- 7 l.kg-1.min-1) and volumes of distribution (2.50 +/- 0.81 vs. 2.05 +/- 0.65 l/kg).",Pharmacokinetics and pharmacodynamics of propofol infusions during general anesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3261954/),[l] / [min],1.58,139210,DB00818,Propofol
,3261954,clearance rates,"Elderly patients (patients older than 60 yr vs. those younger than 60 yr) had significantly decreased clearance rates (1.58 +/- 0.42 vs. 2.19 +/- 0.64 l/min), whereas women (vs. men) had greater clearance rates (33 +/- 8 vs. 26 +/- 7 l.kg-1.min-1) and volumes of distribution (2.50 +/- 0.81 vs. 2.05 +/- 0.65 l/kg).",Pharmacokinetics and pharmacodynamics of propofol infusions during general anesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3261954/),[l] / [min],2.19,139211,DB00818,Propofol
,3261954,clearance rates,"Elderly patients (patients older than 60 yr vs. those younger than 60 yr) had significantly decreased clearance rates (1.58 +/- 0.42 vs. 2.19 +/- 0.64 l/min), whereas women (vs. men) had greater clearance rates (33 +/- 8 vs. 26 +/- 7 l.kg-1.min-1) and volumes of distribution (2.50 +/- 0.81 vs. 2.05 +/- 0.65 l/kg).",Pharmacokinetics and pharmacodynamics of propofol infusions during general anesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3261954/),[l] / [kg·min],33,139212,DB00818,Propofol
,3261954,clearance rates,"Elderly patients (patients older than 60 yr vs. those younger than 60 yr) had significantly decreased clearance rates (1.58 +/- 0.42 vs. 2.19 +/- 0.64 l/min), whereas women (vs. men) had greater clearance rates (33 +/- 8 vs. 26 +/- 7 l.kg-1.min-1) and volumes of distribution (2.50 +/- 0.81 vs. 2.05 +/- 0.65 l/kg).",Pharmacokinetics and pharmacodynamics of propofol infusions during general anesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3261954/),[l] / [kg·min],26,139213,DB00818,Propofol
,3261954,volumes of distribution,"Elderly patients (patients older than 60 yr vs. those younger than 60 yr) had significantly decreased clearance rates (1.58 +/- 0.42 vs. 2.19 +/- 0.64 l/min), whereas women (vs. men) had greater clearance rates (33 +/- 8 vs. 26 +/- 7 l.kg-1.min-1) and volumes of distribution (2.50 +/- 0.81 vs. 2.05 +/- 0.65 l/kg).",Pharmacokinetics and pharmacodynamics of propofol infusions during general anesthesia. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3261954/),[l] / [kg],2.50,139214,DB00818,Propofol
,3261954,volumes of distribution,"Elderly patients (patients older than 60 yr vs. those younger than 60 yr) had significantly decreased clearance rates (1.58 +/- 0.42 vs. 2.19 +/- 0.64 l/min), whereas women (vs. men) had greater clearance rates (33 +/- 8 vs. 26 +/- 7 l.kg-1.min-1) and volumes of distribution (2.50 +/- 0.81 vs. 2.05 +/- 0.65 l/kg).",Pharmacokinetics and pharmacodynamics of propofol infusions during general anesthesia. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3261954/),[l] / [kg],2.05,139215,DB00818,Propofol
,3261954,elimination half-life,Patients undergoing major (intraabdominal) surgery had longer elimination half-life values (136 +/- 40 vs. 108 +/- 29 min).,Pharmacokinetics and pharmacodynamics of propofol infusions during general anesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3261954/),min,136,139216,DB00818,Propofol
,3261954,elimination half-life,Patients undergoing major (intraabdominal) surgery had longer elimination half-life values (136 +/- 40 vs. 108 +/- 29 min).,Pharmacokinetics and pharmacodynamics of propofol infusions during general anesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3261954/),min,108,139217,DB00818,Propofol
,3261954,EC50),"Blood propofol concentrations at which 50% of patients (EC50) were awake and oriented after surgery were 1.07 and 0.95 microgram/ml, respectively.",Pharmacokinetics and pharmacodynamics of propofol infusions during general anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3261954/),[μg] / [ml],1.07,139218,DB00818,Propofol
,3261954,EC50),"Blood propofol concentrations at which 50% of patients (EC50) were awake and oriented after surgery were 1.07 and 0.95 microgram/ml, respectively.",Pharmacokinetics and pharmacodynamics of propofol infusions during general anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3261954/),[μg] / [ml],0.95,139219,DB00818,Propofol
,20407249,elimination half-life,"Remifentanil, due to its pharmacokinetic profile (elimination half-life: 9 min), is advantageous for ambulatory patients, though it is not known whether the high cost compensates the benefits.",Pharmacology of sedation agents and reversal agents. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20407249/),min,9,139670,DB00818,Propofol
,15190236,Fi O2,After tracheal intubation the lungs were ventilated to achieve normocapnia with an oxygen-air mixture (Fi O2 = 0.33).,Relationships between total and unbound propofol in plasma and CSF during continuous drug infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15190236/),,0.33,139755,DB00818,Propofol
,10027030,equilibrium half-life,"The equilibrium half-life between the blood and the brain was 3.5 min, which is comparable to the value of 4.3 min derived from the earlier rapid administration data, suggesting there was no time dependency in the kinetics of cerebral uptake.",Prolonged dysequilibrium between blood and brain concentrations of propofol during infusions in sheep. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10027030/),min,3.5,142985,DB00818,Propofol
,10027030,equilibrium half-life,"The equilibrium half-life between the blood and the brain was 3.5 min, which is comparable to the value of 4.3 min derived from the earlier rapid administration data, suggesting there was no time dependency in the kinetics of cerebral uptake.",Prolonged dysequilibrium between blood and brain concentrations of propofol during infusions in sheep. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10027030/),min,4.3,142986,DB00818,Propofol
,20613468,"time to peak effect, Tpeak","The time to peak effect, Tpeak (median, 0.71 [range, 0.37-1.64] and 1.73 [1.4-2.68] min), and the Ce50 (3.71 [1.88-4.4] and 3.07 [2.95-5.21] microg/ml) were shorter and higher, respectively, in children than in adults.",Pharmacokinetic-pharmacodynamic modeling of propofol in children. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20613468/),min,0.71,144603,DB00818,Propofol
,20613468,"time to peak effect, Tpeak","The time to peak effect, Tpeak (median, 0.71 [range, 0.37-1.64] and 1.73 [1.4-2.68] min), and the Ce50 (3.71 [1.88-4.4] and 3.07 [2.95-5.21] microg/ml) were shorter and higher, respectively, in children than in adults.",Pharmacokinetic-pharmacodynamic modeling of propofol in children. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20613468/),min,1.73,144604,DB00818,Propofol
,20613468,Ce50,"The time to peak effect, Tpeak (median, 0.71 [range, 0.37-1.64] and 1.73 [1.4-2.68] min), and the Ce50 (3.71 [1.88-4.4] and 3.07 [2.95-5.21] microg/ml) were shorter and higher, respectively, in children than in adults.",Pharmacokinetic-pharmacodynamic modeling of propofol in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20613468/),[μg] / [ml],3.71,144605,DB00818,Propofol
,20613468,Ce50,"The time to peak effect, Tpeak (median, 0.71 [range, 0.37-1.64] and 1.73 [1.4-2.68] min), and the Ce50 (3.71 [1.88-4.4] and 3.07 [2.95-5.21] microg/ml) were shorter and higher, respectively, in children than in adults.",Pharmacokinetic-pharmacodynamic modeling of propofol in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20613468/),[μg] / [ml],3.07,144606,DB00818,Propofol
,20613468,kE0,The kE0 linked to the Kataria model was 4.6 [1.4-11] min.,Pharmacokinetic-pharmacodynamic modeling of propofol in children. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20613468/),min,4.6,144607,DB00818,Propofol
,1796609,t1/2,"3. The initial decline in blood propofol concentration was associated with redistribution (t1/2 4 min), the second decline (15-240 min post-dose) was associated with metabolism (t1/2 33 min) and the third decline reflected slow depletion of drug from deep tissue compartments (t1/2 6.4 h).",Distribution in female rats of an anaesthetic intravenous dose of 14C-propofol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1796609/),min,4,145319,DB00818,Propofol
,1796609,t1/2,"3. The initial decline in blood propofol concentration was associated with redistribution (t1/2 4 min), the second decline (15-240 min post-dose) was associated with metabolism (t1/2 33 min) and the third decline reflected slow depletion of drug from deep tissue compartments (t1/2 6.4 h).",Distribution in female rats of an anaesthetic intravenous dose of 14C-propofol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1796609/),min,33,145320,DB00818,Propofol
,1796609,t1/2,"3. The initial decline in blood propofol concentration was associated with redistribution (t1/2 4 min), the second decline (15-240 min post-dose) was associated with metabolism (t1/2 33 min) and the third decline reflected slow depletion of drug from deep tissue compartments (t1/2 6.4 h).",Distribution in female rats of an anaesthetic intravenous dose of 14C-propofol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1796609/),h,6.4,145321,DB00818,Propofol
,9806701,elimination rate constant,The elimination rate constant from the peripheral compartment was fixed to the in vitro rate of degradation of cisatracurium in human plasma (0.0237 min(-1)).,Pharmacokinetics and pharmacodynamics of cisatracurium after a short infusion in patients under propofol anesthesia. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9806701/),1/[min],0.0237,145684,DB00818,Propofol
,9806701,rate of degradation,The elimination rate constant from the peripheral compartment was fixed to the in vitro rate of degradation of cisatracurium in human plasma (0.0237 min(-1)).,Pharmacokinetics and pharmacodynamics of cisatracurium after a short infusion in patients under propofol anesthesia. ,Kdeg-Q12,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9806701/),1/[min],0.0237,145685,DB00818,Propofol
,9806701,terminal half-life,"The mean terminal half-life of cisatracurium was 23.9+/-3.3 min, and its total clearance averaged 3.7+/-0.8 mL x min(-1) x kg(-1).",Pharmacokinetics and pharmacodynamics of cisatracurium after a short infusion in patients under propofol anesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9806701/),min,23.9,145686,DB00818,Propofol
,9806701,total clearance,"The mean terminal half-life of cisatracurium was 23.9+/-3.3 min, and its total clearance averaged 3.7+/-0.8 mL x min(-1) x kg(-1).",Pharmacokinetics and pharmacodynamics of cisatracurium after a short infusion in patients under propofol anesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9806701/),[ml] / [kg·min],3.7,145687,DB00818,Propofol
,9806701,volume of distribution at steady state,"Using this model, the volume of distribution at steady state was significantly increased compared with that obtained when central elimination only was assumed (0.118+/-0.027 vs 0.089+/-0.017 L/kg).",Pharmacokinetics and pharmacodynamics of cisatracurium after a short infusion in patients under propofol anesthesia. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9806701/),[l] / [kg],0.118,145688,DB00818,Propofol
,9806701,volume of distribution at steady state,"Using this model, the volume of distribution at steady state was significantly increased compared with that obtained when central elimination only was assumed (0.118+/-0.027 vs 0.089+/-0.017 L/kg).",Pharmacokinetics and pharmacodynamics of cisatracurium after a short infusion in patients under propofol anesthesia. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9806701/),[l] / [kg],0.089,145689,DB00818,Propofol
,9806701,rate constant,The effect-plasma equilibration rate constant was 0.054+/-0.013 min(-1).,Pharmacokinetics and pharmacodynamics of cisatracurium after a short infusion in patients under propofol anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9806701/),1/[min],0.054,145690,DB00818,Propofol
,9806701,50% effective concentration,"The 50% effective concentration (153+/-33 ng/mL) was 56% higher than that reported in patients anesthetized with volatile anesthetics, which suggests that, compared with inhaled anesthetics, a cisatracurium neuromuscular block is less enhanced by propofol.",Pharmacokinetics and pharmacodynamics of cisatracurium after a short infusion in patients under propofol anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9806701/),[ng] / [ml],153,145691,DB00818,Propofol
,26019354,EC50,The EC50 of propofol in the fentanyl group for LMA insertion was 5.95 ± 0.6 μg/ml and morphine group was 5.75 ± 0.8 μg/ml.,Estimation of effect-site concentration of propofol for laryngeal mask airway insertion using fentanyl or morphine as adjuvant. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26019354/),[μg] / [ml],5.95,145894,DB00818,Propofol
,26019354,EC50,The EC50 of propofol in the fentanyl group for LMA insertion was 5.95 ± 0.6 μg/ml and morphine group was 5.75 ± 0.8 μg/ml.,Estimation of effect-site concentration of propofol for laryngeal mask airway insertion using fentanyl or morphine as adjuvant. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26019354/),[μg] / [ml],5.75,145895,DB00818,Propofol
<,19604146,TBL,"The effect of obstructive jaundice on the distribution and elimination of propofol was studied in 15 patients with obstructive jaundice (total serum bilirubin, TBL >/= 17.1micromol.l(-1)) and in 15 control patients (TBL < 17.1micromol.l(-1)).",Propofol pharmacokinetics in patients with obstructive jaundice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19604146/),[μM] / [l],17.1,145940,DB00818,Propofol
,19604146,volumes of distribution at steady state (V(SS)),"Pharmacokinelic parameters: volumes of distribution at steady state (V(SS)), volumes of distribution at equilibrium (V(r)), volumes of the central compartment (V) and total body clearance (Cl) were similar in patients with obstructive jaundice (mean 12.3 (SD 6.0) litre.kg(-1), 32.99(21.42) litre.kg(-1), 0.241(0.131) litre.kg(-1), and 28.8(8.2) ml.min(-1).",Propofol pharmacokinetics in patients with obstructive jaundice. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19604146/),[l] / [kg],12.3,145941,DB00818,Propofol
,19604146,volumes of distribution at equilibrium (V(r)),"Pharmacokinelic parameters: volumes of distribution at steady state (V(SS)), volumes of distribution at equilibrium (V(r)), volumes of the central compartment (V) and total body clearance (Cl) were similar in patients with obstructive jaundice (mean 12.3 (SD 6.0) litre.kg(-1), 32.99(21.42) litre.kg(-1), 0.241(0.131) litre.kg(-1), and 28.8(8.2) ml.min(-1).",Propofol pharmacokinetics in patients with obstructive jaundice. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19604146/),[l] / [kg],32.99,145942,DB00818,Propofol
,19604146,volumes of the central compartment (V),"Pharmacokinelic parameters: volumes of distribution at steady state (V(SS)), volumes of distribution at equilibrium (V(r)), volumes of the central compartment (V) and total body clearance (Cl) were similar in patients with obstructive jaundice (mean 12.3 (SD 6.0) litre.kg(-1), 32.99(21.42) litre.kg(-1), 0.241(0.131) litre.kg(-1), and 28.8(8.2) ml.min(-1).",Propofol pharmacokinetics in patients with obstructive jaundice. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19604146/),[l] / [kg],32.99,145943,DB00818,Propofol
,19604146,total body clearance (Cl),"Pharmacokinelic parameters: volumes of distribution at steady state (V(SS)), volumes of distribution at equilibrium (V(r)), volumes of the central compartment (V) and total body clearance (Cl) were similar in patients with obstructive jaundice (mean 12.3 (SD 6.0) litre.kg(-1), 32.99(21.42) litre.kg(-1), 0.241(0.131) litre.kg(-1), and 28.8(8.2) ml.min(-1).",Propofol pharmacokinetics in patients with obstructive jaundice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19604146/),[ml] / [min],28.8,145944,DB00818,Propofol
,26474629,recoveries,"The average recoveries of propofol from plasma were in the range of 93.6%-101.1%, and intra-day or inter-day relative standard deviation for measurement was <14%.",[Pharmacokinetics for the solutable type injections of propofol glycoside in rats]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26474629/),%,93.6,146430,DB00818,Propofol
,26474629,recoveries,"The average recoveries of propofol from plasma were in the range of 93.6%-101.1%, and intra-day or inter-day relative standard deviation for measurement was <14%.",[Pharmacokinetics for the solutable type injections of propofol glycoside in rats]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26474629/),%,101.1,146431,DB00818,Propofol
,26474629,elimination half-life (t1/2),"Nevertheless, the propofol elimination half-life (t1/2) value of the newly developed propofol glycoside injections was the same as that of commercial propofol emulsion injection (approximately 1.5 h).",[Pharmacokinetics for the solutable type injections of propofol glycoside in rats]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26474629/),h,1.5,146432,DB00818,Propofol
,21276995,maximal,"Although the estimated propofol plasma concentration reached a maximal value of 15.3 μg ml(-1), no hypotension or bradycardia were observed.",Dogs mean arterial pressure and heart rate responses during high propofol plasma concentrations estimated by a pharmacokinetic model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21276995/),[μg] / [ml],15.3,146686,DB00818,Propofol
,9757923,Hepatic blood flow,"Hepatic blood flow was high and was not affected by switching from parenteral to enteral feeding: 33 +/- 8 ml x min(-1) x kg(-1) (mean +/- SD) and 33 +/- 10 ml min(-1) x kg(-1) on D -3 and D -1, respectively, as compared to 37 +/- 11 ml x min(-1) kg(-1) and 34 +/- 8 ml x min(-1) x kg(-1) on days D + 1 and D + 3, respectively.",Effect of enteral versus parenteral feeding on hepatic blood flow and steady state propofol pharmacokinetics in ICU patients. ,QH-Q55,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9757923/),[ml] / [kg·min],33,147247,DB00818,Propofol
,9757923,Hepatic blood flow,"Hepatic blood flow was high and was not affected by switching from parenteral to enteral feeding: 33 +/- 8 ml x min(-1) x kg(-1) (mean +/- SD) and 33 +/- 10 ml min(-1) x kg(-1) on D -3 and D -1, respectively, as compared to 37 +/- 11 ml x min(-1) kg(-1) and 34 +/- 8 ml x min(-1) x kg(-1) on days D + 1 and D + 3, respectively.",Effect of enteral versus parenteral feeding on hepatic blood flow and steady state propofol pharmacokinetics in ICU patients. ,QH-Q55,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9757923/),[ml] / [kg·min],33,147248,DB00818,Propofol
,9757923,Hepatic blood flow,"Hepatic blood flow was high and was not affected by switching from parenteral to enteral feeding: 33 +/- 8 ml x min(-1) x kg(-1) (mean +/- SD) and 33 +/- 10 ml min(-1) x kg(-1) on D -3 and D -1, respectively, as compared to 37 +/- 11 ml x min(-1) kg(-1) and 34 +/- 8 ml x min(-1) x kg(-1) on days D + 1 and D + 3, respectively.",Effect of enteral versus parenteral feeding on hepatic blood flow and steady state propofol pharmacokinetics in ICU patients. ,QH-Q55,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9757923/),[ml] / [kg·min],37,147249,DB00818,Propofol
,9757923,Hepatic blood flow,"Hepatic blood flow was high and was not affected by switching from parenteral to enteral feeding: 33 +/- 8 ml x min(-1) x kg(-1) (mean +/- SD) and 33 +/- 10 ml min(-1) x kg(-1) on D -3 and D -1, respectively, as compared to 37 +/- 11 ml x min(-1) kg(-1) and 34 +/- 8 ml x min(-1) x kg(-1) on days D + 1 and D + 3, respectively.",Effect of enteral versus parenteral feeding on hepatic blood flow and steady state propofol pharmacokinetics in ICU patients. ,QH-Q55,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9757923/),[ml] / [kg·min],34,147250,DB00818,Propofol
,9757923,Systemic clearance,Systemic clearance of propofol was much higher than liver blood flow with average values on the six observation days ranging from 74.0 to 81.2 ml x min(-1) x kg(-1) and was not affected by switching from parenteral to enteral feeding.,Effect of enteral versus parenteral feeding on hepatic blood flow and steady state propofol pharmacokinetics in ICU patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9757923/),[ml] / [kg·min],74.0 to 81.2,147251,DB00818,Propofol
,1642937,rate,Blood samples for analysis of propofol were taken during the infusion (mean duration 85.6 h; mean rate 2.58 mg kg-1 h-1) and for up to about 42 h after its termination.,Pharmacokinetics of propofol during and after long-term continuous infusion for maintenance of sedation in ICU patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1642937/),,2,149174,DB00818,Propofol
,1642937,total body clearance,"The median propofol total body clearance, derived from the apparent steady state propofol blood concentrations during infusion, was 2.11 litre min-1.",Pharmacokinetics of propofol during and after long-term continuous infusion for maintenance of sedation in ICU patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1642937/),[l] / [min],2.11,149175,DB00818,Propofol
,1642937,half-lives,"Mean half-lives for the three phases were 1.81 (n = 10) min, 70.9 (n = 7) min and 1411 (n = 11) min.",Pharmacokinetics of propofol during and after long-term continuous infusion for maintenance of sedation in ICU patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1642937/),min,1.81,149176,DB00818,Propofol
,1642937,half-lives,"Mean half-lives for the three phases were 1.81 (n = 10) min, 70.9 (n = 7) min and 1411 (n = 11) min.",Pharmacokinetics of propofol during and after long-term continuous infusion for maintenance of sedation in ICU patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1642937/),min,70.9,149177,DB00818,Propofol
,1642937,half-lives,"Mean half-lives for the three phases were 1.81 (n = 10) min, 70.9 (n = 7) min and 1411 (n = 11) min.",Pharmacokinetics of propofol during and after long-term continuous infusion for maintenance of sedation in ICU patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1642937/),min,1411,149178,DB00818,Propofol
,8735519,infusion rate,"The average mean infusion rate of propofol was 0.136 mg kg-1 min-1, and the ketamine infusion rate was maintained at 50 micrograms kg-1 min-1.",Simultaneous infusions of propofol and ketamine in ponies premedicated with detomidine: a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735519/),[mg] / [kg·min],0.136,149255,DB00818,Propofol
,8735519,infusion rate,"The average mean infusion rate of propofol was 0.136 mg kg-1 min-1, and the ketamine infusion rate was maintained at 50 micrograms kg-1 min-1.",Simultaneous infusions of propofol and ketamine in ponies premedicated with detomidine: a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735519/),[μg] / [kg·min],50,149256,DB00818,Propofol
,8735519,elimination half-lives,"The mean (SD) elimination half-lives of propofol and ketamine were 69.0 (8.0) and 89.8 (26.7) minutes, the mean volumes of distribution at steady state were 0.894 (0.161) litre kg-1 and 1.432 (0.324) litre kg-1; the mean body clearances were 33.1 (4.5) and 23.9 (3.8) ml kg-1 min-1 and the mean residence times for the infusion were 87.1 (4.1) and 110.7 (8.2) minutes, respectively.",Simultaneous infusions of propofol and ketamine in ponies premedicated with detomidine: a pharmacokinetic study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735519/),min,69.0,149257,DB00818,Propofol
,8735519,elimination half-lives,"The mean (SD) elimination half-lives of propofol and ketamine were 69.0 (8.0) and 89.8 (26.7) minutes, the mean volumes of distribution at steady state were 0.894 (0.161) litre kg-1 and 1.432 (0.324) litre kg-1; the mean body clearances were 33.1 (4.5) and 23.9 (3.8) ml kg-1 min-1 and the mean residence times for the infusion were 87.1 (4.1) and 110.7 (8.2) minutes, respectively.",Simultaneous infusions of propofol and ketamine in ponies premedicated with detomidine: a pharmacokinetic study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735519/),min,89.8,149258,DB00818,Propofol
,8735519,volumes of distribution at steady state,"The mean (SD) elimination half-lives of propofol and ketamine were 69.0 (8.0) and 89.8 (26.7) minutes, the mean volumes of distribution at steady state were 0.894 (0.161) litre kg-1 and 1.432 (0.324) litre kg-1; the mean body clearances were 33.1 (4.5) and 23.9 (3.8) ml kg-1 min-1 and the mean residence times for the infusion were 87.1 (4.1) and 110.7 (8.2) minutes, respectively.",Simultaneous infusions of propofol and ketamine in ponies premedicated with detomidine: a pharmacokinetic study. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735519/),[l] / [kg],0.894,149259,DB00818,Propofol
,8735519,volumes of distribution at steady state,"The mean (SD) elimination half-lives of propofol and ketamine were 69.0 (8.0) and 89.8 (26.7) minutes, the mean volumes of distribution at steady state were 0.894 (0.161) litre kg-1 and 1.432 (0.324) litre kg-1; the mean body clearances were 33.1 (4.5) and 23.9 (3.8) ml kg-1 min-1 and the mean residence times for the infusion were 87.1 (4.1) and 110.7 (8.2) minutes, respectively.",Simultaneous infusions of propofol and ketamine in ponies premedicated with detomidine: a pharmacokinetic study. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735519/),[l] / [kg],1.432,149260,DB00818,Propofol
,8735519,body clearances,"The mean (SD) elimination half-lives of propofol and ketamine were 69.0 (8.0) and 89.8 (26.7) minutes, the mean volumes of distribution at steady state were 0.894 (0.161) litre kg-1 and 1.432 (0.324) litre kg-1; the mean body clearances were 33.1 (4.5) and 23.9 (3.8) ml kg-1 min-1 and the mean residence times for the infusion were 87.1 (4.1) and 110.7 (8.2) minutes, respectively.",Simultaneous infusions of propofol and ketamine in ponies premedicated with detomidine: a pharmacokinetic study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735519/),[ml] / [kg·min],33.1,149261,DB00818,Propofol
,8735519,body clearances,"The mean (SD) elimination half-lives of propofol and ketamine were 69.0 (8.0) and 89.8 (26.7) minutes, the mean volumes of distribution at steady state were 0.894 (0.161) litre kg-1 and 1.432 (0.324) litre kg-1; the mean body clearances were 33.1 (4.5) and 23.9 (3.8) ml kg-1 min-1 and the mean residence times for the infusion were 87.1 (4.1) and 110.7 (8.2) minutes, respectively.",Simultaneous infusions of propofol and ketamine in ponies premedicated with detomidine: a pharmacokinetic study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735519/),[ml] / [kg·min],23.9,149262,DB00818,Propofol
,8735519,mean residence times,"The mean (SD) elimination half-lives of propofol and ketamine were 69.0 (8.0) and 89.8 (26.7) minutes, the mean volumes of distribution at steady state were 0.894 (0.161) litre kg-1 and 1.432 (0.324) litre kg-1; the mean body clearances were 33.1 (4.5) and 23.9 (3.8) ml kg-1 min-1 and the mean residence times for the infusion were 87.1 (4.1) and 110.7 (8.2) minutes, respectively.",Simultaneous infusions of propofol and ketamine in ponies premedicated with detomidine: a pharmacokinetic study. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735519/),min,87.1,149263,DB00818,Propofol
,8735519,mean residence times,"The mean (SD) elimination half-lives of propofol and ketamine were 69.0 (8.0) and 89.8 (26.7) minutes, the mean volumes of distribution at steady state were 0.894 (0.161) litre kg-1 and 1.432 (0.324) litre kg-1; the mean body clearances were 33.1 (4.5) and 23.9 (3.8) ml kg-1 min-1 and the mean residence times for the infusion were 87.1 (4.1) and 110.7 (8.2) minutes, respectively.",Simultaneous infusions of propofol and ketamine in ponies premedicated with detomidine: a pharmacokinetic study. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735519/),min,110.7,149264,DB00818,Propofol
,8735519,mean residence time,The mean residence time for norketamine was 144 (16) minutes.,Simultaneous infusions of propofol and ketamine in ponies premedicated with detomidine: a pharmacokinetic study. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735519/),min,144,149265,DB00818,Propofol
,8735519,times to,"All the ponies recovered quickly from the anaesthesia; the mean times to sternal recumbency and standing were 11.1 (5.3) and 30.0 (20.8) minutes, respectively, from the end of the infusion.",Simultaneous infusions of propofol and ketamine in ponies premedicated with detomidine: a pharmacokinetic study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735519/),min,11.1,149266,DB00818,Propofol
,8735519,times to,"All the ponies recovered quickly from the anaesthesia; the mean times to sternal recumbency and standing were 11.1 (5.3) and 30.0 (20.8) minutes, respectively, from the end of the infusion.",Simultaneous infusions of propofol and ketamine in ponies premedicated with detomidine: a pharmacokinetic study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8735519/),min,30.0,149267,DB00818,Propofol
,20514950,V,"Population pharmacokinetic analysis of the final group of six females and five males, aged 29 to 70 years and of 16.5 to 44.2% body fat, resulted in a two compartment pharmacokinetic model with coefficients and standard errors of V = 0.102 (0.0155) l/kg(LBM), V2 = 0.257 (0.079) l/kg(LBM), k10 = 0.423 (0.069)/min, k12 = 0.222 (0.051)/min, k21 = 0.084 (0.02)/min and clearance = 0.0418 (0.0023) L x min(-1) x kg(LBM)(-1).",A comparison of parametric and non-parametric approaches to target-controlled infusion of propofol. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20514950/),[l] / [kg],0.102,149279,DB00818,Propofol
,20514950,V2,"Population pharmacokinetic analysis of the final group of six females and five males, aged 29 to 70 years and of 16.5 to 44.2% body fat, resulted in a two compartment pharmacokinetic model with coefficients and standard errors of V = 0.102 (0.0155) l/kg(LBM), V2 = 0.257 (0.079) l/kg(LBM), k10 = 0.423 (0.069)/min, k12 = 0.222 (0.051)/min, k21 = 0.084 (0.02)/min and clearance = 0.0418 (0.0023) L x min(-1) x kg(LBM)(-1).",A comparison of parametric and non-parametric approaches to target-controlled infusion of propofol. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20514950/),[l] / [kg],0.257,149280,DB00818,Propofol
,20514950,k10,"Population pharmacokinetic analysis of the final group of six females and five males, aged 29 to 70 years and of 16.5 to 44.2% body fat, resulted in a two compartment pharmacokinetic model with coefficients and standard errors of V = 0.102 (0.0155) l/kg(LBM), V2 = 0.257 (0.079) l/kg(LBM), k10 = 0.423 (0.069)/min, k12 = 0.222 (0.051)/min, k21 = 0.084 (0.02)/min and clearance = 0.0418 (0.0023) L x min(-1) x kg(LBM)(-1).",A comparison of parametric and non-parametric approaches to target-controlled infusion of propofol. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20514950/),1/[min],0.423,149281,DB00818,Propofol
,20514950,k12,"Population pharmacokinetic analysis of the final group of six females and five males, aged 29 to 70 years and of 16.5 to 44.2% body fat, resulted in a two compartment pharmacokinetic model with coefficients and standard errors of V = 0.102 (0.0155) l/kg(LBM), V2 = 0.257 (0.079) l/kg(LBM), k10 = 0.423 (0.069)/min, k12 = 0.222 (0.051)/min, k21 = 0.084 (0.02)/min and clearance = 0.0418 (0.0023) L x min(-1) x kg(LBM)(-1).",A comparison of parametric and non-parametric approaches to target-controlled infusion of propofol. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20514950/),1/[min],0.222,149282,DB00818,Propofol
,20514950,k21,"Population pharmacokinetic analysis of the final group of six females and five males, aged 29 to 70 years and of 16.5 to 44.2% body fat, resulted in a two compartment pharmacokinetic model with coefficients and standard errors of V = 0.102 (0.0155) l/kg(LBM), V2 = 0.257 (0.079) l/kg(LBM), k10 = 0.423 (0.069)/min, k12 = 0.222 (0.051)/min, k21 = 0.084 (0.02)/min and clearance = 0.0418 (0.0023) L x min(-1) x kg(LBM)(-1).",A comparison of parametric and non-parametric approaches to target-controlled infusion of propofol. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20514950/),1/[min],0.084,149283,DB00818,Propofol
,20514950,clearance,"Population pharmacokinetic analysis of the final group of six females and five males, aged 29 to 70 years and of 16.5 to 44.2% body fat, resulted in a two compartment pharmacokinetic model with coefficients and standard errors of V = 0.102 (0.0155) l/kg(LBM), V2 = 0.257 (0.079) l/kg(LBM), k10 = 0.423 (0.069)/min, k12 = 0.222 (0.051)/min, k21 = 0.084 (0.02)/min and clearance = 0.0418 (0.0023) L x min(-1) x kg(LBM)(-1).",A comparison of parametric and non-parametric approaches to target-controlled infusion of propofol. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20514950/),[kg·l] / [min],0.0418,149284,DB00818,Propofol
,14564578,half-lives of the central,"The half-lives of the central and peripheral compartment ( t(1/2)alpha and t(1/2)beta) were 2.26 +/- 0.69 and 47.9 +/- 22.1 min, respectively.",Pharmacokinetic profile of propofol after a single-dose injection during general anesthesia in Japanese adults. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14564578/),min,2.26,149532,DB00818,Propofol
,14564578,t(1/2)beta,"The half-lives of the central and peripheral compartment ( t(1/2)alpha and t(1/2)beta) were 2.26 +/- 0.69 and 47.9 +/- 22.1 min, respectively.",Pharmacokinetic profile of propofol after a single-dose injection during general anesthesia in Japanese adults. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14564578/),min,47.9,149533,DB00818,Propofol
,14564578,volume of the central compartment (V(c)),"The volume of the central compartment (V(c)) was 0.582 +/- 0.170 l.kg(-1), and the apparent volume of distribution at a steady state (V(dss)) was 2.62 +/- 1.06 l.kg(-1).",Pharmacokinetic profile of propofol after a single-dose injection during general anesthesia in Japanese adults. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14564578/),[l] / [kg],0.582,149534,DB00818,Propofol
,14564578,apparent volume of distribution at a steady state (V(dss)),"The volume of the central compartment (V(c)) was 0.582 +/- 0.170 l.kg(-1), and the apparent volume of distribution at a steady state (V(dss)) was 2.62 +/- 1.06 l.kg(-1).",Pharmacokinetic profile of propofol after a single-dose injection during general anesthesia in Japanese adults. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14564578/),[l] / [kg],2.62,149535,DB00818,Propofol
,14564578,total body clearance (Cl),The total body clearance (Cl) and mean residence time (MRT) were 53.7 +/- 11.9 ml.min(-1).,Pharmacokinetic profile of propofol after a single-dose injection during general anesthesia in Japanese adults. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14564578/),[ml] / [min],53.7,149536,DB00818,Propofol
>,25797054,solubility,The solubility of propofol in the semifluorinated alkane perfluorohexyloctane (F6H8) is very high (>300 mg/ml).,Evaluation of pharmacokinetic properties and anaesthetic effects of propofol in a new perfluorohexyloctane (F6H8) emulsion in rats--A comparative study. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25797054/),[mg] / [ml],300,149780,DB00818,Propofol
,27545305,Cl,"Elderly patients presented decreased Cl (2.1 ml/kg per min vs 2.8 ml/kg per min; P = 0.0123); increased AUC/dose (507.8 μg min/ml (mg/kg) vs 392.2 μg min/ml/(mg/kg); P = 0.0168) and reduced volume of distribution (285.4 ml/kg vs 435.6 ml/kg, P = 0.0434) compared to young adults.",Pharmacokinetics and pharmacodynamics of rocuronium in young adult and elderly patients undergoing elective surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27545305/),[ml] / [kg·min],2.1,152189,DB00818,Propofol
,27545305,Cl,"Elderly patients presented decreased Cl (2.1 ml/kg per min vs 2.8 ml/kg per min; P = 0.0123); increased AUC/dose (507.8 μg min/ml (mg/kg) vs 392.2 μg min/ml/(mg/kg); P = 0.0168) and reduced volume of distribution (285.4 ml/kg vs 435.6 ml/kg, P = 0.0434) compared to young adults.",Pharmacokinetics and pharmacodynamics of rocuronium in young adult and elderly patients undergoing elective surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27545305/),[ml] / [kg·min],2.8,152190,DB00818,Propofol
,27545305,AUC/dose,"Elderly patients presented decreased Cl (2.1 ml/kg per min vs 2.8 ml/kg per min; P = 0.0123); increased AUC/dose (507.8 μg min/ml (mg/kg) vs 392.2 μg min/ml/(mg/kg); P = 0.0168) and reduced volume of distribution (285.4 ml/kg vs 435.6 ml/kg, P = 0.0434) compared to young adults.",Pharmacokinetics and pharmacodynamics of rocuronium in young adult and elderly patients undergoing elective surgery. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27545305/),[min·ml·μg] / [kg·mg],507.8,152191,DB00818,Propofol
,27545305,AUC/dose,"Elderly patients presented decreased Cl (2.1 ml/kg per min vs 2.8 ml/kg per min; P = 0.0123); increased AUC/dose (507.8 μg min/ml (mg/kg) vs 392.2 μg min/ml/(mg/kg); P = 0.0168) and reduced volume of distribution (285.4 ml/kg vs 435.6 ml/kg, P = 0.0434) compared to young adults.",Pharmacokinetics and pharmacodynamics of rocuronium in young adult and elderly patients undergoing elective surgery. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27545305/),[min·ml·μg] / [kg·mg],392.2,152192,DB00818,Propofol
,27545305,volume of distribution,"Elderly patients presented decreased Cl (2.1 ml/kg per min vs 2.8 ml/kg per min; P = 0.0123); increased AUC/dose (507.8 μg min/ml (mg/kg) vs 392.2 μg min/ml/(mg/kg); P = 0.0168) and reduced volume of distribution (285.4 ml/kg vs 435.6 ml/kg, P = 0.0434) compared to young adults.",Pharmacokinetics and pharmacodynamics of rocuronium in young adult and elderly patients undergoing elective surgery. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27545305/),[ml] / [kg],285.4,152193,DB00818,Propofol
,27545305,volume of distribution,"Elderly patients presented decreased Cl (2.1 ml/kg per min vs 2.8 ml/kg per min; P = 0.0123); increased AUC/dose (507.8 μg min/ml (mg/kg) vs 392.2 μg min/ml/(mg/kg); P = 0.0168) and reduced volume of distribution (285.4 ml/kg vs 435.6 ml/kg, P = 0.0434) compared to young adults.",Pharmacokinetics and pharmacodynamics of rocuronium in young adult and elderly patients undergoing elective surgery. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27545305/),[ml] / [kg],435.6,152194,DB00818,Propofol
,27545305,concentrations required to achieve 50% of maximum neuromuscular block (EC50),The concentrations required to achieve 50% of maximum neuromuscular block (EC50) were similar for young adult (338.8 ng/ml) and elderly (462.7 ng/ml) patients (P > 0.05).,Pharmacokinetics and pharmacodynamics of rocuronium in young adult and elderly patients undergoing elective surgery. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27545305/),[ng] / [ml],338.8,152195,DB00818,Propofol
,27545305,concentrations required to achieve 50% of maximum neuromuscular block (EC50),The concentrations required to achieve 50% of maximum neuromuscular block (EC50) were similar for young adult (338.8 ng/ml) and elderly (462.7 ng/ml) patients (P > 0.05).,Pharmacokinetics and pharmacodynamics of rocuronium in young adult and elderly patients undergoing elective surgery. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27545305/),[ng] / [ml],462.7,152196,DB00818,Propofol
,28828532,Peak plasma concentration,"Peak plasma concentration, area under the curve to infinity, elimination half-life, and apparent volume of distribution were significantly larger in morbidly obese than in normal weight patients (3.75 ± 0.56 vs. 2.54 ± 0.32 µg/l, P < 0.001; 2174 ± 335 vs. 1594 ± 251 ng h/l, P < 0.001; 225 ± 55 vs. 158 ± 53 min, P = 0.02; 310 ± 63 vs. 164 ± 41 l, P < 0.001, respectively).",Pharmacokinetic and pharmacodynamics of intravenous dexmedetomidine in morbidly obese patients undergoing laparoscopic surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28828532/),[μg] / [l],3.75,152587,DB00818,Propofol
,28828532,area under the curve to infinity,"Peak plasma concentration, area under the curve to infinity, elimination half-life, and apparent volume of distribution were significantly larger in morbidly obese than in normal weight patients (3.75 ± 0.56 vs. 2.54 ± 0.32 µg/l, P < 0.001; 2174 ± 335 vs. 1594 ± 251 ng h/l, P < 0.001; 225 ± 55 vs. 158 ± 53 min, P = 0.02; 310 ± 63 vs. 164 ± 41 l, P < 0.001, respectively).",Pharmacokinetic and pharmacodynamics of intravenous dexmedetomidine in morbidly obese patients undergoing laparoscopic surgery. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28828532/),[h·ng] / [l],2174,152588,DB00818,Propofol
,28828532,area under the curve to infinity,"Peak plasma concentration, area under the curve to infinity, elimination half-life, and apparent volume of distribution were significantly larger in morbidly obese than in normal weight patients (3.75 ± 0.56 vs. 2.54 ± 0.32 µg/l, P < 0.001; 2174 ± 335 vs. 1594 ± 251 ng h/l, P < 0.001; 225 ± 55 vs. 158 ± 53 min, P = 0.02; 310 ± 63 vs. 164 ± 41 l, P < 0.001, respectively).",Pharmacokinetic and pharmacodynamics of intravenous dexmedetomidine in morbidly obese patients undergoing laparoscopic surgery. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28828532/),min,225,152589,DB00818,Propofol
,28828532,elimination half-life,"Peak plasma concentration, area under the curve to infinity, elimination half-life, and apparent volume of distribution were significantly larger in morbidly obese than in normal weight patients (3.75 ± 0.56 vs. 2.54 ± 0.32 µg/l, P < 0.001; 2174 ± 335 vs. 1594 ± 251 ng h/l, P < 0.001; 225 ± 55 vs. 158 ± 53 min, P = 0.02; 310 ± 63 vs. 164 ± 41 l, P < 0.001, respectively).",Pharmacokinetic and pharmacodynamics of intravenous dexmedetomidine in morbidly obese patients undergoing laparoscopic surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28828532/),[μg] / [l],2.54,152590,DB00818,Propofol
,28828532,elimination half-life,"Peak plasma concentration, area under the curve to infinity, elimination half-life, and apparent volume of distribution were significantly larger in morbidly obese than in normal weight patients (3.75 ± 0.56 vs. 2.54 ± 0.32 µg/l, P < 0.001; 2174 ± 335 vs. 1594 ± 251 ng h/l, P < 0.001; 225 ± 55 vs. 158 ± 53 min, P = 0.02; 310 ± 63 vs. 164 ± 41 l, P < 0.001, respectively).",Pharmacokinetic and pharmacodynamics of intravenous dexmedetomidine in morbidly obese patients undergoing laparoscopic surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28828532/),[h·ng] / [l],2174,152591,DB00818,Propofol
,28828532,elimination half-life,"Peak plasma concentration, area under the curve to infinity, elimination half-life, and apparent volume of distribution were significantly larger in morbidly obese than in normal weight patients (3.75 ± 0.56 vs. 2.54 ± 0.32 µg/l, P < 0.001; 2174 ± 335 vs. 1594 ± 251 ng h/l, P < 0.001; 225 ± 55 vs. 158 ± 53 min, P = 0.02; 310 ± 63 vs. 164 ± 41 l, P < 0.001, respectively).",Pharmacokinetic and pharmacodynamics of intravenous dexmedetomidine in morbidly obese patients undergoing laparoscopic surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28828532/),min,225,152592,DB00818,Propofol
,28828532,elimination half-life,"Peak plasma concentration, area under the curve to infinity, elimination half-life, and apparent volume of distribution were significantly larger in morbidly obese than in normal weight patients (3.75 ± 0.56 vs. 2.54 ± 0.32 µg/l, P < 0.001; 2174 ± 335 vs. 1594 ± 251 ng h/l, P < 0.001; 225 ± 55 vs. 158 ± 53 min, P = 0.02; 310 ± 63 vs. 164 ± 41 l, P < 0.001, respectively).",Pharmacokinetic and pharmacodynamics of intravenous dexmedetomidine in morbidly obese patients undergoing laparoscopic surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28828532/),l,310,152593,DB00818,Propofol
,28828532,apparent volume of distribution,"Peak plasma concentration, area under the curve to infinity, elimination half-life, and apparent volume of distribution were significantly larger in morbidly obese than in normal weight patients (3.75 ± 0.56 vs. 2.54 ± 0.32 µg/l, P < 0.001; 2174 ± 335 vs. 1594 ± 251 ng h/l, P < 0.001; 225 ± 55 vs. 158 ± 53 min, P = 0.02; 310 ± 63 vs. 164 ± 41 l, P < 0.001, respectively).",Pharmacokinetic and pharmacodynamics of intravenous dexmedetomidine in morbidly obese patients undergoing laparoscopic surgery. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28828532/),[h·ng] / [l],1594,152594,DB00818,Propofol
,28828532,apparent volume of distribution,"Peak plasma concentration, area under the curve to infinity, elimination half-life, and apparent volume of distribution were significantly larger in morbidly obese than in normal weight patients (3.75 ± 0.56 vs. 2.54 ± 0.32 µg/l, P < 0.001; 2174 ± 335 vs. 1594 ± 251 ng h/l, P < 0.001; 225 ± 55 vs. 158 ± 53 min, P = 0.02; 310 ± 63 vs. 164 ± 41 l, P < 0.001, respectively).",Pharmacokinetic and pharmacodynamics of intravenous dexmedetomidine in morbidly obese patients undergoing laparoscopic surgery. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28828532/),min,225,152595,DB00818,Propofol
,28828532,apparent volume of distribution,"Peak plasma concentration, area under the curve to infinity, elimination half-life, and apparent volume of distribution were significantly larger in morbidly obese than in normal weight patients (3.75 ± 0.56 vs. 2.54 ± 0.32 µg/l, P < 0.001; 2174 ± 335 vs. 1594 ± 251 ng h/l, P < 0.001; 225 ± 55 vs. 158 ± 53 min, P = 0.02; 310 ± 63 vs. 164 ± 41 l, P < 0.001, respectively).",Pharmacokinetic and pharmacodynamics of intravenous dexmedetomidine in morbidly obese patients undergoing laparoscopic surgery. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28828532/),min,158,152596,DB00818,Propofol
,28828532,apparent volume of distribution,"Peak plasma concentration, area under the curve to infinity, elimination half-life, and apparent volume of distribution were significantly larger in morbidly obese than in normal weight patients (3.75 ± 0.56 vs. 2.54 ± 0.32 µg/l, P < 0.001; 2174 ± 335 vs. 1594 ± 251 ng h/l, P < 0.001; 225 ± 55 vs. 158 ± 53 min, P = 0.02; 310 ± 63 vs. 164 ± 41 l, P < 0.001, respectively).",Pharmacokinetic and pharmacodynamics of intravenous dexmedetomidine in morbidly obese patients undergoing laparoscopic surgery. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28828532/),l,310,152597,DB00818,Propofol
,28828532,apparent volume of distribution,"Peak plasma concentration, area under the curve to infinity, elimination half-life, and apparent volume of distribution were significantly larger in morbidly obese than in normal weight patients (3.75 ± 0.56 vs. 2.54 ± 0.32 µg/l, P < 0.001; 2174 ± 335 vs. 1594 ± 251 ng h/l, P < 0.001; 225 ± 55 vs. 158 ± 53 min, P = 0.02; 310 ± 63 vs. 164 ± 41 l, P < 0.001, respectively).",Pharmacokinetic and pharmacodynamics of intravenous dexmedetomidine in morbidly obese patients undergoing laparoscopic surgery. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28828532/),l,164,152598,DB00818,Propofol
,28828532,clearance,"Although clearance was also higher in obese patients than in normal body weight patients (58.6 ± 10.7 vs. 44.9 ± 9.0 l/h, P = 0.02), it was lower in obese patients than in normal body weight patients after normalization to total body weight (0.47 ± 0.07 vs. 0.64 ± 0.09 l/h/kg, P < 0.001).",Pharmacokinetic and pharmacodynamics of intravenous dexmedetomidine in morbidly obese patients undergoing laparoscopic surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28828532/),[l] / [h],58.6,152599,DB00818,Propofol
,28828532,clearance,"Although clearance was also higher in obese patients than in normal body weight patients (58.6 ± 10.7 vs. 44.9 ± 9.0 l/h, P = 0.02), it was lower in obese patients than in normal body weight patients after normalization to total body weight (0.47 ± 0.07 vs. 0.64 ± 0.09 l/h/kg, P < 0.001).",Pharmacokinetic and pharmacodynamics of intravenous dexmedetomidine in morbidly obese patients undergoing laparoscopic surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28828532/),[l] / [h],44.9,152600,DB00818,Propofol
,28828532,clearance,"Although clearance was also higher in obese patients than in normal body weight patients (58.6 ± 10.7 vs. 44.9 ± 9.0 l/h, P = 0.02), it was lower in obese patients than in normal body weight patients after normalization to total body weight (0.47 ± 0.07 vs. 0.64 ± 0.09 l/h/kg, P < 0.001).",Pharmacokinetic and pharmacodynamics of intravenous dexmedetomidine in morbidly obese patients undergoing laparoscopic surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28828532/),[l] / [h·kg],0.47,152601,DB00818,Propofol
,28828532,clearance,"Although clearance was also higher in obese patients than in normal body weight patients (58.6 ± 10.7 vs. 44.9 ± 9.0 l/h, P = 0.02), it was lower in obese patients than in normal body weight patients after normalization to total body weight (0.47 ± 0.07 vs. 0.64 ± 0.09 l/h/kg, P < 0.001).",Pharmacokinetic and pharmacodynamics of intravenous dexmedetomidine in morbidly obese patients undergoing laparoscopic surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28828532/),[l] / [h·kg],0.64,152602,DB00818,Propofol
,2248844,elimination half-life,Data were consistent with a three-compartment model with a mean (SEM) elimination half-life of 209 (29) min and total body clearance of 40.4 (3.6) ml min-1 kg-1.,Pharmacokinetics of propofol in children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2248844/),min,209,152799,DB00818,Propofol
,2248844,total body clearance,Data were consistent with a three-compartment model with a mean (SEM) elimination half-life of 209 (29) min and total body clearance of 40.4 (3.6) ml min-1 kg-1.,Pharmacokinetics of propofol in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2248844/),[ml] / [kg·min],40.4,152800,DB00818,Propofol
,2248844,apparent volume of distribution at steady state,The mean (SEM) apparent volume of distribution at steady state was 5.0 (2.7) litre kg-1 and volume of the central compartment was 0.6 (0.1) litre kg-1.,Pharmacokinetics of propofol in children. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2248844/),[l] / [kg],5.0,152801,DB00818,Propofol
,2248844,volume of the central compartment,The mean (SEM) apparent volume of distribution at steady state was 5.0 (2.7) litre kg-1 and volume of the central compartment was 0.6 (0.1) litre kg-1.,Pharmacokinetics of propofol in children. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2248844/),[l] / [kg],0.6,152802,DB00818,Propofol
,2248844,ratio of k12:k21,"The mean (SEM) ratio of k12:k21 was 1.4 (0.2), suggesting that, after injection of a single bolus dose in children, propofol is distributed rapidly to the shallow compartment.",Pharmacokinetics of propofol in children. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2248844/),,1.4,152803,DB00818,Propofol
,22580527,V(C),"The typical values of the central and peripheral volume of distribution, and the metabolic and inter-compartmental clearance were V(C) = 24.7 l, V(T) = 112 l, Cl = 2.64 l/min and Q = 0.989 l/min.",Pharmacokinetics and pharmacodynamics of propofol in patients undergoing abdominal aortic surgery. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22580527/),l,24.7,153731,DB00818,Propofol
,22580527,V(T),"The typical values of the central and peripheral volume of distribution, and the metabolic and inter-compartmental clearance were V(C) = 24.7 l, V(T) = 112 l, Cl = 2.64 l/min and Q = 0.989 l/min.",Pharmacokinetics and pharmacodynamics of propofol in patients undergoing abdominal aortic surgery. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22580527/),l,112,153732,DB00818,Propofol
,22580527,Cl,"The typical values of the central and peripheral volume of distribution, and the metabolic and inter-compartmental clearance were V(C) = 24.7 l, V(T) = 112 l, Cl = 2.64 l/min and Q = 0.989 l/min.",Pharmacokinetics and pharmacodynamics of propofol in patients undergoing abdominal aortic surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22580527/),[l] / [min],2.64,153733,DB00818,Propofol
,22580527,Q,"The typical values of the central and peripheral volume of distribution, and the metabolic and inter-compartmental clearance were V(C) = 24.7 l, V(T) = 112 l, Cl = 2.64 l/min and Q = 0.989 l/min.",Pharmacokinetics and pharmacodynamics of propofol in patients undergoing abdominal aortic surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22580527/),[l] / [min],0.989,153734,DB00818,Propofol
,22580527,rate constant,"Delay of the anesthetic effect, with respect to plasma concentrations, was described by the effect compartment with the rate constant for the distribution to the effector compartment equal to 0.240 min(-1).",Pharmacokinetics and pharmacodynamics of propofol in patients undergoing abdominal aortic surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22580527/),1/[min],0.240,153735,DB00818,Propofol
,22580527,EC(50),The BIS index was linked to the effect site concentrations through a sigmoidal E(max) model with EC(50) = 2.19 mg/l.,Pharmacokinetics and pharmacodynamics of propofol in patients undergoing abdominal aortic surgery. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22580527/),[mg] / [l],2.19,153736,DB00818,Propofol
,12411790,degradation rate constant,"The mean degradation rate constant in plasma (1.07 +/- 0.49 min(-1)) was not different from the elimination rate constant (0.97 +/- 0.30 min(-1)), and an excellent correlation (r2 = 0.94) was observed.",Concentration-effect relation of succinylcholine chloride during propofol anesthesia. ,Kinact-Q14,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12411790/),1/[min],1.07,155392,DB00818,Propofol
,12411790,elimination rate constant,"The mean degradation rate constant in plasma (1.07 +/- 0.49 min(-1)) was not different from the elimination rate constant (0.97 +/- 0.30 min(-1)), and an excellent correlation (r2 = 0.94) was observed.",Concentration-effect relation of succinylcholine chloride during propofol anesthesia. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12411790/),1/[min],0.97,155393,DB00818,Propofol
,12411790,Total body clearance,Total body clearance derived using noncompartmental (37 +/- 7 ml x min(-1) x kg(-1)) and compartmental (37 +/- 9 ml x min(-1) x kg(-1)) approaches were similar.,Concentration-effect relation of succinylcholine chloride during propofol anesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12411790/),[ml] / [kg·min],37,155394,DB00818,Propofol
,12411790,Total body clearance,Total body clearance derived using noncompartmental (37 +/- 7 ml x min(-1) x kg(-1)) and compartmental (37 +/- 9 ml x min(-1) x kg(-1)) approaches were similar.,Concentration-effect relation of succinylcholine chloride during propofol anesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12411790/),[ml] / [kg·min],37,155395,DB00818,Propofol
,12411790,rate constant (k(eo)),"The plasma-effect compartment equilibration rate constant (k(eo)) was 0.058 +/- 0.026 min(-1), and the effect compartment concentration at 50% block was 734 +/- 211 ng/ml.",Concentration-effect relation of succinylcholine chloride during propofol anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12411790/),1/[min],0.058,155396,DB00818,Propofol
,12411790,effect compartment concentration at 50% block,"The plasma-effect compartment equilibration rate constant (k(eo)) was 0.058 +/- 0.026 min(-1), and the effect compartment concentration at 50% block was 734 +/- 211 ng/ml.",Concentration-effect relation of succinylcholine chloride during propofol anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12411790/),[ng] / [ml],734,155397,DB00818,Propofol
,2138487,elimination half-life,Non-compartmental analysis estimated that the women undergoing Caesarean section had a similar elimination half-life (mean 81.27 (SD 18.87) min) and apparent volume of distribution at steady state (2.66 (0.63) litre kg-1) as non-obstetric patients (99.45 (29.40) min and 3.36 (1.87) litre kg-1).,Pharmacokinetics of propofol in women undergoing elective caesarean section. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2138487/),min,81.27,156152,DB00818,Propofol
,2138487,apparent volume of distribution at steady state,Non-compartmental analysis estimated that the women undergoing Caesarean section had a similar elimination half-life (mean 81.27 (SD 18.87) min) and apparent volume of distribution at steady state (2.66 (0.63) litre kg-1) as non-obstetric patients (99.45 (29.40) min and 3.36 (1.87) litre kg-1).,Pharmacokinetics of propofol in women undergoing elective caesarean section. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2138487/),[l] / [kg],2.66,156153,DB00818,Propofol
,2138487,apparent volume of distribution at steady state,Non-compartmental analysis estimated that the women undergoing Caesarean section had a similar elimination half-life (mean 81.27 (SD 18.87) min) and apparent volume of distribution at steady state (2.66 (0.63) litre kg-1) as non-obstetric patients (99.45 (29.40) min and 3.36 (1.87) litre kg-1).,Pharmacokinetics of propofol in women undergoing elective caesarean section. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2138487/),min,99.45,156154,DB00818,Propofol
,2138487,apparent volume of distribution at steady state,Non-compartmental analysis estimated that the women undergoing Caesarean section had a similar elimination half-life (mean 81.27 (SD 18.87) min) and apparent volume of distribution at steady state (2.66 (0.63) litre kg-1) as non-obstetric patients (99.45 (29.40) min and 3.36 (1.87) litre kg-1).,Pharmacokinetics of propofol in women undergoing elective caesarean section. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2138487/),[l] / [kg],3.36,156155,DB00818,Propofol
,2138487,Clearance,Clearance was more rapid in the Caesarean section group (39.32 (8.07) ml min-1 kg-1 vs 29.40 (8.72) ml min-1 kg-1) (P less than 0.05).,Pharmacokinetics of propofol in women undergoing elective caesarean section. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2138487/),[ml] / [kg·min],39.32,156156,DB00818,Propofol
,2138487,Clearance,Clearance was more rapid in the Caesarean section group (39.32 (8.07) ml min-1 kg-1 vs 29.40 (8.72) ml min-1 kg-1) (P less than 0.05).,Pharmacokinetics of propofol in women undergoing elective caesarean section. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2138487/),[ml] / [kg·min],29.40,156157,DB00818,Propofol
,19339028,Cp,PropCp reached 7.65+/-2.1 microg ml(-1) at the end of the study.,Correlation between clinical signs of depth of anaesthesia and cerebral state index responses in dogs during induction of anaesthesia with propofol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19339028/),[μg] / [ml],7.65,156197,DB00818,Propofol
,19339028,CSI,CSI values at T0 were 89.2+/-3.8.,Correlation between clinical signs of depth of anaesthesia and cerebral state index responses in dogs during induction of anaesthesia with propofol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19339028/),,89.2,156198,DB00818,Propofol
,19339028,HR,MAP decreased significantly from T0 until loss of corneal reflex (from 98+/-14 mm Hg to 82+/-12 mm Hg); HR did not change significantly (from 101+/-30 bpm to 113+/-16 bpm).,Correlation between clinical signs of depth of anaesthesia and cerebral state index responses in dogs during induction of anaesthesia with propofol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19339028/),bpm,101,156199,DB00818,Propofol
,19339028,HR,MAP decreased significantly from T0 until loss of corneal reflex (from 98+/-14 mm Hg to 82+/-12 mm Hg); HR did not change significantly (from 101+/-30 bpm to 113+/-16 bpm).,Correlation between clinical signs of depth of anaesthesia and cerebral state index responses in dogs during induction of anaesthesia with propofol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19339028/),bpm,113,156200,DB00818,Propofol
,19567545,bispectral index (BIS),Patients were induced and maintained with propofol titrated to maintain a target bispectral index (BIS) of 50 +/- 10.,Propofol requirement titrated to bispectral index: a comparison between hypothermic and normothermic cardiopulmonary bypass. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19567545/),,50,156743,DB00818,Propofol
,19567545,requirement,"Propofol requirement (mean +/- SD) was similar in normothermic and hypothermic groups, both before CPB (4.9 +/- 1.5 mg kg(-1)hr(-1) in Group N, 4.6 +/- 1.5 mg kg(-1)hr(-1) in Group H) and after cessation of bypass (p > 0.05) (4.6 +/- 1.8 mg kg(-1)hr(-1) in Group N and 4.3 +/- 1.7 mg kg(-1)hr(-1) in Group H).",Propofol requirement titrated to bispectral index: a comparison between hypothermic and normothermic cardiopulmonary bypass. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19567545/),[mg] / [kg],4.9,156744,DB00818,Propofol
,19567545,requirement,"Propofol requirement (mean +/- SD) was similar in normothermic and hypothermic groups, both before CPB (4.9 +/- 1.5 mg kg(-1)hr(-1) in Group N, 4.6 +/- 1.5 mg kg(-1)hr(-1) in Group H) and after cessation of bypass (p > 0.05) (4.6 +/- 1.8 mg kg(-1)hr(-1) in Group N and 4.3 +/- 1.7 mg kg(-1)hr(-1) in Group H).",Propofol requirement titrated to bispectral index: a comparison between hypothermic and normothermic cardiopulmonary bypass. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19567545/),[mg] / [kg],4.6,156745,DB00818,Propofol
,19567545,requirement,"Propofol requirement (mean +/- SD) was similar in normothermic and hypothermic groups, both before CPB (4.9 +/- 1.5 mg kg(-1)hr(-1) in Group N, 4.6 +/- 1.5 mg kg(-1)hr(-1) in Group H) and after cessation of bypass (p > 0.05) (4.6 +/- 1.8 mg kg(-1)hr(-1) in Group N and 4.3 +/- 1.7 mg kg(-1)hr(-1) in Group H).",Propofol requirement titrated to bispectral index: a comparison between hypothermic and normothermic cardiopulmonary bypass. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19567545/),[mg] / [kg],4.6,156746,DB00818,Propofol
,19567545,requirement,"Propofol requirement (mean +/- SD) was similar in normothermic and hypothermic groups, both before CPB (4.9 +/- 1.5 mg kg(-1)hr(-1) in Group N, 4.6 +/- 1.5 mg kg(-1)hr(-1) in Group H) and after cessation of bypass (p > 0.05) (4.6 +/- 1.8 mg kg(-1)hr(-1) in Group N and 4.3 +/- 1.7 mg kg(-1)hr(-1) in Group H).",Propofol requirement titrated to bispectral index: a comparison between hypothermic and normothermic cardiopulmonary bypass. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19567545/),[mg] / [kg],4.3,156747,DB00818,Propofol
,8895080,flow rate,"The mobile phase consisted of 0.01 M sodium acetate solution (adjusted to pH 3 with acetic acid)-acetonitrile-methanol (37:47.25:15.75, v/v/v) at a flow rate of 2 ml min-1.",Microdetermination of propofol in plasma by a rapid and sensitive liquid chromatographic method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8895080/),[ml] / [min],2,158109,DB00818,Propofol
,8895080,retention times,"The peaks of both propofol and internal standard under these conditions were sharp and symmetrical, and the retention times were 8.2 and 5.15 min, respectively.",Microdetermination of propofol in plasma by a rapid and sensitive liquid chromatographic method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8895080/),min,8.2,158110,DB00818,Propofol
,8895080,retention times,"The peaks of both propofol and internal standard under these conditions were sharp and symmetrical, and the retention times were 8.2 and 5.15 min, respectively.",Microdetermination of propofol in plasma by a rapid and sensitive liquid chromatographic method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8895080/),min,5.15,158111,DB00818,Propofol
,19236806,effect-site concentration,"Anesthetic induction was carried out with propofol, rocuronium and TCI administered sufentanil aiming for target effect-site concentration of sufentanil 4 or 6 ng/ml.",Pharmacokinetics of sufentanil administered by target-controlled infusion in Chinese surgical patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19236806/),[ng] / [ml],4,158541,DB00818,Propofol
,19236806,effect-site concentration,"Anesthetic induction was carried out with propofol, rocuronium and TCI administered sufentanil aiming for target effect-site concentration of sufentanil 4 or 6 ng/ml.",Pharmacokinetics of sufentanil administered by target-controlled infusion in Chinese surgical patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19236806/),[ng] / [ml],6,158542,DB00818,Propofol
,19236806,central volume of distribution (V(1)),"The pharmacokinetics of TCI administered sufentanil were optimally described by a three-compartment model with the following parameters: the central volume of distribution (V(1))=5.4 L, the volume of distribution at steady-state (Vdss)=195.4 L, systemic clearance (Cl(1))=1.10 L/min, and elimination half-life (t(1/2) gamma)=271.8 minutes.",Pharmacokinetics of sufentanil administered by target-controlled infusion in Chinese surgical patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19236806/),l,5.4,158543,DB00818,Propofol
,19236806,volume of distribution at steady-state (Vdss),"The pharmacokinetics of TCI administered sufentanil were optimally described by a three-compartment model with the following parameters: the central volume of distribution (V(1))=5.4 L, the volume of distribution at steady-state (Vdss)=195.4 L, systemic clearance (Cl(1))=1.10 L/min, and elimination half-life (t(1/2) gamma)=271.8 minutes.",Pharmacokinetics of sufentanil administered by target-controlled infusion in Chinese surgical patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19236806/),l,195.4,158544,DB00818,Propofol
,19236806,systemic clearance (Cl(1)),"The pharmacokinetics of TCI administered sufentanil were optimally described by a three-compartment model with the following parameters: the central volume of distribution (V(1))=5.4 L, the volume of distribution at steady-state (Vdss)=195.4 L, systemic clearance (Cl(1))=1.10 L/min, and elimination half-life (t(1/2) gamma)=271.8 minutes.",Pharmacokinetics of sufentanil administered by target-controlled infusion in Chinese surgical patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19236806/),[l] / [min],1.10,158545,DB00818,Propofol
,19236806,elimination half-life (t(1/2) gamma),"The pharmacokinetics of TCI administered sufentanil were optimally described by a three-compartment model with the following parameters: the central volume of distribution (V(1))=5.4 L, the volume of distribution at steady-state (Vdss)=195.4 L, systemic clearance (Cl(1))=1.10 L/min, and elimination half-life (t(1/2) gamma)=271.8 minutes.",Pharmacokinetics of sufentanil administered by target-controlled infusion in Chinese surgical patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19236806/),min,271.8,158546,DB00818,Propofol
,12902187,area under the blood concentration-time curve (AUC),"In ewes, the area under the blood concentration-time curve (AUC) and C(max) (8.6 mgh/mL and 9.5mg/mL, respectively) was higher than those of the fetus (1.6 mgh/mL and 1.19 mg/mL, respectively).",Transplacental transfer of propofol in pregnant ewes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12902187/),[mgh] / [ml],8.6,159345,DB00818,Propofol
,12902187,area under the blood concentration-time curve (AUC),"In ewes, the area under the blood concentration-time curve (AUC) and C(max) (8.6 mgh/mL and 9.5mg/mL, respectively) was higher than those of the fetus (1.6 mgh/mL and 1.19 mg/mL, respectively).",Transplacental transfer of propofol in pregnant ewes. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12902187/),[mgh] / [ml],1.6,159346,DB00818,Propofol
,12902187,C(max),"In ewes, the area under the blood concentration-time curve (AUC) and C(max) (8.6 mgh/mL and 9.5mg/mL, respectively) was higher than those of the fetus (1.6 mgh/mL and 1.19 mg/mL, respectively).",Transplacental transfer of propofol in pregnant ewes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12902187/),[mg] / [ml],9.5,159347,DB00818,Propofol
,12902187,C(max),"In ewes, the area under the blood concentration-time curve (AUC) and C(max) (8.6 mgh/mL and 9.5mg/mL, respectively) was higher than those of the fetus (1.6 mgh/mL and 1.19 mg/mL, respectively).",Transplacental transfer of propofol in pregnant ewes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12902187/),[mg] / [ml],1.19,159348,DB00818,Propofol
,12902187,half-life,The mean half-life was 0.5h in the dam and 1.1h in the fetus.,Transplacental transfer of propofol in pregnant ewes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12902187/),h,0.5,159349,DB00818,Propofol
,12902187,half-life,The mean half-life was 0.5h in the dam and 1.1h in the fetus.,Transplacental transfer of propofol in pregnant ewes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12902187/),h,1.1,159350,DB00818,Propofol
,11748515,effect-site concentrations,"Sufentanil was administered by target-controlled infusion, with target effect-site concentrations ranging from 0.4 to 4.5 ng/mL.",Pharmacokinetics of sufentanil in patients undergoing coronary artery bypass graft surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11748515/),[ng] / [ml],0.4 to 4.5,161310,DB00818,Propofol
,11748515,V(1),"The first model determined was a simple 3-compartment model, without any covariates, which had these parameters: V(1) = 5.7 L, V(2) = 18.1 L, V(3) = 225 L, Cl(1) = 0.69 L/min, Cl(2) = 3.1 L/min, and Cl(3) = 1.4 L/min.",Pharmacokinetics of sufentanil in patients undergoing coronary artery bypass graft surgery. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11748515/),l,5.7,161311,DB00818,Propofol
,11748515,V(2),"The first model determined was a simple 3-compartment model, without any covariates, which had these parameters: V(1) = 5.7 L, V(2) = 18.1 L, V(3) = 225 L, Cl(1) = 0.69 L/min, Cl(2) = 3.1 L/min, and Cl(3) = 1.4 L/min.",Pharmacokinetics of sufentanil in patients undergoing coronary artery bypass graft surgery. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11748515/),l,18.1,161312,DB00818,Propofol
,11748515,V(3),"The first model determined was a simple 3-compartment model, without any covariates, which had these parameters: V(1) = 5.7 L, V(2) = 18.1 L, V(3) = 225 L, Cl(1) = 0.69 L/min, Cl(2) = 3.1 L/min, and Cl(3) = 1.4 L/min.",Pharmacokinetics of sufentanil in patients undergoing coronary artery bypass graft surgery. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11748515/),l,225,161313,DB00818,Propofol
,11748515,Cl(1),"The first model determined was a simple 3-compartment model, without any covariates, which had these parameters: V(1) = 5.7 L, V(2) = 18.1 L, V(3) = 225 L, Cl(1) = 0.69 L/min, Cl(2) = 3.1 L/min, and Cl(3) = 1.4 L/min.",Pharmacokinetics of sufentanil in patients undergoing coronary artery bypass graft surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11748515/),[l] / [min],0.69,161314,DB00818,Propofol
,11748515,Cl(2),"The first model determined was a simple 3-compartment model, without any covariates, which had these parameters: V(1) = 5.7 L, V(2) = 18.1 L, V(3) = 225 L, Cl(1) = 0.69 L/min, Cl(2) = 3.1 L/min, and Cl(3) = 1.4 L/min.",Pharmacokinetics of sufentanil in patients undergoing coronary artery bypass graft surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11748515/),[l] / [min],3.1,161315,DB00818,Propofol
,11748515,Cl(3),"The first model determined was a simple 3-compartment model, without any covariates, which had these parameters: V(1) = 5.7 L, V(2) = 18.1 L, V(3) = 225 L, Cl(1) = 0.69 L/min, Cl(2) = 3.1 L/min, and Cl(3) = 1.4 L/min.",Pharmacokinetics of sufentanil in patients undergoing coronary artery bypass graft surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11748515/),[l] / [min],1.4,161316,DB00818,Propofol
,19608809,effect,Hemorrhagic shock decreased the effect-site concentration that produced 50% of the maximal BIS effect from 11.6 +/- 3.8 to 9.1 +/- 1.7 microg/mL and that producing a 50% probability of movement from 26.8 +/- 1.0 to 20.6 +/- 1.0 microg/mL.,The influence of hemorrhagic shock on the electroencephalographic and immobilizing effects of propofol in a swine model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19608809/),[μg] / [ml],11.6,161493,DB00818,Propofol
,19608809,effect,Hemorrhagic shock decreased the effect-site concentration that produced 50% of the maximal BIS effect from 11.6 +/- 3.8 to 9.1 +/- 1.7 microg/mL and that producing a 50% probability of movement from 26.8 +/- 1.0 to 20.6 +/- 1.0 microg/mL.,The influence of hemorrhagic shock on the electroencephalographic and immobilizing effects of propofol in a swine model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19608809/),[μg] / [ml],9.1,161494,DB00818,Propofol
,19608809,50% probability of movement,Hemorrhagic shock decreased the effect-site concentration that produced 50% of the maximal BIS effect from 11.6 +/- 3.8 to 9.1 +/- 1.7 microg/mL and that producing a 50% probability of movement from 26.8 +/- 1.0 to 20.6 +/- 1.0 microg/mL.,The influence of hemorrhagic shock on the electroencephalographic and immobilizing effects of propofol in a swine model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19608809/),[μg] / [ml],26.8,161495,DB00818,Propofol
,19608809,50% probability of movement,Hemorrhagic shock decreased the effect-site concentration that produced 50% of the maximal BIS effect from 11.6 +/- 3.8 to 9.1 +/- 1.7 microg/mL and that producing a 50% probability of movement from 26.8 +/- 1.0 to 20.6 +/- 1.0 microg/mL.,The influence of hemorrhagic shock on the electroencephalographic and immobilizing effects of propofol in a swine model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19608809/),[μg] / [ml],20.6,161496,DB00818,Propofol
,9743405,Kp,"Brain Kp calculated from tissue disposition curve and ratio of brain:plasma area under the curves were 8.8 and 13, and 7.2 and 9.1 for emulsion and lipid-free formulations, respectively.",Formulation-dependent brain and lung distribution kinetics of propofol in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9743405/),,8.8,161785,DB00818,Propofol
,9743405,Kp,"Brain Kp calculated from tissue disposition curve and ratio of brain:plasma area under the curves were 8.8 and 13, and 7.2 and 9.1 for emulsion and lipid-free formulations, respectively.",Formulation-dependent brain and lung distribution kinetics of propofol in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9743405/),,13,161786,DB00818,Propofol
,9743405,Kp,"Brain Kp calculated from tissue disposition curve and ratio of brain:plasma area under the curves were 8.8 and 13, and 7.2 and 9.1 for emulsion and lipid-free formulations, respectively.",Formulation-dependent brain and lung distribution kinetics of propofol in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9743405/),,7.2,161787,DB00818,Propofol
,9743405,ratio of brain:plasma area under the curves,"Brain Kp calculated from tissue disposition curve and ratio of brain:plasma area under the curves were 8.8 and 13, and 7.2 and 9.1 for emulsion and lipid-free formulations, respectively.",Formulation-dependent brain and lung distribution kinetics of propofol in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9743405/),,13,161788,DB00818,Propofol
,9743405,ratio of brain:plasma area under the curves,"Brain Kp calculated from tissue disposition curve and ratio of brain:plasma area under the curves were 8.8 and 13, and 7.2 and 9.1 for emulsion and lipid-free formulations, respectively.",Formulation-dependent brain and lung distribution kinetics of propofol in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9743405/),,7.2,161789,DB00818,Propofol
,9743405,ratio of brain:plasma area under the curves,"Brain Kp calculated from tissue disposition curve and ratio of brain:plasma area under the curves were 8.8 and 13, and 7.2 and 9.1 for emulsion and lipid-free formulations, respectively.",Formulation-dependent brain and lung distribution kinetics of propofol in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9743405/),,9.1,161790,DB00818,Propofol
,9743405,BT,"BT were 2.4 and 2.5 min for emulsion and lipid-free formulations, respectively.",Formulation-dependent brain and lung distribution kinetics of propofol in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9743405/),min,2.4,161791,DB00818,Propofol
,9743405,BT,"BT were 2.4 and 2.5 min for emulsion and lipid-free formulations, respectively.",Formulation-dependent brain and lung distribution kinetics of propofol in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9743405/),min,2.5,161792,DB00818,Propofol
,2611067,Vss,Propofol was distributed rapidly and extensively (Vss 10.9 (1.2) litre kg-1) and cleared rapidly from the body (Cl 30.6 (2.9) ml min-1 kg-1).,Pharmacokinetics of propofol in young children after a single dose. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2611067/),[l] / [kg],10.9,161793,DB00818,Propofol
,2611067,Cl,Propofol was distributed rapidly and extensively (Vss 10.9 (1.2) litre kg-1) and cleared rapidly from the body (Cl 30.6 (2.9) ml min-1 kg-1).,Pharmacokinetics of propofol in young children after a single dose. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2611067/),[ml] / [kg·min],30.6,161794,DB00818,Propofol
,2611067,central compartment volume,"With the exception of a larger central compartment volume (V alpha 722 (113) ml kg-1), these data are similar to those reported for young adults who received an identical dose and who underwent sampling over the same period.",Pharmacokinetics of propofol in young children after a single dose. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2611067/),[ml] / [kg],722,161795,DB00818,Propofol
,2611067,V alpha,"With the exception of a larger central compartment volume (V alpha 722 (113) ml kg-1), these data are similar to those reported for young adults who received an identical dose and who underwent sampling over the same period.",Pharmacokinetics of propofol in young children after a single dose. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2611067/),[ml] / [kg],722,161796,DB00818,Propofol
,18947168,area under the time-concentration curve (AUC0-t),"The area under the time-concentration curve (AUC0-t) was 24.07 microg.min/ml, and AUCinf was 24.71 microg.min/ml.",Anesthetic properties of propofol in African clawed frogs (Xenopus laevis). ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18947168/),[min·μg] / [ml],24.07,162495,DB00818,Propofol
,18947168,AUCinf,"The area under the time-concentration curve (AUC0-t) was 24.07 microg.min/ml, and AUCinf was 24.71 microg.min/ml.",Anesthetic properties of propofol in African clawed frogs (Xenopus laevis). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18947168/),[min·μg] / [ml],24.71,162496,DB00818,Propofol
,18947168,elimination half-life,The elimination half-life was 1.18 h.,Anesthetic properties of propofol in African clawed frogs (Xenopus laevis). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18947168/),h,1.18,162497,DB00818,Propofol
,25740275,ke0,The aim of this study was to evaluate the Es predicted by the Marsh pharmacokinetic model (ke0 0.26min(-1)) in loss of consciousness during fast or slow induction.,[Comparative study between fast and slow induction of propofol given by target-controlled infusion: expected propofol concentration at the effect site. Randomized controlled trial]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25740275/),1/[min],0.26,162584,DB00818,Propofol
,25740275,ke0,"In slow induction group (S), target-controlled infusion (TCI) of propofol with plasma, Marsh pharmacokinetic model (ke0 0.26min(-1)) with target concentration (Tc) at 2.0-μg.",[Comparative study between fast and slow induction of propofol given by target-controlled infusion: expected propofol concentration at the effect site. Randomized controlled trial]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25740275/),1/[min],0.26,162585,DB00818,Propofol
,25740275,target concentration (Tc),"In slow induction group (S), target-controlled infusion (TCI) of propofol with plasma, Marsh pharmacokinetic model (ke0 0.26min(-1)) with target concentration (Tc) at 2.0-μg.",[Comparative study between fast and slow induction of propofol given by target-controlled infusion: expected propofol concentration at the effect site. Randomized controlled trial]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25740275/),μg,2.0,162586,DB00818,Propofol
,25740275,Tc,"in rapid induction group, Tc for loss of consciousness was significantly lower compared to slow induction group (1.67±0.76 and 2.50±0.56μg.mL(-1), respectively, p=0.004).",[Comparative study between fast and slow induction of propofol given by target-controlled infusion: expected propofol concentration at the effect site. Randomized controlled trial]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25740275/),[μg] / [ml],1.67,162587,DB00818,Propofol
,25740275,Tc,"in rapid induction group, Tc for loss of consciousness was significantly lower compared to slow induction group (1.67±0.76 and 2.50±0.56μg.mL(-1), respectively, p=0.004).",[Comparative study between fast and slow induction of propofol given by target-controlled infusion: expected propofol concentration at the effect site. Randomized controlled trial]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25740275/),[μg] / [ml],2.50,162588,DB00818,Propofol
,12459664,infusion rate,A propofol infusion rate of 4 mg.,"Pharmacokinetics of propofol infusions in critically ill neonates, infants, and children in an intensive care unit. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12459664/),mg,4,163755,DB00818,Propofol
,24059121,volume of distribution based on the terminal phase (V),"The volume of distribution based on the terminal phase (V): P group, (34.56 +/- 16.11) mL; L group, (33.37 +/- 29.87) mL; H group,(7.29 +/- 3.20) mL; S group,(35.46 +/- 13.58) mL; P < 0.05).","[Influence of 20% lipid emulsion on drug concentration, distribution volume and pharmacology effect of continuous infusion of propofol in rabbits]. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24059121/),ml,34.56,164618,DB00818,Propofol
,24059121,volume of distribution based on the terminal phase (V),"The volume of distribution based on the terminal phase (V): P group, (34.56 +/- 16.11) mL; L group, (33.37 +/- 29.87) mL; H group,(7.29 +/- 3.20) mL; S group,(35.46 +/- 13.58) mL; P < 0.05).","[Influence of 20% lipid emulsion on drug concentration, distribution volume and pharmacology effect of continuous infusion of propofol in rabbits]. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24059121/),ml,33.37,164619,DB00818,Propofol
,24059121,volume of distribution based on the terminal phase (V),"The volume of distribution based on the terminal phase (V): P group, (34.56 +/- 16.11) mL; L group, (33.37 +/- 29.87) mL; H group,(7.29 +/- 3.20) mL; S group,(35.46 +/- 13.58) mL; P < 0.05).","[Influence of 20% lipid emulsion on drug concentration, distribution volume and pharmacology effect of continuous infusion of propofol in rabbits]. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24059121/),ml,7.29,164620,DB00818,Propofol
,24059121,volume of distribution based on the terminal phase (V),"The volume of distribution based on the terminal phase (V): P group, (34.56 +/- 16.11) mL; L group, (33.37 +/- 29.87) mL; H group,(7.29 +/- 3.20) mL; S group,(35.46 +/- 13.58) mL; P < 0.05).","[Influence of 20% lipid emulsion on drug concentration, distribution volume and pharmacology effect of continuous infusion of propofol in rabbits]. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24059121/),ml,35.46,164621,DB00818,Propofol
,24059121,volume of distribution at steady state (Vss),"The volume of distribution at steady state (Vss): P group, (11.13 +/- 3.21) mL; L group, (13.87 +/- 4.09) mL; H group, (4.82 +/- 1.46) mL; S group, (11.61 +/- 4.11) mL P < 0.05)).","[Influence of 20% lipid emulsion on drug concentration, distribution volume and pharmacology effect of continuous infusion of propofol in rabbits]. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24059121/),ml,11.13,164622,DB00818,Propofol
,24059121,volume of distribution at steady state (Vss),"The volume of distribution at steady state (Vss): P group, (11.13 +/- 3.21) mL; L group, (13.87 +/- 4.09) mL; H group, (4.82 +/- 1.46) mL; S group, (11.61 +/- 4.11) mL P < 0.05)).","[Influence of 20% lipid emulsion on drug concentration, distribution volume and pharmacology effect of continuous infusion of propofol in rabbits]. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24059121/),ml,13.87,164623,DB00818,Propofol
,24059121,volume of distribution at steady state (Vss),"The volume of distribution at steady state (Vss): P group, (11.13 +/- 3.21) mL; L group, (13.87 +/- 4.09) mL; H group, (4.82 +/- 1.46) mL; S group, (11.61 +/- 4.11) mL P < 0.05)).","[Influence of 20% lipid emulsion on drug concentration, distribution volume and pharmacology effect of continuous infusion of propofol in rabbits]. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24059121/),ml,4.82,164624,DB00818,Propofol
,24059121,volume of distribution at steady state (Vss),"The volume of distribution at steady state (Vss): P group, (11.13 +/- 3.21) mL; L group, (13.87 +/- 4.09) mL; H group, (4.82 +/- 1.46) mL; S group, (11.61 +/- 4.11) mL P < 0.05)).","[Influence of 20% lipid emulsion on drug concentration, distribution volume and pharmacology effect of continuous infusion of propofol in rabbits]. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24059121/),ml,11.61,164625,DB00818,Propofol
,8318329,infusion rate,"In the seventh dog, the infusion rate was increased to 0.6 mg kg-1 min-1 in order to achieve surgical anaesthesia.",Pharmacokinetics of propofol administered by infusion in dogs undergoing surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8318329/),[mg] / [kg·min],0.6,164654,DB00818,Propofol
,8318329,elimination half-life,"The mean elimination half-life was 322.3 (sem 27.0) min, mean volume of distribution at steady state 6.510 (0.524) litre kg-1, mean body clearance 50.1 (3.9) ml kg-1 min-1 and mean residence time 131.6 (8.9) min.",Pharmacokinetics of propofol administered by infusion in dogs undergoing surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8318329/),min,322.3,164655,DB00818,Propofol
,8318329,volume of distribution at steady state,"The mean elimination half-life was 322.3 (sem 27.0) min, mean volume of distribution at steady state 6.510 (0.524) litre kg-1, mean body clearance 50.1 (3.9) ml kg-1 min-1 and mean residence time 131.6 (8.9) min.",Pharmacokinetics of propofol administered by infusion in dogs undergoing surgery. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8318329/),[l] / [kg],6.510,164656,DB00818,Propofol
,8318329,body clearance,"The mean elimination half-life was 322.3 (sem 27.0) min, mean volume of distribution at steady state 6.510 (0.524) litre kg-1, mean body clearance 50.1 (3.9) ml kg-1 min-1 and mean residence time 131.6 (8.9) min.",Pharmacokinetics of propofol administered by infusion in dogs undergoing surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8318329/),[ml] / [kg·min],50.1,164657,DB00818,Propofol
,8318329,mean residence time,"The mean elimination half-life was 322.3 (sem 27.0) min, mean volume of distribution at steady state 6.510 (0.524) litre kg-1, mean body clearance 50.1 (3.9) ml kg-1 min-1 and mean residence time 131.6 (8.9) min.",Pharmacokinetics of propofol administered by infusion in dogs undergoing surgery. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8318329/),min,131.6,164658,DB00818,Propofol
,8318329,time to extubation,The mean time to extubation was 7.6 min and to standing unaided was 30.7 min from the end of the infusion.,Pharmacokinetics of propofol administered by infusion in dogs undergoing surgery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8318329/),min,7.6,164659,DB00818,Propofol
,8318329,time to extubation,The mean time to extubation was 7.6 min and to standing unaided was 30.7 min from the end of the infusion.,Pharmacokinetics of propofol administered by infusion in dogs undergoing surgery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8318329/),min,30.7,164660,DB00818,Propofol
,1496826,Clearance,"Clearance of propofol by all species was rapid, ranging from about 30-80 ml/kg per min in rats, dogs and pigs to about 340 ml/kg per min in rabbits.",The pharmacokinetics of propofol in laboratory animals. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1496826/),[ml] / [kg·min],30-80,165553,DB00818,Propofol
,1496826,Clearance,"Clearance of propofol by all species was rapid, ranging from about 30-80 ml/kg per min in rats, dogs and pigs to about 340 ml/kg per min in rabbits.",The pharmacokinetics of propofol in laboratory animals. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1496826/),[ml] / [kg·min],340,165554,DB00818,Propofol
,23110290,initial effect site concentration,Twenty five patients (group II) received propofol and remifentanil at an initial effect site concentration of 4 μg mL(1) and 4 ng mL(-1) respectively.,Comparison of target controlled infusion and total intravenous anaesthesia with propofol and remifentanil for lumbar microdiscectomy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23110290/),ml(1)·μg,4,165913,DB00818,Propofol
,23110290,initial effect site concentration,Twenty five patients (group II) received propofol and remifentanil at an initial effect site concentration of 4 μg mL(1) and 4 ng mL(-1) respectively.,Comparison of target controlled infusion and total intravenous anaesthesia with propofol and remifentanil for lumbar microdiscectomy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23110290/),[ng] / [ml],4,165914,DB00818,Propofol
,24032636,ke0,"This study compared the predicted effect-site concentration of propofol at loss and recovery of consciousness when using target-controlled infusion devices with the same pharmacokinetic model (Marsh) but a different plasma effect-site equilibration rate constant (ke0 ), the Diprifusor(TM) (ke0 0.26 min(-1) ) and Base Primea™ (ke0 1.21 min(-1) ).",Influence of a modified propofol equilibration rate constant (k(e0)) on the effect-site concentration at loss and recovery of consciousness with the Marsh model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24032636/),1/[min],0.26,167697,DB00818,Propofol
,24032636,ke0,"This study compared the predicted effect-site concentration of propofol at loss and recovery of consciousness when using target-controlled infusion devices with the same pharmacokinetic model (Marsh) but a different plasma effect-site equilibration rate constant (ke0 ), the Diprifusor(TM) (ke0 0.26 min(-1) ) and Base Primea™ (ke0 1.21 min(-1) ).",Influence of a modified propofol equilibration rate constant (k(e0)) on the effect-site concentration at loss and recovery of consciousness with the Marsh model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24032636/),1/[min],1.21,167698,DB00818,Propofol
,24032636,effect-site concentration at loss of consciousness,"Although the total dose of propofol and time until loss of consciousness were comparable, the effect-site concentration at loss of consciousness was significantly lower with the Diprifusor than with the Base Primea (1.2 (0.3) μg.ml(-1) vs 4.5 (0.9) μg.ml(-1) , respectively, p < 0.001).",Influence of a modified propofol equilibration rate constant (k(e0)) on the effect-site concentration at loss and recovery of consciousness with the Marsh model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24032636/),[μg] / [ml],1.2,167699,DB00818,Propofol
,24032636,effect-site concentration at loss of consciousness,"Although the total dose of propofol and time until loss of consciousness were comparable, the effect-site concentration at loss of consciousness was significantly lower with the Diprifusor than with the Base Primea (1.2 (0.3) μg.ml(-1) vs 4.5 (0.9) μg.ml(-1) , respectively, p < 0.001).",Influence of a modified propofol equilibration rate constant (k(e0)) on the effect-site concentration at loss and recovery of consciousness with the Marsh model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24032636/),[μg] / [ml],4.5,167700,DB00818,Propofol
,24032636,effect-site concentration at recovery of consciousness,"The effect-site concentration at recovery of consciousness was significantly higher with the Diprifusor than with the Base Primea (1.8 (0.4) μg.ml(-1) vs 1.5 (0.2) μg.ml(-1) , respectively, p = 0.01).",Influence of a modified propofol equilibration rate constant (k(e0)) on the effect-site concentration at loss and recovery of consciousness with the Marsh model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24032636/),[μg] / [ml],1.8,167701,DB00818,Propofol
,24032636,effect-site concentration at recovery of consciousness,"The effect-site concentration at recovery of consciousness was significantly higher with the Diprifusor than with the Base Primea (1.8 (0.4) μg.ml(-1) vs 1.5 (0.2) μg.ml(-1) , respectively, p = 0.01).",Influence of a modified propofol equilibration rate constant (k(e0)) on the effect-site concentration at loss and recovery of consciousness with the Marsh model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24032636/),[μg] / [ml],1.5,167702,DB00818,Propofol
,20053624,area under plasma concentration-time curve,"The mean (confidence interval) for area under plasma concentration-time curve, elimination half-life, mean residence time, and clearance was 41 min microg ml(-1) (+/-7.7), 44.8 min (+/-21.3), 13.7 min (+/-3.2), and 45.8 ml min(-1) kg(-1) (+/-6.5), respectively.",Pharmacokinetic profile in relation to anaesthesia characteristics after a 5% micellar microemulsion of propofol in the horse. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20053624/),[min·μg] / [ml],41,168611,DB00818,Propofol
,20053624,clearance,"The mean (confidence interval) for area under plasma concentration-time curve, elimination half-life, mean residence time, and clearance was 41 min microg ml(-1) (+/-7.7), 44.8 min (+/-21.3), 13.7 min (+/-3.2), and 45.8 ml min(-1) kg(-1) (+/-6.5), respectively.",Pharmacokinetic profile in relation to anaesthesia characteristics after a 5% micellar microemulsion of propofol in the horse. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20053624/),[ml] / [kg·min],45.8,168612,DB00818,Propofol
,29933228,intrinsic clearance (CLint),"We found that NBIF underwent massive glucuronidation and oxidation by human liver microsomes (HLM) in this study with the intrinsic clearance (CLint) values of 12.43, 10.04, 2.01, and 6.99 μL/min/mg for M2, M3, M4, and M5, respectively.",In vitrometabolic mapping of neobavaisoflavone in human cytochromes P450 and UDP-glucuronosyltransferase enzymes by ultra high-performance liquid chromatography coupled with quadrupole time-of-flight tandem mass spectrometry. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29933228/),[μl] / [mg·min],12.43,169016,DB00818,Propofol
,29933228,intrinsic clearance (CLint),"We found that NBIF underwent massive glucuronidation and oxidation by human liver microsomes (HLM) in this study with the intrinsic clearance (CLint) values of 12.43, 10.04, 2.01, and 6.99 μL/min/mg for M2, M3, M4, and M5, respectively.",In vitrometabolic mapping of neobavaisoflavone in human cytochromes P450 and UDP-glucuronosyltransferase enzymes by ultra high-performance liquid chromatography coupled with quadrupole time-of-flight tandem mass spectrometry. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29933228/),[μl] / [mg·min],10.04,169017,DB00818,Propofol
,29933228,intrinsic clearance (CLint),"We found that NBIF underwent massive glucuronidation and oxidation by human liver microsomes (HLM) in this study with the intrinsic clearance (CLint) values of 12.43, 10.04, 2.01, and 6.99 μL/min/mg for M2, M3, M4, and M5, respectively.",In vitrometabolic mapping of neobavaisoflavone in human cytochromes P450 and UDP-glucuronosyltransferase enzymes by ultra high-performance liquid chromatography coupled with quadrupole time-of-flight tandem mass spectrometry. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29933228/),[μl] / [mg·min],2.01,169018,DB00818,Propofol
,29933228,intrinsic clearance (CLint),"We found that NBIF underwent massive glucuronidation and oxidation by human liver microsomes (HLM) in this study with the intrinsic clearance (CLint) values of 12.43, 10.04, 2.01, and 6.99 μL/min/mg for M2, M3, M4, and M5, respectively.",In vitrometabolic mapping of neobavaisoflavone in human cytochromes P450 and UDP-glucuronosyltransferase enzymes by ultra high-performance liquid chromatography coupled with quadrupole time-of-flight tandem mass spectrometry. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29933228/),[μl] / [mg·min],6.99,169019,DB00818,Propofol
,29933228,CLint,"Additionally, the CLint values of G1 and G2 by HLM were 271.90 and 651.38 μL/min/mg, respectively, whereas their respective parameters were 59.96 and 949.01 μL/min/mg by human intestine microsomes (HIM).",In vitrometabolic mapping of neobavaisoflavone in human cytochromes P450 and UDP-glucuronosyltransferase enzymes by ultra high-performance liquid chromatography coupled with quadrupole time-of-flight tandem mass spectrometry. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29933228/),[μl] / [mg·min],271.90,169020,DB00818,Propofol
,29933228,CLint,"Additionally, the CLint values of G1 and G2 by HLM were 271.90 and 651.38 μL/min/mg, respectively, whereas their respective parameters were 59.96 and 949.01 μL/min/mg by human intestine microsomes (HIM).",In vitrometabolic mapping of neobavaisoflavone in human cytochromes P450 and UDP-glucuronosyltransferase enzymes by ultra high-performance liquid chromatography coupled with quadrupole time-of-flight tandem mass spectrometry. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29933228/),[μl] / [mg·min],651.38,169021,DB00818,Propofol
,29933228,CLint,"Additionally, the CLint values of G1 and G2 by HLM were 271.90 and 651.38 μL/min/mg, respectively, whereas their respective parameters were 59.96 and 949.01 μL/min/mg by human intestine microsomes (HIM).",In vitrometabolic mapping of neobavaisoflavone in human cytochromes P450 and UDP-glucuronosyltransferase enzymes by ultra high-performance liquid chromatography coupled with quadrupole time-of-flight tandem mass spectrometry. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29933228/),[μl] / [mg·min],59.96,169022,DB00818,Propofol
,29933228,CLint,"Additionally, the CLint values of G1 and G2 by HLM were 271.90 and 651.38 μL/min/mg, respectively, whereas their respective parameters were 59.96 and 949.01 μL/min/mg by human intestine microsomes (HIM).",In vitrometabolic mapping of neobavaisoflavone in human cytochromes P450 and UDP-glucuronosyltransferase enzymes by ultra high-performance liquid chromatography coupled with quadrupole time-of-flight tandem mass spectrometry. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29933228/),[μl] / [mg·min],949.01,169023,DB00818,Propofol
,9560536,Pp,"Fifteen minutes after the cessation of propofol infusion, Pp decreased to 1.5 micrograms.","[Pharmacokinetics of propofol and ketamine during and after total intravenous anesthesia with propofol, fentanyl and ketamine for pediatric patients]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9560536/),μg,1.5,169344,DB00818,Propofol
,9560536,Pk,Pk values at 15 minutes and 120 minutes after the cessation of the infusion were 93 ng.,"[Pharmacokinetics of propofol and ketamine during and after total intravenous anesthesia with propofol, fentanyl and ketamine for pediatric patients]. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9560536/),ng,93,169345,DB00818,Propofol
,12496748,CL,"The population pharmacokinetic parameters were as follows: CL = 2.2 + 0.27 x T(c) - 0.049 x TG (mean, 2.1 L/min); volume of central compartment, 22.2 L; CL (distribution), 1.5 L/min; and volume of peripheral compartment, 168 L.",Population pharmacokinetic and pharmacodynamic modeling of propofol for long-term sedation in critically ill patients: a comparison between propofol 6% and propofol 1%. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12496748/),,2,170285,DB00818,Propofol
,12496748,CL,"The population pharmacokinetic parameters were as follows: CL = 2.2 + 0.27 x T(c) - 0.049 x TG (mean, 2.1 L/min); volume of central compartment, 22.2 L; CL (distribution), 1.5 L/min; and volume of peripheral compartment, 168 L.",Population pharmacokinetic and pharmacodynamic modeling of propofol for long-term sedation in critically ill patients: a comparison between propofol 6% and propofol 1%. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12496748/),[l] / [min],2.1,170286,DB00818,Propofol
,12496748,volume of central compartment,"The population pharmacokinetic parameters were as follows: CL = 2.2 + 0.27 x T(c) - 0.049 x TG (mean, 2.1 L/min); volume of central compartment, 22.2 L; CL (distribution), 1.5 L/min; and volume of peripheral compartment, 168 L.",Population pharmacokinetic and pharmacodynamic modeling of propofol for long-term sedation in critically ill patients: a comparison between propofol 6% and propofol 1%. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12496748/),l,22.2,170287,DB00818,Propofol
,12496748,CL (distribution),"The population pharmacokinetic parameters were as follows: CL = 2.2 + 0.27 x T(c) - 0.049 x TG (mean, 2.1 L/min); volume of central compartment, 22.2 L; CL (distribution), 1.5 L/min; and volume of peripheral compartment, 168 L.",Population pharmacokinetic and pharmacodynamic modeling of propofol for long-term sedation in critically ill patients: a comparison between propofol 6% and propofol 1%. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12496748/),[l] / [min],1.5,170288,DB00818,Propofol
,12496748,volume of peripheral compartment,"The population pharmacokinetic parameters were as follows: CL = 2.2 + 0.27 x T(c) - 0.049 x TG (mean, 2.1 L/min); volume of central compartment, 22.2 L; CL (distribution), 1.5 L/min; and volume of peripheral compartment, 168 L.",Population pharmacokinetic and pharmacodynamic modeling of propofol for long-term sedation in critically ill patients: a comparison between propofol 6% and propofol 1%. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12496748/),l,168,170289,DB00818,Propofol
,12496748,concentration causing half of the maximal effect,"The values for the inverse logit of the concentration causing half of the maximal effect for Ramsay sedation scores of 2 through 6 were 0.13 +/- 0.09, 0.31 +/- 0.17, 0.56 +/- 0.24, 0.79 +/- 0.31, and 1.78 +/- 0.65 mg/L, respectively (population mean +/- SE).",Population pharmacokinetic and pharmacodynamic modeling of propofol for long-term sedation in critically ill patients: a comparison between propofol 6% and propofol 1%. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12496748/),[mg] / [l],0.13,170290,DB00818,Propofol
,12496748,concentration causing half of the maximal effect,"The values for the inverse logit of the concentration causing half of the maximal effect for Ramsay sedation scores of 2 through 6 were 0.13 +/- 0.09, 0.31 +/- 0.17, 0.56 +/- 0.24, 0.79 +/- 0.31, and 1.78 +/- 0.65 mg/L, respectively (population mean +/- SE).",Population pharmacokinetic and pharmacodynamic modeling of propofol for long-term sedation in critically ill patients: a comparison between propofol 6% and propofol 1%. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12496748/),[mg] / [l],0.31,170291,DB00818,Propofol
,12496748,concentration causing half of the maximal effect,"The values for the inverse logit of the concentration causing half of the maximal effect for Ramsay sedation scores of 2 through 6 were 0.13 +/- 0.09, 0.31 +/- 0.17, 0.56 +/- 0.24, 0.79 +/- 0.31, and 1.78 +/- 0.65 mg/L, respectively (population mean +/- SE).",Population pharmacokinetic and pharmacodynamic modeling of propofol for long-term sedation in critically ill patients: a comparison between propofol 6% and propofol 1%. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12496748/),[mg] / [l],0.56,170292,DB00818,Propofol
,12496748,concentration causing half of the maximal effect,"The values for the inverse logit of the concentration causing half of the maximal effect for Ramsay sedation scores of 2 through 6 were 0.13 +/- 0.09, 0.31 +/- 0.17, 0.56 +/- 0.24, 0.79 +/- 0.31, and 1.78 +/- 0.65 mg/L, respectively (population mean +/- SE).",Population pharmacokinetic and pharmacodynamic modeling of propofol for long-term sedation in critically ill patients: a comparison between propofol 6% and propofol 1%. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12496748/),[mg] / [l],0.79,170293,DB00818,Propofol
,12496748,concentration causing half of the maximal effect,"The values for the inverse logit of the concentration causing half of the maximal effect for Ramsay sedation scores of 2 through 6 were 0.13 +/- 0.09, 0.31 +/- 0.17, 0.56 +/- 0.24, 0.79 +/- 0.31, and 1.78 +/- 0.65 mg/L, respectively (population mean +/- SE).",Population pharmacokinetic and pharmacodynamic modeling of propofol for long-term sedation in critically ill patients: a comparison between propofol 6% and propofol 1%. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12496748/),[mg] / [l],1.78,170294,DB00818,Propofol
,27044652,anae,"Mean anaesthesia time and time to extubation in the TCI-2 group were 73.90 (±20.29) and 8.04 (±5.46) minutes, respectively.",Evaluation and optimisation of propofol pharmacokinetic parameters in cats for target-controlled infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27044652/),min,73.90,170769,DB00818,Propofol
,27044652,time,"Mean anaesthesia time and time to extubation in the TCI-2 group were 73.90 (±20.29) and 8.04 (±5.46) minutes, respectively.",Evaluation and optimisation of propofol pharmacokinetic parameters in cats for target-controlled infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27044652/),min,73.90,170770,DB00818,Propofol
,27044652,time to extubation,"Mean anaesthesia time and time to extubation in the TCI-2 group were 73.90 (±20.29) and 8.04 (±5.46) minutes, respectively.",Evaluation and optimisation of propofol pharmacokinetic parameters in cats for target-controlled infusion. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27044652/),min,8.04,170771,DB00818,Propofol
,33950785,"maximum concentrations (Cmax,)","Mean (SD) maximum concentrations (Cmax,) of morphine in plasma were 6.8 (4.56), 9.56 (8.29), 9.30 (3.35) and 18.99 (9.41) ng/mL for the groups Dex + Mor, Dex + Maro + Mor, Maro + Mor and Mor respectively.","Evaluation of analgesic interaction between morphine, maropitant and dexmedetomidine in dogs undergoing ovariohysterectomy. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33950785/),[ng] / [ml],6.8,171104,DB00818,Propofol
,33950785,"maximum concentrations (Cmax,)","Mean (SD) maximum concentrations (Cmax,) of morphine in plasma were 6.8 (4.56), 9.56 (8.29), 9.30 (3.35) and 18.99 (9.41) ng/mL for the groups Dex + Mor, Dex + Maro + Mor, Maro + Mor and Mor respectively.","Evaluation of analgesic interaction between morphine, maropitant and dexmedetomidine in dogs undergoing ovariohysterectomy. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33950785/),[ng] / [ml],9.56,171105,DB00818,Propofol
,33950785,"maximum concentrations (Cmax,)","Mean (SD) maximum concentrations (Cmax,) of morphine in plasma were 6.8 (4.56), 9.56 (8.29), 9.30 (3.35) and 18.99 (9.41) ng/mL for the groups Dex + Mor, Dex + Maro + Mor, Maro + Mor and Mor respectively.","Evaluation of analgesic interaction between morphine, maropitant and dexmedetomidine in dogs undergoing ovariohysterectomy. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33950785/),[ng] / [ml],9.30,171106,DB00818,Propofol
,33950785,"maximum concentrations (Cmax,)","Mean (SD) maximum concentrations (Cmax,) of morphine in plasma were 6.8 (4.56), 9.56 (8.29), 9.30 (3.35) and 18.99 (9.41) ng/mL for the groups Dex + Mor, Dex + Maro + Mor, Maro + Mor and Mor respectively.","Evaluation of analgesic interaction between morphine, maropitant and dexmedetomidine in dogs undergoing ovariohysterectomy. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33950785/),[ng] / [ml],18.99,171107,DB00818,Propofol
,1928855,central compartment volume,"The AIH only altered the central compartment volume (65.5 +/- 15.6 l in the control group vs 83.6 +/- 13.3 l in group II, p less than 0.01).",[Pharmacokinetics of propofol injected after deliberate preoperative hemodilution]. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1928855/),l,65.5,171206,DB00818,Propofol
,1928855,central compartment volume,"The AIH only altered the central compartment volume (65.5 +/- 15.6 l in the control group vs 83.6 +/- 13.3 l in group II, p less than 0.01).",[Pharmacokinetics of propofol injected after deliberate preoperative hemodilution]. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1928855/),l,83.6,171207,DB00818,Propofol
,1928855,Initial concentrations,"Initial concentrations were not significantly different in the two groups (2,892 +/- 762 ng.ml-1 in controls vs 2,373 +/- 589 ng.ml-1 in the others).",[Pharmacokinetics of propofol injected after deliberate preoperative hemodilution]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1928855/),[ng] / [ml],"2,892",171208,DB00818,Propofol
,1928855,Initial concentrations,"Initial concentrations were not significantly different in the two groups (2,892 +/- 762 ng.ml-1 in controls vs 2,373 +/- 589 ng.ml-1 in the others).",[Pharmacokinetics of propofol injected after deliberate preoperative hemodilution]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1928855/),[ng] / [ml],"2,373",171209,DB00818,Propofol
,16491890,effect-site concentration,Fentanyl was injected repeatedly to insure maintenance of the effect-site concentration in the 2.0 to 2.5 ng x ml(-1) range with off line computer similation program.,[Recovery from propofol anesthesia is delayed in hepatectomy patients due to altered pharmacodynamics]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16491890/),[ng] / [ml],2.0 to 2.5,171269,DB00818,Propofol
,9527730,maximum concentration of paracetamol (Cmax),"During propofol sedation the maximum concentration of paracetamol (Cmax) was 115+/-26.8 micromol/L, time to peak concentration (Tmax) 50+/-38.8 min, and the area under the curve during the first 60 min (AUC60) 4793+/-1538 micromol x min/L, versus Cmax 99+/-20.8, Tmax 69+/-41.9 and AUC60 3897+/-1310 during saline infusion.",Propofol sedation and gastric emptying in volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9527730/),[μM] / [l],115,171773,DB00818,Propofol
,9527730,time to peak concentration (Tmax),"During propofol sedation the maximum concentration of paracetamol (Cmax) was 115+/-26.8 micromol/L, time to peak concentration (Tmax) 50+/-38.8 min, and the area under the curve during the first 60 min (AUC60) 4793+/-1538 micromol x min/L, versus Cmax 99+/-20.8, Tmax 69+/-41.9 and AUC60 3897+/-1310 during saline infusion.",Propofol sedation and gastric emptying in volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9527730/),min,50,171774,DB00818,Propofol
,9527730,area under the curve during the first 60 min (AUC60),"During propofol sedation the maximum concentration of paracetamol (Cmax) was 115+/-26.8 micromol/L, time to peak concentration (Tmax) 50+/-38.8 min, and the area under the curve during the first 60 min (AUC60) 4793+/-1538 micromol x min/L, versus Cmax 99+/-20.8, Tmax 69+/-41.9 and AUC60 3897+/-1310 during saline infusion.",Propofol sedation and gastric emptying in volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9527730/),[min·μM] / [l],4793,171775,DB00818,Propofol
,9527730,Cmax,"During propofol sedation the maximum concentration of paracetamol (Cmax) was 115+/-26.8 micromol/L, time to peak concentration (Tmax) 50+/-38.8 min, and the area under the curve during the first 60 min (AUC60) 4793+/-1538 micromol x min/L, versus Cmax 99+/-20.8, Tmax 69+/-41.9 and AUC60 3897+/-1310 during saline infusion.",Propofol sedation and gastric emptying in volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9527730/),,99,171776,DB00818,Propofol
,9527730,Tmax,"During propofol sedation the maximum concentration of paracetamol (Cmax) was 115+/-26.8 micromol/L, time to peak concentration (Tmax) 50+/-38.8 min, and the area under the curve during the first 60 min (AUC60) 4793+/-1538 micromol x min/L, versus Cmax 99+/-20.8, Tmax 69+/-41.9 and AUC60 3897+/-1310 during saline infusion.",Propofol sedation and gastric emptying in volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9527730/),,69,171777,DB00818,Propofol
,9527730,AUC60,"During propofol sedation the maximum concentration of paracetamol (Cmax) was 115+/-26.8 micromol/L, time to peak concentration (Tmax) 50+/-38.8 min, and the area under the curve during the first 60 min (AUC60) 4793+/-1538 micromol x min/L, versus Cmax 99+/-20.8, Tmax 69+/-41.9 and AUC60 3897+/-1310 during saline infusion.",Propofol sedation and gastric emptying in volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9527730/),,3897,171778,DB00818,Propofol
,9527730,OCT,"OCT was significantly shorter during the control study, 180+/-32.4 min, than during propofol sedation, 217+/-64.9 min (P<0.05).",Propofol sedation and gastric emptying in volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9527730/),min,180,171779,DB00818,Propofol
,9527730,OCT,"OCT was significantly shorter during the control study, 180+/-32.4 min, than during propofol sedation, 217+/-64.9 min (P<0.05).",Propofol sedation and gastric emptying in volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9527730/),min,217,171780,DB00818,Propofol
,12883403,central volume of distribution,"A two-compartment model for GPI 15715 (central volume of distribution, 0.07 l/kg; clearance, 7 ml.",Pharmacokinetics and clinical pharmacodynamics of the new propofol prodrug GPI 15715 in volunteers. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12883403/),[l] / [kg],0.07,173339,DB00818,Propofol
,12883403,clearance,"A two-compartment model for GPI 15715 (central volume of distribution, 0.07 l/kg; clearance, 7 ml.",Pharmacokinetics and clinical pharmacodynamics of the new propofol prodrug GPI 15715 in volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12883403/),ml,7,173340,DB00818,Propofol
,12883403,terminal half-life,"kg-1 min-1; terminal half-life, 46 min) and a three-compartment model for propofol (half-lives: 2.2, 20, 477 min) best described the data.",Pharmacokinetics and clinical pharmacodynamics of the new propofol prodrug GPI 15715 in volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12883403/),min,46,173341,DB00818,Propofol
,12883403,half-lives,"kg-1 min-1; terminal half-life, 46 min) and a three-compartment model for propofol (half-lives: 2.2, 20, 477 min) best described the data.",Pharmacokinetics and clinical pharmacodynamics of the new propofol prodrug GPI 15715 in volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12883403/),min,2.2,173342,DB00818,Propofol
,12883403,half-lives,"kg-1 min-1; terminal half-life, 46 min) and a three-compartment model for propofol (half-lives: 2.2, 20, 477 min) best described the data.",Pharmacokinetics and clinical pharmacodynamics of the new propofol prodrug GPI 15715 in volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12883403/),min,"20, 477",173343,DB00818,Propofol
,19372331,constant C(t),"During Session B, in addition to this propofol infusion scheme, a target-controlled infusion of midazolam (constant C(t): 125 ng/mL) was given from 15 min before the start until 6 h after termination of the propofol infusion.",Mixed-effects modeling of the influence of midazolam on propofol pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19372331/),[ng] / [ml],125,173648,DB00818,Propofol
,19372331,C(blood),"In the presence of midazolam (C(blood): 224.8 +/- 41.6 ng/mL), the blood propofol concentration increased by 25.1% +/- 13.3% compared with when propofol was given as single drug.",Mixed-effects modeling of the influence of midazolam on propofol pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19372331/),[ng] / [ml],224.8,173649,DB00818,Propofol
,19372331,C(blood),"Midazolam (C(blood): 225 ng/mL) reduced propofol Cl(1) from 1.94 to 1.61 L/min, Cl(2) from 2.86 to 1.52 L/min, and Cl(3) from 0.95 to 0.73 L/min.",Mixed-effects modeling of the influence of midazolam on propofol pharmacokinetics. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19372331/),[ng] / [ml],225,173650,DB00818,Propofol
,19372331,Cl(1),"Midazolam (C(blood): 225 ng/mL) reduced propofol Cl(1) from 1.94 to 1.61 L/min, Cl(2) from 2.86 to 1.52 L/min, and Cl(3) from 0.95 to 0.73 L/min.",Mixed-effects modeling of the influence of midazolam on propofol pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19372331/),[l] / [min],1.94 to 1.61,173651,DB00818,Propofol
,19372331,Cl(2),"Midazolam (C(blood): 225 ng/mL) reduced propofol Cl(1) from 1.94 to 1.61 L/min, Cl(2) from 2.86 to 1.52 L/min, and Cl(3) from 0.95 to 0.73 L/min.",Mixed-effects modeling of the influence of midazolam on propofol pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19372331/),[l] / [min],2.86 to 1.52,173652,DB00818,Propofol
,19372331,Cl(3),"Midazolam (C(blood): 225 ng/mL) reduced propofol Cl(1) from 1.94 to 1.61 L/min, Cl(2) from 2.86 to 1.52 L/min, and Cl(3) from 0.95 to 0.73 L/min.",Mixed-effects modeling of the influence of midazolam on propofol pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19372331/),[l] / [min],0.95 to 0.73,173653,DB00818,Propofol
,23302977,Ce50 BIS,"A separate analysis for the dark- and red-haired subjects estimated a median (95% confidence interval) Ce50 BIS of 2.71 μg/mL (2.28-3.36 μg/mL) and 2.57 μg/mL (1.68-3.60 μg/mL), respectively.",Bispectral index dynamics during propofol hypnosis is similar in red-haired and dark-haired subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23302977/),[μg] / [ml],2.71,177215,DB00818,Propofol
,23302977,Ce50 BIS,"A separate analysis for the dark- and red-haired subjects estimated a median (95% confidence interval) Ce50 BIS of 2.71 μg/mL (2.28-3.36 μg/mL) and 2.57 μg/mL (1.68-3.60 μg/mL), respectively.",Bispectral index dynamics during propofol hypnosis is similar in red-haired and dark-haired subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23302977/),[μg] / [ml],2.57,177216,DB00818,Propofol
,17457124,time to achieve a recovery of train-of-four ratio,The primary endpoint of the study was the time to achieve a recovery of train-of-four ratio to 0.9.,"Early reversal of profound rocuronium-induced neuromuscular blockade by sugammadex in a randomized multicenter study: efficacy, safety, and pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17457124/),,0.9,177448,DB00818,Propofol
,17457124,time to recovery,"The mean time to recovery of the train-of-four ratio to 0.9 after dosing at 3, 5, and 15 min decreased from 52.1, 51.7, and 35.6 min, respectively, after administration of placebo to 1.8, 1.5, and 1.4 min, respectively, after 8 mg/kg sugammadex.","Early reversal of profound rocuronium-induced neuromuscular blockade by sugammadex in a randomized multicenter study: efficacy, safety, and pharmacokinetics. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17457124/),min,0.9,177449,DB00818,Propofol
,17457124,time to recovery,"The mean time to recovery of the train-of-four ratio to 0.9 after dosing at 3, 5, and 15 min decreased from 52.1, 51.7, and 35.6 min, respectively, after administration of placebo to 1.8, 1.5, and 1.4 min, respectively, after 8 mg/kg sugammadex.","Early reversal of profound rocuronium-induced neuromuscular blockade by sugammadex in a randomized multicenter study: efficacy, safety, and pharmacokinetics. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17457124/),min,52.1,177450,DB00818,Propofol
,17457124,time to recovery,"The mean time to recovery of the train-of-four ratio to 0.9 after dosing at 3, 5, and 15 min decreased from 52.1, 51.7, and 35.6 min, respectively, after administration of placebo to 1.8, 1.5, and 1.4 min, respectively, after 8 mg/kg sugammadex.","Early reversal of profound rocuronium-induced neuromuscular blockade by sugammadex in a randomized multicenter study: efficacy, safety, and pharmacokinetics. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17457124/),min,51.7,177451,DB00818,Propofol
,17457124,time to recovery,"The mean time to recovery of the train-of-four ratio to 0.9 after dosing at 3, 5, and 15 min decreased from 52.1, 51.7, and 35.6 min, respectively, after administration of placebo to 1.8, 1.5, and 1.4 min, respectively, after 8 mg/kg sugammadex.","Early reversal of profound rocuronium-induced neuromuscular blockade by sugammadex in a randomized multicenter study: efficacy, safety, and pharmacokinetics. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17457124/),min,35.6,177452,DB00818,Propofol
,17457124,time to recovery,"The mean time to recovery of the train-of-four ratio to 0.9 after dosing at 3, 5, and 15 min decreased from 52.1, 51.7, and 35.6 min, respectively, after administration of placebo to 1.8, 1.5, and 1.4 min, respectively, after 8 mg/kg sugammadex.","Early reversal of profound rocuronium-induced neuromuscular blockade by sugammadex in a randomized multicenter study: efficacy, safety, and pharmacokinetics. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17457124/),min,1.8,177453,DB00818,Propofol
,17457124,time to recovery,"The mean time to recovery of the train-of-four ratio to 0.9 after dosing at 3, 5, and 15 min decreased from 52.1, 51.7, and 35.6 min, respectively, after administration of placebo to 1.8, 1.5, and 1.4 min, respectively, after 8 mg/kg sugammadex.","Early reversal of profound rocuronium-induced neuromuscular blockade by sugammadex in a randomized multicenter study: efficacy, safety, and pharmacokinetics. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17457124/),min,1.5,177454,DB00818,Propofol
,17457124,time to recovery,"The mean time to recovery of the train-of-four ratio to 0.9 after dosing at 3, 5, and 15 min decreased from 52.1, 51.7, and 35.6 min, respectively, after administration of placebo to 1.8, 1.5, and 1.4 min, respectively, after 8 mg/kg sugammadex.","Early reversal of profound rocuronium-induced neuromuscular blockade by sugammadex in a randomized multicenter study: efficacy, safety, and pharmacokinetics. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17457124/),min,1.4,177455,DB00818,Propofol
,17457124,cumulative excretion,The median cumulative excretion of rocuronium in the urine over 24 h was 26% in the placebo group and increased to 58-74% after 4-8 mg/kg sugammadex.,"Early reversal of profound rocuronium-induced neuromuscular blockade by sugammadex in a randomized multicenter study: efficacy, safety, and pharmacokinetics. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17457124/),%,26,177456,DB00818,Propofol
,17457124,cumulative excretion,The median cumulative excretion of rocuronium in the urine over 24 h was 26% in the placebo group and increased to 58-74% after 4-8 mg/kg sugammadex.,"Early reversal of profound rocuronium-induced neuromuscular blockade by sugammadex in a randomized multicenter study: efficacy, safety, and pharmacokinetics. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17457124/),%,58-74,177457,DB00818,Propofol
,17457124,plasma clearances,"The mean plasma clearances of sugammadex and rocuronium were 0.084 and 0.26 l/min, respectively.","Early reversal of profound rocuronium-induced neuromuscular blockade by sugammadex in a randomized multicenter study: efficacy, safety, and pharmacokinetics. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17457124/),[l] / [min],0.084,177458,DB00818,Propofol
,17457124,plasma clearances,"The mean plasma clearances of sugammadex and rocuronium were 0.084 and 0.26 l/min, respectively.","Early reversal of profound rocuronium-induced neuromuscular blockade by sugammadex in a randomized multicenter study: efficacy, safety, and pharmacokinetics. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17457124/),[l] / [min],0.26,177459,DB00818,Propofol
,8572357,heart rate,"Without propofol pretreatment, the increase to 8% desflurane transiently increased heart rate (from 63 +/- 3 beats/min to 108 +/- 5 beats/min, mean +/- SEM; P < 0.01), mean arterial pressure (from 73 +/- 1 mmHg to 118 +/- 6 mmHg; P < 0.01), and epinephrine concentration (from 14 +/- 1 pg.ml-1 to 279 +/- 51 pg.ml-1; P < 0.05).",Propofol fails to attenuate the cardiovascular response to rapid increases in desflurane concentration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8572357/),[beats] / [min],63,177505,DB00818,Propofol
,8572357,heart rate,"Without propofol pretreatment, the increase to 8% desflurane transiently increased heart rate (from 63 +/- 3 beats/min to 108 +/- 5 beats/min, mean +/- SEM; P < 0.01), mean arterial pressure (from 73 +/- 1 mmHg to 118 +/- 6 mmHg; P < 0.01), and epinephrine concentration (from 14 +/- 1 pg.ml-1 to 279 +/- 51 pg.ml-1; P < 0.05).",Propofol fails to attenuate the cardiovascular response to rapid increases in desflurane concentration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8572357/),[beats] / [min],108,177506,DB00818,Propofol
,8572357,peak plasma epinephrine concentration,"The peak plasma epinephrine concentration was attenuated by each propofol pretreatment (158 +/- 35 pg.ml-1, propofol given 2 min before, and 146 + 41 pg.ml-1, propofol given 5 min before; P < 0.05), but neither propofol pretreatment modified the cardiovascular or norepinephrine responses.",Propofol fails to attenuate the cardiovascular response to rapid increases in desflurane concentration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8572357/),[pg] / [ml],158,177507,DB00818,Propofol
,8572357,peak plasma epinephrine concentration,"The peak plasma epinephrine concentration was attenuated by each propofol pretreatment (158 +/- 35 pg.ml-1, propofol given 2 min before, and 146 + 41 pg.ml-1, propofol given 5 min before; P < 0.05), but neither propofol pretreatment modified the cardiovascular or norepinephrine responses.",Propofol fails to attenuate the cardiovascular response to rapid increases in desflurane concentration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8572357/),[pg] / [ml],146,177508,DB00818,Propofol
,3264120,half-time,"Rapid and slow propofol distribution half-times were observed, followed by an elimination phase with a half-time of 4-5 h.",Pharmacokinetics and protein binding of propofol in patients with cirrhosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3264120/),h,4-5,177943,DB00818,Propofol
,3264120,total body clearance,Propofol total body clearance was reduced (1.99 +/- 0.68 l.min-1) in the patients with cirrhosis but did not differ significantly from that in the control patients (2.30 +/- 0.61 l.min-1).,Pharmacokinetics and protein binding of propofol in patients with cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3264120/),[l] / [min],1.99,177944,DB00818,Propofol
,3264120,total body clearance,Propofol total body clearance was reduced (1.99 +/- 0.68 l.min-1) in the patients with cirrhosis but did not differ significantly from that in the control patients (2.30 +/- 0.61 l.min-1).,Pharmacokinetics and protein binding of propofol in patients with cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3264120/),[l] / [min],2.30,177945,DB00818,Propofol
,15951325,arterial concentrations,"The groups had comparable mean (95% CI) arterial concentrations of propofol, 4.8 (3.5-6.1) microg ml(-1) in the patients given clonidine, and 4.6 (3.4-5.7) microg ml(-1) in the patients given placebo (P=0.81).",Effect of clonidine pre-medication on propofol requirements during lower extremity vascular surgery: a randomized controlled trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15951325/),[μg] / [ml],4.8,178440,DB00818,Propofol
,15951325,arterial concentrations,"The groups had comparable mean (95% CI) arterial concentrations of propofol, 4.8 (3.5-6.1) microg ml(-1) in the patients given clonidine, and 4.6 (3.4-5.7) microg ml(-1) in the patients given placebo (P=0.81).",Effect of clonidine pre-medication on propofol requirements during lower extremity vascular surgery: a randomized controlled trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15951325/),[μg] / [ml],4.6,178441,DB00818,Propofol
,15951325,plasma concentration,"However, the average plasma concentration predicted by the target-controlled infusion was less in the clonidine group [3.2 (2.9-3.5)] than in the group given placebo [3.6 (3.3-3.9)] microg ml(-1) (P<0.05).",Effect of clonidine pre-medication on propofol requirements during lower extremity vascular surgery: a randomized controlled trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15951325/),[μg] / [ml],3.2,178442,DB00818,Propofol
,15951325,plasma concentration,"However, the average plasma concentration predicted by the target-controlled infusion was less in the clonidine group [3.2 (2.9-3.5)] than in the group given placebo [3.6 (3.3-3.9)] microg ml(-1) (P<0.05).",Effect of clonidine pre-medication on propofol requirements during lower extremity vascular surgery: a randomized controlled trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15951325/),[μg] / [ml],3.6,178443,DB00818,Propofol
,19442072,clearance,Median propofol clearance (19.6 mL kg(-1) min(-1)) is significantly lower and interindividual variability (range 3.7-78 mL kg(-1) min(-1)) in propofol clearance in neonates is extensive.,Is propofol the perfect hypnotic agent for procedural sedation in neonates? ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19442072/),[ml] / [kg·min],19.6,178845,DB00818,Propofol
,22774843,pseudo-steady state concentrations,"Blood propofol concentrations during the infusion ranged between 1.52 and 7.65 μg/mL; pseudo-steady state concentrations 3.64-6.78 μg/mL, and concentrations on assuming standing position 0.75-1.40 μg/mL.",Real time monitoring of propofol blood concentration in ponies anaesthetized with propofol and ketamine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22774843/),[μg] / [ml],3.64-6.78,179623,DB00818,Propofol
,22774843,clearance,"Propofol clearance and volume of distribution were 31.4 (SD 6.1) mL/min/kg and 220.7 (132.0) mL/kg, respectively.",Real time monitoring of propofol blood concentration in ponies anaesthetized with propofol and ketamine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22774843/),[ml] / [kg·min],31.4,179624,DB00818,Propofol
,22774843,volume of distribution,"Propofol clearance and volume of distribution were 31.4 (SD 6.1) mL/min/kg and 220.7 (132.0) mL/kg, respectively.",Real time monitoring of propofol blood concentration in ponies anaesthetized with propofol and ketamine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22774843/),[ml] / [kg],220.7,179625,DB00818,Propofol
,18719441,particle size,"The pH, osmolarity, and particle size of microemulsion propofol are 7.5, 280 mOsm/l, and 67.0 +/- 28.5 nm, respectively.","Physicochemical properties, pharmacokinetics, and pharmacodynamics of a reformulated microemulsion propofol in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18719441/),,67.0,179765,DB00818,Propofol
,18719441,concentration,The aqueous free propofol concentration in microemulsion propofol was 63.3 +/- 1.2 mug/ml.,"Physicochemical properties, pharmacokinetics, and pharmacodynamics of a reformulated microemulsion propofol in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18719441/),μg,63,179766,DB00818,Propofol
,18719441,V1,"Although microemulsion propofol had nonlinear pharmacokinetics, a two-compartment model with linear pharmacokinetics best described the time course of the propofol concentration as follows: V1 = 0.143 l/kg, k10 = 0.175 min, k12 = 0.126 min, k21 = 0.043 min.","Physicochemical properties, pharmacokinetics, and pharmacodynamics of a reformulated microemulsion propofol in rats. ",V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18719441/),[l] / [kg],0.143,179767,DB00818,Propofol
,18719441,k10,"Although microemulsion propofol had nonlinear pharmacokinetics, a two-compartment model with linear pharmacokinetics best described the time course of the propofol concentration as follows: V1 = 0.143 l/kg, k10 = 0.175 min, k12 = 0.126 min, k21 = 0.043 min.","Physicochemical properties, pharmacokinetics, and pharmacodynamics of a reformulated microemulsion propofol in rats. ","K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18719441/),min,0.175,179768,DB00818,Propofol
,18719441,k12,"Although microemulsion propofol had nonlinear pharmacokinetics, a two-compartment model with linear pharmacokinetics best described the time course of the propofol concentration as follows: V1 = 0.143 l/kg, k10 = 0.175 min, k12 = 0.126 min, k21 = 0.043 min.","Physicochemical properties, pharmacokinetics, and pharmacodynamics of a reformulated microemulsion propofol in rats. ","K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18719441/),min,0.126,179769,DB00818,Propofol
,18719441,k21,"Although microemulsion propofol had nonlinear pharmacokinetics, a two-compartment model with linear pharmacokinetics best described the time course of the propofol concentration as follows: V1 = 0.143 l/kg, k10 = 0.175 min, k12 = 0.126 min, k21 = 0.043 min.","Physicochemical properties, pharmacokinetics, and pharmacodynamics of a reformulated microemulsion propofol in rats. ","K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18719441/),min,0.043,179770,DB00818,Propofol
,18719441,E0,"The pharmacodynamic parameters in a sigmoid Emax model were as follows: E0 = 1.18, Emax = 0.636, Ce50 = 1.87 mug/ml, gamma = 1.28, ke0 = 1.02 min.","Physicochemical properties, pharmacokinetics, and pharmacodynamics of a reformulated microemulsion propofol in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18719441/),,1.18,179771,DB00818,Propofol
,18719441,Emax,"The pharmacodynamic parameters in a sigmoid Emax model were as follows: E0 = 1.18, Emax = 0.636, Ce50 = 1.87 mug/ml, gamma = 1.28, ke0 = 1.02 min.","Physicochemical properties, pharmacokinetics, and pharmacodynamics of a reformulated microemulsion propofol in rats. ",Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18719441/),,0.636,179772,DB00818,Propofol
,18719441,Ce50,"The pharmacodynamic parameters in a sigmoid Emax model were as follows: E0 = 1.18, Emax = 0.636, Ce50 = 1.87 mug/ml, gamma = 1.28, ke0 = 1.02 min.","Physicochemical properties, pharmacokinetics, and pharmacodynamics of a reformulated microemulsion propofol in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18719441/),[μg] / [ml],1.87,179773,DB00818,Propofol
,18719441,gamma,"The pharmacodynamic parameters in a sigmoid Emax model were as follows: E0 = 1.18, Emax = 0.636, Ce50 = 1.87 mug/ml, gamma = 1.28, ke0 = 1.02 min.","Physicochemical properties, pharmacokinetics, and pharmacodynamics of a reformulated microemulsion propofol in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18719441/),,1.28,179774,DB00818,Propofol
,18719441,ke0,"The pharmacodynamic parameters in a sigmoid Emax model were as follows: E0 = 1.18, Emax = 0.636, Ce50 = 1.87 mug/ml, gamma = 1.28, ke0 = 1.02 min.","Physicochemical properties, pharmacokinetics, and pharmacodynamics of a reformulated microemulsion propofol in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18719441/),min,1.02,179775,DB00818,Propofol
,17721240,t(1/2) k(e0),"The best model based was a fixed (Bispectral Index > or = 90) plus sigmoidal model (Bispectral Index < 90) with two values of k(e0), one for the bolus (t(1/2) k(e0) = 1.2 min) and one for the infusions (t(1/2) k(e0) = 2.2 min).",Influence of administration rate on propofol plasma-effect site equilibration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17721240/),min,1.2,179965,DB00818,Propofol
,17721240,t(1/2) k(e0),"The best model based was a fixed (Bispectral Index > or = 90) plus sigmoidal model (Bispectral Index < 90) with two values of k(e0), one for the bolus (t(1/2) k(e0) = 1.2 min) and one for the infusions (t(1/2) k(e0) = 2.2 min).",Influence of administration rate on propofol plasma-effect site equilibration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17721240/),min,2.2,179966,DB00818,Propofol
,8541435,secretion rates,Secretion rates were calculated on a pharmacokinetic basis an revealed secretion rates of 0.3 to 97.3 micrograms/min for adrenalin and 6.7 und 402.8 micrograms/min for noradrenaline.,[Quantitative assessment of catecholamine secretion as a rational principle of anesthesia management in pheochromocytoma surgery]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8541435/),[μg] / [min],0.3 to 97.3,181080,DB00818,Propofol
,8541435,secretion rates,Secretion rates were calculated on a pharmacokinetic basis an revealed secretion rates of 0.3 to 97.3 micrograms/min for adrenalin and 6.7 und 402.8 micrograms/min for noradrenaline.,[Quantitative assessment of catecholamine secretion as a rational principle of anesthesia management in pheochromocytoma surgery]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8541435/),[μg] / [min],6.7,181081,DB00818,Propofol
,8541435,secretion rates,Secretion rates were calculated on a pharmacokinetic basis an revealed secretion rates of 0.3 to 97.3 micrograms/min for adrenalin and 6.7 und 402.8 micrograms/min for noradrenaline.,[Quantitative assessment of catecholamine secretion as a rational principle of anesthesia management in pheochromocytoma surgery]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8541435/),[μg] / [min],402.8,181082,DB00818,Propofol
,8541435,total dose,Over a period of 69.2 +/- 39.8 min during resection of the tumor the total dose was 7017 +/- 12433 micrograms.,[Quantitative assessment of catecholamine secretion as a rational principle of anesthesia management in pheochromocytoma surgery]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8541435/),μg,7017,181083,DB00818,Propofol
,23602008,concentration,Mean propofol concentration was 6.2 mg/L during maintenance and 1.8 mg/L during emergence from anesthesia.,Evaluation of propofol anesthesia in morbidly obese children and adolescents. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23602008/),[mg] / [l],6.2,181317,DB00818,Propofol
,23602008,concentration,Mean propofol concentration was 6.2 mg/L during maintenance and 1.8 mg/L during emergence from anesthesia.,Evaluation of propofol anesthesia in morbidly obese children and adolescents. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23602008/),[mg] / [l],1.8,181318,DB00818,Propofol
,16645444,Cp,"Cp values of samples taken from the radial artery after cross clamping of the aorta were significantly (P < 0.05) increased compared with pre-cross clamp values (1.8 +/- 0.4 microg/ml), and the mean Cp after aortic cross clamping varied between 3.0 and 5.3 microg/ml.",Influence of the descending thoracic aortic cross clamping on bispectral index value and plasma propofol concentration in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16645444/),[μg] / [ml],1.8,181358,DB00818,Propofol
,16645444,Cp,"Cp values of samples taken from the radial artery after cross clamping of the aorta were significantly (P < 0.05) increased compared with pre-cross clamp values (1.8 +/- 0.4 microg/ml), and the mean Cp after aortic cross clamping varied between 3.0 and 5.3 microg/ml.",Influence of the descending thoracic aortic cross clamping on bispectral index value and plasma propofol concentration in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16645444/),[μg] / [ml],3.0 and 5.3,181359,DB00818,Propofol
,2363548,octanol/water partition coefficient,"This lipophilic (octanol/water partition coefficient: 1000) and weak base (pKa = 4.5) is a potent short-acting hypnotic agent, which can be used for anaesthetic induction or maintenance.",[Pharmacokinetics of etomidate]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2363548/),,1000,182659,DB00818,Propofol
,2363548,pKa,"This lipophilic (octanol/water partition coefficient: 1000) and weak base (pKa = 4.5) is a potent short-acting hypnotic agent, which can be used for anaesthetic induction or maintenance.",[Pharmacokinetics of etomidate]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2363548/),,4.5,182660,DB00818,Propofol
,2363548,distribution half-lives,"The plasma concentration curve fits an open three compartment pharmacokinetic model, with distribution half-lives of 2.6 and 20 min, and terminal elimination half-life of about 4-5 h.",[Pharmacokinetics of etomidate]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2363548/),min,2.6,182661,DB00818,Propofol
,2363548,distribution half-lives,"The plasma concentration curve fits an open three compartment pharmacokinetic model, with distribution half-lives of 2.6 and 20 min, and terminal elimination half-life of about 4-5 h.",[Pharmacokinetics of etomidate]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2363548/),min,20,182662,DB00818,Propofol
,2363548,terminal elimination half-life,"The plasma concentration curve fits an open three compartment pharmacokinetic model, with distribution half-lives of 2.6 and 20 min, and terminal elimination half-life of about 4-5 h.",[Pharmacokinetics of etomidate]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2363548/),h,4-5,182663,DB00818,Propofol
,2363548,t1/2,Hypnotic plasma concentrations (greater than 0.2 microgram.ml-1) are observed during the intermediate distribution phase (t1/2 approximately 20 min); they reflect the short lasting pharmacodynamic effect.,[Pharmacokinetics of etomidate]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2363548/),min,20,182664,DB00818,Propofol
,19307972,Wobble,"Wobble median value was 7.4% (3.8, 8.4) for group adjusted and 8.2% (7.0, 9.6) for group TBW.",No adjustment vs. adjustment formula as input weight for propofol target-controlled infusion in morbidly obese patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19307972/),%,7.4,182834,DB00818,Propofol
,19307972,Wobble,"Wobble median value was 7.4% (3.8, 8.4) for group adjusted and 8.2% (7.0, 9.6) for group TBW.",No adjustment vs. adjustment formula as input weight for propofol target-controlled infusion in morbidly obese patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19307972/),%,8.2,182835,DB00818,Propofol
more,28455212,elimination half-life,Plasma concentrations of tramadol rapidly decreased in the first 2 hours for both doses with an elimination half-life of more than 40 minutes.,Cardiovascular effects and intraoperative pharmacokinetics of tramadol in sheep undergoing spinal surgery. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28455212/),min,40,183661,DB00818,Propofol
,16102683,Cp50,"Cp50 of the Classic, Fastrach, and ProSeal LMA insertion were 3.2+/-0.34, 4.0+/-0.22, and 4.9+/-0.20 microg/mL (mean+/-SD), respectively.","Propofol concentration requirement for laryngeal mask airway insertion was highest with the ProSeal, next highest with the Fastrach, and lowest with the Classic type, with target-controlled infusion. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16102683/),[μg] / [ml],3.2,185392,DB00818,Propofol
,16102683,Cp50,"Cp50 of the Classic, Fastrach, and ProSeal LMA insertion were 3.2+/-0.34, 4.0+/-0.22, and 4.9+/-0.20 microg/mL (mean+/-SD), respectively.","Propofol concentration requirement for laryngeal mask airway insertion was highest with the ProSeal, next highest with the Fastrach, and lowest with the Classic type, with target-controlled infusion. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16102683/),[μg] / [ml],4.0,185393,DB00818,Propofol
,16102683,Cp50,"Cp50 of the Classic, Fastrach, and ProSeal LMA insertion were 3.2+/-0.34, 4.0+/-0.22, and 4.9+/-0.20 microg/mL (mean+/-SD), respectively.","Propofol concentration requirement for laryngeal mask airway insertion was highest with the ProSeal, next highest with the Fastrach, and lowest with the Classic type, with target-controlled infusion. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16102683/),[μg] / [ml],4.9,185394,DB00818,Propofol
,15087613,elimination clearance,"Alfentanil decreased the elimination clearance of propofol from 2.1 l/min to 1.9 l/min, the distribution clearance from 2.7 l/min to 2.0 l/min, and the peripheral volume of distribution from 179 l to 141 l.",Mixed-effects modeling of the influence of alfentanil on propofol pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15087613/),[l] / [min],2.1,186485,DB00818,Propofol
,15087613,elimination clearance,"Alfentanil decreased the elimination clearance of propofol from 2.1 l/min to 1.9 l/min, the distribution clearance from 2.7 l/min to 2.0 l/min, and the peripheral volume of distribution from 179 l to 141 l.",Mixed-effects modeling of the influence of alfentanil on propofol pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15087613/),[l] / [min],1.9,186486,DB00818,Propofol
,15087613,distribution clearance,"Alfentanil decreased the elimination clearance of propofol from 2.1 l/min to 1.9 l/min, the distribution clearance from 2.7 l/min to 2.0 l/min, and the peripheral volume of distribution from 179 l to 141 l.",Mixed-effects modeling of the influence of alfentanil on propofol pharmacokinetics. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15087613/),[l] / [min],2.7,186487,DB00818,Propofol
,15087613,distribution clearance,"Alfentanil decreased the elimination clearance of propofol from 2.1 l/min to 1.9 l/min, the distribution clearance from 2.7 l/min to 2.0 l/min, and the peripheral volume of distribution from 179 l to 141 l.",Mixed-effects modeling of the influence of alfentanil on propofol pharmacokinetics. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15087613/),[l] / [min],2.0,186488,DB00818,Propofol
,15087613,peripheral volume of distribution,"Alfentanil decreased the elimination clearance of propofol from 2.1 l/min to 1.9 l/min, the distribution clearance from 2.7 l/min to 2.0 l/min, and the peripheral volume of distribution from 179 l to 141 l.",Mixed-effects modeling of the influence of alfentanil on propofol pharmacokinetics. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15087613/),l,179,186489,DB00818,Propofol
,15087613,peripheral volume of distribution,"Alfentanil decreased the elimination clearance of propofol from 2.1 l/min to 1.9 l/min, the distribution clearance from 2.7 l/min to 2.0 l/min, and the peripheral volume of distribution from 179 l to 141 l.",Mixed-effects modeling of the influence of alfentanil on propofol pharmacokinetics. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15087613/),l,141,186490,DB00818,Propofol
,3063133,respiratory rate,"Ventilation was performed mechanically during the entire operative period (N2O/O2 - FiO2:0.33, tidal volume 10 ml/kg, respiratory rate: 14/min).",[Response of human growth hormone to anesthesia induction with propofol]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3063133/),1/[min],14,187266,DB00818,Propofol
,24738799,ke0,Sixty-four patients were sedated with incremental increases in effect-site target concentration of propofol while using six different ke0 values within the range 0.2-1.2 min(-1).,A novel technique to determine an 'apparent ke0 ' value for use with the Marsh pharmacokinetic model for propofol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24738799/),1/[min],0.2-1.2,189228,DB00818,Propofol
,24738799,',"A median 'apparent ke0' value of 0.61 min(-1) (95% CI 0.37-0.78 min(-1)) led to the greatest probability of achieving a stable clinical effect when the effect-site target was fixed at the effect-site concentration displayed by the target-controlled infusion system, at the time when a desired depth of sedation had been reached.",A novel technique to determine an 'apparent ke0 ' value for use with the Marsh pharmacokinetic model for propofol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24738799/),1/[min],0.61,189229,DB00818,Propofol
,24738799,apparent ke0',"A median 'apparent ke0' value of 0.61 min(-1) (95% CI 0.37-0.78 min(-1)) led to the greatest probability of achieving a stable clinical effect when the effect-site target was fixed at the effect-site concentration displayed by the target-controlled infusion system, at the time when a desired depth of sedation had been reached.",A novel technique to determine an 'apparent ke0 ' value for use with the Marsh pharmacokinetic model for propofol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24738799/),1/[min],0.61,189230,DB00818,Propofol
,22252501,K(i),"Efavirenz potently inhibited UGT1A4-mediated trifluoperazine N-glucuronidation and UGT1A9-mediated propofol glucuronidation, with K(i) values of 2.0 and 9.4 μM, respectively.","Effect of efavirenz on UDP-glucuronosyltransferase 1A1, 1A4, 1A6, and 1A9 activities in human liver microsomes. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22252501/),μM,2.0,189955,DB00818,Propofol
,22252501,K(i),"Efavirenz potently inhibited UGT1A4-mediated trifluoperazine N-glucuronidation and UGT1A9-mediated propofol glucuronidation, with K(i) values of 2.0 and 9.4 μM, respectively.","Effect of efavirenz on UDP-glucuronosyltransferase 1A1, 1A4, 1A6, and 1A9 activities in human liver microsomes. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22252501/),μM,9.4,189956,DB00818,Propofol
,22252501,[I]/,"[I]/K(i) ratios of efavirenz for trifluoperazine N-glucuronidation and propofol glucuronidation were 6.5 and 1.37, respectively.","Effect of efavirenz on UDP-glucuronosyltransferase 1A1, 1A4, 1A6, and 1A9 activities in human liver microsomes. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22252501/),,6.5,189957,DB00818,Propofol
,22252501,[I]/,"[I]/K(i) ratios of efavirenz for trifluoperazine N-glucuronidation and propofol glucuronidation were 6.5 and 1.37, respectively.","Effect of efavirenz on UDP-glucuronosyltransferase 1A1, 1A4, 1A6, and 1A9 activities in human liver microsomes. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22252501/),,1.37,189958,DB00818,Propofol
,22252501,K(i) ratios,"[I]/K(i) ratios of efavirenz for trifluoperazine N-glucuronidation and propofol glucuronidation were 6.5 and 1.37, respectively.","Effect of efavirenz on UDP-glucuronosyltransferase 1A1, 1A4, 1A6, and 1A9 activities in human liver microsomes. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22252501/),,6.5,189959,DB00818,Propofol
,22252501,K(i) ratios,"[I]/K(i) ratios of efavirenz for trifluoperazine N-glucuronidation and propofol glucuronidation were 6.5 and 1.37, respectively.","Effect of efavirenz on UDP-glucuronosyltransferase 1A1, 1A4, 1A6, and 1A9 activities in human liver microsomes. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22252501/),,1.37,189960,DB00818,Propofol
,22252501,K(i),"Efavirenz also moderately inhibited UGT1A1-mediated 17β-estradiol 3-glucuronidation, with a K(i) value of 40.3 μM, but did not inhibit UGT1A6-mediated 1-naphthol glucuronidation.","Effect of efavirenz on UDP-glucuronosyltransferase 1A1, 1A4, 1A6, and 1A9 activities in human liver microsomes. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22252501/),μM,40.3,189961,DB00818,Propofol
,29599632,effect-site concentration (Ce),"After the effect-site concentration (Ce) of remifentanil reached 2 ng/mL, propofol TCI induction was started.",Comparison of the Effects of Dexmedetomidine on the Induction of Anaesthesia Using Marsh and Schnider Pharmacokinetic Models of Propofol Target-Controlled Infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29599632/),[ng] / [ml],2,190627,DB00818,Propofol
,29599632,plasma concentration (Cpt),"Anaesthesia induction commenced in the Marsh group at a target plasma concentration (Cpt) of 2 μg/mL, whereas it started in the Schnider group at a target effect-site concentration (Cet) of 2 μg/mL.",Comparison of the Effects of Dexmedetomidine on the Induction of Anaesthesia Using Marsh and Schnider Pharmacokinetic Models of Propofol Target-Controlled Infusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29599632/),[μg] / [ml],2,190628,DB00818,Propofol
,29599632,effect-site concentration (Cet),"Anaesthesia induction commenced in the Marsh group at a target plasma concentration (Cpt) of 2 μg/mL, whereas it started in the Schnider group at a target effect-site concentration (Cet) of 2 μg/mL.",Comparison of the Effects of Dexmedetomidine on the Induction of Anaesthesia Using Marsh and Schnider Pharmacokinetic Models of Propofol Target-Controlled Infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29599632/),[μg] / [ml],2,190629,DB00818,Propofol
,29599632,target concentration (Ct),"If induction was delayed after 3 min, the target concentration (Ct) was gradually increased to 0.5 μg/mL every 30 sec until successful induction.",Comparison of the Effects of Dexmedetomidine on the Induction of Anaesthesia Using Marsh and Schnider Pharmacokinetic Models of Propofol Target-Controlled Infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29599632/),[μg] / [ml],0.5,190630,DB00818,Propofol
,29599632,Ct,The Ct for successful induction in the Schnider group was significantly lower than in the Marsh group (3.48 [0.90] versus 4.02 [0.67] μg/mL; P = 0.01).,Comparison of the Effects of Dexmedetomidine on the Induction of Anaesthesia Using Marsh and Schnider Pharmacokinetic Models of Propofol Target-Controlled Infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29599632/),[μg] / [ml],3.48,190631,DB00818,Propofol
,29599632,Ct,The Ct for successful induction in the Schnider group was significantly lower than in the Marsh group (3.48 [0.90] versus 4.02 [0.67] μg/mL; P = 0.01).,Comparison of the Effects of Dexmedetomidine on the Induction of Anaesthesia Using Marsh and Schnider Pharmacokinetic Models of Propofol Target-Controlled Infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29599632/),[μg] / [ml],4.02,190632,DB00818,Propofol
,29599632,induction time,The induction time was also shorter in the Schnider group as compared with the Marsh group (134.96 [50.91] versus 161.59 [39.64]) sec; P = 0.02).,Comparison of the Effects of Dexmedetomidine on the Induction of Anaesthesia Using Marsh and Schnider Pharmacokinetic Models of Propofol Target-Controlled Infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29599632/),s,134.96,190633,DB00818,Propofol
,29599632,induction time,The induction time was also shorter in the Schnider group as compared with the Marsh group (134.96 [50.91] versus 161.59 [39.64]) sec; P = 0.02).,Comparison of the Effects of Dexmedetomidine on the Induction of Anaesthesia Using Marsh and Schnider Pharmacokinetic Models of Propofol Target-Controlled Infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29599632/),s,161.59,190634,DB00818,Propofol
,31806432,target plasma concentration (TPC),"Dogs were allocated to group fTCI [target plasma concentration (TPC) 1 ng mL-1] or group PNB (nerve stimulator-guided femoral-sciatic block using 0.2 and 0.1 mL kg-1 of levobupivacaine 0.5%, respectively).",Peripheral nerve block versus systemic analgesia in dogs undergoing tibial plateau levelling osteotomy: Analgesic efficacy and pharmacoeconomics comparison. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31806432/),[ng] / [ml],1,190829,DB00818,Propofol
<,17154474,Mw,Amphiphilic chitosan-based polymers (Mw < 20 kDa) self-assemble in aqueous media at low micromolar concentrations to give previously unknown micellar clusters of 100-300 nm in size.,Carbohydrate-based micelle clusters which enhance hydrophobic drug bioavailability by up to 1 order of magnitude. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17154474/),kda,20,190969,DB00818,Propofol
,11506100,effect compartment concentration at 50% block (EC50),"With the parametric approach, the effect compartment concentration at 50% block (EC50) significantly increased with the dose (136 vs. 157 vs. 209 ng/ml), whereas the effect compartment equilibration rate constant decreased (0.0675 vs. 0.0568 vs. 0.0478 min(-1)).",Concentration-effect relationship of cisatracurium at three different dose levels in the anesthetized patient. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11506100/),[ng] / [ml],136,191220,DB00818,Propofol
,11506100,effect compartment concentration at 50% block (EC50),"With the parametric approach, the effect compartment concentration at 50% block (EC50) significantly increased with the dose (136 vs. 157 vs. 209 ng/ml), whereas the effect compartment equilibration rate constant decreased (0.0675 vs. 0.0568 vs. 0.0478 min(-1)).",Concentration-effect relationship of cisatracurium at three different dose levels in the anesthetized patient. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11506100/),[ng] / [ml],157,191221,DB00818,Propofol
,11506100,effect compartment concentration at 50% block (EC50),"With the parametric approach, the effect compartment concentration at 50% block (EC50) significantly increased with the dose (136 vs. 157 vs. 209 ng/ml), whereas the effect compartment equilibration rate constant decreased (0.0675 vs. 0.0568 vs. 0.0478 min(-1)).",Concentration-effect relationship of cisatracurium at three different dose levels in the anesthetized patient. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11506100/),[ng] / [ml],209,191222,DB00818,Propofol
,11506100,rate constant,"With the parametric approach, the effect compartment concentration at 50% block (EC50) significantly increased with the dose (136 vs. 157 vs. 209 ng/ml), whereas the effect compartment equilibration rate constant decreased (0.0675 vs. 0.0568 vs. 0.0478 min(-1)).",Concentration-effect relationship of cisatracurium at three different dose levels in the anesthetized patient. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11506100/),1/[min],0.0675,191223,DB00818,Propofol
,11506100,rate constant,"With the parametric approach, the effect compartment concentration at 50% block (EC50) significantly increased with the dose (136 vs. 157 vs. 209 ng/ml), whereas the effect compartment equilibration rate constant decreased (0.0675 vs. 0.0568 vs. 0.0478 min(-1)).",Concentration-effect relationship of cisatracurium at three different dose levels in the anesthetized patient. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11506100/),1/[min],0.0568,191224,DB00818,Propofol
,11506100,rate constant,"With the parametric approach, the effect compartment concentration at 50% block (EC50) significantly increased with the dose (136 vs. 157 vs. 209 ng/ml), whereas the effect compartment equilibration rate constant decreased (0.0675 vs. 0.0568 vs. 0.0478 min(-1)).",Concentration-effect relationship of cisatracurium at three different dose levels in the anesthetized patient. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11506100/),1/[min],0.0478,191225,DB00818,Propofol
,10969297,plasma target concentrations,The range of plasma target concentrations was 2-5 microgram/ml for propofol and 0.2-1 ng/ml for sufentanil.,Predictive accuracy of target-controlled propofol and sufentanil coinfusion in long-lasting surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10969297/),[μg] / [ml],2-5,192254,DB00818,Propofol
,10969297,plasma target concentrations,The range of plasma target concentrations was 2-5 microgram/ml for propofol and 0.2-1 ng/ml for sufentanil.,Predictive accuracy of target-controlled propofol and sufentanil coinfusion in long-lasting surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10969297/),[ng] / [ml],0.2-1,192255,DB00818,Propofol
,10969297,wobble,"The wobble values were 11.6% and 22.3% for propofol and sufentanil, respectively.",Predictive accuracy of target-controlled propofol and sufentanil coinfusion in long-lasting surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10969297/),%,11.6,192256,DB00818,Propofol
,10969297,wobble,"The wobble values were 11.6% and 22.3% for propofol and sufentanil, respectively.",Predictive accuracy of target-controlled propofol and sufentanil coinfusion in long-lasting surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10969297/),%,22.3,192257,DB00818,Propofol
,33085795,elimination clearance,"The extrapolated adult (70 kg) population propofol elimination clearance (1.64 L min-1 , estimated relative standard error = 6.02%) is in line with estimates from previous population pharmacokinetic studies.",Population pharmacokinetics of propofol in neonates and infants: Gestational and postnatal age to determine clearance maturation. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33085795/),[l] / [min],1.64,192277,DB00818,Propofol
,12131108,onset time of maximum effect,"With hypothermia, the central volume of distribution of neostigmine decreased by 38%, and onset time of maximum effect increased (4.6 vs. 5.6 min).",The influence of mild hypothermia on the pharmacokinetics and time course of action of neostigmine in anesthetized volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12131108/),min,4.6,192750,DB00818,Propofol
,12131108,onset time of maximum effect,"With hypothermia, the central volume of distribution of neostigmine decreased by 38%, and onset time of maximum effect increased (4.6 vs. 5.6 min).",The influence of mild hypothermia on the pharmacokinetics and time course of action of neostigmine in anesthetized volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12131108/),min,5.6,192751,DB00818,Propofol
,12131108,clearance,"Hypothermia did not change the clearance (696 ml/min), maximum effect, or duration of action of neostigmine.",The influence of mild hypothermia on the pharmacokinetics and time course of action of neostigmine in anesthetized volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12131108/),[ml] / [min],696,192752,DB00818,Propofol
,9084533,central volume of distribution,"The central volume of distribution was 0.228 L/kg, and the inter-compartment transfer rate constants (min-1) were: k10 0.166, K12 0.091, k13 0.124, k21 0.045, and k31 0.0098.",Pharmacokinetics and concentration-effect relationship after propofol infusion. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9084533/),[l] / [kg],0.228,192842,DB00818,Propofol
,9084533,K12,"The central volume of distribution was 0.228 L/kg, and the inter-compartment transfer rate constants (min-1) were: k10 0.166, K12 0.091, k13 0.124, k21 0.045, and k31 0.0098.",Pharmacokinetics and concentration-effect relationship after propofol infusion. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9084533/),,0.091,192843,DB00818,Propofol
,9084533,k21,"The central volume of distribution was 0.228 L/kg, and the inter-compartment transfer rate constants (min-1) were: k10 0.166, K12 0.091, k13 0.124, k21 0.045, and k31 0.0098.",Pharmacokinetics and concentration-effect relationship after propofol infusion. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9084533/),,0.045,192844,DB00818,Propofol
,9084533,k31,"The central volume of distribution was 0.228 L/kg, and the inter-compartment transfer rate constants (min-1) were: k10 0.166, K12 0.091, k13 0.124, k21 0.045, and k31 0.0098.",Pharmacokinetics and concentration-effect relationship after propofol infusion. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9084533/),,0.0098,192845,DB00818,Propofol
,22701256,volume of distribution (V1) clearance (Cl),"Initial volume of distribution (V1) clearance (Cl) and steady state volume of distribution (Vd(ss)) was 13.5 ± 3.3 l, 1.08 ± 0.42 l/min, and 77.69 ± 48.0 l, respectively.",Propofol pharmacokinetics in young healthy Indian subjects. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22701256/),l,13.5,193724,DB00818,Propofol
,22701256,steady state volume of distribution (Vd(ss)),"Initial volume of distribution (V1) clearance (Cl) and steady state volume of distribution (Vd(ss)) was 13.5 ± 3.3 l, 1.08 ± 0.42 l/min, and 77.69 ± 48.0 l, respectively.",Propofol pharmacokinetics in young healthy Indian subjects. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22701256/),l,77.69,193725,DB00818,Propofol
,8531130,plasma concentration,Our results support the hypothesis that a 'threshold' plasma concentration (1.7-1.8 micrograms/ml) exists for propofol anesthesia.,Effects of propofol on nociceptive response and power spectra of electroencephalographic and systemic arterial pressure signals in the rat: correlation with plasma concentration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8531130/),[μg] / [ml],1.7-1.8,194115,DB00818,Propofol
,16428538,central volume of distribution,Pharmacokinetic population analysis showed a small central volume of distribution (3.55 L) and reduced clearance (1.31 L/min) for propofol.,The performance of a target-controlled infusion of propofol in combination with remifentanil: a clinical investigation with two propofol formulations. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16428538/),l,3.55,194841,DB00818,Propofol
,16428538,clearance,Pharmacokinetic population analysis showed a small central volume of distribution (3.55 L) and reduced clearance (1.31 L/min) for propofol.,The performance of a target-controlled infusion of propofol in combination with remifentanil: a clinical investigation with two propofol formulations. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16428538/),[l] / [min],1.31,194842,DB00818,Propofol
,16492821,Onset time,"Onset time was 2.5 +/- 0.8 min, recovery to 25% of baseline twitch height was 37.6 +/- 10.2 min, and the 25%-75% recovery index was 10.9 +/- 3.7 min.",Pharmacokinetics and pharmacodynamics of a 0.1 mg/kg dose of cisatracurium besylate in children during N2O/O2/propofol anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16492821/),min,2.5,197103,DB00818,Propofol
,16492821,recovery to 25% of baseline twitch height,"Onset time was 2.5 +/- 0.8 min, recovery to 25% of baseline twitch height was 37.6 +/- 10.2 min, and the 25%-75% recovery index was 10.9 +/- 3.7 min.",Pharmacokinetics and pharmacodynamics of a 0.1 mg/kg dose of cisatracurium besylate in children during N2O/O2/propofol anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16492821/),min,37.6,197104,DB00818,Propofol
,16492821,25%-75% recovery index,"Onset time was 2.5 +/- 0.8 min, recovery to 25% of baseline twitch height was 37.6 +/- 10.2 min, and the 25%-75% recovery index was 10.9 +/- 3.7 min.",Pharmacokinetics and pharmacodynamics of a 0.1 mg/kg dose of cisatracurium besylate in children during N2O/O2/propofol anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16492821/),min,10.9,197105,DB00818,Propofol
,16492821,Distribution,"Distribution and elimination half-lives were 3.5 +/- 0.9 min and 22.9 +/- 4.5 min, respectively.",Pharmacokinetics and pharmacodynamics of a 0.1 mg/kg dose of cisatracurium besylate in children during N2O/O2/propofol anesthesia. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16492821/),min,3.5,197106,DB00818,Propofol
,16492821,elimination half-lives,"Distribution and elimination half-lives were 3.5 +/- 0.9 min and 22.9 +/- 4.5 min, respectively.",Pharmacokinetics and pharmacodynamics of a 0.1 mg/kg dose of cisatracurium besylate in children during N2O/O2/propofol anesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16492821/),min,22.9,197107,DB00818,Propofol
,16492821,Steady-state volume of distribution,Steady-state volume of distribution (0.207 +/- 0.031 L/kg) and total body clearance (6.8 +/- 0.7 mL/min/kg) were significantly larger than those published for adults.,Pharmacokinetics and pharmacodynamics of a 0.1 mg/kg dose of cisatracurium besylate in children during N2O/O2/propofol anesthesia. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16492821/),[l] / [kg],0.207,197108,DB00818,Propofol
,16492821,total body clearance,Steady-state volume of distribution (0.207 +/- 0.031 L/kg) and total body clearance (6.8 +/- 0.7 mL/min/kg) were significantly larger than those published for adults.,Pharmacokinetics and pharmacodynamics of a 0.1 mg/kg dose of cisatracurium besylate in children during N2O/O2/propofol anesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16492821/),[ml] / [kg·min],6.8,197109,DB00818,Propofol
,16492821,rate constant,"Although the plasma-effect compartment equilibration rate constant was twofold faster (0.115 +/- 0.025 min(-1)) than that published for cisatracurium in adults, the effect compartment concentration corresponding to 50% block was similar (129 +/- 27 ng/mL).",Pharmacokinetics and pharmacodynamics of a 0.1 mg/kg dose of cisatracurium besylate in children during N2O/O2/propofol anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16492821/),1/[min],0.115,197110,DB00818,Propofol
,6979270,awakening,"After a single injection the awakening concentration was independent of dose, with a mean value of 1.04 micrograms/ml.",Blood disoprofol levels in anesthetised patients. Correlation of concentrations after single or repeated doses with hypnotic activity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6979270/),[μg] / [ml],1.04,197874,DB00818,Propofol
,6979270,concentration,"After a single injection the awakening concentration was independent of dose, with a mean value of 1.04 micrograms/ml.",Blood disoprofol levels in anesthetised patients. Correlation of concentrations after single or repeated doses with hypnotic activity. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6979270/),[μg] / [ml],1.04,197875,DB00818,Propofol
,10416064,recovery,The recovery of propofol in serum samples from the lowest to the highest concentration ranged from 96.84 to 100.16% (n = 5).,Chromatographic assay and pharmacokinetic studies of propofol in human serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10416064/),%,96.84 to 100.16,198849,DB00818,Propofol
,15957725,Time to eye-opening,"Time to eye-opening was 11.63+/-4.2 min in Caucasians, 13.23+/-4.9 min in Chinese, 16.97+/-5.2 min in Malays and 22.3+/-6.6 min in Indians.","Comparison of propofol consumption and recovery time in Caucasians from Italy, with Chinese, Malays and Indians from Malaysia. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15957725/),min,11.63,199186,DB00818,Propofol
,15957725,Time to eye-opening,"Time to eye-opening was 11.63+/-4.2 min in Caucasians, 13.23+/-4.9 min in Chinese, 16.97+/-5.2 min in Malays and 22.3+/-6.6 min in Indians.","Comparison of propofol consumption and recovery time in Caucasians from Italy, with Chinese, Malays and Indians from Malaysia. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15957725/),min,13.23,199187,DB00818,Propofol
,15957725,Time to eye-opening,"Time to eye-opening was 11.63+/-4.2 min in Caucasians, 13.23+/-4.9 min in Chinese, 16.97+/-5.2 min in Malays and 22.3+/-6.6 min in Indians.","Comparison of propofol consumption and recovery time in Caucasians from Italy, with Chinese, Malays and Indians from Malaysia. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15957725/),min,16.97,199188,DB00818,Propofol
,15957725,Time to eye-opening,"Time to eye-opening was 11.63+/-4.2 min in Caucasians, 13.23+/-4.9 min in Chinese, 16.97+/-5.2 min in Malays and 22.3+/-6.6 min in Indians.","Comparison of propofol consumption and recovery time in Caucasians from Italy, with Chinese, Malays and Indians from Malaysia. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15957725/),min,22.3,199189,DB00818,Propofol
,18179652,plasma concentration,Mean DMED plasma concentration ranged from 0.23 to 0.47 ng mL(-1) for both groups during the 24-hour CRI with a mean elimination half-life of approximately 0.46 hour.,Dexmedetomidine constant rate infusion for 24 hours during and after propofol or isoflurane anaesthesia in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18179652/),[ng] / [ml],0.23 to 0.47,199977,DB00818,Propofol
,18179652,elimination half-life,Mean DMED plasma concentration ranged from 0.23 to 0.47 ng mL(-1) for both groups during the 24-hour CRI with a mean elimination half-life of approximately 0.46 hour.,Dexmedetomidine constant rate infusion for 24 hours during and after propofol or isoflurane anaesthesia in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18179652/),h,0.46,199978,DB00818,Propofol
,18027600,half-time,"For this reason the context-sensitive half-time of remifentanil is only 3-5 min, irrespective of the duration of infusion; it is thus context-INsensitive.",[Remifentanil--could it open a new era in our anesthesia practice in Japan?]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18027600/),min,3-5,200144,DB00818,Propofol
,32448336,clearance,"For IV, IM and SC administration, clearance was 1.29, 1.65 and 1.40 L/hour/kg, volume of distribution was 6.8, 14.2 and 40.1 L/kg, the elimination half-life was 3.7, 5.7, 22 h, and the area under the plasma concentration-time curved extrapolated to infinity was 15.7, 12.4 and 16.4 ng/mL/hour, respectively.","Pharmacokinetics and analgesic effects of intravenous, intramuscular or subcutaneous buprenorphine in dogs undergoing ovariohysterectomy: a randomized, prospective, masked, clinical trial. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32448336/),[l] / [h·kg],1.29,200615,DB00818,Propofol
,32448336,clearance,"For IV, IM and SC administration, clearance was 1.29, 1.65 and 1.40 L/hour/kg, volume of distribution was 6.8, 14.2 and 40.1 L/kg, the elimination half-life was 3.7, 5.7, 22 h, and the area under the plasma concentration-time curved extrapolated to infinity was 15.7, 12.4 and 16.4 ng/mL/hour, respectively.","Pharmacokinetics and analgesic effects of intravenous, intramuscular or subcutaneous buprenorphine in dogs undergoing ovariohysterectomy: a randomized, prospective, masked, clinical trial. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32448336/),[l] / [h·kg],1.65,200616,DB00818,Propofol
,32448336,clearance,"For IV, IM and SC administration, clearance was 1.29, 1.65 and 1.40 L/hour/kg, volume of distribution was 6.8, 14.2 and 40.1 L/kg, the elimination half-life was 3.7, 5.7, 22 h, and the area under the plasma concentration-time curved extrapolated to infinity was 15.7, 12.4 and 16.4 ng/mL/hour, respectively.","Pharmacokinetics and analgesic effects of intravenous, intramuscular or subcutaneous buprenorphine in dogs undergoing ovariohysterectomy: a randomized, prospective, masked, clinical trial. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32448336/),[l] / [h·kg],1.40,200617,DB00818,Propofol
,32448336,volume of distribution,"For IV, IM and SC administration, clearance was 1.29, 1.65 and 1.40 L/hour/kg, volume of distribution was 6.8, 14.2 and 40.1 L/kg, the elimination half-life was 3.7, 5.7, 22 h, and the area under the plasma concentration-time curved extrapolated to infinity was 15.7, 12.4 and 16.4 ng/mL/hour, respectively.","Pharmacokinetics and analgesic effects of intravenous, intramuscular or subcutaneous buprenorphine in dogs undergoing ovariohysterectomy: a randomized, prospective, masked, clinical trial. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32448336/),[l] / [kg],6.8,200618,DB00818,Propofol
,32448336,volume of distribution,"For IV, IM and SC administration, clearance was 1.29, 1.65 and 1.40 L/hour/kg, volume of distribution was 6.8, 14.2 and 40.1 L/kg, the elimination half-life was 3.7, 5.7, 22 h, and the area under the plasma concentration-time curved extrapolated to infinity was 15.7, 12.4 and 16.4 ng/mL/hour, respectively.","Pharmacokinetics and analgesic effects of intravenous, intramuscular or subcutaneous buprenorphine in dogs undergoing ovariohysterectomy: a randomized, prospective, masked, clinical trial. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32448336/),[l] / [kg],14.2,200619,DB00818,Propofol
,32448336,volume of distribution,"For IV, IM and SC administration, clearance was 1.29, 1.65 and 1.40 L/hour/kg, volume of distribution was 6.8, 14.2 and 40.1 L/kg, the elimination half-life was 3.7, 5.7, 22 h, and the area under the plasma concentration-time curved extrapolated to infinity was 15.7, 12.4 and 16.4 ng/mL/hour, respectively.","Pharmacokinetics and analgesic effects of intravenous, intramuscular or subcutaneous buprenorphine in dogs undergoing ovariohysterectomy: a randomized, prospective, masked, clinical trial. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32448336/),[l] / [kg],40.1,200620,DB00818,Propofol
,32448336,elimination half-life,"For IV, IM and SC administration, clearance was 1.29, 1.65 and 1.40 L/hour/kg, volume of distribution was 6.8, 14.2 and 40.1 L/kg, the elimination half-life was 3.7, 5.7, 22 h, and the area under the plasma concentration-time curved extrapolated to infinity was 15.7, 12.4 and 16.4 ng/mL/hour, respectively.","Pharmacokinetics and analgesic effects of intravenous, intramuscular or subcutaneous buprenorphine in dogs undergoing ovariohysterectomy: a randomized, prospective, masked, clinical trial. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32448336/),h,3.7,200621,DB00818,Propofol
,32448336,elimination half-life,"For IV, IM and SC administration, clearance was 1.29, 1.65 and 1.40 L/hour/kg, volume of distribution was 6.8, 14.2 and 40.1 L/kg, the elimination half-life was 3.7, 5.7, 22 h, and the area under the plasma concentration-time curved extrapolated to infinity was 15.7, 12.4 and 16.4 ng/mL/hour, respectively.","Pharmacokinetics and analgesic effects of intravenous, intramuscular or subcutaneous buprenorphine in dogs undergoing ovariohysterectomy: a randomized, prospective, masked, clinical trial. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32448336/),h,5.7,200622,DB00818,Propofol
,32448336,elimination half-life,"For IV, IM and SC administration, clearance was 1.29, 1.65 and 1.40 L/hour/kg, volume of distribution was 6.8, 14.2 and 40.1 L/kg, the elimination half-life was 3.7, 5.7, 22 h, and the area under the plasma concentration-time curved extrapolated to infinity was 15.7, 12.4 and 16.4 ng/mL/hour, respectively.","Pharmacokinetics and analgesic effects of intravenous, intramuscular or subcutaneous buprenorphine in dogs undergoing ovariohysterectomy: a randomized, prospective, masked, clinical trial. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32448336/),h,22,200623,DB00818,Propofol
,32448336,area under the plasma concentration-time curved extrapolated to infinity,"For IV, IM and SC administration, clearance was 1.29, 1.65 and 1.40 L/hour/kg, volume of distribution was 6.8, 14.2 and 40.1 L/kg, the elimination half-life was 3.7, 5.7, 22 h, and the area under the plasma concentration-time curved extrapolated to infinity was 15.7, 12.4 and 16.4 ng/mL/hour, respectively.","Pharmacokinetics and analgesic effects of intravenous, intramuscular or subcutaneous buprenorphine in dogs undergoing ovariohysterectomy: a randomized, prospective, masked, clinical trial. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32448336/),[ng] / [h·ml],15.7,200624,DB00818,Propofol
,32448336,area under the plasma concentration-time curved extrapolated to infinity,"For IV, IM and SC administration, clearance was 1.29, 1.65 and 1.40 L/hour/kg, volume of distribution was 6.8, 14.2 and 40.1 L/kg, the elimination half-life was 3.7, 5.7, 22 h, and the area under the plasma concentration-time curved extrapolated to infinity was 15.7, 12.4 and 16.4 ng/mL/hour, respectively.","Pharmacokinetics and analgesic effects of intravenous, intramuscular or subcutaneous buprenorphine in dogs undergoing ovariohysterectomy: a randomized, prospective, masked, clinical trial. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32448336/),[ng] / [h·ml],12.4,200625,DB00818,Propofol
,32448336,area under the plasma concentration-time curved extrapolated to infinity,"For IV, IM and SC administration, clearance was 1.29, 1.65 and 1.40 L/hour/kg, volume of distribution was 6.8, 14.2 and 40.1 L/kg, the elimination half-life was 3.7, 5.7, 22 h, and the area under the plasma concentration-time curved extrapolated to infinity was 15.7, 12.4 and 16.4 ng/mL/hour, respectively.","Pharmacokinetics and analgesic effects of intravenous, intramuscular or subcutaneous buprenorphine in dogs undergoing ovariohysterectomy: a randomized, prospective, masked, clinical trial. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32448336/),[ng] / [h·ml],16.4,200626,DB00818,Propofol
,32448336,Bioavailability,"Bioavailability for IM and SC was 62.6 and 40%, respectively.","Pharmacokinetics and analgesic effects of intravenous, intramuscular or subcutaneous buprenorphine in dogs undergoing ovariohysterectomy: a randomized, prospective, masked, clinical trial. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32448336/),%,62.6,200627,DB00818,Propofol
,32448336,Bioavailability,"Bioavailability for IM and SC was 62.6 and 40%, respectively.","Pharmacokinetics and analgesic effects of intravenous, intramuscular or subcutaneous buprenorphine in dogs undergoing ovariohysterectomy: a randomized, prospective, masked, clinical trial. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32448336/),%,40,200628,DB00818,Propofol
,32448336,Maximum plasma concentrations,"Maximum plasma concentrations of buprenorphine were 6.2 and 1.3 ng/mL at 0.14 and 0.33 h after IM and SC administration, respectively.","Pharmacokinetics and analgesic effects of intravenous, intramuscular or subcutaneous buprenorphine in dogs undergoing ovariohysterectomy: a randomized, prospective, masked, clinical trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32448336/),[ng] / [ml],6.2,200629,DB00818,Propofol
,32448336,Maximum plasma concentrations,"Maximum plasma concentrations of buprenorphine were 6.2 and 1.3 ng/mL at 0.14 and 0.33 h after IM and SC administration, respectively.","Pharmacokinetics and analgesic effects of intravenous, intramuscular or subcutaneous buprenorphine in dogs undergoing ovariohysterectomy: a randomized, prospective, masked, clinical trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32448336/),[ng] / [ml],1.3,200630,DB00818,Propofol
,10383543,clearance (CL),"The average values for clearance (CL), volume of distribution at steady-state (Vd,ss ), elimination half-life (t1/2,z ) and distribution half-life (t1/2, lambda2) observed in the three groups were 32+/-1.5 ml kg-1 min-1, 2. 0+/-0.18 l kg-1, 95+/-5.6 min and 3.4+/-0.20 min, respectively (mean+/-s.e.mean, n=24) and no significant differences were noted between the three formulations (P >0.05).","Pharmacokinetics, induction of anaesthesia and safety characteristics of propofol 6% SAZN vs propofol 1% SAZN and Diprivan-10 after bolus injection. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10383543/),[ml] / [kg·min],32,203431,DB00818,Propofol
,10383543,"volume of distribution at steady-state (Vd,ss )","The average values for clearance (CL), volume of distribution at steady-state (Vd,ss ), elimination half-life (t1/2,z ) and distribution half-life (t1/2, lambda2) observed in the three groups were 32+/-1.5 ml kg-1 min-1, 2. 0+/-0.18 l kg-1, 95+/-5.6 min and 3.4+/-0.20 min, respectively (mean+/-s.e.mean, n=24) and no significant differences were noted between the three formulations (P >0.05).","Pharmacokinetics, induction of anaesthesia and safety characteristics of propofol 6% SAZN vs propofol 1% SAZN and Diprivan-10 after bolus injection. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10383543/),[l] / [kg],2. 0,203432,DB00818,Propofol
,10383543,"volume of distribution at steady-state (Vd,ss )","The average values for clearance (CL), volume of distribution at steady-state (Vd,ss ), elimination half-life (t1/2,z ) and distribution half-life (t1/2, lambda2) observed in the three groups were 32+/-1.5 ml kg-1 min-1, 2. 0+/-0.18 l kg-1, 95+/-5.6 min and 3.4+/-0.20 min, respectively (mean+/-s.e.mean, n=24) and no significant differences were noted between the three formulations (P >0.05).","Pharmacokinetics, induction of anaesthesia and safety characteristics of propofol 6% SAZN vs propofol 1% SAZN and Diprivan-10 after bolus injection. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10383543/),min,95,203433,DB00818,Propofol
,10383543,"elimination half-life (t1/2,z )","The average values for clearance (CL), volume of distribution at steady-state (Vd,ss ), elimination half-life (t1/2,z ) and distribution half-life (t1/2, lambda2) observed in the three groups were 32+/-1.5 ml kg-1 min-1, 2. 0+/-0.18 l kg-1, 95+/-5.6 min and 3.4+/-0.20 min, respectively (mean+/-s.e.mean, n=24) and no significant differences were noted between the three formulations (P >0.05).","Pharmacokinetics, induction of anaesthesia and safety characteristics of propofol 6% SAZN vs propofol 1% SAZN and Diprivan-10 after bolus injection. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10383543/),[l] / [kg],2. 0,203434,DB00818,Propofol
,10383543,"elimination half-life (t1/2,z )","The average values for clearance (CL), volume of distribution at steady-state (Vd,ss ), elimination half-life (t1/2,z ) and distribution half-life (t1/2, lambda2) observed in the three groups were 32+/-1.5 ml kg-1 min-1, 2. 0+/-0.18 l kg-1, 95+/-5.6 min and 3.4+/-0.20 min, respectively (mean+/-s.e.mean, n=24) and no significant differences were noted between the three formulations (P >0.05).","Pharmacokinetics, induction of anaesthesia and safety characteristics of propofol 6% SAZN vs propofol 1% SAZN and Diprivan-10 after bolus injection. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10383543/),min,95,203435,DB00818,Propofol
,10383543,"distribution half-life (t1/2, lambda2)","The average values for clearance (CL), volume of distribution at steady-state (Vd,ss ), elimination half-life (t1/2,z ) and distribution half-life (t1/2, lambda2) observed in the three groups were 32+/-1.5 ml kg-1 min-1, 2. 0+/-0.18 l kg-1, 95+/-5.6 min and 3.4+/-0.20 min, respectively (mean+/-s.e.mean, n=24) and no significant differences were noted between the three formulations (P >0.05).","Pharmacokinetics, induction of anaesthesia and safety characteristics of propofol 6% SAZN vs propofol 1% SAZN and Diprivan-10 after bolus injection. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10383543/),min,3.4,203436,DB00818,Propofol
,10383543,"half-life of the additional initial distribution phase (t1/2,lambda1 )","The half-life of the additional initial distribution phase (t1/2,lambda1 ) in all subjects ranged from 0.1 to 0.6 min.","Pharmacokinetics, induction of anaesthesia and safety characteristics of propofol 6% SAZN vs propofol 1% SAZN and Diprivan-10 after bolus injection. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10383543/),min,0.1 to 0.6,203437,DB00818,Propofol
,10383543,induction time,"The induction time did not vary between the three formulations and the average induction time observed in the three groups was 51+/-1.3 s which corresponded to an induction dose of propofol of 2.1+/-0.06 mg kg-1 (mean+/-s.e. mean, n=24).","Pharmacokinetics, induction of anaesthesia and safety characteristics of propofol 6% SAZN vs propofol 1% SAZN and Diprivan-10 after bolus injection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10383543/),s,51,203438,DB00818,Propofol
,24738800,ke0,We studied the use of a new ke0 value (0.6 min(-1)) for the Marsh pharmacokinetic model for propofol.,Induction of general anaesthesia by effect-site target-controlled infusion of propofol: influence of pharmacokinetic model and ke0 value. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24738800/),1/[min],0.6,203844,DB00818,Propofol
,24738800,ke0,"Median (IQR [range]) induction times were shorter with the Marsh model in effect-site control mode with a ke0 of either 0.6 min(-1) (81 (61-101 [49-302])s, p < 0.01), or 1.2 min(-1) (78 (68-208 [51-325])s, p < 0.05), than with the Marsh model in blood concentration control (132 (90-246 [57-435])).",Induction of general anaesthesia by effect-site target-controlled infusion of propofol: influence of pharmacokinetic model and ke0 value. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24738800/),1/[min],0.6,203845,DB00818,Propofol
,24738800,ke0,"Median (IQR [range]) induction times were shorter with the Marsh model in effect-site control mode with a ke0 of either 0.6 min(-1) (81 (61-101 [49-302])s, p < 0.01), or 1.2 min(-1) (78 (68-208 [51-325])s, p < 0.05), than with the Marsh model in blood concentration control (132 (90-246 [57-435])).",Induction of general anaesthesia by effect-site target-controlled infusion of propofol: influence of pharmacokinetic model and ke0 value. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24738800/),1/[min],1.2,203846,DB00818,Propofol
,24738800,ke0,"Median (IQR [range]) induction times were shorter with the Marsh model in effect-site control mode with a ke0 of either 0.6 min(-1) (81 (61-101 [49-302])s, p < 0.01), or 1.2 min(-1) (78 (68-208 [51-325])s, p < 0.05), than with the Marsh model in blood concentration control (132 (90-246 [57-435])).",Induction of general anaesthesia by effect-site target-controlled infusion of propofol: influence of pharmacokinetic model and ke0 value. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24738800/),,132,203847,DB00818,Propofol
,24738800,induction times,"The Schnider model in effect-site control produced induction times that were longer (298 (282-398 [58-513])s) than those observed with the Marsh model in blood control (p < 0.05), or either effect-site control mode (p < 0.001).",Induction of general anaesthesia by effect-site target-controlled infusion of propofol: influence of pharmacokinetic model and ke0 value. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24738800/),s,298,203848,DB00818,Propofol
,19690247,duration of action,"The median (range) duration of action was 32 (18-49), 38 (25-66), and 42 (24-66) min in the IBW, CBW20%, and CBW40% groups, respectively (P = 0.001 for comparison of the IBW and CBW40% group).",Should dosing of rocuronium in obese patients be based on ideal or corrected body weight? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19690247/),min,32,204201,DB00818,Propofol
,19690247,duration of action,"The median (range) duration of action was 32 (18-49), 38 (25-66), and 42 (24-66) min in the IBW, CBW20%, and CBW40% groups, respectively (P = 0.001 for comparison of the IBW and CBW40% group).",Should dosing of rocuronium in obese patients be based on ideal or corrected body weight? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19690247/),min,38,204202,DB00818,Propofol
,19690247,duration of action,"The median (range) duration of action was 32 (18-49), 38 (25-66), and 42 (24-66) min in the IBW, CBW20%, and CBW40% groups, respectively (P = 0.001 for comparison of the IBW and CBW40% group).",Should dosing of rocuronium in obese patients be based on ideal or corrected body weight? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19690247/),min,42,204203,DB00818,Propofol
,19690247,onset time,There were no significant differences in onset time (85 vs 84 vs 80 s) or in intubation conditions 90 s after administration of rocuronium.,Should dosing of rocuronium in obese patients be based on ideal or corrected body weight? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19690247/),s,85,204204,DB00818,Propofol
,19690247,onset time,There were no significant differences in onset time (85 vs 84 vs 80 s) or in intubation conditions 90 s after administration of rocuronium.,Should dosing of rocuronium in obese patients be based on ideal or corrected body weight? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19690247/),s,84,204205,DB00818,Propofol
,19690247,onset time,There were no significant differences in onset time (85 vs 84 vs 80 s) or in intubation conditions 90 s after administration of rocuronium.,Should dosing of rocuronium in obese patients be based on ideal or corrected body weight? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19690247/),s,80,204206,DB00818,Propofol
,8310787,clearance,"Propofol clearance (1.53 [1.02-2.10] L.min-1 x kg-1 versus 1.65 [1.39-1.78] L.min-1 x kg-1 in normal patients), and half-lives elimination were not modified by renal failure.",Pharmacokinetics of propofol and its conjugates after continuous infusion in normal and in renal failure patients: a preliminary study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8310787/),[l] / [kg·min],1.53,205318,DB00818,Propofol
,8310787,clearance,"Propofol clearance (1.53 [1.02-2.10] L.min-1 x kg-1 versus 1.65 [1.39-1.78] L.min-1 x kg-1 in normal patients), and half-lives elimination were not modified by renal failure.",Pharmacokinetics of propofol and its conjugates after continuous infusion in normal and in renal failure patients: a preliminary study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8310787/),[l] / [kg·min],1.65,205319,DB00818,Propofol
,8310787,volume of distribution at steady state,"Renal failure patients exhibited a higher volume of distribution at steady state as compared to normal patients (19.28 [11.71-76.81] L.kg-1 versus 8.60 [6.58-9.81] L.kg-1, p < 0.05).",Pharmacokinetics of propofol and its conjugates after continuous infusion in normal and in renal failure patients: a preliminary study. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8310787/),[l] / [kg],19.28,205320,DB00818,Propofol
,8310787,volume of distribution at steady state,"Renal failure patients exhibited a higher volume of distribution at steady state as compared to normal patients (19.28 [11.71-76.81] L.kg-1 versus 8.60 [6.58-9.81] L.kg-1, p < 0.05).",Pharmacokinetics of propofol and its conjugates after continuous infusion in normal and in renal failure patients: a preliminary study. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8310787/),[l] / [kg],8.60,205321,DB00818,Propofol
,20498770,K(e0)s,K(e0)s from these two methods were 0.3692 and 0.3788/min.,Titration of the plasma effect site equilibrium rate constant of propofol; a link method of 'Concentration-Probability-Time'. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20498770/),1/[min],0.3692,205582,DB00818,Propofol
,20498770,K(e0)s,K(e0)s from these two methods were 0.3692 and 0.3788/min.,Titration of the plasma effect site equilibrium rate constant of propofol; a link method of 'Concentration-Probability-Time'. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20498770/),1/[min],0.3788,205583,DB00818,Propofol
,9563075,clearance (Cl),"The average values for clearance (Cl), volume of distribution at steady-state (Vd,ss) and terminal half-life (t1/2, lambda 2) were 107 +/- 4 ml/min/kg, 1.38 +/- 0.06 l/kg and 16 +/- 1 min, respectively (mean +/- S.E. n = 22).",Influence of different fat emulsion-based intravenous formulations on the pharmacokinetics and pharmacodynamics of propofol. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9563075/),[ml] / [kg·min],107,206482,DB00818,Propofol
,9563075,"volume of distribution at steady-state (Vd,ss)","The average values for clearance (Cl), volume of distribution at steady-state (Vd,ss) and terminal half-life (t1/2, lambda 2) were 107 +/- 4 ml/min/kg, 1.38 +/- 0.06 l/kg and 16 +/- 1 min, respectively (mean +/- S.E. n = 22).",Influence of different fat emulsion-based intravenous formulations on the pharmacokinetics and pharmacodynamics of propofol. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9563075/),[l] / [kg],1.38,206483,DB00818,Propofol
,9563075,"terminal half-life (t1/2, lambda 2)","The average values for clearance (Cl), volume of distribution at steady-state (Vd,ss) and terminal half-life (t1/2, lambda 2) were 107 +/- 4 ml/min/kg, 1.38 +/- 0.06 l/kg and 16 +/- 1 min, respectively (mean +/- S.E. n = 22).",Influence of different fat emulsion-based intravenous formulations on the pharmacokinetics and pharmacodynamics of propofol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9563075/),min,16,206484,DB00818,Propofol
,7978186,peak plasma concentrations,The peak plasma concentrations were P 10.6 +/- 1.5 micrograms.,[Total intravenous anesthesia with methohexital-alfentanil or propofol-alfentanil in hypogastric laparotomy. Clinical aspects and the effects of stress reaction]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7978186/),μg,10.6,207603,DB00818,Propofol
,7978186,M,ml-1 and M 12.4 +/- 2.6 micrograms.,[Total intravenous anesthesia with methohexital-alfentanil or propofol-alfentanil in hypogastric laparotomy. Clinical aspects and the effects of stress reaction]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7978186/),μg,12.4,207604,DB00818,Propofol
,7978186,recovery times,"The median recovery times were Iso 15 min, M-A 50 min, and P-A 25 min (P < 0.05).",[Total intravenous anesthesia with methohexital-alfentanil or propofol-alfentanil in hypogastric laparotomy. Clinical aspects and the effects of stress reaction]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7978186/),min,15,207605,DB00818,Propofol
,7978186,recovery times,"The median recovery times were Iso 15 min, M-A 50 min, and P-A 25 min (P < 0.05).",[Total intravenous anesthesia with methohexital-alfentanil or propofol-alfentanil in hypogastric laparotomy. Clinical aspects and the effects of stress reaction]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7978186/),min,50,207606,DB00818,Propofol
,7978186,recovery times,"The median recovery times were Iso 15 min, M-A 50 min, and P-A 25 min (P < 0.05).",[Total intravenous anesthesia with methohexital-alfentanil or propofol-alfentanil in hypogastric laparotomy. Clinical aspects and the effects of stress reaction]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7978186/),min,25,207607,DB00818,Propofol
,17555608,Clearance,Clearance varied from 9.1 to 55.8 mL min-1 kg-1.,An investigation of potential genetic determinants of propofol requirements and recovery from anaesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17555608/),[ml] / [kg·min],9.1 to 55.8,208272,DB00818,Propofol
,12067002,infusion rates,"The infusion rates (mg kg(-1) h(-1)) of propofol were (mean (SD)) 4.1 (1.0) and 4.5 (1.3) for males and females, respectively.",Propofol metabolites in man following propofol induction and maintenance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12067002/),[mg] / [h·kg],4.1,208652,DB00818,Propofol
,12067002,infusion rates,"The infusion rates (mg kg(-1) h(-1)) of propofol were (mean (SD)) 4.1 (1.0) and 4.5 (1.3) for males and females, respectively.",Propofol metabolites in man following propofol induction and maintenance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12067002/),[mg] / [h·kg],4.5,208653,DB00818,Propofol
,12067002,Total recovery,"Total recovery of propofol in the metabolites studied amounts to 38%, of which 62% was via the PG metabolite and 38% via cytochrome P-450.",Propofol metabolites in man following propofol induction and maintenance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12067002/),%,38,208654,DB00818,Propofol
,12067002,Total recovery,"Total recovery of propofol in the metabolites studied amounts to 38%, of which 62% was via the PG metabolite and 38% via cytochrome P-450.",Propofol metabolites in man following propofol induction and maintenance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12067002/),%,62,208655,DB00818,Propofol
,15674525,infusion rate,"The infusion rate of propofol for achieving the sedation score of level 3 (drowsy, responds to verbal stimulation) was 1.74 +/- 0.82 mg kg(-1) h(-1) (mean +/- SD, n = 7) when the plasma propofol concentration and the total body clearance were 0.85 +/- 0.24 microg ml(-1) and 1.83 +/- 0.54 l min(-1) (mean +/- SD, n =7), respectively.",Plasma concentration for optimal sedation and total body clearance of propofol in patients after esophagectomy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15674525/),[mg] / [h·kg],1.74,209673,DB00818,Propofol
,15674525,concentration,"The infusion rate of propofol for achieving the sedation score of level 3 (drowsy, responds to verbal stimulation) was 1.74 +/- 0.82 mg kg(-1) h(-1) (mean +/- SD, n = 7) when the plasma propofol concentration and the total body clearance were 0.85 +/- 0.24 microg ml(-1) and 1.83 +/- 0.54 l min(-1) (mean +/- SD, n =7), respectively.",Plasma concentration for optimal sedation and total body clearance of propofol in patients after esophagectomy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15674525/),[μg] / [ml],0.85,209674,DB00818,Propofol
,15674525,total body clearance,"The infusion rate of propofol for achieving the sedation score of level 3 (drowsy, responds to verbal stimulation) was 1.74 +/- 0.82 mg kg(-1) h(-1) (mean +/- SD, n = 7) when the plasma propofol concentration and the total body clearance were 0.85 +/- 0.24 microg ml(-1) and 1.83 +/- 0.54 l min(-1) (mean +/- SD, n =7), respectively.",Plasma concentration for optimal sedation and total body clearance of propofol in patients after esophagectomy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15674525/),[l] / [min],1.83,209675,DB00818,Propofol
,19931154,ICG-PDR,"Baseline ICG-PDR levels of group P compared to group D were 24.7 +/- 14.4 vs 22.2 +/- 10.7, respectively, and after the study, ICG-PDR levels (26.5 +/- 13.7 vs 23.7 +/- 12.4) did not differ in groups (P > .05).",Effects of propofol and dexmedetomidine on indocyanine green elimination assessed with LIMON to patients with early septic shock: a pilot study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19931154/),,24.7,209966,DB00818,Propofol
,19931154,ICG-PDR,"Baseline ICG-PDR levels of group P compared to group D were 24.7 +/- 14.4 vs 22.2 +/- 10.7, respectively, and after the study, ICG-PDR levels (26.5 +/- 13.7 vs 23.7 +/- 12.4) did not differ in groups (P > .05).",Effects of propofol and dexmedetomidine on indocyanine green elimination assessed with LIMON to patients with early septic shock: a pilot study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19931154/),,22.2,209967,DB00818,Propofol
,19931154,ICG-PDR,"Baseline ICG-PDR levels of group P compared to group D were 24.7 +/- 14.4 vs 22.2 +/- 10.7, respectively, and after the study, ICG-PDR levels (26.5 +/- 13.7 vs 23.7 +/- 12.4) did not differ in groups (P > .05).",Effects of propofol and dexmedetomidine on indocyanine green elimination assessed with LIMON to patients with early septic shock: a pilot study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19931154/),,26.5,209968,DB00818,Propofol
,19931154,ICG-PDR,"Baseline ICG-PDR levels of group P compared to group D were 24.7 +/- 14.4 vs 22.2 +/- 10.7, respectively, and after the study, ICG-PDR levels (26.5 +/- 13.7 vs 23.7 +/- 12.4) did not differ in groups (P > .05).",Effects of propofol and dexmedetomidine on indocyanine green elimination assessed with LIMON to patients with early septic shock: a pilot study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19931154/),,23.7,209969,DB00818,Propofol
,2784338,plasma levels,"Propofol plasma levels were high (4,600 +/- 2,200 ng/ml-1) at intubation time; however, at extraction time (group 1) or 25 minutes after induction (group 2), plasma levels were close to anaesthetic threshold.",[The pharmacokinetics of propofol used in cesarean section; a preliminary study in the newborn infant]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2784338/),[ng] / [ml],4,210099,DB00818,Propofol
,17897267,clearance (CL),Median clearance (CL) was 13.6 (range 3.7-78.2) ml.min(-1).,Maturational pharmacokinetics of single intravenous bolus of propofol. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17897267/),[ml] / [min],13.6,210769,DB00818,Propofol
,17897267,apparent volume of distribution at steady state (V(ss)),kg(-1) and median apparent volume of distribution at steady state (V(ss)) was 3.7 (1.33-7.96) l.kg(-1).,Maturational pharmacokinetics of single intravenous bolus of propofol. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17897267/),[l] / [kg],3.7,210770,DB00818,Propofol
,17897267,CL,"Following allometric scaling and standardization to 70 kg, median CL was 442 (range 97-2184) ml.min(-1).70 kg(-1).",Maturational pharmacokinetics of single intravenous bolus of propofol. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17897267/),[ml] / [70·kg·min],442,210771,DB00818,Propofol
,9174287,retention times,"The analyte and internal standard had retention times of 6.3 and 10.5 min, respectively.",Determination of propofol in rat whole blood and plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9174287/),min,6.3,211364,DB00818,Propofol
,9174287,retention times,"The analyte and internal standard had retention times of 6.3 and 10.5 min, respectively.",Determination of propofol in rat whole blood and plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9174287/),min,10.5,211365,DB00818,Propofol
,33538243,relative bioavailability,The in vivo pharmacokinetic parameters in the rat model confirmed the improvement in the relative bioavailability with optimized niosomal gel (relative bioavailability = 12.12) in comparison to the control propofol gel.,Optimization of propofol loaded niosomal gel for transdermal delivery. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33538243/),,12.12,211987,DB00818,Propofol
,32880998,V1,"The population pharmacokinetic parameters were as follows: V1 = 1.14 L, V2 = 77.6 L, CL1 = 0.00182 L/min, CL2 = 0.0461 L/min.",Pharmacokinetics and effects on clinical and physiological parameters following a single bolus dose of propofol in common marmosets (Callithrix jacchus). ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32880998/),l,1.14,212524,DB00818,Propofol
,32880998,V2,"The population pharmacokinetic parameters were as follows: V1 = 1.14 L, V2 = 77.6 L, CL1 = 0.00182 L/min, CL2 = 0.0461 L/min.",Pharmacokinetics and effects on clinical and physiological parameters following a single bolus dose of propofol in common marmosets (Callithrix jacchus). ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32880998/),l,77.6,212525,DB00818,Propofol
,32880998,CL1,"The population pharmacokinetic parameters were as follows: V1 = 1.14 L, V2 = 77.6 L, CL1 = 0.00182 L/min, CL2 = 0.0461 L/min.",Pharmacokinetics and effects on clinical and physiological parameters following a single bolus dose of propofol in common marmosets (Callithrix jacchus). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32880998/),[l] / [min],0.00182,212526,DB00818,Propofol
,32880998,CL2,"The population pharmacokinetic parameters were as follows: V1 = 1.14 L, V2 = 77.6 L, CL1 = 0.00182 L/min, CL2 = 0.0461 L/min.",Pharmacokinetics and effects on clinical and physiological parameters following a single bolus dose of propofol in common marmosets (Callithrix jacchus). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32880998/),[l] / [min],0.0461,212527,DB00818,Propofol
,30669968,concentration at half maximum effect (EC50),"For the sigmoidal Emax model, the propofol concentration at half maximum effect (EC50) was 3.51 and 2.14 mg/L and Hill coefficient 1.43 and 6.85 for BIS and cAAI, respectively.",Population pharmacokinetic-pharmacodynamic model of propofol in adolescents undergoing scoliosis surgery with intraoperative wake-up test: a study using Bispectral index and composite auditory evoked potentials as pharmacodynamic endpoints. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30669968/),[mg] / [l],3.51,213820,DB00818,Propofol
,30669968,concentration at half maximum effect (EC50),"For the sigmoidal Emax model, the propofol concentration at half maximum effect (EC50) was 3.51 and 2.14 mg/L and Hill coefficient 1.43 and 6.85 for BIS and cAAI, respectively.",Population pharmacokinetic-pharmacodynamic model of propofol in adolescents undergoing scoliosis surgery with intraoperative wake-up test: a study using Bispectral index and composite auditory evoked potentials as pharmacodynamic endpoints. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30669968/),[mg] / [l],2.14,213821,DB00818,Propofol
,30669968,Hill coefficient,"For the sigmoidal Emax model, the propofol concentration at half maximum effect (EC50) was 3.51 and 2.14 mg/L and Hill coefficient 1.43 and 6.85 for BIS and cAAI, respectively.",Population pharmacokinetic-pharmacodynamic model of propofol in adolescents undergoing scoliosis surgery with intraoperative wake-up test: a study using Bispectral index and composite auditory evoked potentials as pharmacodynamic endpoints. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30669968/),,1.43,213822,DB00818,Propofol
,30669968,Hill coefficient,"For the sigmoidal Emax model, the propofol concentration at half maximum effect (EC50) was 3.51 and 2.14 mg/L and Hill coefficient 1.43 and 6.85 for BIS and cAAI, respectively.",Population pharmacokinetic-pharmacodynamic model of propofol in adolescents undergoing scoliosis surgery with intraoperative wake-up test: a study using Bispectral index and composite auditory evoked potentials as pharmacodynamic endpoints. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30669968/),,6.85,213823,DB00818,Propofol
,30669968,keo,"The delay in PD effect in relation to plasma concentration was best described by a two compartment effect-site model with a keo of 0.102 min- 1, ke12 of 0.121 min- 1 and ke21 of 0.172 min- 1.",Population pharmacokinetic-pharmacodynamic model of propofol in adolescents undergoing scoliosis surgery with intraoperative wake-up test: a study using Bispectral index and composite auditory evoked potentials as pharmacodynamic endpoints. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30669968/),1·min-,0.102,213824,DB00818,Propofol
,30669968,ke12,"The delay in PD effect in relation to plasma concentration was best described by a two compartment effect-site model with a keo of 0.102 min- 1, ke12 of 0.121 min- 1 and ke21 of 0.172 min- 1.",Population pharmacokinetic-pharmacodynamic model of propofol in adolescents undergoing scoliosis surgery with intraoperative wake-up test: a study using Bispectral index and composite auditory evoked potentials as pharmacodynamic endpoints. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30669968/),1·min-,0.121,213825,DB00818,Propofol
,30669968,ke21,"The delay in PD effect in relation to plasma concentration was best described by a two compartment effect-site model with a keo of 0.102 min- 1, ke12 of 0.121 min- 1 and ke21 of 0.172 min- 1.",Population pharmacokinetic-pharmacodynamic model of propofol in adolescents undergoing scoliosis surgery with intraoperative wake-up test: a study using Bispectral index and composite auditory evoked potentials as pharmacodynamic endpoints. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30669968/),1·min-,0.172,213826,DB00818,Propofol
,25724290,V 1,"The estimates of parameters were: V 1 (L) = 1.69, V 2 (L) = 27.2 + 0.929 × (weight - 25), Cl (L min(-1)) = 0.893 × (weight/23.6)(0.966), Q (L min(-1)) = 1.3; E 0 = 76.9; E max = 35.4, Ce 50 (μg mL(-1)) = 3.47 - (0.095 × age) - (1.63 × mean infusion rate of remifentanil in µg kg(-1) min(-1)); γ = 2.1; and k e0 (min(-1)) = 0.371.",Population pharmacokinetic and pharmacodynamic model of propofol externally validated in children. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25724290/),,1.69,214124,DB00818,Propofol
,25724290,V 2,"The estimates of parameters were: V 1 (L) = 1.69, V 2 (L) = 27.2 + 0.929 × (weight - 25), Cl (L min(-1)) = 0.893 × (weight/23.6)(0.966), Q (L min(-1)) = 1.3; E 0 = 76.9; E max = 35.4, Ce 50 (μg mL(-1)) = 3.47 - (0.095 × age) - (1.63 × mean infusion rate of remifentanil in µg kg(-1) min(-1)); γ = 2.1; and k e0 (min(-1)) = 0.371.",Population pharmacokinetic and pharmacodynamic model of propofol externally validated in children. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25724290/),,27,214125,DB00818,Propofol
,25724290,Q,"The estimates of parameters were: V 1 (L) = 1.69, V 2 (L) = 27.2 + 0.929 × (weight - 25), Cl (L min(-1)) = 0.893 × (weight/23.6)(0.966), Q (L min(-1)) = 1.3; E 0 = 76.9; E max = 35.4, Ce 50 (μg mL(-1)) = 3.47 - (0.095 × age) - (1.63 × mean infusion rate of remifentanil in µg kg(-1) min(-1)); γ = 2.1; and k e0 (min(-1)) = 0.371.",Population pharmacokinetic and pharmacodynamic model of propofol externally validated in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25724290/),[l] / [min],1,214126,DB00818,Propofol
,25724290,E 0,"The estimates of parameters were: V 1 (L) = 1.69, V 2 (L) = 27.2 + 0.929 × (weight - 25), Cl (L min(-1)) = 0.893 × (weight/23.6)(0.966), Q (L min(-1)) = 1.3; E 0 = 76.9; E max = 35.4, Ce 50 (μg mL(-1)) = 3.47 - (0.095 × age) - (1.63 × mean infusion rate of remifentanil in µg kg(-1) min(-1)); γ = 2.1; and k e0 (min(-1)) = 0.371.",Population pharmacokinetic and pharmacodynamic model of propofol externally validated in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25724290/),,76.9,214127,DB00818,Propofol
,25724290,E max,"The estimates of parameters were: V 1 (L) = 1.69, V 2 (L) = 27.2 + 0.929 × (weight - 25), Cl (L min(-1)) = 0.893 × (weight/23.6)(0.966), Q (L min(-1)) = 1.3; E 0 = 76.9; E max = 35.4, Ce 50 (μg mL(-1)) = 3.47 - (0.095 × age) - (1.63 × mean infusion rate of remifentanil in µg kg(-1) min(-1)); γ = 2.1; and k e0 (min(-1)) = 0.371.",Population pharmacokinetic and pharmacodynamic model of propofol externally validated in children. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25724290/),,35.4,214128,DB00818,Propofol
,25724290,γ,"The estimates of parameters were: V 1 (L) = 1.69, V 2 (L) = 27.2 + 0.929 × (weight - 25), Cl (L min(-1)) = 0.893 × (weight/23.6)(0.966), Q (L min(-1)) = 1.3; E 0 = 76.9; E max = 35.4, Ce 50 (μg mL(-1)) = 3.47 - (0.095 × age) - (1.63 × mean infusion rate of remifentanil in µg kg(-1) min(-1)); γ = 2.1; and k e0 (min(-1)) = 0.371.",Population pharmacokinetic and pharmacodynamic model of propofol externally validated in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25724290/),,2.1,214129,DB00818,Propofol
,25724290,k e0,"The estimates of parameters were: V 1 (L) = 1.69, V 2 (L) = 27.2 + 0.929 × (weight - 25), Cl (L min(-1)) = 0.893 × (weight/23.6)(0.966), Q (L min(-1)) = 1.3; E 0 = 76.9; E max = 35.4, Ce 50 (μg mL(-1)) = 3.47 - (0.095 × age) - (1.63 × mean infusion rate of remifentanil in µg kg(-1) min(-1)); γ = 2.1; and k e0 (min(-1)) = 0.371.",Population pharmacokinetic and pharmacodynamic model of propofol externally validated in children. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25724290/),1/[min],0.371,214130,DB00818,Propofol
,21948069,k(e0),"The 2-stage, pooled, and mixed effects approaches yielded k(e0) of 1.06, 1.24, and 0.72 min(-1); γ of 1.10, 0.83, and 0.93; EC50 of 3.18, 3.44, and 3.00 mcg/ml.",Pharmacodynamic modeling of propofol-induced tidal volume depression in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21948069/),1/[min],1.06,215013,DB00818,Propofol
,21948069,k(e0),"The 2-stage, pooled, and mixed effects approaches yielded k(e0) of 1.06, 1.24, and 0.72 min(-1); γ of 1.10, 0.83, and 0.93; EC50 of 3.18, 3.44, and 3.00 mcg/ml.",Pharmacodynamic modeling of propofol-induced tidal volume depression in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21948069/),1/[min],1.24,215014,DB00818,Propofol
,21948069,k(e0),"The 2-stage, pooled, and mixed effects approaches yielded k(e0) of 1.06, 1.24, and 0.72 min(-1); γ of 1.10, 0.83, and 0.93; EC50 of 3.18, 3.44, and 3.00 mcg/ml.",Pharmacodynamic modeling of propofol-induced tidal volume depression in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21948069/),1/[min],0.72,215015,DB00818,Propofol
,21948069,γ,"The 2-stage, pooled, and mixed effects approaches yielded k(e0) of 1.06, 1.24, and 0.72 min(-1); γ of 1.10, 0.83, and 0.93; EC50 of 3.18, 3.44, and 3.00 mcg/ml.",Pharmacodynamic modeling of propofol-induced tidal volume depression in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21948069/),,1.10,215016,DB00818,Propofol
,21948069,γ,"The 2-stage, pooled, and mixed effects approaches yielded k(e0) of 1.06, 1.24, and 0.72 min(-1); γ of 1.10, 0.83, and 0.93; EC50 of 3.18, 3.44, and 3.00 mcg/ml.",Pharmacodynamic modeling of propofol-induced tidal volume depression in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21948069/),,0.83,215017,DB00818,Propofol
,21948069,γ,"The 2-stage, pooled, and mixed effects approaches yielded k(e0) of 1.06, 1.24, and 0.72 min(-1); γ of 1.10, 0.83, and 0.93; EC50 of 3.18, 3.44, and 3.00 mcg/ml.",Pharmacodynamic modeling of propofol-induced tidal volume depression in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21948069/),,0.93,215018,DB00818,Propofol
,21948069,EC50,"The 2-stage, pooled, and mixed effects approaches yielded k(e0) of 1.06, 1.24, and 0.72 min(-1); γ of 1.10, 0.83, and 0.93; EC50 of 3.18, 3.44, and 3.00 mcg/ml.",Pharmacodynamic modeling of propofol-induced tidal volume depression in children. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21948069/),[mcg] / [ml],3.18,215019,DB00818,Propofol
,21948069,EC50,"The 2-stage, pooled, and mixed effects approaches yielded k(e0) of 1.06, 1.24, and 0.72 min(-1); γ of 1.10, 0.83, and 0.93; EC50 of 3.18, 3.44, and 3.00 mcg/ml.",Pharmacodynamic modeling of propofol-induced tidal volume depression in children. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21948069/),[mcg] / [ml],3.44,215020,DB00818,Propofol
,21948069,EC50,"The 2-stage, pooled, and mixed effects approaches yielded k(e0) of 1.06, 1.24, and 0.72 min(-1); γ of 1.10, 0.83, and 0.93; EC50 of 3.18, 3.44, and 3.00 mcg/ml.",Pharmacodynamic modeling of propofol-induced tidal volume depression in children. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21948069/),[mcg] / [ml],3.00,215021,DB00818,Propofol
greater,15380727,absolute recovery,The absolute recovery of the analyte was greater than 96%.,A new method for the quantitation of propofol in human plasma: efficient solid-phase extraction and liquid chromatography/APCI-triple quadrupole mass spectrometry detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15380727/),%,96,215329,DB00818,Propofol
,15380727,signal-to-noise ratio,The limit of quantification for propofol in plasma at a signal-to-noise ratio of 10 was 5 ng/ml.,A new method for the quantitation of propofol in human plasma: efficient solid-phase extraction and liquid chromatography/APCI-triple quadrupole mass spectrometry detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15380727/),[ng] / [ml],10,215330,DB00818,Propofol
,15380727,signal-to-noise ratio,The limit of quantification for propofol in plasma at a signal-to-noise ratio of 10 was 5 ng/ml.,A new method for the quantitation of propofol in human plasma: efficient solid-phase extraction and liquid chromatography/APCI-triple quadrupole mass spectrometry detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15380727/),[ng] / [ml],5,215331,DB00818,Propofol
,7793651,Apparent renal fluoride,"Apparent renal fluoride and HFIP clearances (mean +/- SE) were 51.8 +/- 4.5 and 52.6 +/- 6.1 ml/min, and apparent elimination half-lives were 21.4 +/- 2.8 and 20.1 +/- 2.6 h, respectively.",Clinical sevoflurane metabolism and disposition. I. Sevoflurane and metabolite pharmacokinetics. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7793651/),[ml] / [min],51.8,216581,DB00818,Propofol
,7793651,clearances,"Apparent renal fluoride and HFIP clearances (mean +/- SE) were 51.8 +/- 4.5 and 52.6 +/- 6.1 ml/min, and apparent elimination half-lives were 21.4 +/- 2.8 and 20.1 +/- 2.6 h, respectively.",Clinical sevoflurane metabolism and disposition. I. Sevoflurane and metabolite pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7793651/),[ml] / [min],52.6,216582,DB00818,Propofol
,7793651,apparent elimination half-lives,"Apparent renal fluoride and HFIP clearances (mean +/- SE) were 51.8 +/- 4.5 and 52.6 +/- 6.1 ml/min, and apparent elimination half-lives were 21.4 +/- 2.8 and 20.1 +/- 2.6 h, respectively.",Clinical sevoflurane metabolism and disposition. I. Sevoflurane and metabolite pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7793651/),h,21.4,216583,DB00818,Propofol
,7793651,apparent elimination half-lives,"Apparent renal fluoride and HFIP clearances (mean +/- SE) were 51.8 +/- 4.5 and 52.6 +/- 6.1 ml/min, and apparent elimination half-lives were 21.4 +/- 2.8 and 20.1 +/- 2.6 h, respectively.",Clinical sevoflurane metabolism and disposition. I. Sevoflurane and metabolite pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7793651/),h,20.1,216584,DB00818,Propofol
,7793651,Renal,"Renal HFIP and net fluoride excretion were 4,300 +/- 540 and 3,300 +/- 540 mumol.",Clinical sevoflurane metabolism and disposition. I. Sevoflurane and metabolite pharmacokinetics. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7793651/),μM,"4,300",216585,DB00818,Propofol
,7793651,HFIP,"Renal HFIP and net fluoride excretion were 4,300 +/- 540 and 3,300 +/- 540 mumol.",Clinical sevoflurane metabolism and disposition. I. Sevoflurane and metabolite pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7793651/),μM,"4,300",216586,DB00818,Propofol
,7793651,net fluoride excretion,"Renal HFIP and net fluoride excretion were 4,300 +/- 540 and 3,300 +/- 540 mumol.",Clinical sevoflurane metabolism and disposition. I. Sevoflurane and metabolite pharmacokinetics. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7793651/),μM,"3,300",216587,DB00818,Propofol
,15505444,BIS,"In a randomized, prospective design, 20 patients received propofol at a target concentration of 3 microg/ml, whereas in 20 patients propofol was titrated to maintain a BIS value of 40-50.",Impact of bispectral index monitoring on stress response and propofol consumption in patients undergoing coronary artery bypass surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15505444/),,40-50,216645,DB00818,Propofol
,20587019,Recovery,Recovery from anaesthesia after a 30 min administration of Org 25435 was slow (13.7 min).,"First administration to man of Org 25435, an intravenous anaesthetic: A Phase 1 Clinical Trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20587019/),min,13.7,217912,DB00818,Propofol
,25500489,initial target concentration,60 patients who underwent elective surgery were randomly assigned to plasma target-controlled infusion by Marsh's (n = 30) or Schnider's (n = 30) model with an initial target concentration of 4 μg×mL-1.,Hemodynamic responses during induction: comparison of Marsh and Schnider pharmacokinetic models. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25500489/),[μg] / [ml],4,218942,DB00818,Propofol
,25500489,Time to loss of responsiveness (LOR),"Time to loss of responsiveness (LOR), and time for NI to decrease to 64 was faster in Marsh than in Schnider (1.51 ± 0.8 minutes vs. 2.8 ± 1.2 min, p < 0.001; 3.3 ± 2.0 minutes vs. 5.2 ± 2.3 minutes, p < 0.01, respectively).",Hemodynamic responses during induction: comparison of Marsh and Schnider pharmacokinetic models. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25500489/),min,1.51,218943,DB00818,Propofol
,25500489,Time to loss of responsiveness (LOR),"Time to loss of responsiveness (LOR), and time for NI to decrease to 64 was faster in Marsh than in Schnider (1.51 ± 0.8 minutes vs. 2.8 ± 1.2 min, p < 0.001; 3.3 ± 2.0 minutes vs. 5.2 ± 2.3 minutes, p < 0.01, respectively).",Hemodynamic responses during induction: comparison of Marsh and Schnider pharmacokinetic models. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25500489/),min,2.8,218944,DB00818,Propofol
,25500489,Time to loss of responsiveness (LOR),"Time to loss of responsiveness (LOR), and time for NI to decrease to 64 was faster in Marsh than in Schnider (1.51 ± 0.8 minutes vs. 2.8 ± 1.2 min, p < 0.001; 3.3 ± 2.0 minutes vs. 5.2 ± 2.3 minutes, p < 0.01, respectively).",Hemodynamic responses during induction: comparison of Marsh and Schnider pharmacokinetic models. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25500489/),min,3.3,218945,DB00818,Propofol
,25500489,Time to loss of responsiveness (LOR),"Time to loss of responsiveness (LOR), and time for NI to decrease to 64 was faster in Marsh than in Schnider (1.51 ± 0.8 minutes vs. 2.8 ± 1.2 min, p < 0.001; 3.3 ± 2.0 minutes vs. 5.2 ± 2.3 minutes, p < 0.01, respectively).",Hemodynamic responses during induction: comparison of Marsh and Schnider pharmacokinetic models. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25500489/),min,5.2,218946,DB00818,Propofol
,25500489,time for,"Time to loss of responsiveness (LOR), and time for NI to decrease to 64 was faster in Marsh than in Schnider (1.51 ± 0.8 minutes vs. 2.8 ± 1.2 min, p < 0.001; 3.3 ± 2.0 minutes vs. 5.2 ± 2.3 minutes, p < 0.01, respectively).",Hemodynamic responses during induction: comparison of Marsh and Schnider pharmacokinetic models. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25500489/),min,2.8,218947,DB00818,Propofol
,25500489,time for,"Time to loss of responsiveness (LOR), and time for NI to decrease to 64 was faster in Marsh than in Schnider (1.51 ± 0.8 minutes vs. 2.8 ± 1.2 min, p < 0.001; 3.3 ± 2.0 minutes vs. 5.2 ± 2.3 minutes, p < 0.01, respectively).",Hemodynamic responses during induction: comparison of Marsh and Schnider pharmacokinetic models. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25500489/),min,3.3,218948,DB00818,Propofol
,25500489,time for,"Time to loss of responsiveness (LOR), and time for NI to decrease to 64 was faster in Marsh than in Schnider (1.51 ± 0.8 minutes vs. 2.8 ± 1.2 min, p < 0.001; 3.3 ± 2.0 minutes vs. 5.2 ± 2.3 minutes, p < 0.01, respectively).",Hemodynamic responses during induction: comparison of Marsh and Schnider pharmacokinetic models. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25500489/),min,5.2,218949,DB00818,Propofol
,19493418,effect-site concentration (Ce),"When an Observer's Assessment of Alertness/Sedation (OAA/S) score of 1 was achieved, remifentanil (effect-site concentration (Ce) of 4.0 ng/ml) and rocuronium 0.9 mg/kg were administered.",Relationship between depth of anesthesia and effect-site concentration of propofol during induction with the target-controlled infusion technique in elderly patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19493418/),[ng] / [ml],4.0,218989,DB00818,Propofol
,19493418,Ce,"When an OAA/S score of 1 was achieved, Ce of propofol were (1.7 +/- 0.4) microg/ml, (1.9 +/- 0.3) microg/ml, (1.9 +/- 0.4) microg/ml and the BIS values were 64 +/- 5, 65 +/- 8, and 62 +/- 8 in Groups S1, S2 and S3.",Relationship between depth of anesthesia and effect-site concentration of propofol during induction with the target-controlled infusion technique in elderly patients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19493418/),[μg] / [ml],1.7,218990,DB00818,Propofol
,19493418,Ce,"When an OAA/S score of 1 was achieved, Ce of propofol were (1.7 +/- 0.4) microg/ml, (1.9 +/- 0.3) microg/ml, (1.9 +/- 0.4) microg/ml and the BIS values were 64 +/- 5, 65 +/- 8, and 62 +/- 8 in Groups S1, S2 and S3.",Relationship between depth of anesthesia and effect-site concentration of propofol during induction with the target-controlled infusion technique in elderly patients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19493418/),[μg] / [ml],1.9,218991,DB00818,Propofol
,19493418,Ce,"When an OAA/S score of 1 was achieved, Ce of propofol were (1.7 +/- 0.4) microg/ml, (1.9 +/- 0.3) microg/ml, (1.9 +/- 0.4) microg/ml and the BIS values were 64 +/- 5, 65 +/- 8, and 62 +/- 8 in Groups S1, S2 and S3.",Relationship between depth of anesthesia and effect-site concentration of propofol during induction with the target-controlled infusion technique in elderly patients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19493418/),[μg] / [ml],1.9,218992,DB00818,Propofol
,19493418,BIS,"When an OAA/S score of 1 was achieved, Ce of propofol were (1.7 +/- 0.4) microg/ml, (1.9 +/- 0.3) microg/ml, (1.9 +/- 0.4) microg/ml and the BIS values were 64 +/- 5, 65 +/- 8, and 62 +/- 8 in Groups S1, S2 and S3.",Relationship between depth of anesthesia and effect-site concentration of propofol during induction with the target-controlled infusion technique in elderly patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19493418/),,64,218993,DB00818,Propofol
,19493418,BIS,"When an OAA/S score of 1 was achieved, Ce of propofol were (1.7 +/- 0.4) microg/ml, (1.9 +/- 0.3) microg/ml, (1.9 +/- 0.4) microg/ml and the BIS values were 64 +/- 5, 65 +/- 8, and 62 +/- 8 in Groups S1, S2 and S3.",Relationship between depth of anesthesia and effect-site concentration of propofol during induction with the target-controlled infusion technique in elderly patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19493418/),,65,218994,DB00818,Propofol
,19493418,BIS,"When an OAA/S score of 1 was achieved, Ce of propofol were (1.7 +/- 0.4) microg/ml, (1.9 +/- 0.3) microg/ml, (1.9 +/- 0.4) microg/ml and the BIS values were 64 +/- 5, 65 +/- 8, and 62 +/- 8 in Groups S1, S2 and S3.",Relationship between depth of anesthesia and effect-site concentration of propofol during induction with the target-controlled infusion technique in elderly patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19493418/),,62,218995,DB00818,Propofol
,19493418,Ce,"Before intubation, Ce of propofol was (2.8 +/- 0.2) microg/ml, (2.8 +/- 0.3) microg/ml, (2.7 +/- 0.3) microg/ml, and the BIS values were 48 +/- 7, 51 +/- 7, and 47 +/- 5 in Groups S1, S2 and S3.",Relationship between depth of anesthesia and effect-site concentration of propofol during induction with the target-controlled infusion technique in elderly patients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19493418/),[μg] / [ml],2.8,218996,DB00818,Propofol
,19493418,Ce,"Before intubation, Ce of propofol was (2.8 +/- 0.2) microg/ml, (2.8 +/- 0.3) microg/ml, (2.7 +/- 0.3) microg/ml, and the BIS values were 48 +/- 7, 51 +/- 7, and 47 +/- 5 in Groups S1, S2 and S3.",Relationship between depth of anesthesia and effect-site concentration of propofol during induction with the target-controlled infusion technique in elderly patients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19493418/),[μg] / [ml],2.8,218997,DB00818,Propofol
,19493418,Ce,"Before intubation, Ce of propofol was (2.8 +/- 0.2) microg/ml, (2.8 +/- 0.3) microg/ml, (2.7 +/- 0.3) microg/ml, and the BIS values were 48 +/- 7, 51 +/- 7, and 47 +/- 5 in Groups S1, S2 and S3.",Relationship between depth of anesthesia and effect-site concentration of propofol during induction with the target-controlled infusion technique in elderly patients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19493418/),[μg] / [ml],2.7,218998,DB00818,Propofol
,19493418,BIS,"Before intubation, Ce of propofol was (2.8 +/- 0.2) microg/ml, (2.8 +/- 0.3) microg/ml, (2.7 +/- 0.3) microg/ml, and the BIS values were 48 +/- 7, 51 +/- 7, and 47 +/- 5 in Groups S1, S2 and S3.",Relationship between depth of anesthesia and effect-site concentration of propofol during induction with the target-controlled infusion technique in elderly patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19493418/),,48,218999,DB00818,Propofol
,19493418,BIS,"Before intubation, Ce of propofol was (2.8 +/- 0.2) microg/ml, (2.8 +/- 0.3) microg/ml, (2.7 +/- 0.3) microg/ml, and the BIS values were 48 +/- 7, 51 +/- 7, and 47 +/- 5 in Groups S1, S2 and S3.",Relationship between depth of anesthesia and effect-site concentration of propofol during induction with the target-controlled infusion technique in elderly patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19493418/),,51,219000,DB00818,Propofol
,19493418,BIS,"Before intubation, Ce of propofol was (2.8 +/- 0.2) microg/ml, (2.8 +/- 0.3) microg/ml, (2.7 +/- 0.3) microg/ml, and the BIS values were 48 +/- 7, 51 +/- 7, and 47 +/- 5 in Groups S1, S2 and S3.",Relationship between depth of anesthesia and effect-site concentration of propofol during induction with the target-controlled infusion technique in elderly patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19493418/),,47,219001,DB00818,Propofol
,19493418,Ce,"During the TCI induction, Ce of propofol with (1.9 +/- 0.3) microg/ml may make the elderly patients unconscious.",Relationship between depth of anesthesia and effect-site concentration of propofol during induction with the target-controlled infusion technique in elderly patients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19493418/),[μg] / [ml],1.9,219002,DB00818,Propofol
,19493418,Ce,When remifentanil with a Ce of 4.0 ng/ml is added a Ce of propofol with (2.8 +/- 0.3) microg/ml is suitable for intubation.,Relationship between depth of anesthesia and effect-site concentration of propofol during induction with the target-controlled infusion technique in elderly patients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19493418/),[ng] / [ml],4.0,219003,DB00818,Propofol
,19493418,Ce,When remifentanil with a Ce of 4.0 ng/ml is added a Ce of propofol with (2.8 +/- 0.3) microg/ml is suitable for intubation.,Relationship between depth of anesthesia and effect-site concentration of propofol during induction with the target-controlled infusion technique in elderly patients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19493418/),[μg] / [ml],2.8,219004,DB00818,Propofol
,27294779,ce50,"This model shows that ce50, γ and ke0 change with time and patients, given a mean (95% confidence interval) of 3.89 (3.52-4.26)mg/l, 4.63 (4.13-5.13) and 0.36 (0.31-0.4)min(-1), respectively.",Adaptive pharmacokinetic and pharmacodynamic modelling to predict propofol effect using BIS-guided anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27294779/),[mg] / [l],3.89,219386,DB00818,Propofol
,27294779,γ,"This model shows that ce50, γ and ke0 change with time and patients, given a mean (95% confidence interval) of 3.89 (3.52-4.26)mg/l, 4.63 (4.13-5.13) and 0.36 (0.31-0.4)min(-1), respectively.",Adaptive pharmacokinetic and pharmacodynamic modelling to predict propofol effect using BIS-guided anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27294779/),1/[min],4.63,219387,DB00818,Propofol
,27294779,ke0,"This model shows that ce50, γ and ke0 change with time and patients, given a mean (95% confidence interval) of 3.89 (3.52-4.26)mg/l, 4.63 (4.13-5.13) and 0.36 (0.31-0.4)min(-1), respectively.",Adaptive pharmacokinetic and pharmacodynamic modelling to predict propofol effect using BIS-guided anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27294779/),1/[min],0.36,219388,DB00818,Propofol
,10534314,apparent K(m),"Estimates of apparent K(m) and V(max) for propofol hydroxylation by microsomes from a male beagle dog were 7.3 microM and 3.8 nmol/mg/min, respectively.",Propofol hydroxylation by dog liver microsomes: assay development and dog breed differences. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10534314/),μM,7.3,219971,DB00818,Propofol
,10534314,V(max),"Estimates of apparent K(m) and V(max) for propofol hydroxylation by microsomes from a male beagle dog were 7.3 microM and 3.8 nmol/mg/min, respectively.",Propofol hydroxylation by dog liver microsomes: assay development and dog breed differences. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10534314/),[nM] / [mg·min],3.8,219972,DB00818,Propofol
,10534314,hydroxylase,"At a substrate concentration of 20 microM, propofol hydroxylase activity was significantly lower (p =.032) in greyhound microsomes (1.7 +/- 0.4 nmol/mg/min) compared with beagle microsomes (5.1 +/- 1.3 nmol/mg/min) but was not statistically different (p =.42) compared with mixed-breed microsomes (3.1 +/- 1.2 nmol/mg/min).",Propofol hydroxylation by dog liver microsomes: assay development and dog breed differences. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10534314/),[nM] / [mg·min],1.7,219973,DB00818,Propofol
,10534314,hydroxylase,"At a substrate concentration of 20 microM, propofol hydroxylase activity was significantly lower (p =.032) in greyhound microsomes (1.7 +/- 0.4 nmol/mg/min) compared with beagle microsomes (5.1 +/- 1.3 nmol/mg/min) but was not statistically different (p =.42) compared with mixed-breed microsomes (3.1 +/- 1.2 nmol/mg/min).",Propofol hydroxylation by dog liver microsomes: assay development and dog breed differences. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10534314/),[nM] / [mg·min],5.1,219974,DB00818,Propofol
,10534314,hydroxylase,"At a substrate concentration of 20 microM, propofol hydroxylase activity was significantly lower (p =.032) in greyhound microsomes (1.7 +/- 0.4 nmol/mg/min) compared with beagle microsomes (5.1 +/- 1.3 nmol/mg/min) but was not statistically different (p =.42) compared with mixed-breed microsomes (3.1 +/- 1.2 nmol/mg/min).",Propofol hydroxylation by dog liver microsomes: assay development and dog breed differences. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10534314/),[nM] / [mg·min],3.1,219975,DB00818,Propofol
,10534314,activity,"At a substrate concentration of 20 microM, propofol hydroxylase activity was significantly lower (p =.032) in greyhound microsomes (1.7 +/- 0.4 nmol/mg/min) compared with beagle microsomes (5.1 +/- 1.3 nmol/mg/min) but was not statistically different (p =.42) compared with mixed-breed microsomes (3.1 +/- 1.2 nmol/mg/min).",Propofol hydroxylation by dog liver microsomes: assay development and dog breed differences. ,fm enzyme-Q5,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10534314/),[nM] / [mg·min],1.7,219976,DB00818,Propofol
,10534314,activity,"At a substrate concentration of 20 microM, propofol hydroxylase activity was significantly lower (p =.032) in greyhound microsomes (1.7 +/- 0.4 nmol/mg/min) compared with beagle microsomes (5.1 +/- 1.3 nmol/mg/min) but was not statistically different (p =.42) compared with mixed-breed microsomes (3.1 +/- 1.2 nmol/mg/min).",Propofol hydroxylation by dog liver microsomes: assay development and dog breed differences. ,fm enzyme-Q5,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10534314/),[nM] / [mg·min],5.1,219977,DB00818,Propofol
,10534314,activity,"At a substrate concentration of 20 microM, propofol hydroxylase activity was significantly lower (p =.032) in greyhound microsomes (1.7 +/- 0.4 nmol/mg/min) compared with beagle microsomes (5.1 +/- 1.3 nmol/mg/min) but was not statistically different (p =.42) compared with mixed-breed microsomes (3.1 +/- 1.2 nmol/mg/min).",Propofol hydroxylation by dog liver microsomes: assay development and dog breed differences. ,fm enzyme-Q5,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10534314/),[nM] / [mg·min],3.1,219978,DB00818,Propofol
,25558191,Gastric pH,Gastric pH of the placebo and tramadol groups was 1.97 versus 1.98 (P = 0.092) respectively.,Effect of single oral dose of tramadol on gastric secretions pH. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25558191/),,1.97,221407,DB00818,Propofol
,25558191,Gastric pH,Gastric pH of the placebo and tramadol groups was 1.97 versus 1.98 (P = 0.092) respectively.,Effect of single oral dose of tramadol on gastric secretions pH. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25558191/),,1.98,221408,DB00818,Propofol
,27004426,EC50,"Mean effect-site EC50 ± SD of propofol for successful i-gel insertion was significantly higher for men than women (5.46 ± 0.26 μg/ml vs. 3.82 ± 0.34 μg/ml, p < 0.01).",Male patients require higher optimal effect-site concentrations of propofol during i-gel insertion with dexmedetomidine 0.5 μg/kg. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27004426/),[μg] / [ml],5.46,222382,DB00818,Propofol
,27004426,EC50,"Mean effect-site EC50 ± SD of propofol for successful i-gel insertion was significantly higher for men than women (5.46 ± 0.26 μg/ml vs. 3.82 ± 0.34 μg/ml, p < 0.01).",Male patients require higher optimal effect-site concentrations of propofol during i-gel insertion with dexmedetomidine 0.5 μg/kg. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27004426/),[μg] / [ml],3.82,222383,DB00818,Propofol
,27004426,EC50,"Using isotonic regression with a bootstrapping approach, the estimated EC50 (95% confidence interval) of propofol was also higher in men [5.32 (4.45-6.20) μg/ml vs. 3.75 (3.05-4.43) μg/ml].",Male patients require higher optimal effect-site concentrations of propofol during i-gel insertion with dexmedetomidine 0.5 μg/kg. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27004426/),[μg] / [ml],5.32,222384,DB00818,Propofol
,27004426,EC50,"Using isotonic regression with a bootstrapping approach, the estimated EC50 (95% confidence interval) of propofol was also higher in men [5.32 (4.45-6.20) μg/ml vs. 3.75 (3.05-4.43) μg/ml].",Male patients require higher optimal effect-site concentrations of propofol during i-gel insertion with dexmedetomidine 0.5 μg/kg. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27004426/),[μg] / [ml],3.75,222385,DB00818,Propofol
,27004426,EC95,"The estimated EC95 (95% confidence interval) of propofol in men and women were 5.93 (4.72-6.88) μg/ml and 4.52 (3.02-5.70) μg/ml, respectively.",Male patients require higher optimal effect-site concentrations of propofol during i-gel insertion with dexmedetomidine 0.5 μg/kg. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27004426/),[μg] / [ml],5.93,222386,DB00818,Propofol
,27004426,EC95,"The estimated EC95 (95% confidence interval) of propofol in men and women were 5.93 (4.72-6.88) μg/ml and 4.52 (3.02-5.70) μg/ml, respectively.",Male patients require higher optimal effect-site concentrations of propofol during i-gel insertion with dexmedetomidine 0.5 μg/kg. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27004426/),[μg] / [ml],4.52,222387,DB00818,Propofol
,10073737,free fraction in blood,Propofol free fraction in blood was 1.2-1.7% at total concentrations ranging from 2.80 to 179 microM (0.5 to 32 microg ml(-1)).,Binding of propofol to blood components: implications for pharmacokinetics and for pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10073737/),%,1.2-1.7,222519,DB00818,Propofol
,10073737,total concentrations,Propofol free fraction in blood was 1.2-1.7% at total concentrations ranging from 2.80 to 179 microM (0.5 to 32 microg ml(-1)).,Binding of propofol to blood components: implications for pharmacokinetics and for pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10073737/),μM,2.80 to 179,222520,DB00818,Propofol
,10073737,total concentrations,Propofol free fraction in blood was 1.2-1.7% at total concentrations ranging from 2.80 to 179 microM (0.5 to 32 microg ml(-1)).,Binding of propofol to blood components: implications for pharmacokinetics and for pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10073737/),μ,0.5 to 32,222521,DB00818,Propofol
,9623432,venous serum propofol concentrations,Mean measured venous serum propofol concentrations obtained between 20 and 35 min after the optimal sedation level was reached were 1.6 (SD 0.2) micrograms ml-1 in the anxious patients compared with 1.7 (0.3) micrograms ml-1 in the control group (study 1) and 1.4 (0.27) micrograms ml-1 in study 2.,Pharmacokinetics of propofol during conscious sedation using target-controlled infusion in anxious patients undergoing dental treatment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9623432/),[μg] / [ml],1.6,223765,DB00818,Propofol
,9623432,venous serum propofol concentrations,Mean measured venous serum propofol concentrations obtained between 20 and 35 min after the optimal sedation level was reached were 1.6 (SD 0.2) micrograms ml-1 in the anxious patients compared with 1.7 (0.3) micrograms ml-1 in the control group (study 1) and 1.4 (0.27) micrograms ml-1 in study 2.,Pharmacokinetics of propofol during conscious sedation using target-controlled infusion in anxious patients undergoing dental treatment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9623432/),[μg] / [ml],1.7,223766,DB00818,Propofol
,9623432,venous serum propofol concentrations,Mean measured venous serum propofol concentrations obtained between 20 and 35 min after the optimal sedation level was reached were 1.6 (SD 0.2) micrograms ml-1 in the anxious patients compared with 1.7 (0.3) micrograms ml-1 in the control group (study 1) and 1.4 (0.27) micrograms ml-1 in study 2.,Pharmacokinetics of propofol during conscious sedation using target-controlled infusion in anxious patients undergoing dental treatment. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9623432/),[μg] / [ml],1.4,223767,DB00818,Propofol
,12717125,clearances,"The clearances of the two most active isomers (Cis-Trans and Trans-Trans) were lower in the pancuronium-mivacurium group (17.6 +/- 5.1, 14.7 +/- 5.3 ml.",Potentiation of mivacurium blockade by low dose of pancuronium: a pharmacokinetic study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12717125/),ml,17.6,224536,DB00818,Propofol
,12717125,clearances,"The clearances of the two most active isomers (Cis-Trans and Trans-Trans) were lower in the pancuronium-mivacurium group (17.6 +/- 5.1, 14.7 +/- 5.3 ml.",Potentiation of mivacurium blockade by low dose of pancuronium: a pharmacokinetic study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12717125/),ml,14.7,224537,DB00818,Propofol
,25725779,r.c.,"The mean Rb r.c. was 1.56 ± 0.35 μg/ml, with minimum and maximum values of 1.09 and 2.08 μg/ml, respectively.",Effective method of continuous rocuronium administration based on effect-site concentrations using a pharmacokinetic/pharmacodynamic model during propofol-remifentanil anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25725779/),[μg] / [ml],1.56,224992,DB00818,Propofol
,25725779,minimum,"The mean Rb r.c. was 1.56 ± 0.35 μg/ml, with minimum and maximum values of 1.09 and 2.08 μg/ml, respectively.",Effective method of continuous rocuronium administration based on effect-site concentrations using a pharmacokinetic/pharmacodynamic model during propofol-remifentanil anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25725779/),[μg] / [ml],1.09,224993,DB00818,Propofol
,25725779,minimum,"The mean Rb r.c. was 1.56 ± 0.35 μg/ml, with minimum and maximum values of 1.09 and 2.08 μg/ml, respectively.",Effective method of continuous rocuronium administration based on effect-site concentrations using a pharmacokinetic/pharmacodynamic model during propofol-remifentanil anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25725779/),[μg] / [ml],2.08,224994,DB00818,Propofol
,25725779,maximum,"The mean Rb r.c. was 1.56 ± 0.35 μg/ml, with minimum and maximum values of 1.09 and 2.08 μg/ml, respectively.",Effective method of continuous rocuronium administration based on effect-site concentrations using a pharmacokinetic/pharmacodynamic model during propofol-remifentanil anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25725779/),[μg] / [ml],2.08,224995,DB00818,Propofol
,25725779,recovery period,"The %T1 did not increase above 10 % in any of the patients during continuous administration of Rb, and the recovery period to %T1 > 25 % ranged from 9 to 29 min.",Effective method of continuous rocuronium administration based on effect-site concentrations using a pharmacokinetic/pharmacodynamic model during propofol-remifentanil anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25725779/),min,9 to 29,224996,DB00818,Propofol
,11296436,time for extubation,The average time for extubation was 18 minutes after discontinuation of propofol infusion.,[Evaluation of emergence from total intravenous anesthesia with propofol for long neurosurgery]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11296436/),min,18,226357,DB00818,Propofol
,22701254,CL,"The typical value of CL, V1, Q2, V2, Q3 and V3 were 1.28 L · min(-1), 10.1 × (age/44)-0.465 × (1 + 0.352 × sex) L, 0.819 L · min(-1), 36.0 L, 0.405 × (bodyweight/60)1.58 L · min(-1) and 272 L, respectively.",Propofol pharmacokinetics in China: a multicentric study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22701254/),[l] / [min],1.28,228154,DB00818,Propofol
,22701254,V3,"The typical value of CL, V1, Q2, V2, Q3 and V3 were 1.28 L · min(-1), 10.1 × (age/44)-0.465 × (1 + 0.352 × sex) L, 0.819 L · min(-1), 36.0 L, 0.405 × (bodyweight/60)1.58 L · min(-1) and 272 L, respectively.",Propofol pharmacokinetics in China: a multicentric study. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22701254/),l,272,228155,DB00818,Propofol
,3500758,terminal half-life,"Data analysis indicates a 3 compartment model with a terminal half-life of 480 +/- 141 min, clearance of 0.0352 +/- 0.0014 l/min/kg and volume of distribution of 24.2 +/- 6.2 l/kg.",[Pharmacokinetics of propofol as an induction agents in adults]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3500758/),min,480,228707,DB00818,Propofol
,3500758,clearance,"Data analysis indicates a 3 compartment model with a terminal half-life of 480 +/- 141 min, clearance of 0.0352 +/- 0.0014 l/min/kg and volume of distribution of 24.2 +/- 6.2 l/kg.",[Pharmacokinetics of propofol as an induction agents in adults]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3500758/),[l] / [kg·min],0.0352,228708,DB00818,Propofol
,3500758,volume of distribution,"Data analysis indicates a 3 compartment model with a terminal half-life of 480 +/- 141 min, clearance of 0.0352 +/- 0.0014 l/min/kg and volume of distribution of 24.2 +/- 6.2 l/kg.",[Pharmacokinetics of propofol as an induction agents in adults]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3500758/),[l] / [kg],24.2,228709,DB00818,Propofol
,25628234,C e50,The C e50 and propofol biophase concentration at the time of postoperative orientation were low and equaled 1.40 and 1.13 mg/L.,Pharmacokinetics and pharmacodynamics of propofol in cancer patients undergoing major lung surgery. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25628234/),[mg] / [l],1.40,229510,DB00818,Propofol
,25628234,biophase concentration,The C e50 and propofol biophase concentration at the time of postoperative orientation were low and equaled 1.40 and 1.13 mg/L.,Pharmacokinetics and pharmacodynamics of propofol in cancer patients undergoing major lung surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25628234/),[mg] / [l],1.13,229511,DB00818,Propofol
,19488525,Maximal,"Maximal and minimal mean concentrations at the effector site (ng.mL(-1)) of remifentanil were 3.5 and 2.4, respectively.",Target-controlled total intravenous anesthesia associated with femoral nerve block for arthroscopic knee meniscectomy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19488525/),[ng] / [ml],3.5,229565,DB00818,Propofol
,19488525,minimal mean concentrations at,"Maximal and minimal mean concentrations at the effector site (ng.mL(-1)) of remifentanil were 3.5 and 2.4, respectively.",Target-controlled total intravenous anesthesia associated with femoral nerve block for arthroscopic knee meniscectomy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19488525/),[ng] / [ml],3.5,229566,DB00818,Propofol
,19488525,minimal mean concentrations at,"Maximal and minimal mean concentrations at the effector site (ng.mL(-1)) of remifentanil were 3.5 and 2.4, respectively.",Target-controlled total intravenous anesthesia associated with femoral nerve block for arthroscopic knee meniscectomy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19488525/),[ng] / [ml],2.4,229567,DB00818,Propofol
,19488525,Maximal,"Maximal and minimal mean concentrations of propofol at the effector site (microg.mL(-1)) were 3.1 and 2.6, respectively.",Target-controlled total intravenous anesthesia associated with femoral nerve block for arthroscopic knee meniscectomy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19488525/),[μg] / [ml],3.1,229568,DB00818,Propofol
,19488525,minimal mean concentrations,"Maximal and minimal mean concentrations of propofol at the effector site (microg.mL(-1)) were 3.1 and 2.6, respectively.",Target-controlled total intravenous anesthesia associated with femoral nerve block for arthroscopic knee meniscectomy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19488525/),[μg] / [ml],3.1,229569,DB00818,Propofol
,19488525,minimal mean concentrations,"Maximal and minimal mean concentrations of propofol at the effector site (microg.mL(-1)) were 3.1 and 2.6, respectively.",Target-controlled total intravenous anesthesia associated with femoral nerve block for arthroscopic knee meniscectomy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19488525/),[μg] / [ml],2.6,229570,DB00818,Propofol
,19488525,flow of infusion,The mean flow of infusion of propofol and remifentanil was 8.54 mg.,Target-controlled total intravenous anesthesia associated with femoral nerve block for arthroscopic knee meniscectomy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19488525/),mg,8.54,229571,DB00818,Propofol
,19488525,hospital discharge time,Mean hospital discharge time was 180 min.,Target-controlled total intravenous anesthesia associated with femoral nerve block for arthroscopic knee meniscectomy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19488525/),min,180,229572,DB00818,Propofol
,2382846,terminal phase (T1/2,"Derived pharmacokinetic parameters showed a long terminal phase (T1/2 = 1878 +/- 672 min), a large volume of distribution at steady state (Vdss = 1666 +/- 756 l), and a high total body clearance (Cl = 1.57 +/- 0.56 l/min).",Pharmacokinetics of long-term propofol infusion used for sedation in ICU patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2382846/),min,1878,230678,DB00818,Propofol
,2382846,volume of distribution at steady state (Vdss,"Derived pharmacokinetic parameters showed a long terminal phase (T1/2 = 1878 +/- 672 min), a large volume of distribution at steady state (Vdss = 1666 +/- 756 l), and a high total body clearance (Cl = 1.57 +/- 0.56 l/min).",Pharmacokinetics of long-term propofol infusion used for sedation in ICU patients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2382846/),l,1666,230679,DB00818,Propofol
,2382846,total body clearance (Cl,"Derived pharmacokinetic parameters showed a long terminal phase (T1/2 = 1878 +/- 672 min), a large volume of distribution at steady state (Vdss = 1666 +/- 756 l), and a high total body clearance (Cl = 1.57 +/- 0.56 l/min).",Pharmacokinetics of long-term propofol infusion used for sedation in ICU patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2382846/),[l] / [min],1.57,230680,DB00818,Propofol
,3877295,terminal half-life,"Data analysis indicates a 3 compartment model, with a terminal half-life of 286 (s.e.m. +/- 36) min, clearance of 1803 +/- 125 ml/min, and volume of distribution of 755 +/- 109 litres.",Pharmacokinetics of propofol ('Diprivan') as an induction agent. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3877295/),min,286,230796,DB00818,Propofol
,3877295,clearance,"Data analysis indicates a 3 compartment model, with a terminal half-life of 286 (s.e.m. +/- 36) min, clearance of 1803 +/- 125 ml/min, and volume of distribution of 755 +/- 109 litres.",Pharmacokinetics of propofol ('Diprivan') as an induction agent. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3877295/),[ml] / [min],1803,230797,DB00818,Propofol
,3877295,volume of distribution,"Data analysis indicates a 3 compartment model, with a terminal half-life of 286 (s.e.m. +/- 36) min, clearance of 1803 +/- 125 ml/min, and volume of distribution of 755 +/- 109 litres.",Pharmacokinetics of propofol ('Diprivan') as an induction agent. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3877295/),l,755,230798,DB00818,Propofol
,11573657,V1,"The pharmacokinetic parameters were: V1=4.88 litre, V2=24.50 litre, V3 (litre)=115+147 x gender (gender: male=1, female=2), Cl1 (litre min(-1))=-0.29+0.022 x weight+0.22 x gender, Cl2 (litre min(-1))=2.84-0.65 x gender (male=1, female=2), and Cl3=0.788 litre min(-1).",Gender differences in the pharmacokinetics of propofol in elderly patients during and after continuous infusion. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11573657/),l,4.88,231202,DB00818,Propofol
,11573657,V2,"The pharmacokinetic parameters were: V1=4.88 litre, V2=24.50 litre, V3 (litre)=115+147 x gender (gender: male=1, female=2), Cl1 (litre min(-1))=-0.29+0.022 x weight+0.22 x gender, Cl2 (litre min(-1))=2.84-0.65 x gender (male=1, female=2), and Cl3=0.788 litre min(-1).",Gender differences in the pharmacokinetics of propofol in elderly patients during and after continuous infusion. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11573657/),l,24.50,231203,DB00818,Propofol
,11573657,Cl2,"The pharmacokinetic parameters were: V1=4.88 litre, V2=24.50 litre, V3 (litre)=115+147 x gender (gender: male=1, female=2), Cl1 (litre min(-1))=-0.29+0.022 x weight+0.22 x gender, Cl2 (litre min(-1))=2.84-0.65 x gender (male=1, female=2), and Cl3=0.788 litre min(-1).",Gender differences in the pharmacokinetics of propofol in elderly patients during and after continuous infusion. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11573657/),[l] / [min],2.84,231204,DB00818,Propofol
,11573657,Cl3,"The pharmacokinetic parameters were: V1=4.88 litre, V2=24.50 litre, V3 (litre)=115+147 x gender (gender: male=1, female=2), Cl1 (litre min(-1))=-0.29+0.022 x weight+0.22 x gender, Cl2 (litre min(-1))=2.84-0.65 x gender (male=1, female=2), and Cl3=0.788 litre min(-1).",Gender differences in the pharmacokinetics of propofol in elderly patients during and after continuous infusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11573657/),[l] / [min],0.788,231205,DB00818,Propofol
,9423145,bioavailability,"Nasal bioavailability in dogs anesthetized with pentobarbital was 85 +/- 4%, whereas in dogs anesthetized with the short-acting anesthetic propofol, bioavailability was 32 +/- 7%.","Intranasal absorption of the platelet glycoprotein IIb/IIIa receptor antagonist, DMP 755, and the effect of anesthesia on nasal bioavailability. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9423145/),%,85,231915,DB00818,Propofol
,9423145,bioavailability,"Nasal bioavailability in dogs anesthetized with pentobarbital was 85 +/- 4%, whereas in dogs anesthetized with the short-acting anesthetic propofol, bioavailability was 32 +/- 7%.","Intranasal absorption of the platelet glycoprotein IIb/IIIa receptor antagonist, DMP 755, and the effect of anesthesia on nasal bioavailability. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9423145/),%,32,231916,DB00818,Propofol
,22283551,elimination,"Propofol showed a long elimination half-life (t(1/2λ2) 7.55 ± 9.86 h), whereas ketamine was characterized by shorter half-life (t(1/2λ2) 4 ± 3.4 h) owing to its rapid biotransformation into norketamine.",Pharmacokinetics of ketamine and propofol combination administered as ketofol via continuous infusion in cats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/22283551/),h,7.55,232582,DB00818,Propofol
,22283551,half-life (t(1/2λ2),"Propofol showed a long elimination half-life (t(1/2λ2) 7.55 ± 9.86 h), whereas ketamine was characterized by shorter half-life (t(1/2λ2) 4 ± 3.4 h) owing to its rapid biotransformation into norketamine.",Pharmacokinetics of ketamine and propofol combination administered as ketofol via continuous infusion in cats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22283551/),h,4,232583,DB00818,Propofol
,12401612,half-lives,"Propofol was produced with half-lives of 5.3 +/- 0.6 min in rats, 2.1 +/- 0.6 min in rabbits, and 4.4 +/- 2.4 min in pigs.","Propofol phosphate, a water-soluble propofol prodrug: in vivo evaluation. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12401612/),min,5.3,232754,DB00818,Propofol
,12401612,half-lives,"Propofol was produced with half-lives of 5.3 +/- 0.6 min in rats, 2.1 +/- 0.6 min in rabbits, and 4.4 +/- 2.4 min in pigs.","Propofol phosphate, a water-soluble propofol prodrug: in vivo evaluation. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12401612/),min,2.1,232755,DB00818,Propofol
,12401612,half-lives,"Propofol was produced with half-lives of 5.3 +/- 0.6 min in rats, 2.1 +/- 0.6 min in rabbits, and 4.4 +/- 2.4 min in pigs.","Propofol phosphate, a water-soluble propofol prodrug: in vivo evaluation. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12401612/),min,4.4,232756,DB00818,Propofol
,12401612,elimination half-life,"The elimination half-life was 24 +/- 12 min in rats, 21 +/- 16 min in rabbits, and 225 +/- 56 min in pigs.","Propofol phosphate, a water-soluble propofol prodrug: in vivo evaluation. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12401612/),min,24,232757,DB00818,Propofol
,12401612,elimination half-life,"The elimination half-life was 24 +/- 12 min in rats, 21 +/- 16 min in rabbits, and 225 +/- 56 min in pigs.","Propofol phosphate, a water-soluble propofol prodrug: in vivo evaluation. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12401612/),min,21,232758,DB00818,Propofol
,12401612,elimination half-life,"The elimination half-life was 24 +/- 12 min in rats, 21 +/- 16 min in rabbits, and 225 +/- 56 min in pigs.","Propofol phosphate, a water-soluble propofol prodrug: in vivo evaluation. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12401612/),min,225,232759,DB00818,Propofol
,2816243,concentrations at apparent steady state,The mean concentrations at apparent steady state were in the range of 4.3 to 5.6 micrograms/ml during the infusion.,Pharmacokinetics of propofol during continuous infusion for pediatric anesthesia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2816243/),[μg] / [ml],4.3 to 5.6,233066,DB00818,Propofol
,2816243,total body clearance,"The mean total body clearance, derived from the apparent steady state concentrations in the blood, was 0.0394 litres/kg/minute.",Pharmacokinetics of propofol during continuous infusion for pediatric anesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2816243/),[l] / [kg·min],0.0394,233067,DB00818,Propofol
,2816243,blood concentration,The mean propofol blood concentration at awakening was found to be 2.3 micrograms/ml.,Pharmacokinetics of propofol during continuous infusion for pediatric anesthesia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2816243/),[μg] / [ml],2.3,233068,DB00818,Propofol
,18835886,recovery,Median propofol metabolite recovery was 64% (range 34-98%).,Urinary propofol metabolites in early life after single intravenous bolus. ,fm-Q45,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18835886/),%,64,233652,DB00818,Propofol
,9260658,half like,"After an induction dose administration of 2.5 mg kg-1, the maternal and umbilical vein blood were found to have comparable concentrations of propofol, with a mean half like of about 3.5 min; on the contrary no detectable levels of the drug were found in amniotic fluid.",Propofol assay in biological fluids in pregnant women. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9260658/),min,3.5,233961,DB00818,Propofol
>,9260658,drug,The drug recoveries > 98% and the response was linear over the range 0.05-40 micrograms ml-1.,Propofol assay in biological fluids in pregnant women. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9260658/),%,98,233962,DB00818,Propofol
>,9260658,recoveries,The drug recoveries > 98% and the response was linear over the range 0.05-40 micrograms ml-1.,Propofol assay in biological fluids in pregnant women. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9260658/),%,98,233963,DB00818,Propofol
,14515060,area under the curve (AUC),A unimodal distribution of bupropion and hydroxybupropion kinetic parameters was detected with a mean (range) area under the curve (AUC) of 3.64 (0.89-8.14) micromol.h/l for bupropion and 25.5 (6.72-75.3) micromol.h/l for hydroxybupropion.,Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14515060/),[h·μM] / [l],3.64,234498,DB00818,Propofol
,14515060,area under the curve (AUC),A unimodal distribution of bupropion and hydroxybupropion kinetic parameters was detected with a mean (range) area under the curve (AUC) of 3.64 (0.89-8.14) micromol.h/l for bupropion and 25.5 (6.72-75.3) micromol.h/l for hydroxybupropion.,Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14515060/),[h·μM] / [l],25.5,234499,DB00818,Propofol
,7908181,elimination half-life,"Mean elimination half-life, blood clearance, mean residence time, and mean volume of distribution at steady state, were 486.2 minutes, 34.4 ml/kg/min, 301.8 minutes, and 6.04 L/kg, respectively, in the absence of medetomidine, and 136.9 minutes, 36.2 ml/kg/min, 215.1 minutes, and 3.38 L/kg, respectively, in the presence of medetomidine.",Effect of medetomidine on the pharmacokinetics of propofol in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7908181/),min,486.2,234588,DB00818,Propofol
,7908181,blood clearance,"Mean elimination half-life, blood clearance, mean residence time, and mean volume of distribution at steady state, were 486.2 minutes, 34.4 ml/kg/min, 301.8 minutes, and 6.04 L/kg, respectively, in the absence of medetomidine, and 136.9 minutes, 36.2 ml/kg/min, 215.1 minutes, and 3.38 L/kg, respectively, in the presence of medetomidine.",Effect of medetomidine on the pharmacokinetics of propofol in dogs. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7908181/),[ml] / [kg·min],34.4,234589,DB00818,Propofol
,7908181,blood clearance,"Mean elimination half-life, blood clearance, mean residence time, and mean volume of distribution at steady state, were 486.2 minutes, 34.4 ml/kg/min, 301.8 minutes, and 6.04 L/kg, respectively, in the absence of medetomidine, and 136.9 minutes, 36.2 ml/kg/min, 215.1 minutes, and 3.38 L/kg, respectively, in the presence of medetomidine.",Effect of medetomidine on the pharmacokinetics of propofol in dogs. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7908181/),min,301.8,234590,DB00818,Propofol
,7908181,mean residence time,"Mean elimination half-life, blood clearance, mean residence time, and mean volume of distribution at steady state, were 486.2 minutes, 34.4 ml/kg/min, 301.8 minutes, and 6.04 L/kg, respectively, in the absence of medetomidine, and 136.9 minutes, 36.2 ml/kg/min, 215.1 minutes, and 3.38 L/kg, respectively, in the presence of medetomidine.",Effect of medetomidine on the pharmacokinetics of propofol in dogs. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7908181/),[ml] / [kg·min],34.4,234591,DB00818,Propofol
,7908181,mean residence time,"Mean elimination half-life, blood clearance, mean residence time, and mean volume of distribution at steady state, were 486.2 minutes, 34.4 ml/kg/min, 301.8 minutes, and 6.04 L/kg, respectively, in the absence of medetomidine, and 136.9 minutes, 36.2 ml/kg/min, 215.1 minutes, and 3.38 L/kg, respectively, in the presence of medetomidine.",Effect of medetomidine on the pharmacokinetics of propofol in dogs. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7908181/),min,301.8,234592,DB00818,Propofol
,7908181,volume of distribution at steady state,"Mean elimination half-life, blood clearance, mean residence time, and mean volume of distribution at steady state, were 486.2 minutes, 34.4 ml/kg/min, 301.8 minutes, and 6.04 L/kg, respectively, in the absence of medetomidine, and 136.9 minutes, 36.2 ml/kg/min, 215.1 minutes, and 3.38 L/kg, respectively, in the presence of medetomidine.",Effect of medetomidine on the pharmacokinetics of propofol in dogs. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7908181/),[l] / [kg],6.04,234593,DB00818,Propofol
,7908181,volume of distribution at steady state,"Mean elimination half-life, blood clearance, mean residence time, and mean volume of distribution at steady state, were 486.2 minutes, 34.4 ml/kg/min, 301.8 minutes, and 6.04 L/kg, respectively, in the absence of medetomidine, and 136.9 minutes, 36.2 ml/kg/min, 215.1 minutes, and 3.38 L/kg, respectively, in the presence of medetomidine.",Effect of medetomidine on the pharmacokinetics of propofol in dogs. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7908181/),min,215.1,234594,DB00818,Propofol
,7908181,volume of distribution at steady state,"Mean elimination half-life, blood clearance, mean residence time, and mean volume of distribution at steady state, were 486.2 minutes, 34.4 ml/kg/min, 301.8 minutes, and 6.04 L/kg, respectively, in the absence of medetomidine, and 136.9 minutes, 36.2 ml/kg/min, 215.1 minutes, and 3.38 L/kg, respectively, in the presence of medetomidine.",Effect of medetomidine on the pharmacokinetics of propofol in dogs. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7908181/),[l] / [kg],3.38,234595,DB00818,Propofol
,7908181,time to walking without ataxia,Mean time to walking without ataxia was 174 minutes in the nonpremedicated dogs (with a median blood propofol concentration of 2.2 micrograms/ml) and was 160 minutes in the premedicated dogs in which median blood propofol concentration was 1.03 microgram/ml.,Effect of medetomidine on the pharmacokinetics of propofol in dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7908181/),min,174,234596,DB00818,Propofol
,7908181,time to walking without ataxia,Mean time to walking without ataxia was 174 minutes in the nonpremedicated dogs (with a median blood propofol concentration of 2.2 micrograms/ml) and was 160 minutes in the premedicated dogs in which median blood propofol concentration was 1.03 microgram/ml.,Effect of medetomidine on the pharmacokinetics of propofol in dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7908181/),min,160,234597,DB00818,Propofol
,31231918,ED50,"The ED50 of propofol was 1.651 mg/kg (95% CI, 1.561-1.722 mg/kg) in Group A and 1.991 mg/kg (95% CI, 1.902-2.081 mg/kg) in Group B.",ED50 of propofol in combination with low-dose sufentanil for intravenous anaesthesia in hysteroscopy. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31231918/),[mg] / [kg],1.651,235173,DB00818,Propofol
,31231918,ED50,"The ED50 of propofol was 1.651 mg/kg (95% CI, 1.561-1.722 mg/kg) in Group A and 1.991 mg/kg (95% CI, 1.902-2.081 mg/kg) in Group B.",ED50 of propofol in combination with low-dose sufentanil for intravenous anaesthesia in hysteroscopy. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31231918/),[mg] / [kg],1.991,235174,DB00818,Propofol
,31231918,ED95,"The ED95 of propofol was 1.827 mg/kg (95% CI, 1.746-2.236 mg/kg) in Group A and 2.153 mg/kg (95% CI, 2.070-2.73 7 mg/kg) in Group B.",ED50 of propofol in combination with low-dose sufentanil for intravenous anaesthesia in hysteroscopy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31231918/),[mg] / [kg],1.827,235175,DB00818,Propofol
,31231918,ED95,"The ED95 of propofol was 1.827 mg/kg (95% CI, 1.746-2.236 mg/kg) in Group A and 2.153 mg/kg (95% CI, 2.070-2.73 7 mg/kg) in Group B.",ED50 of propofol in combination with low-dose sufentanil for intravenous anaesthesia in hysteroscopy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31231918/),[mg] / [kg],2.153,235176,DB00818,Propofol
,31231918,ED50,"The ED50 values for propofol when co-administered with low-dose sufentanil for intravenous anaesthesia in hysteroscopy were 1.651 mg/kg (sufentanil 0.2 μg/kg) and 1.991 mg/kg (sufentanil 0.1 μg/kg). (www.chictr.org.cn, registration number: ChiCTR1900021224).",ED50 of propofol in combination with low-dose sufentanil for intravenous anaesthesia in hysteroscopy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31231918/),[mg] / [kg],1.651,235177,DB00818,Propofol
,31231918,ED50,"The ED50 values for propofol when co-administered with low-dose sufentanil for intravenous anaesthesia in hysteroscopy were 1.651 mg/kg (sufentanil 0.2 μg/kg) and 1.991 mg/kg (sufentanil 0.1 μg/kg). (www.chictr.org.cn, registration number: ChiCTR1900021224).",ED50 of propofol in combination with low-dose sufentanil for intravenous anaesthesia in hysteroscopy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31231918/),[mg] / [kg],1.991,235178,DB00818,Propofol
,29797070,dose per weight,Mean (± SD) propofol dose per weight (mg/kg) was 6.5 ± 2.1 for CF patients versus 3.8 ± 1.6 for non-CF patients (p < 0.001).,Sedation with Propofol for Bronchoscopy in Cystic Fibrosis Lung Transplant Recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29797070/),,6.5,235635,DB00818,Propofol
,29797070,dose per weight,Mean (± SD) propofol dose per weight (mg/kg) was 6.5 ± 2.1 for CF patients versus 3.8 ± 1.6 for non-CF patients (p < 0.001).,Sedation with Propofol for Bronchoscopy in Cystic Fibrosis Lung Transplant Recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29797070/),,3.8,235636,DB00818,Propofol
,8969394,infusion rate,Patients were anesthetized using a continuous infusion of alfentanil (mean infusion rate: 1 microgram/kg/min) and propofol administered by TCI.,Administration of propofol by target-controlled infusion in patients undergoing coronary artery surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8969394/),[μg] / [kg·min],1,237365,DB00818,Propofol
,8969394,target concentrations,"In the period during and after bypass, the mean target concentrations required to maintain anesthesia was 2.22 micrograms/mL.",Administration of propofol by target-controlled infusion in patients undergoing coronary artery surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8969394/),[μg] / [ml],2.22,237366,DB00818,Propofol
,9229987,recovery score,"Recovery times were significantly shorter for remifentanil-isoflurane than for remifentanil-propofol (Table 3): spontaneous ventilation 5.1 vs 8.1 min (P < 0.05), extubation 5.5 vs 8.6 min (P < 0.02), post-anaesthesia recovery score > or = 9 of 10 points 6.2 vs 11.3 min (P < 0.01), and arrival at PACU 16.2 vs 19.2 min (P < 0.01).",[Remifentanil with propofol or isoflurane. A comparison of the recovery times after arthroscopic surgery]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9229987/),min,6.2,237367,DB00818,Propofol
,9229987,recovery score,"Recovery times were significantly shorter for remifentanil-isoflurane than for remifentanil-propofol (Table 3): spontaneous ventilation 5.1 vs 8.1 min (P < 0.05), extubation 5.5 vs 8.6 min (P < 0.02), post-anaesthesia recovery score > or = 9 of 10 points 6.2 vs 11.3 min (P < 0.01), and arrival at PACU 16.2 vs 19.2 min (P < 0.01).",[Remifentanil with propofol or isoflurane. A comparison of the recovery times after arthroscopic surgery]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9229987/),min,11.3,237368,DB00818,Propofol
,9229987,recovery score,"Recovery times were significantly shorter for remifentanil-isoflurane than for remifentanil-propofol (Table 3): spontaneous ventilation 5.1 vs 8.1 min (P < 0.05), extubation 5.5 vs 8.6 min (P < 0.02), post-anaesthesia recovery score > or = 9 of 10 points 6.2 vs 11.3 min (P < 0.01), and arrival at PACU 16.2 vs 19.2 min (P < 0.01).",[Remifentanil with propofol or isoflurane. A comparison of the recovery times after arthroscopic surgery]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9229987/),min,16.2,237369,DB00818,Propofol
,9229987,recovery score,"Recovery times were significantly shorter for remifentanil-isoflurane than for remifentanil-propofol (Table 3): spontaneous ventilation 5.1 vs 8.1 min (P < 0.05), extubation 5.5 vs 8.6 min (P < 0.02), post-anaesthesia recovery score > or = 9 of 10 points 6.2 vs 11.3 min (P < 0.01), and arrival at PACU 16.2 vs 19.2 min (P < 0.01).",[Remifentanil with propofol or isoflurane. A comparison of the recovery times after arthroscopic surgery]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9229987/),min,19.2,237370,DB00818,Propofol
,16672092,Bispectral Index,"For both groups, the objective was to achieve a Bispectral Index of 50.",Feasibility of closed-loop titration of propofol guided by the Bispectral Index for general anaesthesia induction: a prospective randomized study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16672092/),,50,237382,DB00818,Propofol
,16672092,duration of,"Bispectral Index overshoot (-9 +/- 13% vs. -16 +/- 20%, P = 0.035) and mean duration of induction (381 +/- 106 s vs. 490 +/- 131 s, P = 0.004) were lower in the closed-loop group than in the TCI group.",Feasibility of closed-loop titration of propofol guided by the Bispectral Index for general anaesthesia induction: a prospective randomized study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16672092/),s,381,237383,DB00818,Propofol
,16672092,duration of,"Bispectral Index overshoot (-9 +/- 13% vs. -16 +/- 20%, P = 0.035) and mean duration of induction (381 +/- 106 s vs. 490 +/- 131 s, P = 0.004) were lower in the closed-loop group than in the TCI group.",Feasibility of closed-loop titration of propofol guided by the Bispectral Index for general anaesthesia induction: a prospective randomized study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16672092/),s,490,237384,DB00818,Propofol
,32337104,ED50,"The potency of HX0969W (ED50 [95% CI], 46.49 [43.89-49.29] mg/kg) was similar to that of fospropofol disodium (43.66 [43.57-43.75] mg/kg), but was lower than that of propofol (4.82 [4.8-14.82] mg/kg).","The preclinical pharmacological study on HX0969W, a novel water-soluble pro-drug of propofol, in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32337104/),[mg] / [kg],46.49,238160,DB00818,Propofol
,32337104,ED50,"The potency of HX0969W (ED50 [95% CI], 46.49 [43.89-49.29] mg/kg) was similar to that of fospropofol disodium (43.66 [43.57-43.75] mg/kg), but was lower than that of propofol (4.82 [4.8-14.82] mg/kg).","The preclinical pharmacological study on HX0969W, a novel water-soluble pro-drug of propofol, in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32337104/),[mg] / [kg],43.66,238161,DB00818,Propofol
,32337104,ED50,"The potency of HX0969W (ED50 [95% CI], 46.49 [43.89-49.29] mg/kg) was similar to that of fospropofol disodium (43.66 [43.57-43.75] mg/kg), but was lower than that of propofol (4.82 [4.8-14.82] mg/kg).","The preclinical pharmacological study on HX0969W, a novel water-soluble pro-drug of propofol, in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32337104/),[mg] / [kg],4.82,238162,DB00818,Propofol
,15564932,tpeak,The mean tpeak was 80 +/- 20 s in adults and 132 +/- 49 s in children (P < 0.001).,Estimation of the plasma effect site equilibration rate constant (ke0) of propofol in children using the time to peak effect: comparison with adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15564932/),s,80,238287,DB00818,Propofol
,15564932,tpeak,The mean tpeak was 80 +/- 20 s in adults and 132 +/- 49 s in children (P < 0.001).,Estimation of the plasma effect site equilibration rate constant (ke0) of propofol in children using the time to peak effect: comparison with adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15564932/),s,132,238288,DB00818,Propofol
,15564932,ke0,The median ke0 in children was 0.41 min(-1) with the model of Kataria and 0.91 min(-1) with the Paedfusor model (P < 0.01).,Estimation of the plasma effect site equilibration rate constant (ke0) of propofol in children using the time to peak effect: comparison with adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15564932/),1/[min],0.41,238289,DB00818,Propofol
,15564932,ke0,The median ke0 in children was 0.41 min(-1) with the model of Kataria and 0.91 min(-1) with the Paedfusor model (P < 0.01).,Estimation of the plasma effect site equilibration rate constant (ke0) of propofol in children using the time to peak effect: comparison with adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15564932/),1/[min],0.91,238290,DB00818,Propofol
,15564932,t1/2 ke0,"The corresponding t1/2 ke0 values, in minutes, were 1.7 and 0.8, respectively (P < 0.01).",Estimation of the plasma effect site equilibration rate constant (ke0) of propofol in children using the time to peak effect: comparison with adults. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15564932/),min,1.7,238291,DB00818,Propofol
,15564932,t1/2 ke0,"The corresponding t1/2 ke0 values, in minutes, were 1.7 and 0.8, respectively (P < 0.01).",Estimation of the plasma effect site equilibration rate constant (ke0) of propofol in children using the time to peak effect: comparison with adults. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15564932/),min,0.8,238292,DB00818,Propofol
,17583594,T(PEAK),"The mean T(PEAK) was 145 +/- 35 s (50-224 s) and 74+/-24 s (38-143 s) in Groups AAI and BIS, respectively (P < 0.01 between groups).",A comparison between bispectral index analysis and auditory-evoked potentials for monitoring the time to peak effect to calculate the plasma effect site equilibration rate constant of propofol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17583594/),s,145,238293,DB00818,Propofol
,17583594,T(PEAK),"The mean T(PEAK) was 145 +/- 35 s (50-224 s) and 74+/-24 s (38-143 s) in Groups AAI and BIS, respectively (P < 0.01 between groups).",A comparison between bispectral index analysis and auditory-evoked potentials for monitoring the time to peak effect to calculate the plasma effect site equilibration rate constant of propofol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17583594/),s,74,238294,DB00818,Propofol
,17583594,k(e0),"The median k(e0) in Group AAI was 0.64 min(-1) with the model of Marsh, 0.17 min(-1) with the Schnider model, 0.78 min(-1) with the Tackley model and 0.93 min(-1) with the Shafer model.",A comparison between bispectral index analysis and auditory-evoked potentials for monitoring the time to peak effect to calculate the plasma effect site equilibration rate constant of propofol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17583594/),1/[min],0.64,238295,DB00818,Propofol
,17583594,k(e0),"The median k(e0) in Group AAI was 0.64 min(-1) with the model of Marsh, 0.17 min(-1) with the Schnider model, 0.78 min(-1) with the Tackley model and 0.93 min(-1) with the Shafer model.",A comparison between bispectral index analysis and auditory-evoked potentials for monitoring the time to peak effect to calculate the plasma effect site equilibration rate constant of propofol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17583594/),1/[min],0.17,238296,DB00818,Propofol
,17583594,k(e0),"The median k(e0) in Group AAI was 0.64 min(-1) with the model of Marsh, 0.17 min(-1) with the Schnider model, 0.78 min(-1) with the Tackley model and 0.93 min(-1) with the Shafer model.",A comparison between bispectral index analysis and auditory-evoked potentials for monitoring the time to peak effect to calculate the plasma effect site equilibration rate constant of propofol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17583594/),1/[min],0.78,238297,DB00818,Propofol
,17583594,k(e0),"The median k(e0) in Group AAI was 0.64 min(-1) with the model of Marsh, 0.17 min(-1) with the Schnider model, 0.78 min(-1) with the Tackley model and 0.93 min(-1) with the Shafer model.",A comparison between bispectral index analysis and auditory-evoked potentials for monitoring the time to peak effect to calculate the plasma effect site equilibration rate constant of propofol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17583594/),1/[min],0.93,238298,DB00818,Propofol
,17583594,k(e0),"The median k(e0) in Group BIS was 1.87 min(-1) with the model of Marsh, 0.83 min(-1) with the Schnider model, 2.14 min(-1) with the Tackley model and 2.48 min(-1) with the Shafer model (P < 0.01 between groups and models).",A comparison between bispectral index analysis and auditory-evoked potentials for monitoring the time to peak effect to calculate the plasma effect site equilibration rate constant of propofol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17583594/),1/[min],1.87,238299,DB00818,Propofol
,17583594,k(e0),"The median k(e0) in Group BIS was 1.87 min(-1) with the model of Marsh, 0.83 min(-1) with the Schnider model, 2.14 min(-1) with the Tackley model and 2.48 min(-1) with the Shafer model (P < 0.01 between groups and models).",A comparison between bispectral index analysis and auditory-evoked potentials for monitoring the time to peak effect to calculate the plasma effect site equilibration rate constant of propofol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17583594/),1/[min],0.83,238300,DB00818,Propofol
,17583594,k(e0),"The median k(e0) in Group BIS was 1.87 min(-1) with the model of Marsh, 0.83 min(-1) with the Schnider model, 2.14 min(-1) with the Tackley model and 2.48 min(-1) with the Shafer model (P < 0.01 between groups and models).",A comparison between bispectral index analysis and auditory-evoked potentials for monitoring the time to peak effect to calculate the plasma effect site equilibration rate constant of propofol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17583594/),1/[min],2.14,238301,DB00818,Propofol
,17583594,k(e0),"The median k(e0) in Group BIS was 1.87 min(-1) with the model of Marsh, 0.83 min(-1) with the Schnider model, 2.14 min(-1) with the Tackley model and 2.48 min(-1) with the Shafer model (P < 0.01 between groups and models).",A comparison between bispectral index analysis and auditory-evoked potentials for monitoring the time to peak effect to calculate the plasma effect site equilibration rate constant of propofol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17583594/),1/[min],2.48,238302,DB00818,Propofol
,7914736,blood clearance,"Propofol blood clearance was 29.8 +/- 6.51 ml/min/kg, and volume of distribution was 3.60 +/- 1.34 L/kg, resulting in a blood elimination half-life of 144 +/- 46 minutes.",Clinical pharmacokinetics of propofol given as a constant-rate infusion and in combination with epidural blockade. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7914736/),[ml] / [kg·min],29.8,240059,DB00818,Propofol
,7914736,volume of distribution,"Propofol blood clearance was 29.8 +/- 6.51 ml/min/kg, and volume of distribution was 3.60 +/- 1.34 L/kg, resulting in a blood elimination half-life of 144 +/- 46 minutes.",Clinical pharmacokinetics of propofol given as a constant-rate infusion and in combination with epidural blockade. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7914736/),[l] / [kg],3.60,240060,DB00818,Propofol
,7914736,blood elimination half-life,"Propofol blood clearance was 29.8 +/- 6.51 ml/min/kg, and volume of distribution was 3.60 +/- 1.34 L/kg, resulting in a blood elimination half-life of 144 +/- 46 minutes.",Clinical pharmacokinetics of propofol given as a constant-rate infusion and in combination with epidural blockade. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7914736/),min,144,240061,DB00818,Propofol
,31797395,BIS,Propofol infusion was started at 2000 mg/h until loss of consciousness and then guided by target BIS values (40-60).,Population Pharmacokinetic-Pharmacodynamic Modeling for Propofol Anesthesia Guided by the Bispectral Index (BIS). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31797395/),,40-60,240656,DB00818,Propofol
,29451620,time to patient extubation,"Propofol target-controlled infusion was discontinued when orotracheal extubation was indicated, and the time to patient extubation was significantly higher in the hypothermic on-pump group than in the off-pump group (459 versus 273 min, p=0.0048).",Application of a pharmacokinetics-pharmacodynamics approach to the free propofol plasma levels during coronary artery bypass grafting surgery with hypothermic cardiopulmonary bypass. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29451620/),min,459,243502,DB00818,Propofol
,29451620,time to patient extubation,"Propofol target-controlled infusion was discontinued when orotracheal extubation was indicated, and the time to patient extubation was significantly higher in the hypothermic on-pump group than in the off-pump group (459 versus 273 min, p=0.0048).",Application of a pharmacokinetics-pharmacodynamics approach to the free propofol plasma levels during coronary artery bypass grafting surgery with hypothermic cardiopulmonary bypass. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29451620/),min,273,243503,DB00818,Propofol
,8130049,infusion rate,Initially we studied 10 children undergoing minor procedures with spontaneous ventilation; mean duration of surgery was 38 min and mean propofol infusion rate 497 micrograms kg-1 min-1.,A prospective evaluation of pharmacokinetic model controlled infusion of propofol in paediatric patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8130049/),[μg] / [kg·min],497,243725,DB00818,Propofol
,8130049,infusion rate,Mean propofol infusion rate required to maintain anaesthesia was 474 micrograms kg-1 min-1 (range 125-737 micrograms kg-1 min-1).,A prospective evaluation of pharmacokinetic model controlled infusion of propofol in paediatric patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8130049/),[μg] / [kg·min],474,243726,DB00818,Propofol
,8130049,blood concentration,"The mean blood concentration required for satisfactory anaesthesia was 6.6 micrograms ml-1 (range 3-11 micrograms ml-1) and the mean blood concentration at the time of waking, which occurred 40 min after switching off the infusion, 0.86 microgram ml-1 (range 0.40-1.45 micrograms ml-1).",A prospective evaluation of pharmacokinetic model controlled infusion of propofol in paediatric patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8130049/),[μg] / [ml],6.6,243727,DB00818,Propofol
,8130049,blood concentration at,"The mean blood concentration required for satisfactory anaesthesia was 6.6 micrograms ml-1 (range 3-11 micrograms ml-1) and the mean blood concentration at the time of waking, which occurred 40 min after switching off the infusion, 0.86 microgram ml-1 (range 0.40-1.45 micrograms ml-1).",A prospective evaluation of pharmacokinetic model controlled infusion of propofol in paediatric patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8130049/),[μg] / [ml],0.86,243728,DB00818,Propofol
,25150710,infusion rate,"The aminophylline infusion rate was 0.69 (period 3), 1.37 (period 4), and 2.62 (period 5) mg/kg/h.",Impact of aminophylline on the pharmacodynamics of propofol in beagle dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25150710/),[mg] / [h·kg],0.69,244982,DB00818,Propofol
,25150710,infusion rate,"The aminophylline infusion rate was 0.69 (period 3), 1.37 (period 4), and 2.62 (period 5) mg/kg/h.",Impact of aminophylline on the pharmacodynamics of propofol in beagle dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25150710/),[mg] / [h·kg],1.37,244983,DB00818,Propofol
,25150710,infusion rate,"The aminophylline infusion rate was 0.69 (period 3), 1.37 (period 4), and 2.62 (period 5) mg/kg/h.",Impact of aminophylline on the pharmacodynamics of propofol in beagle dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25150710/),[mg] / [h·kg],2.62,244984,DB00818,Propofol
,25150710,k(e0),"Pharmacodynamic parameter estimates of propofol were: k(e0) = 0.805/min, E0 = 0.76, Emax = 0.398, Ce(50 na) = 2.38 μg/mL (without aminophylline-exposure), C(e50 wa) = 4.49 μg/mL (with aminophylline-exposure), and γ = 2.21.",Impact of aminophylline on the pharmacodynamics of propofol in beagle dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25150710/),1/[min],0.805,244985,DB00818,Propofol
,25150710,E0,"Pharmacodynamic parameter estimates of propofol were: k(e0) = 0.805/min, E0 = 0.76, Emax = 0.398, Ce(50 na) = 2.38 μg/mL (without aminophylline-exposure), C(e50 wa) = 4.49 μg/mL (with aminophylline-exposure), and γ = 2.21.",Impact of aminophylline on the pharmacodynamics of propofol in beagle dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25150710/),,0.76,244986,DB00818,Propofol
,25150710,Emax,"Pharmacodynamic parameter estimates of propofol were: k(e0) = 0.805/min, E0 = 0.76, Emax = 0.398, Ce(50 na) = 2.38 μg/mL (without aminophylline-exposure), C(e50 wa) = 4.49 μg/mL (with aminophylline-exposure), and γ = 2.21.",Impact of aminophylline on the pharmacodynamics of propofol in beagle dogs. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25150710/),,0.398,244987,DB00818,Propofol
,25150710,Ce(50 na),"Pharmacodynamic parameter estimates of propofol were: k(e0) = 0.805/min, E0 = 0.76, Emax = 0.398, Ce(50 na) = 2.38 μg/mL (without aminophylline-exposure), C(e50 wa) = 4.49 μg/mL (with aminophylline-exposure), and γ = 2.21.",Impact of aminophylline on the pharmacodynamics of propofol in beagle dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25150710/),[μg] / [ml],2.38,244988,DB00818,Propofol
,25150710,C(e50 wa),"Pharmacodynamic parameter estimates of propofol were: k(e0) = 0.805/min, E0 = 0.76, Emax = 0.398, Ce(50 na) = 2.38 μg/mL (without aminophylline-exposure), C(e50 wa) = 4.49 μg/mL (with aminophylline-exposure), and γ = 2.21.",Impact of aminophylline on the pharmacodynamics of propofol in beagle dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25150710/),[μg] / [ml],4.49,244989,DB00818,Propofol
,25150710,γ,"Pharmacodynamic parameter estimates of propofol were: k(e0) = 0.805/min, E0 = 0.76, Emax = 0.398, Ce(50 na) = 2.38 μg/mL (without aminophylline-exposure), C(e50 wa) = 4.49 μg/mL (with aminophylline-exposure), and γ = 2.21.",Impact of aminophylline on the pharmacodynamics of propofol in beagle dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25150710/),,2.21,244990,DB00818,Propofol
,12392590,clearance (CL),"Pharmacokinetic parameters in the weight-proportional model were clearance (CL) = 35 ml kg-1 min-1, volume of central compartment (V1) = 12 l, intercompartmental clearance (Q) = 0.35 l min-1 and volume of peripheral compartment (V2) = 24 l.",Pharmacokinetics and effects of propofol 6% for short-term sedation in paediatric patients following cardiac surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12392590/),[ml] / [kg·min],35,245354,DB00818,Propofol
,12392590,volume of central compartment (V1),"Pharmacokinetic parameters in the weight-proportional model were clearance (CL) = 35 ml kg-1 min-1, volume of central compartment (V1) = 12 l, intercompartmental clearance (Q) = 0.35 l min-1 and volume of peripheral compartment (V2) = 24 l.",Pharmacokinetics and effects of propofol 6% for short-term sedation in paediatric patients following cardiac surgery. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12392590/),l,12,245355,DB00818,Propofol
,12392590,intercompartmental clearance (Q),"Pharmacokinetic parameters in the weight-proportional model were clearance (CL) = 35 ml kg-1 min-1, volume of central compartment (V1) = 12 l, intercompartmental clearance (Q) = 0.35 l min-1 and volume of peripheral compartment (V2) = 24 l.",Pharmacokinetics and effects of propofol 6% for short-term sedation in paediatric patients following cardiac surgery. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12392590/),[l] / [min],0.35,245356,DB00818,Propofol
,12392590,volume of peripheral compartment (V2),"Pharmacokinetic parameters in the weight-proportional model were clearance (CL) = 35 ml kg-1 min-1, volume of central compartment (V1) = 12 l, intercompartmental clearance (Q) = 0.35 l min-1 and volume of peripheral compartment (V2) = 24 l.",Pharmacokinetics and effects of propofol 6% for short-term sedation in paediatric patients following cardiac surgery. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12392590/),l,24,245357,DB00818,Propofol
,12392590,CL,"Compared with the population pharmacokinetics in adults following cardiac surgery and when normalized for body weight, statistically significant differences were observed the parameters CL and V1 (35 vs 29 ml kg-1 min-1 and 0.78 vs 0.26 l kg-1P < 0.05), whereas the values for Q and V2 were similar (23 vs 18 ml kg-1 min-1 and 1.6 vs 1.8 l kg-1, P > 0.05).",Pharmacokinetics and effects of propofol 6% for short-term sedation in paediatric patients following cardiac surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12392590/),[ml] / [kg·min],35,245358,DB00818,Propofol
,12392590,CL,"Compared with the population pharmacokinetics in adults following cardiac surgery and when normalized for body weight, statistically significant differences were observed the parameters CL and V1 (35 vs 29 ml kg-1 min-1 and 0.78 vs 0.26 l kg-1P < 0.05), whereas the values for Q and V2 were similar (23 vs 18 ml kg-1 min-1 and 1.6 vs 1.8 l kg-1, P > 0.05).",Pharmacokinetics and effects of propofol 6% for short-term sedation in paediatric patients following cardiac surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12392590/),[ml] / [kg·min],29,245359,DB00818,Propofol
,12392590,V1,"Compared with the population pharmacokinetics in adults following cardiac surgery and when normalized for body weight, statistically significant differences were observed the parameters CL and V1 (35 vs 29 ml kg-1 min-1 and 0.78 vs 0.26 l kg-1P < 0.05), whereas the values for Q and V2 were similar (23 vs 18 ml kg-1 min-1 and 1.6 vs 1.8 l kg-1, P > 0.05).",Pharmacokinetics and effects of propofol 6% for short-term sedation in paediatric patients following cardiac surgery. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12392590/),[l] / [kg],0.78,245360,DB00818,Propofol
,12392590,V1,"Compared with the population pharmacokinetics in adults following cardiac surgery and when normalized for body weight, statistically significant differences were observed the parameters CL and V1 (35 vs 29 ml kg-1 min-1 and 0.78 vs 0.26 l kg-1P < 0.05), whereas the values for Q and V2 were similar (23 vs 18 ml kg-1 min-1 and 1.6 vs 1.8 l kg-1, P > 0.05).",Pharmacokinetics and effects of propofol 6% for short-term sedation in paediatric patients following cardiac surgery. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12392590/),[l] / [kg],0.26,245361,DB00818,Propofol
,12392590,Q,"Compared with the population pharmacokinetics in adults following cardiac surgery and when normalized for body weight, statistically significant differences were observed the parameters CL and V1 (35 vs 29 ml kg-1 min-1 and 0.78 vs 0.26 l kg-1P < 0.05), whereas the values for Q and V2 were similar (23 vs 18 ml kg-1 min-1 and 1.6 vs 1.8 l kg-1, P > 0.05).",Pharmacokinetics and effects of propofol 6% for short-term sedation in paediatric patients following cardiac surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12392590/),[ml] / [kg·min],23,245362,DB00818,Propofol
,12392590,Q,"Compared with the population pharmacokinetics in adults following cardiac surgery and when normalized for body weight, statistically significant differences were observed the parameters CL and V1 (35 vs 29 ml kg-1 min-1 and 0.78 vs 0.26 l kg-1P < 0.05), whereas the values for Q and V2 were similar (23 vs 18 ml kg-1 min-1 and 1.6 vs 1.8 l kg-1, P > 0.05).",Pharmacokinetics and effects of propofol 6% for short-term sedation in paediatric patients following cardiac surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12392590/),[ml] / [kg·min],18,245363,DB00818,Propofol
,12392590,V2,"Compared with the population pharmacokinetics in adults following cardiac surgery and when normalized for body weight, statistically significant differences were observed the parameters CL and V1 (35 vs 29 ml kg-1 min-1 and 0.78 vs 0.26 l kg-1P < 0.05), whereas the values for Q and V2 were similar (23 vs 18 ml kg-1 min-1 and 1.6 vs 1.8 l kg-1, P > 0.05).",Pharmacokinetics and effects of propofol 6% for short-term sedation in paediatric patients following cardiac surgery. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12392590/),[ml] / [kg·min],18,245364,DB00818,Propofol
,12392590,V2,"Compared with the population pharmacokinetics in adults following cardiac surgery and when normalized for body weight, statistically significant differences were observed the parameters CL and V1 (35 vs 29 ml kg-1 min-1 and 0.78 vs 0.26 l kg-1P < 0.05), whereas the values for Q and V2 were similar (23 vs 18 ml kg-1 min-1 and 1.6 vs 1.8 l kg-1, P > 0.05).",Pharmacokinetics and effects of propofol 6% for short-term sedation in paediatric patients following cardiac surgery. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12392590/),[l] / [kg],1.6,245365,DB00818,Propofol
,12392590,V2,"Compared with the population pharmacokinetics in adults following cardiac surgery and when normalized for body weight, statistically significant differences were observed the parameters CL and V1 (35 vs 29 ml kg-1 min-1 and 0.78 vs 0.26 l kg-1P < 0.05), whereas the values for Q and V2 were similar (23 vs 18 ml kg-1 min-1 and 1.6 vs 1.8 l kg-1, P > 0.05).",Pharmacokinetics and effects of propofol 6% for short-term sedation in paediatric patients following cardiac surgery. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12392590/),[l] / [kg],1.8,245366,DB00818,Propofol
,8512110,first-pass uptake,"The first-pass uptake of propofol (mean +/- SEM) was 61.3 +/- 4.9% and 60 +/- 3.7% of the injected dose in control cats and in cats whose lungs were mechanically ventilated, respectively.",Pulmonary uptake of propofol in cats. Effect of fentanyl and halothane. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8512110/),%,61.3,246044,DB00818,Propofol
,8512110,first-pass uptake,"The first-pass uptake of propofol (mean +/- SEM) was 61.3 +/- 4.9% and 60 +/- 3.7% of the injected dose in control cats and in cats whose lungs were mechanically ventilated, respectively.",Pulmonary uptake of propofol in cats. Effect of fentanyl and halothane. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8512110/),%,60,246045,DB00818,Propofol
,14975208,effect-site concentration,The target effect-site concentration was set at 3 microg/ml and the infusion was lasted for 15 minutes.,Concentrations of propofol in cerebral spinal fluid: target-controlled infusion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14975208/),[μg] / [ml],3,246764,DB00818,Propofol
,10422929,PWRmax,"Preload-adjusted PWRmax amounted to 3.90+/-1.75 W x ml(-2) x 10(4), 3.98+/-1.69, 3.94+/-1.70, and 3.88+/-1.72, respectively (mean+/-SD).",Contractility in humans after coronary artery surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10422929/),[10(4·w] / [(ml)^2],3.90,247618,DB00818,Propofol
,10422929,PWRmax,"Preload-adjusted PWRmax amounted to 3.90+/-1.75 W x ml(-2) x 10(4), 3.98+/-1.69, 3.94+/-1.70, and 3.88+/-1.72, respectively (mean+/-SD).",Contractility in humans after coronary artery surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10422929/),,3.98,247619,DB00818,Propofol
,10422929,PWRmax,"Preload-adjusted PWRmax amounted to 3.90+/-1.75 W x ml(-2) x 10(4), 3.98+/-1.69, 3.94+/-1.70, and 3.88+/-1.72, respectively (mean+/-SD).",Contractility in humans after coronary artery surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10422929/),[10(4·w] / [(ml)^2],3.94,247620,DB00818,Propofol
,10422929,PWRmax,"Preload-adjusted PWRmax amounted to 3.90+/-1.75 W x ml(-2) x 10(4), 3.98+/-1.69, 3.94+/-1.70, and 3.88+/-1.72, respectively (mean+/-SD).",Contractility in humans after coronary artery surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10422929/),[10(4·w] / [(ml)^2],3.88,247621,DB00818,Propofol
,21518104,k(e0),"The final population models were comparable with each other; the two-stage and the mixed-effect approaches resulted in a k(e0) of 2.38 and 2.66 min(-1), γ of 5.29 and 5.68, and EC(50) of 4.73 and 4.84 μg·ml(-1), respectively.",Two-stage vs mixed-effect approach to pharmacodynamic modeling of propofol in children using state entropy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21518104/),1/[min],2.38,247658,DB00818,Propofol
,21518104,k(e0),"The final population models were comparable with each other; the two-stage and the mixed-effect approaches resulted in a k(e0) of 2.38 and 2.66 min(-1), γ of 5.29 and 5.68, and EC(50) of 4.73 and 4.84 μg·ml(-1), respectively.",Two-stage vs mixed-effect approach to pharmacodynamic modeling of propofol in children using state entropy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21518104/),1/[min],2.66,247659,DB00818,Propofol
,21518104,γ,"The final population models were comparable with each other; the two-stage and the mixed-effect approaches resulted in a k(e0) of 2.38 and 2.66 min(-1), γ of 5.29 and 5.68, and EC(50) of 4.73 and 4.84 μg·ml(-1), respectively.",Two-stage vs mixed-effect approach to pharmacodynamic modeling of propofol in children using state entropy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21518104/),,5.29,247660,DB00818,Propofol
,21518104,γ,"The final population models were comparable with each other; the two-stage and the mixed-effect approaches resulted in a k(e0) of 2.38 and 2.66 min(-1), γ of 5.29 and 5.68, and EC(50) of 4.73 and 4.84 μg·ml(-1), respectively.",Two-stage vs mixed-effect approach to pharmacodynamic modeling of propofol in children using state entropy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21518104/),,5.68,247661,DB00818,Propofol
,21518104,EC(50),"The final population models were comparable with each other; the two-stage and the mixed-effect approaches resulted in a k(e0) of 2.38 and 2.66 min(-1), γ of 5.29 and 5.68, and EC(50) of 4.73 and 4.84 μg·ml(-1), respectively.",Two-stage vs mixed-effect approach to pharmacodynamic modeling of propofol in children using state entropy. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21518104/),[μg] / [ml],4.73,247662,DB00818,Propofol
,21518104,EC(50),"The final population models were comparable with each other; the two-stage and the mixed-effect approaches resulted in a k(e0) of 2.38 and 2.66 min(-1), γ of 5.29 and 5.68, and EC(50) of 4.73 and 4.84 μg·ml(-1), respectively.",Two-stage vs mixed-effect approach to pharmacodynamic modeling of propofol in children using state entropy. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21518104/),[μg] / [ml],4.84,247663,DB00818,Propofol
,21518104,k(e0),"The bootstrap estimates of the PD parameters were mean (SD) k(e0) = 2.38 (0.10), γ = 5.30 (0.30), and EC(50) = 4.73 (0.14).",Two-stage vs mixed-effect approach to pharmacodynamic modeling of propofol in children using state entropy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21518104/),,2.38,247664,DB00818,Propofol
,21518104,γ,"The bootstrap estimates of the PD parameters were mean (SD) k(e0) = 2.38 (0.10), γ = 5.30 (0.30), and EC(50) = 4.73 (0.14).",Two-stage vs mixed-effect approach to pharmacodynamic modeling of propofol in children using state entropy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21518104/),,5.30,247665,DB00818,Propofol
,21518104,EC(50),"The bootstrap estimates of the PD parameters were mean (SD) k(e0) = 2.38 (0.10), γ = 5.30 (0.30), and EC(50) = 4.73 (0.14).",Two-stage vs mixed-effect approach to pharmacodynamic modeling of propofol in children using state entropy. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21518104/),,4.73,247666,DB00818,Propofol
,25170571,ED50,"Compared with etomidate, CPMM was half as potent as a hypnotic (ED50 approximately 0.8 mg/kg), was more rapidly metabolized, and had a shorter duration of sedative-hypnotic action.",Advancing novel anesthetics: pharmacodynamic and pharmacokinetic studies of cyclopropyl-methoxycarbonyl metomidate in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25170571/),[mg] / [kg],0.8,248749,DB00818,Propofol
,25170571,half-time,"Adrenocortical recovery was faster in dogs after CPMM infusion versus etomidate infusion (half-time: 215 vs. 1,623 min, respectively).",Advancing novel anesthetics: pharmacodynamic and pharmacokinetic studies of cyclopropyl-methoxycarbonyl metomidate in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25170571/),min,215,248750,DB00818,Propofol
,25170571,half-time,"Adrenocortical recovery was faster in dogs after CPMM infusion versus etomidate infusion (half-time: 215 vs. 1,623 min, respectively).",Advancing novel anesthetics: pharmacodynamic and pharmacokinetic studies of cyclopropyl-methoxycarbonyl metomidate in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25170571/),min,"1,623",248751,DB00818,Propofol
,16273909,concentrations,"Mean +/- SD plasma marbofloxacin concentrations 2 and 6 hours after the fifth dose were 2.36 +/- 0.52 microg/mL and 1.81 +/- 0.21 microg/mL, respectively.",Evaluation of the concentration of marbofloxacin in alveolar macrophages and pulmonary epithelial lining fluid after administration in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16273909/),[μg] / [ml],2.36,250270,DB00818,Propofol
,16273909,concentrations,"Mean +/- SD plasma marbofloxacin concentrations 2 and 6 hours after the fifth dose were 2.36 +/- 0.52 microg/mL and 1.81 +/- 0.21 microg/mL, respectively.",Evaluation of the concentration of marbofloxacin in alveolar macrophages and pulmonary epithelial lining fluid after administration in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16273909/),[μg] / [ml],1.81,250271,DB00818,Propofol
,16273909,concentration,"Mean +/- SD marbofloxacin concentration 6 hours after the fifth dose in AMs (37.43 +/- 24.61 microg/mL) was significantly greater than that in plasma (1.81 +/- 0.21 microg/mL) and ELF (0.82 +/- 0.34 microg/mL), resulting in a mean AM concentration-to-plasma concentration ratio of 20.4, a mean AM:ELF ratio of 60.8, and a mean ELF-to-plasma ratio of 0.46.",Evaluation of the concentration of marbofloxacin in alveolar macrophages and pulmonary epithelial lining fluid after administration in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16273909/),[μg] / [ml],37,250272,DB00818,Propofol
,16273909,concentration,"Mean +/- SD marbofloxacin concentration 6 hours after the fifth dose in AMs (37.43 +/- 24.61 microg/mL) was significantly greater than that in plasma (1.81 +/- 0.21 microg/mL) and ELF (0.82 +/- 0.34 microg/mL), resulting in a mean AM concentration-to-plasma concentration ratio of 20.4, a mean AM:ELF ratio of 60.8, and a mean ELF-to-plasma ratio of 0.46.",Evaluation of the concentration of marbofloxacin in alveolar macrophages and pulmonary epithelial lining fluid after administration in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16273909/),μ,1,250273,DB00818,Propofol
,16273909,concentration,"Mean +/- SD marbofloxacin concentration 6 hours after the fifth dose in AMs (37.43 +/- 24.61 microg/mL) was significantly greater than that in plasma (1.81 +/- 0.21 microg/mL) and ELF (0.82 +/- 0.34 microg/mL), resulting in a mean AM concentration-to-plasma concentration ratio of 20.4, a mean AM:ELF ratio of 60.8, and a mean ELF-to-plasma ratio of 0.46.",Evaluation of the concentration of marbofloxacin in alveolar macrophages and pulmonary epithelial lining fluid after administration in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16273909/),μg,0.82,250274,DB00818,Propofol
,16273909,concentration-to-plasma concentration ratio,"Mean +/- SD marbofloxacin concentration 6 hours after the fifth dose in AMs (37.43 +/- 24.61 microg/mL) was significantly greater than that in plasma (1.81 +/- 0.21 microg/mL) and ELF (0.82 +/- 0.34 microg/mL), resulting in a mean AM concentration-to-plasma concentration ratio of 20.4, a mean AM:ELF ratio of 60.8, and a mean ELF-to-plasma ratio of 0.46.",Evaluation of the concentration of marbofloxacin in alveolar macrophages and pulmonary epithelial lining fluid after administration in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16273909/),,20.4,250275,DB00818,Propofol
,16273909,ratio,"Mean +/- SD marbofloxacin concentration 6 hours after the fifth dose in AMs (37.43 +/- 24.61 microg/mL) was significantly greater than that in plasma (1.81 +/- 0.21 microg/mL) and ELF (0.82 +/- 0.34 microg/mL), resulting in a mean AM concentration-to-plasma concentration ratio of 20.4, a mean AM:ELF ratio of 60.8, and a mean ELF-to-plasma ratio of 0.46.",Evaluation of the concentration of marbofloxacin in alveolar macrophages and pulmonary epithelial lining fluid after administration in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16273909/),,60.8,250276,DB00818,Propofol
,16273909,-to-plasma ratio,"Mean +/- SD marbofloxacin concentration 6 hours after the fifth dose in AMs (37.43 +/- 24.61 microg/mL) was significantly greater than that in plasma (1.81 +/- 0.21 microg/mL) and ELF (0.82 +/- 0.34 microg/mL), resulting in a mean AM concentration-to-plasma concentration ratio of 20.4, a mean AM:ELF ratio of 60.8, and a mean ELF-to-plasma ratio of 0.46.",Evaluation of the concentration of marbofloxacin in alveolar macrophages and pulmonary epithelial lining fluid after administration in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16273909/),,0.46,250277,DB00818,Propofol
,10598622,cardiac output,"During the experiment, cardiac output was 3.90+/-0.72 l/min (mean +/- SD).",First-pass lung uptake and pulmonary clearance of propofol: assessment with a recirculatory indocyanine green pharmacokinetic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10598622/),[l] / [min],3.90,250524,DB00818,Propofol
,10598622,blood volume,"The blood volume in heart and lungs, measured with ICG, was 0.66+/-0.07 l.",First-pass lung uptake and pulmonary clearance of propofol: assessment with a recirculatory indocyanine green pharmacokinetic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10598622/),l,0.66,250525,DB00818,Propofol
,10598622,pulmonary tissue compartment,A pulmonary tissue compartment of 0.47+/-0.16 l was found for propofol.,First-pass lung uptake and pulmonary clearance of propofol: assessment with a recirculatory indocyanine green pharmacokinetic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10598622/),l,0.47,250526,DB00818,Propofol
,10598622,pulmonary first-pass elimination,The pulmonary first-pass elimination of propofol was 1.14+/-0.23 l/min.,First-pass lung uptake and pulmonary clearance of propofol: assessment with a recirculatory indocyanine green pharmacokinetic model. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10598622/),[l] / [min],1.14,250527,DB00818,Propofol
,26752560,clearance,"Mean population parameter estimates for maternal propofol clearance and central volume of distribution were 4.17 L/min and 37.7 L, respectively, in a typical ewe with a median heart rate of 135 beats/min.",Propofol Pharmacokinetics and Estimation of Fetal Propofol Exposure during Mid-Gestational Fetal Surgery: A Maternal-Fetal Sheep Model. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26752560/),[l] / [min],4.17,250722,DB00818,Propofol
,26752560,central volume of distribution,"Mean population parameter estimates for maternal propofol clearance and central volume of distribution were 4.17 L/min and 37.7 L, respectively, in a typical ewe with a median heart rate of 135 beats/min.",Propofol Pharmacokinetics and Estimation of Fetal Propofol Exposure during Mid-Gestational Fetal Surgery: A Maternal-Fetal Sheep Model. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26752560/),l,37.7,250723,DB00818,Propofol
,26752560,inter-compartment clearance,The estimated population maternal-fetal inter-compartment clearance was 0.0138 L/min and the volume of distribution of propofol in the fetus was 0.144 L.,Propofol Pharmacokinetics and Estimation of Fetal Propofol Exposure during Mid-Gestational Fetal Surgery: A Maternal-Fetal Sheep Model. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26752560/),[l] / [min],0.0138,250724,DB00818,Propofol
,26752560,volume of distribution,The estimated population maternal-fetal inter-compartment clearance was 0.0138 L/min and the volume of distribution of propofol in the fetus was 0.144 L.,Propofol Pharmacokinetics and Estimation of Fetal Propofol Exposure during Mid-Gestational Fetal Surgery: A Maternal-Fetal Sheep Model. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26752560/),l,0.144,250725,DB00818,Propofol
,18027597,alpha,"Remifentanil has short half-lives: the values of alpha and beta decay are about 2 and 15 min, respectively.",[Pharmacokinetic simulations of remifentanil]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18027597/),min,2,252357,DB00818,Propofol
,18027597,beta decay,"Remifentanil has short half-lives: the values of alpha and beta decay are about 2 and 15 min, respectively.",[Pharmacokinetic simulations of remifentanil]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18027597/),min,15,252358,DB00818,Propofol
,22956531,ECe(50),"The ECe(50) of propofol was 3.4 μg/mL (95% CI: 2.9, 3.7 μg/mL) with the Marsh model and 4.5 μg/mL (95% CI: 4.1, 4.8 μg/mL) with the Schnider model (P < 0.001).",The effective effect-site propofol concentration for induction and intubation with two pharmacokinetic models in morbidly obese patients using total body weight. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22956531/),[μg] / [ml],3.4,252953,DB00818,Propofol
,22956531,ECe(50),"The ECe(50) of propofol was 3.4 μg/mL (95% CI: 2.9, 3.7 μg/mL) with the Marsh model and 4.5 μg/mL (95% CI: 4.1, 4.8 μg/mL) with the Schnider model (P < 0.001).",The effective effect-site propofol concentration for induction and intubation with two pharmacokinetic models in morbidly obese patients using total body weight. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22956531/),[μg] / [ml],4.5,252954,DB00818,Propofol
,22956531,ECe(95),"The ECe(95) values were 4.2 μg/mL (95% CI: 3.8, 6.2 μg/mL) and 5.5 μg/mL (95% CI: 5.0, 7.2 μg/mL) with Marsh and Schnider models, respectively.",The effective effect-site propofol concentration for induction and intubation with two pharmacokinetic models in morbidly obese patients using total body weight. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22956531/),[μg] / [ml],4.2,252955,DB00818,Propofol
,22956531,ECe(95),"The ECe(95) values were 4.2 μg/mL (95% CI: 3.8, 6.2 μg/mL) and 5.5 μg/mL (95% CI: 5.0, 7.2 μg/mL) with Marsh and Schnider models, respectively.",The effective effect-site propofol concentration for induction and intubation with two pharmacokinetic models in morbidly obese patients using total body weight. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22956531/),[μg] / [ml],5.5,252956,DB00818,Propofol
,7734250,Apparent steady state blood propofol concentrations,Apparent steady state blood propofol concentrations were 3.41 (SD 0.69) micrograms ml-1 in the weight-corrected group and 3.46 (0.79) microgram ml-1 in the standard dose group.,Propofol administered by a manual infusion regimen. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7734250/),[μg] / [ml],3.41,255240,DB00818,Propofol
,7734250,Apparent steady state blood propofol concentrations,Apparent steady state blood propofol concentrations were 3.41 (SD 0.69) micrograms ml-1 in the weight-corrected group and 3.46 (0.79) microgram ml-1 in the standard dose group.,Propofol administered by a manual infusion regimen. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7734250/),[μg] / [ml],3.46,255241,DB00818,Propofol
,2265045,T1/2 alpha,The pharmacokinetic values for propofol were described by a three-compartment mammillary model with rapid distribution phases (T1/2 alpha mean (SEM) 3.1 (2.0) min and T1/2 beta 44 (9.1) min) and a slower final phase of T1/2 gamma 520 (96) min.,Pharmacokinetic interaction of propofol and fentanyl: single bolus injection study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2265045/),min,3.1,255342,DB00818,Propofol
,2265045,T1/2 beta,The pharmacokinetic values for propofol were described by a three-compartment mammillary model with rapid distribution phases (T1/2 alpha mean (SEM) 3.1 (2.0) min and T1/2 beta 44 (9.1) min) and a slower final phase of T1/2 gamma 520 (96) min.,Pharmacokinetic interaction of propofol and fentanyl: single bolus injection study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2265045/),min,44,255343,DB00818,Propofol
,2265045,T1/2 gamma,The pharmacokinetic values for propofol were described by a three-compartment mammillary model with rapid distribution phases (T1/2 alpha mean (SEM) 3.1 (2.0) min and T1/2 beta 44 (9.1) min) and a slower final phase of T1/2 gamma 520 (96) min.,Pharmacokinetic interaction of propofol and fentanyl: single bolus injection study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2265045/),min,520,255344,DB00818,Propofol
,2265045,clearance,The clearance of propofol was rapid (mean 1.6 (0.24) litre min-1).,Pharmacokinetic interaction of propofol and fentanyl: single bolus injection study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2265045/),[l] / [min],1.6,255345,DB00818,Propofol
,2265045,Vss,Propofol was distributed initially into a relatively large central compartment (mean 23.7 (6.6) litre) and was extensively redistributed (mean Vss 593 (157) litre).,Pharmacokinetic interaction of propofol and fentanyl: single bolus injection study. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2265045/),l,593,255346,DB00818,Propofol
,3261062,maximum mean,"3. The blood concentration of propofol declined in a biphasic manner from a maximum mean value of 0.44 microgram/ml, 2 min after injection.",Disposition in male volunteers of a subanaesthetic intravenous dose of an oil in water emulsion of 14C-propofol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3261062/),[μg] / [ml],0.44,256504,DB00818,Propofol
,3261062,half-lives,"The half-lives of the first and second exponential phases, mean values 5 min and 97 min respectively, varied widely among subjects.",Disposition in male volunteers of a subanaesthetic intravenous dose of an oil in water emulsion of 14C-propofol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3261062/),min,5,256505,DB00818,Propofol
,3261062,half-lives,"The half-lives of the first and second exponential phases, mean values 5 min and 97 min respectively, varied widely among subjects.",Disposition in male volunteers of a subanaesthetic intravenous dose of an oil in water emulsion of 14C-propofol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3261062/),min,97,256506,DB00818,Propofol
,3261062,total body clearance,"4. Propofol has a volume of distribution equivalent to about 3 to 4 times body weight, and a mean total body clearance of 2.2 1/min.",Disposition in male volunteers of a subanaesthetic intravenous dose of an oil in water emulsion of 14C-propofol. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3261062/),[1] / [min],2.2,256507,DB00818,Propofol
,27376816,plasma concentrations,"The target plasma concentrations of propofol required at light anesthetic depth was 9.77±0.23 μg/mL, while 12.52±0.69 μg/mL at deep anesthetic depth.",Propofol target-controlled infusion modeling in rabbits: Pharmacokinetic and pharmacodynamic analysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27376816/),[μg] / [ml],9.77,256698,DB00818,Propofol
,27376816,plasma concentrations,"The target plasma concentrations of propofol required at light anesthetic depth was 9.77±0.23 μg/mL, while 12.52±0.69 μg/mL at deep anesthetic depth.",Propofol target-controlled infusion modeling in rabbits: Pharmacokinetic and pharmacodynamic analysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27376816/),[μg] / [ml],12.52,256699,DB00818,Propofol
,27376816,NI,"NI was 76.17±4.25 at light anesthetic depth, while 27.41±5.77 at deep anesthetic depth.",Propofol target-controlled infusion modeling in rabbits: Pharmacokinetic and pharmacodynamic analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27376816/),,76.17,256700,DB00818,Propofol
,27376816,NI,"NI was 76.17±4.25 at light anesthetic depth, while 27.41±5.77 at deep anesthetic depth.",Propofol target-controlled infusion modeling in rabbits: Pharmacokinetic and pharmacodynamic analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27376816/),,27.41,256701,DB00818,Propofol
,27376816,elimination rate constant (ke0),"The effect-site elimination rate constant (ke0) was 0.263/min, and the propofol dose required to achieve a 50% decrease in the NI value from baseline was 11.19 μg/mL (95% CI, 10.25-13.67).",Propofol target-controlled infusion modeling in rabbits: Pharmacokinetic and pharmacodynamic analysis. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27376816/),1/[min],0.263,256702,DB00818,Propofol
,24228141,tpeak,An observed tpeak of 1.6 min for LCT propofol was obtained from an earlier study.,The comparison of predictive performance in bispectral index prediction during target effect-site controlled infusion of propofol using different blood effect-site equilibration rate constants in the same pharmacokinetic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24228141/),min,1.6,259857,DB00818,Propofol
,24228141,k e0_model,"Another 40 patients received a target controlled infusions of microemulsion propofol (k e0_model = 0.187/min, group Bmicro = 20) or LCT propofol (k e0_model = 0.26/min, group BLCT = 20) and remifentanil.",The comparison of predictive performance in bispectral index prediction during target effect-site controlled infusion of propofol using different blood effect-site equilibration rate constants in the same pharmacokinetic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24228141/),1/[min],0.187,259858,DB00818,Propofol
,24228141,k e0_model,"Another 40 patients received a target controlled infusions of microemulsion propofol (k e0_model = 0.187/min, group Bmicro = 20) or LCT propofol (k e0_model = 0.26/min, group BLCT = 20) and remifentanil.",The comparison of predictive performance in bispectral index prediction during target effect-site controlled infusion of propofol using different blood effect-site equilibration rate constants in the same pharmacokinetic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24228141/),1/[min],0.26,259859,DB00818,Propofol
,24228141,tpeak,Observed tpeak of microemulsion propofol was 1.68 min.,The comparison of predictive performance in bispectral index prediction during target effect-site controlled infusion of propofol using different blood effect-site equilibration rate constants in the same pharmacokinetic model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24228141/),min,1.68,259860,DB00818,Propofol
,21264558,estimated,The estimated plasma concentration (C(p)) of propofol for the two groups was set at 1 μg·mL(-1) and increased by 1 μg·mL(-1) every minute to gradually reach 5 μg·mL(-1) after 5 min.,Geographic differences in the target-controlled infusion estimated concentration of propofol: bispectral index response curves. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21264558/),[μg] / [ml],1,260121,DB00818,Propofol
,21264558,plasma concentration (C(p)),The estimated plasma concentration (C(p)) of propofol for the two groups was set at 1 μg·mL(-1) and increased by 1 μg·mL(-1) every minute to gradually reach 5 μg·mL(-1) after 5 min.,Geographic differences in the target-controlled infusion estimated concentration of propofol: bispectral index response curves. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21264558/),[μg] / [ml],1,260122,DB00818,Propofol
,21264558,plasma concentration (C(p)),The estimated plasma concentration (C(p)) of propofol for the two groups was set at 1 μg·mL(-1) and increased by 1 μg·mL(-1) every minute to gradually reach 5 μg·mL(-1) after 5 min.,Geographic differences in the target-controlled infusion estimated concentration of propofol: bispectral index response curves. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21264558/),[μg] / [ml],5,260123,DB00818,Propofol
,21264558,BIS,"After 5 min, the BIS value in the Chinese group was lower than in the Austrian group (mean ± standard deviation [SD], 47.2 ± 3.6 vs 63.6 ± 5.4, respectively; P = 0.0006).",Geographic differences in the target-controlled infusion estimated concentration of propofol: bispectral index response curves. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21264558/),,47.2,260124,DB00818,Propofol
,21264558,BIS,"After 5 min, the BIS value in the Chinese group was lower than in the Austrian group (mean ± standard deviation [SD], 47.2 ± 3.6 vs 63.6 ± 5.4, respectively; P = 0.0006).",Geographic differences in the target-controlled infusion estimated concentration of propofol: bispectral index response curves. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21264558/),,63.6,260125,DB00818,Propofol
,21264558,C(p),"The estimated C(p) at loss of consciousness (LOC), predicted C(e) at LOC, and time to LOC, were lower in the Chinese group than in the Austrian group (3.3 ± 0.8 μg·mL(-1), 1.6 ± 0.4 μg·mL(-1), 2.8 ± 0.6 min, respectively, vs 4.6 ± 2.8 μg·mL(-1), 2.4 ± 1.5 μg·mL(-1), 3.9 ± 0.5 min, respectively; P < 0.0001).",Geographic differences in the target-controlled infusion estimated concentration of propofol: bispectral index response curves. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21264558/),[μg] / [ml],3.3,260126,DB00818,Propofol
,21264558,C(p),"The estimated C(p) at loss of consciousness (LOC), predicted C(e) at LOC, and time to LOC, were lower in the Chinese group than in the Austrian group (3.3 ± 0.8 μg·mL(-1), 1.6 ± 0.4 μg·mL(-1), 2.8 ± 0.6 min, respectively, vs 4.6 ± 2.8 μg·mL(-1), 2.4 ± 1.5 μg·mL(-1), 3.9 ± 0.5 min, respectively; P < 0.0001).",Geographic differences in the target-controlled infusion estimated concentration of propofol: bispectral index response curves. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21264558/),[μg] / [ml],1.6,260127,DB00818,Propofol
,21264558,C(p),"The estimated C(p) at loss of consciousness (LOC), predicted C(e) at LOC, and time to LOC, were lower in the Chinese group than in the Austrian group (3.3 ± 0.8 μg·mL(-1), 1.6 ± 0.4 μg·mL(-1), 2.8 ± 0.6 min, respectively, vs 4.6 ± 2.8 μg·mL(-1), 2.4 ± 1.5 μg·mL(-1), 3.9 ± 0.5 min, respectively; P < 0.0001).",Geographic differences in the target-controlled infusion estimated concentration of propofol: bispectral index response curves. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21264558/),[μg] / [ml],4.6,260128,DB00818,Propofol
,21264558,C(e),"The estimated C(p) at loss of consciousness (LOC), predicted C(e) at LOC, and time to LOC, were lower in the Chinese group than in the Austrian group (3.3 ± 0.8 μg·mL(-1), 1.6 ± 0.4 μg·mL(-1), 2.8 ± 0.6 min, respectively, vs 4.6 ± 2.8 μg·mL(-1), 2.4 ± 1.5 μg·mL(-1), 3.9 ± 0.5 min, respectively; P < 0.0001).",Geographic differences in the target-controlled infusion estimated concentration of propofol: bispectral index response curves. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21264558/),[μg] / [ml],1.6,260129,DB00818,Propofol
,21264558,C(e),"The estimated C(p) at loss of consciousness (LOC), predicted C(e) at LOC, and time to LOC, were lower in the Chinese group than in the Austrian group (3.3 ± 0.8 μg·mL(-1), 1.6 ± 0.4 μg·mL(-1), 2.8 ± 0.6 min, respectively, vs 4.6 ± 2.8 μg·mL(-1), 2.4 ± 1.5 μg·mL(-1), 3.9 ± 0.5 min, respectively; P < 0.0001).",Geographic differences in the target-controlled infusion estimated concentration of propofol: bispectral index response curves. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21264558/),min,2.8,260130,DB00818,Propofol
,21264558,C(e),"The estimated C(p) at loss of consciousness (LOC), predicted C(e) at LOC, and time to LOC, were lower in the Chinese group than in the Austrian group (3.3 ± 0.8 μg·mL(-1), 1.6 ± 0.4 μg·mL(-1), 2.8 ± 0.6 min, respectively, vs 4.6 ± 2.8 μg·mL(-1), 2.4 ± 1.5 μg·mL(-1), 3.9 ± 0.5 min, respectively; P < 0.0001).",Geographic differences in the target-controlled infusion estimated concentration of propofol: bispectral index response curves. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21264558/),[μg] / [ml],4.6,260131,DB00818,Propofol
,21264558,time to LOC,"The estimated C(p) at loss of consciousness (LOC), predicted C(e) at LOC, and time to LOC, were lower in the Chinese group than in the Austrian group (3.3 ± 0.8 μg·mL(-1), 1.6 ± 0.4 μg·mL(-1), 2.8 ± 0.6 min, respectively, vs 4.6 ± 2.8 μg·mL(-1), 2.4 ± 1.5 μg·mL(-1), 3.9 ± 0.5 min, respectively; P < 0.0001).",Geographic differences in the target-controlled infusion estimated concentration of propofol: bispectral index response curves. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21264558/),min,2.8,260132,DB00818,Propofol
,21264558,time to LOC,"The estimated C(p) at loss of consciousness (LOC), predicted C(e) at LOC, and time to LOC, were lower in the Chinese group than in the Austrian group (3.3 ± 0.8 μg·mL(-1), 1.6 ± 0.4 μg·mL(-1), 2.8 ± 0.6 min, respectively, vs 4.6 ± 2.8 μg·mL(-1), 2.4 ± 1.5 μg·mL(-1), 3.9 ± 0.5 min, respectively; P < 0.0001).",Geographic differences in the target-controlled infusion estimated concentration of propofol: bispectral index response curves. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21264558/),min,3.9,260133,DB00818,Propofol
,16827068,Ce,"The Ce associated with auditory evoked potentials at 50% of the maximum effect (Ce50) for adults was 6.45 (0.59) microg/mL(-1), which was significantly higher than that estimated by either model for children (Kataria, 2.06 [0.24] microg/mL(-1); Paedfusor, 3.56 [0.22] microg/mL; P<0.001 between adults and children for both models).",[Pharmacodynamics of propofol in children and adults: comparison based on the auditory evoked potentials index]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16827068/),[μg] / [ml],6.45,260198,DB00818,Propofol
,16827068,Ce,"The Ce associated with auditory evoked potentials at 50% of the maximum effect (Ce50) for adults was 6.45 (0.59) microg/mL(-1), which was significantly higher than that estimated by either model for children (Kataria, 2.06 [0.24] microg/mL(-1); Paedfusor, 3.56 [0.22] microg/mL; P<0.001 between adults and children for both models).",[Pharmacodynamics of propofol in children and adults: comparison based on the auditory evoked potentials index]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16827068/),[μg] / [ml],2.06,260199,DB00818,Propofol
,16827068,Ce,"The Ce associated with auditory evoked potentials at 50% of the maximum effect (Ce50) for adults was 6.45 (0.59) microg/mL(-1), which was significantly higher than that estimated by either model for children (Kataria, 2.06 [0.24] microg/mL(-1); Paedfusor, 3.56 [0.22] microg/mL; P<0.001 between adults and children for both models).",[Pharmacodynamics of propofol in children and adults: comparison based on the auditory evoked potentials index]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16827068/),[μg] / [ml],3.56,260200,DB00818,Propofol
,15315624,CL,The PK of propofol (basic model) was described by a one-compartment model with (typical value [interindividual coefficient of variation percent (CV%)]) CL=2.30 l min(-1) (27%) and V=8.40 l (80%).,Influence of formulation on propofol pharmacokinetics and pharmacodynamics in anesthetized patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15315624/),[l] / [min],2.30,260510,DB00818,Propofol
,15315624,V,The PK of propofol (basic model) was described by a one-compartment model with (typical value [interindividual coefficient of variation percent (CV%)]) CL=2.30 l min(-1) (27%) and V=8.40 l (80%).,Influence of formulation on propofol pharmacokinetics and pharmacodynamics in anesthetized patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15315624/),l,8.40,260511,DB00818,Propofol
,11927473,clinical duration,"After the second bolus, clinical duration was 20 +/- 6 min in the propofol group vs 39 +/- 8 min in the isoflurane group (P <0.05).",Rocuronium pharmacokinetic-pharmacodynamic relationship under stable propofol or isoflurane anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11927473/),min,20,260546,DB00818,Propofol
,11927473,clinical duration,"After the second bolus, clinical duration was 20 +/- 6 min in the propofol group vs 39 +/- 8 min in the isoflurane group (P <0.05).",Rocuronium pharmacokinetic-pharmacodynamic relationship under stable propofol or isoflurane anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11927473/),min,39,260547,DB00818,Propofol
,11927473,effect compartment concentration corresponding to 50,"The effect compartment concentration corresponding to 50% block, EC50, was higher under propofol anesthesia: 1008 vs 592 microg x L(-1) (P <0.05).",Rocuronium pharmacokinetic-pharmacodynamic relationship under stable propofol or isoflurane anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11927473/),[μg] / [l],1008,260548,DB00818,Propofol
,11927473,effect compartment concentration corresponding to 50,"The effect compartment concentration corresponding to 50% block, EC50, was higher under propofol anesthesia: 1008 vs 592 microg x L(-1) (P <0.05).",Rocuronium pharmacokinetic-pharmacodynamic relationship under stable propofol or isoflurane anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11927473/),[μg] / [l],592,260549,DB00818,Propofol
,11927473,EC50,"The effect compartment concentration corresponding to 50% block, EC50, was higher under propofol anesthesia: 1008 vs 592 microg x L(-1) (P <0.05).",Rocuronium pharmacokinetic-pharmacodynamic relationship under stable propofol or isoflurane anesthesia. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11927473/),[μg] / [l],1008,260550,DB00818,Propofol
,11927473,EC50,"The effect compartment concentration corresponding to 50% block, EC50, was higher under propofol anesthesia: 1008 vs 592 microg x L(-1) (P <0.05).",Rocuronium pharmacokinetic-pharmacodynamic relationship under stable propofol or isoflurane anesthesia. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11927473/),[μg] / [l],592,260551,DB00818,Propofol
,16508393,Cl,"Typical values were Cl = 0.70 . (BW/8.9)0.61 l/min, Vc = 18.8 l, Q = 0.35 l/min, and Vss = 146 l.",Propofol pharmacokinetics and pharmacodynamics for depth of sedation in nonventilated infants after major craniofacial surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16508393/),[l] / [min],0.70,261115,DB00818,Propofol
,16508393,Cl,"Typical values were Cl = 0.70 . (BW/8.9)0.61 l/min, Vc = 18.8 l, Q = 0.35 l/min, and Vss = 146 l.",Propofol pharmacokinetics and pharmacodynamics for depth of sedation in nonventilated infants after major craniofacial surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16508393/),[l] / [min],0.61,261116,DB00818,Propofol
,16508393,Vc,"Typical values were Cl = 0.70 . (BW/8.9)0.61 l/min, Vc = 18.8 l, Q = 0.35 l/min, and Vss = 146 l.",Propofol pharmacokinetics and pharmacodynamics for depth of sedation in nonventilated infants after major craniofacial surgery. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16508393/),l,18.8,261117,DB00818,Propofol
,16508393,Q,"Typical values were Cl = 0.70 . (BW/8.9)0.61 l/min, Vc = 18.8 l, Q = 0.35 l/min, and Vss = 146 l.",Propofol pharmacokinetics and pharmacodynamics for depth of sedation in nonventilated infants after major craniofacial surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16508393/),[l] / [min],0.35,261118,DB00818,Propofol
,16508393,Vss,"Typical values were Cl = 0.70 . (BW/8.9)0.61 l/min, Vc = 18.8 l, Q = 0.35 l/min, and Vss = 146 l.",Propofol pharmacokinetics and pharmacodynamics for depth of sedation in nonventilated infants after major craniofacial surgery. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16508393/),l,146,261119,DB00818,Propofol
,16508393,concentration at half maximum effect,The propofol concentration at half maximum effect was 1.76 mg/l (coefficient of variation = 47%) for the COMFORT-Behavior scale and 3.71 mg/l (coefficient of variation = 145%) for the Bispectral Index.,Propofol pharmacokinetics and pharmacodynamics for depth of sedation in nonventilated infants after major craniofacial surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16508393/),[mg] / [l],1.76,261120,DB00818,Propofol
,16508393,concentration at half maximum effect,The propofol concentration at half maximum effect was 1.76 mg/l (coefficient of variation = 47%) for the COMFORT-Behavior scale and 3.71 mg/l (coefficient of variation = 145%) for the Bispectral Index.,Propofol pharmacokinetics and pharmacodynamics for depth of sedation in nonventilated infants after major craniofacial surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16508393/),[mg] / [l],3.71,261121,DB00818,Propofol
,25243731,EC50,"A decreased EC50 (2.47 vs. 3.17 mg/L) and increased slope (2.71 vs. 1.30) of the sigmoidal Emax relationship was observed for the AAI index, as compared with the BIS measurements.",Melatonin and clonidine premedication has similar impact on the pharmacokinetics and pharmacodynamics of propofol target controlled-infusions. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25243731/),[mg] / [l],2.47,263208,DB00818,Propofol
,25243731,EC50,"A decreased EC50 (2.47 vs. 3.17 mg/L) and increased slope (2.71 vs. 1.30) of the sigmoidal Emax relationship was observed for the AAI index, as compared with the BIS measurements.",Melatonin and clonidine premedication has similar impact on the pharmacokinetics and pharmacodynamics of propofol target controlled-infusions. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25243731/),[mg] / [l],3.17,263209,DB00818,Propofol
,21973271,CL,"In a three-compartment pharmacokinetic model, TBW proved to be the most predictive covariate for clearance from the central compartment (CL) in the 20 morbidly obese patients (CL 2.33 L/min × [TBW/70]^[0.72]).",Population pharmacokinetics and pharmacodynamics of propofol in morbidly obese patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21973271/),[l] / [70·[tbw·min],2.33,264105,DB00818,Propofol
,21973271,CL,Similar results were obtained when the morbidly obese patients and the 44 lean patients were analysed together (CL 2.22 L/min × [TBW/70]^[0.67]).,Population pharmacokinetics and pharmacodynamics of propofol in morbidly obese patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21973271/),[l] / [70·[tbw·min],2.22,264106,DB00818,Propofol
,21973271,concentration at half-maximum effect [EC(50)],The depth of anaesthesia in the morbidly obese patients was adequately described by a two-compartment biophase-distribution model with a sigmoid maximum possible effect (E(max)) pharmacodynamic model (concentration at half-maximum effect [EC(50)] 2.12 mg/L) without covariates.,Population pharmacokinetics and pharmacodynamics of propofol in morbidly obese patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21973271/),[mg] / [l],2.12,264107,DB00818,Propofol
,30117213,half-time,"The equilibration half-time (1.48 minutes) increased with age, but could be predicted using allometry in those under 40 years.",Modeling the pharmacokinetics and pharmacodynamics of sevoflurane using compartment models in children and adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30117213/),min,1.48,264246,DB00818,Propofol
,25327817,clearance from the second compartment (CLD2),"No differences were noted between treatments with the exception of clearance from the second compartment (CLD2), which was 23.6 and 38.8 mL kg(-1) minute(-1) in the P and P28 treatments, respectively.",Pharmacokinetics and pharmacodynamics of propofol with or without 2% benzyl alcohol following a single induction dose administered intravenously in cats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25327817/),[ml] / [kg·minute],23.6,264639,DB00818,Propofol
,25327817,clearance from the second compartment (CLD2),"No differences were noted between treatments with the exception of clearance from the second compartment (CLD2), which was 23.6 and 38.8 mL kg(-1) minute(-1) in the P and P28 treatments, respectively.",Pharmacokinetics and pharmacodynamics of propofol with or without 2% benzyl alcohol following a single induction dose administered intravenously in cats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25327817/),[ml] / [kg·minute],38.8,264640,DB00818,Propofol
,12190804,ThalfKeo,Propofol TCI using the pharmacokinetic set of Marsh et al. incorporated in the Diprifusor (ThalfKeo of 2.6 min) was used.,Target-controlled infusion of propofol induction with or without plasma concentration constraint in high-risk adult patients undergoing cardiac surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12190804/),min,2.6,264704,DB00818,Propofol
,12190804,Cp,"At LOC, mean Cp was 1.9 micro g/ml in both groups but mean Ce was 1.08 +/- 0.31 and 1.43 +/- 0.42 micro g/ml in groups 1 and 2, respectively (P < 0.01).",Target-controlled infusion of propofol induction with or without plasma concentration constraint in high-risk adult patients undergoing cardiac surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12190804/),[μg] / [ml],1.9,264705,DB00818,Propofol
,12190804,Ce,"At LOC, mean Cp was 1.9 micro g/ml in both groups but mean Ce was 1.08 +/- 0.31 and 1.43 +/- 0.42 micro g/ml in groups 1 and 2, respectively (P < 0.01).",Target-controlled infusion of propofol induction with or without plasma concentration constraint in high-risk adult patients undergoing cardiac surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12190804/),[μg] / [ml],1.08,264706,DB00818,Propofol
,12190804,Ce,"At LOC, mean Cp was 1.9 micro g/ml in both groups but mean Ce was 1.08 +/- 0.31 and 1.43 +/- 0.42 micro g/ml in groups 1 and 2, respectively (P < 0.01).",Target-controlled infusion of propofol induction with or without plasma concentration constraint in high-risk adult patients undergoing cardiac surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12190804/),[μg] / [ml],1.43,264707,DB00818,Propofol
,12190804,induction time,The mean induction time was 12.8 +/- 7.1 min in group 1 and 8.5 +/- 2.7 min in group 2 (P < 0.05).,Target-controlled infusion of propofol induction with or without plasma concentration constraint in high-risk adult patients undergoing cardiac surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12190804/),min,12.8,264708,DB00818,Propofol
,12190804,induction time,The mean induction time was 12.8 +/- 7.1 min in group 1 and 8.5 +/- 2.7 min in group 2 (P < 0.05).,Target-controlled infusion of propofol induction with or without plasma concentration constraint in high-risk adult patients undergoing cardiac surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12190804/),min,8.5,264709,DB00818,Propofol
,20077775,time to spontaneous recovery,"The time to spontaneous recovery with a twitch height of 25% and a reappearance of the fourth response in train-of-four ratio (TOF ratio) nerve stimulation was twenty minutes, even after a five-hour infusion, and was not affected by the length of the infusion.",[Estimated blood concentration of rocuronium administrated by continuous infusion to maintain an appropriate neuromuscular blockade under propofol anesthesia]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20077775/),min,twenty,264946,DB00818,Propofol
,29247451,V1,"The final pharmacokinetic parameter values were as follows: V1 = 60.6 L, V2 = 222 L, Cl1 = 0.825 L/min and Cl2 = 4.48 L/min.",Pharmacokinetics of dexmedetomidine administered to patients with end-stage renal failure and secondary hyperparathyroidism undergoing general anaesthesia. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29247451/),l,60.6,265352,DB00818,Propofol
,29247451,V2,"The final pharmacokinetic parameter values were as follows: V1 = 60.6 L, V2 = 222 L, Cl1 = 0.825 L/min and Cl2 = 4.48 L/min.",Pharmacokinetics of dexmedetomidine administered to patients with end-stage renal failure and secondary hyperparathyroidism undergoing general anaesthesia. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29247451/),l,222,265353,DB00818,Propofol
,29247451,Cl1,"The final pharmacokinetic parameter values were as follows: V1 = 60.6 L, V2 = 222 L, Cl1 = 0.825 L/min and Cl2 = 4.48 L/min.",Pharmacokinetics of dexmedetomidine administered to patients with end-stage renal failure and secondary hyperparathyroidism undergoing general anaesthesia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29247451/),[l] / [min],0.825,265354,DB00818,Propofol
,29247451,Cl2,"The final pharmacokinetic parameter values were as follows: V1 = 60.6 L, V2 = 222 L, Cl1 = 0.825 L/min and Cl2 = 4.48 L/min.",Pharmacokinetics of dexmedetomidine administered to patients with end-stage renal failure and secondary hyperparathyroidism undergoing general anaesthesia. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29247451/),[l] / [min],4.48,265355,DB00818,Propofol
,23040653,k(e0),"The PK-PD model of propofol, published by Schnider et al., calculated a k(e0) value of 0.456min(-1) and a corresponding time to peak effect (t peak) of 1.6min.",[Reevaluation of the time course of the effect of propofol described with the Schnider pharmacokinetic model]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23040653/),1/[min],0.456,265632,DB00818,Propofol
,23040653,time to peak effect (t peak),"The PK-PD model of propofol, published by Schnider et al., calculated a k(e0) value of 0.456min(-1) and a corresponding time to peak effect (t peak) of 1.6min.",[Reevaluation of the time course of the effect of propofol described with the Schnider pharmacokinetic model]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23040653/),min,1.6,265633,DB00818,Propofol
,23040653,plasma target,"The study included 35 healthy adult patients (18-90 years) scheduled for elective surgery with standard monitoring and using the BIS XP(®) (Aspect), and who received a propofol infusion to reach a plasma target of 12 μg/ml in 4min.",[Reevaluation of the time course of the effect of propofol described with the Schnider pharmacokinetic model]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23040653/),[μg] / [ml],12,265634,DB00818,Propofol
,23040653,k(e0),"The population k(e0) obtained was 0.144min(-1) (SD±0.048), very different from the original model (P<.001).",[Reevaluation of the time course of the effect of propofol described with the Schnider pharmacokinetic model]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23040653/),1/[min],0.144,265635,DB00818,Propofol
,23040653,t peak,This value corresponds with a t peak of 2.45min.,[Reevaluation of the time course of the effect of propofol described with the Schnider pharmacokinetic model]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23040653/),min,2.45,265636,DB00818,Propofol
,23040653,BIS,"With a baseline BIS of 95.8 (SD±2.34), the BIS at LOC was 77.48 (SD±9.6) and 74.65(SD±6.3) at ROC (P=.027).",[Reevaluation of the time course of the effect of propofol described with the Schnider pharmacokinetic model]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23040653/),,77.48,265637,DB00818,Propofol
,23040653,BIS,"With a baseline BIS of 95.8 (SD±2.34), the BIS at LOC was 77.48 (SD±9.6) and 74.65(SD±6.3) at ROC (P=.027).",[Reevaluation of the time course of the effect of propofol described with the Schnider pharmacokinetic model]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23040653/),,74.65,265638,DB00818,Propofol
,23040653,Ce,"The calculated Ce in the original model at LOC and ROC were 5.9 (SD±1.35)/1.08 μg/ml (SD±0.32) (P<.001), respectively, and 2.3 (SD±0.63)/2.0 μg/ml (SD±0.65) (NS) for the new model.",[Reevaluation of the time course of the effect of propofol described with the Schnider pharmacokinetic model]. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23040653/),[μg] / [ml],5.9,265639,DB00818,Propofol
,23040653,Ce,"The calculated Ce in the original model at LOC and ROC were 5.9 (SD±1.35)/1.08 μg/ml (SD±0.32) (P<.001), respectively, and 2.3 (SD±0.63)/2.0 μg/ml (SD±0.65) (NS) for the new model.",[Reevaluation of the time course of the effect of propofol described with the Schnider pharmacokinetic model]. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23040653/),[μg] / [ml],1.08,265640,DB00818,Propofol
,23040653,Ce,"The calculated Ce in the original model at LOC and ROC were 5.9 (SD±1.35)/1.08 μg/ml (SD±0.32) (P<.001), respectively, and 2.3 (SD±0.63)/2.0 μg/ml (SD±0.65) (NS) for the new model.",[Reevaluation of the time course of the effect of propofol described with the Schnider pharmacokinetic model]. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23040653/),[μg] / [ml],2.3,265641,DB00818,Propofol
,23040653,Ce,"The calculated Ce in the original model at LOC and ROC were 5.9 (SD±1.35)/1.08 μg/ml (SD±0.32) (P<.001), respectively, and 2.3 (SD±0.63)/2.0 μg/ml (SD±0.65) (NS) for the new model.",[Reevaluation of the time course of the effect of propofol described with the Schnider pharmacokinetic model]. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23040653/),[μg] / [ml],2.0,265642,DB00818,Propofol
,3129956,constant target plasma alfentanil concentration,Alfentanil was administered as an exponentially decreasing infusion using a computer-assisted infusion device with a constant target plasma alfentanil concentration of 300 ng/ml.,Disposition kinetics of propofol during alfentanil anaesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3129956/),[ng] / [ml],300,265999,DB00818,Propofol
,3129956,elimination half-life,The elimination half-life of alfentanil was approximately 75 minutes (SD 21).,Disposition kinetics of propofol during alfentanil anaesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3129956/),min,75,266000,DB00818,Propofol
,32870155,flow rate,"Chromatographic separation was acquired on an ACE Excel 3 Super C18 column (2.1 × 50 mm, 3 µm) using gradient elution at a flow rate of 0.5 mL/min.",A simplified and sensitive LC-APCI-MS/MS method for the quantification of propofol: Application to a bioequivalence study in healthy Chinese subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32870155/),[ml] / [min],0.5,266537,DB00818,Propofol
,16571960,median recovery time,Sugammadex decreased median recovery time in a dose-dependent manner from 21.0 min in the placebo group to 1.1 min in the group receiving 4.0 mg/kg sugammadex.,Reversal of rocuronium-induced neuromuscular block by the selective relaxant binding agent sugammadex: a dose-finding and safety study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16571960/),min,21.0,266635,DB00818,Propofol
,16571960,median recovery time,Sugammadex decreased median recovery time in a dose-dependent manner from 21.0 min in the placebo group to 1.1 min in the group receiving 4.0 mg/kg sugammadex.,Reversal of rocuronium-induced neuromuscular block by the selective relaxant binding agent sugammadex: a dose-finding and safety study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16571960/),min,1.1,266636,DB00818,Propofol
,2646847,first-stage elimination half-life (t1/2 beta),The first-stage elimination half-life (t1/2 beta) of propofol in children was shorter (mean 9.3 +/- 3.8 (s.d.) min) than the values found in adults.,Propofol as an induction agent in children: pain on injection and pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2646847/),min,9.3,268515,DB00818,Propofol
,12459665,Induction time,"Induction time was 14% longer with IDD-D Propofol than with Diprivan (N = 24, protocols 1 and 2 combined, 53.3 +/- 12.1 s and 46.9 +/- 7.8 s, respectively; P = 0.002).",Pharmacodynamics and pharmacokinetics of propofol in a medium-chain triglyceride emulsion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12459665/),s,53.3,272684,DB00818,Propofol
,12459665,Induction time,"Induction time was 14% longer with IDD-D Propofol than with Diprivan (N = 24, protocols 1 and 2 combined, 53.3 +/- 12.1 s and 46.9 +/- 7.8 s, respectively; P = 0.002).",Pharmacodynamics and pharmacokinetics of propofol in a medium-chain triglyceride emulsion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12459665/),s,46.9,272685,DB00818,Propofol
,12459665,Emergence time,"Emergence time was not significantly different for protocol 1 but was marginally longer (P = 0.04) for IDD-D Propofol in protocol 2 (1,197 +/- 445 s [n = 11] and 1,254 +/- 468 s [n = 12], respectively).",Pharmacodynamics and pharmacokinetics of propofol in a medium-chain triglyceride emulsion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12459665/),s,"1,197",272686,DB00818,Propofol
,12459665,Emergence time,"Emergence time was not significantly different for protocol 1 but was marginally longer (P = 0.04) for IDD-D Propofol in protocol 2 (1,197 +/- 445 s [n = 11] and 1,254 +/- 468 s [n = 12], respectively).",Pharmacodynamics and pharmacokinetics of propofol in a medium-chain triglyceride emulsion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12459665/),s,"1,254",272687,DB00818,Propofol
,10360845,rate constant,The plasma effect-site equilibration rate constant was 0.456 min(-1).,The influence of age on propofol pharmacodynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10360845/),1/[min],0.456,272697,DB00818,Propofol
,10360845,time to peak effect,The predicted time to peak effect after bolus injection ranging was 1.7 min.,The influence of age on propofol pharmacodynamics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10360845/),min,1.7,272698,DB00818,Propofol
,10360845,time to peak effect,"The time to peak effect assessed visually was 1.6 min (range, 1-2.4 min).",The influence of age on propofol pharmacodynamics. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10360845/),min,1.6,272699,DB00818,Propofol
,10360845,C50,"The steady state observations showed increasing sensitivity to propofol in elderly patients, with C50 values for loss of consciousness of 2.35, 1.8, and 1.25 microg/ml in volunteers who were 25, 50, and 75 yr old, respectively.",The influence of age on propofol pharmacodynamics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10360845/),[μg] / [ml],2.35,272700,DB00818,Propofol
,10360845,C50,"The steady state observations showed increasing sensitivity to propofol in elderly patients, with C50 values for loss of consciousness of 2.35, 1.8, and 1.25 microg/ml in volunteers who were 25, 50, and 75 yr old, respectively.",The influence of age on propofol pharmacodynamics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10360845/),[μg] / [ml],1.8,272701,DB00818,Propofol
,10360845,C50,"The steady state observations showed increasing sensitivity to propofol in elderly patients, with C50 values for loss of consciousness of 2.35, 1.8, and 1.25 microg/ml in volunteers who were 25, 50, and 75 yr old, respectively.",The influence of age on propofol pharmacodynamics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10360845/),[μg] / [ml],1.25,272702,DB00818,Propofol
,18509810,effect-site peaks,"The plasma target regimen gave predicted effect-site peaks in the different models ranging from 3.6 to 7.2 microg/mL, reached after 2(3/4) to 4 minutes.","TCI : Target controlled infusion, or totally confused infusion? Call for an optimised population based pharmacokinetic model for propofol. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18509810/),[μg] / [ml],3.6 to 7.2,274166,DB00818,Propofol
,18509810,plasma concentration over-shoots,The predicted plasma concentration over-shoots varied from 5.0 to 13.4 microg/mL.,"TCI : Target controlled infusion, or totally confused infusion? Call for an optimised population based pharmacokinetic model for propofol. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18509810/),[μg] / [ml],5.0 to 13.4,274167,DB00818,Propofol
